




---

# CPDD 77th Annual Scientific Meeting Program



---

**June 13-18, 2015**

**Arizona Biltmore  
Phoenix, Arizona**



**Also at  
the Arizona Biltmore  
International Narcotics  
Research Conference  
June 15-19, 2015**



## **Program Notes**

This year's oral session titles are the Program Committee's salute to the transition of CPDD's Executive Officers. Hail to the Chiefs!

Please be advised that no photographing of presentations or data is permitted.

Badges must be worn at all times and are required for admission into all events and sessions.

## BOARD OF DIRECTORS

Eric Strain, M.D., President  
Frank Vocci, Jr., PhD, Past-President  
Sandra Comer, PhD, President-Elect  
Linda B. Cottler, PhD, MPH, Treasurer  
Michael T. Bardo, PhD  
Alan J. Budney, PhD  
Howard Chilcoat, ScD  
Timothy P. Condon, PhD  
Linda P. Dwoskin, PhD  
Linda A. Dykstra, PhD

Toby Eisenstein, PhD  
Margaret Haney, PhD  
Carl L. Hart, PhD  
Sarah H. Heil, PhD  
Stephen T. Higgins, PhD  
Marc J. Kaufman, PhD  
A. Thomas McLellan, PhD  
Gregory M. Miller, PhD  
Charles O’Keeffe, MBA  
Thomas E. Prisinzano, PhD

## EXECUTIVE OFFICER

Martin W. Adler, PhD

## EXECUTIVE OFFICER - ELECT

Loretta P. Finnegan, MD

## DIRECTOR, EXECUTIVE OFFICE

Ellen B. Geller, MA

## SCIENTIFIC PROGRAM COMMITTEE

Elise Weerts, PhD, Chair  
Martin W. Adler, PhD, *ex officio*  
Loretta P. Finnegan, MD, *ex officio*  
Ellen B. Geller, MA, *ex officio*  
Michael Bardo, PhD  
Ziva Cooper, PhD  
Linda Cottler, PhD, MPH  
Kelly Dunn, PhD  
Linda P. Dwoskin, PhD  
Deborah Hasin, PhD  
Michael Kuhar, PhD  
Matthew Johnson, PhD  
Kathryn McHugh, PhD  
F. Gerald Moeller, MD

**PRE-MEETING SATELLITES**

*8<sup>th</sup> Meeting of the International Women’s and Children’s and Gender Group*  
Chaired by Wendee Wechsberg

**Frank Lloyd Wright**  
June 12

*The 2015 NIDA International Forum: Building International Collaborative Research on Drug Abuse*  
Chaired by Steven Gust

**McArthur Ballroom 1-4**  
June 12 and June 13

*The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)*  
Chaired by Morgan Drake

**McArthur Ballroom 5/6**  
June 13

*NDSN Professional Development Workshop*

**Sedona**  
June 12 (8:00 AM - 5:00 PM)

**CPDD REGISTRATION**

<b>Saturday, June 13</b>	<b>West Foyer Conference Center</b>	<b>1:30 PM - 5:30 PM</b>
<b>Sunday, June 14 - Wednesday June 17</b>	<b>West Foyer Conference Center</b>	<b>8:00 AM - 5:00 PM</b>
<b>Thursday, June 18</b>	<b>West Foyer Conference Center</b>	<b>8:00 AM - 3:00 PM</b>

**OPENING RECEPTION**  
**Gold and Aztec Rooms**  
**(Cash Bar)**

**Saturday, June 13**  
**7:00 PM - 9:00 PM**  
*(Pre-registrants can pick up badges only)*

**Plenary Session**

**AZ Biltmore Ballroom  
9:00 - 11:15 AM**

- 9:00 *Welcome*  
CPDD President Eric C. Strain
- 9:10 *Presentation of the Stephen G. Holtzman Travel Award for Preclinical Investigation to Chloe J. Jordan*  
Introduction by Yung-Fong Sung
- 9:25 *Presentation of the CPDD/NIDA Media Award to Jeff Foote, Nicole Kosanke and Carrie Williams*  
Introduction by Bertha Madras
- 9:40 *Presentation of the Martin and Toby Adler Distinguished Service Award to Cora Lee Wetherington*  
Introduction by Loretta Finnegan
- 9:50 *Presentation of the Joseph Cochin Young Investigator Award to Adam Leventhal*  
Introduction by Jennifer Tidey
- 10:00 *Presentation of the Mentorship Award to Michael Nader*  
Introduction by Joshua Lile
- 10:10 *Presentation of the Nathan B. Eddy Award to Roland Griffiths*  
Introduction by Eric C. Strain
- 10:25 *Nathan B. Eddy Award Lecture: My fascination with mood-altering drugs: Hypnotics, caffeine and psilocybin*  
Roland R. Griffiths, Johns Hopkins University, Baltimore, MD

**CPDD Early Career Travel Awards Luncheon  
(By Invitation Only)**

**Aztec  
11:30 - 1:00 PM**

**President's Lecture**

**AZ Biltmore Ballroom  
1:30 - 2:30 PM**

*A Tale of Two C's*  
Dr. Martin W. Adler, Temple University School of Medicine

**Symposium I**

**AZ Biltmore Ballroom  
3:00 - 5:00 PM**

**FEMALES AND FLOWERS: SEX DIFFERENCES IN THE  
DEPENDENCE-RELATED EFFECTS OF  $\Delta^9$ -THC**

Chairs: Jenny Wiley and Cora Lee Wetherington

- 3:00 *Sex differences in antinociceptive tolerance to THC*  
Rebecca Craft, Washington State University, Pullman, WA
- 3:25 *Sex-dependent effects of cannabis in the human laboratory*  
Ziva D. Cooper, Columbia University and NYSPI, New York, NY
- 3:50 *Evaluation of sex differences in a rodent model of cannabinoid dependence*  
Julie A. Marusich, RTI International, Research Triangle Park, NC

- 4:15 *Affective, psychosocial, and neuropsychological sex differences in adolescent and young adult marijuana users*  
Natania A. Crane, University of Illinois at Chicago, Chicago, IL
- 4:40 *DISCUSSANT: What's sex got to do with it?*  
Jenny Wiley, RTI International, Research Triangle Park, NC

## **Symposium II**

**McArthur Ballroom 1/2**  
**3:00 - 5:00 PM**

### **NALOXONE FOR OVERDOSE PREVENTION: EXPANSION TO MULTIPLE SETTINGS AND POPULATIONS**

Chairs: Caleb J. Banta-Green and Phillip O. Coffin

- 3:00 *Naloxone provision to pain patients in primary care practice: Results from the naloxone for opioid safety evaluation*  
Phillip O. Coffin, University of California San Francisco, San Francisco, CA
- 3:25 *Overdose risk characteristics of opiate users enrolled in an overdose prevention trial in an emergency department*  
Caleb J. Banta-Green, Boston University School of Medicine, Boston, MA
- 3:50 *Implementation of naloxone rescue kit distribution in addiction treatment settings in Massachusetts*  
Alexander Y. Walley, Boston University School of Medicine, Boston, MA
- 4:15 *Two paths forward for overdose prevention: Implementing pharmacy-based naloxone and naloxone at release from prison in Rhode Island*  
Traci C. Green, Warrant Alpert Medical School at Brown University, Providence, RI
- 4:40 *DISCUSSANT: The importance of integrating naloxone distribution in diverse clinical and non-clinical settings*  
Redonna K. Chandler, National Institute on Drug Abuse, Bethesda, MD

## **Oral Communications I**

**McArthur Ballroom 4**  
**3:00 - 5:00 PM**

### **MIXING ADDICTIONS: POLYDRUG ABUSE**

Chairs: Roger D. Spealman and Michelle R. Lofwall

- 3:00 *Modulation of reinstated polydrug (cocaine/heroin) seeking by noradrenergic  $\alpha_2$  agonists*  
R. D. Spealman<sup>1</sup>, J. Bergman<sup>2</sup>, <sup>1</sup>New England Primate Research Center, Harvard Medical School, Southborough, MA, <sup>2</sup>McLean Hospital, Harvard Medical School, Belmont, MA
- 3:15 *Modeling the opioid system's effects on cocaine reinforcement in environmentally enriched and impoverished rats using an economic demand function*  
R. S. Hofford<sup>1</sup>, J. S. Beckmann<sup>1</sup>, M. T. Bardo<sup>2</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY
- 3:30 *Identifying predictive profiles of amphetamine, heroin, and polysubstance dependence using machine learning approaches*  
W. Ahn<sup>1</sup>, G. Vasilev<sup>2</sup>, F. Moeller<sup>1</sup>, J. Vassileva<sup>1</sup>, <sup>1</sup>Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Bulgarian Addictions Institute, Sofia, Bulgaria

- 3:45 *Alcohol and tobacco use in cocaine-dependent participants provided treatment with buprenorphine/naloxone and naltrexone*  
A. Hasson, M. Hillhouse, C. Thomas, L. Mooney, W. Ling, UCLA, Los Angeles, CA
- 4:00 *A pilot trial of vigabatrin for the treatment of cocaine and alcohol dependence*  
K. M. Kampman<sup>1</sup>, H. M. Pettinati<sup>2</sup>, K. G. Lynch<sup>3</sup>, J. G. Plebani<sup>2</sup>, K. Williams<sup>2</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 4:15 *Can dronabinol, a CBI agonist, suppress opioid withdrawal in humans?*  
M. R. Lofwall<sup>1</sup>, S. Babalonis<sup>1</sup>, C. Elayi<sup>2</sup>, P. A. Nuzzo<sup>1</sup>, K. E. Gill<sup>1</sup>, S. L. Walsh<sup>1</sup>, <sup>1</sup>Behavioral Science, Center on Drug and Alcohol Abuse, University of Kentucky, Lexington, KY, <sup>2</sup>Internal Medicine, University of Kentucky, Lexington, KY
- 4:30 *Effects of cannabis use on opioid injection frequency*  
K. F. Corsi<sup>2</sup>, J. M. Davis<sup>2</sup>, A. Kral<sup>1</sup>, R. Bluthenthal<sup>3</sup>, R. E. Booth<sup>2</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>Psychiatry, University of Colorado Denver, Denver, CO, <sup>3</sup>Preventive Medicine, University of Southern California, Los Angeles, CA
- 4:45 *Symmetrical discounting of the future and the past in heavy smokers and alcohol drinkers*  
L. Moody<sup>2,1</sup>, W. K. Bickel<sup>2</sup>, <sup>1</sup>Virginia Tech, Roanoke, VA, <sup>2</sup>Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA

## Oral Communications 2

McArthur Ballroom 5/6

3:00 - 5:00 PM

### MEASURING ANGUISH: TRAUMA & STRESS

Chairs: Philip H. Smith and David V. Flores

- 3:00 *Trauma exacerbates the effect of genetic variants in the dopamine system on cannabis use*  
J. L. Meyers<sup>1</sup>, M. Uddin<sup>2</sup>, S. Galea<sup>1</sup>, A. Aiello<sup>3</sup>, D. Wildman<sup>2</sup>, K. C. Koenen<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>University of Champagne-Urbana, Urbana, IL, <sup>3</sup>University of North Carolina Chapel Hill, Chapel Hill, NC
- 3:15 *Distress tolerance moderates the relationship between trauma symptoms and depression in substance users*  
A. M. Heads<sup>1</sup>, J. Schmitz<sup>2</sup>, C. Amador<sup>1</sup>, A. Vujanovic<sup>1</sup>, J. Hamilton<sup>1</sup>, J. Vincent<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, <sup>2</sup>University of Texas Houston, Houston, TX
- 3:30 *Field evidence for stress-induced drug use*  
M. A. Furnari, W. J. Kowalczyk, M. L. Jobes, K. A. Phillips, D. Epstein, K. L. Preston, NIDA, Baltimore, MD
- 3:45 *Childhood trauma and initiation of drug use in adolescence*  
H. Carliner<sup>1</sup>, E. Dunn<sup>2</sup>, K. Keyes<sup>1</sup>, S. S. Martins<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York City, NY, <sup>2</sup>Psychiatry, Massachusetts General Hospital, Boston, MA
- 4:00 *History of trauma associated with post-deployment relationship dysfunction in military veterans with concurrent PTSD and substance use disorders*  
K. L. Ayers<sup>1</sup>, S. E. Back<sup>1,3</sup>, F. Beylotte<sup>2</sup>, K. Koon<sup>1</sup>, <sup>1</sup>Psychiatry, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Psychiatry, Medical University of South Carolina, Charleston, SC, <sup>3</sup>Psychiatry, Ralph H. Johnson VA Medical Center, Charleston, SC



- 4:15 *Perpetrator vs. victim substance use associated elder abuse*  
D. V. Flores<sup>1</sup>, J. Burnett<sup>2</sup>, J. Booker<sup>3</sup>, <sup>1</sup>Graduate College of Social Work, University of Houston, Houston, TX, <sup>2</sup>Internal Medicine, Geriatric and Palliative Care, University of Texas Medical School at Houston, Houston, TX, <sup>3</sup>Adult Protective Services, Department of Family and Protective Services, Houston, TX
- 4:30 *Childhood adversity, stress-sensitization, and lower likelihood of cigarette smoking cessation in a U.S. nationally representative sample: A study of sex differences*  
P. H. Smith<sup>2</sup>, L. Oberleitner<sup>1</sup>, K. Z. Smith<sup>2</sup>, S. Mckee<sup>2</sup>, <sup>1</sup>School of Medicine, DSA, Yale University, New Haven, CT, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT
- 4:45 *Childhood maltreatment and alcohol use in young adulthood: The role of self-regulation*  
S. Shin<sup>1</sup>, L. Peasley<sup>1</sup>, T. Wills<sup>2</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Cancer Center, University of Hawaii, Honolulu, HI

### **Primm-Singleton Awardees Reception**

**AZ Biltmore History Room  
5:00 - 6:00 PM**

### **Members-In-Training Committee Meeting**

**AZ Biltmore Ballroom  
6:00 - 7:00 PM**

### **Workshop I**

**McArthur Ballroom 1/2  
7:00 - 9:00 PM**

#### **EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS (CO-SPONSORED BY CPDD INTERNATIONAL PROGRAMS COMMITTEE)**

Chairs: James C. Anthony and Jan Copeland

*Dr. James Anthony will introduce speakers and will moderate and encourage discussions, Q&A from the floor*

James C. Anthony, Michigan State University, East Lansing, MI

*Dr. Jan Copeland will moderate and encourage discussions and Q&A from the floor*

Jan Copeland, University of New South Wales, Sydney, NSW, Australia

*“Queremos aprender” – Issues of clinical intervention research with Mexican heritage families*

Ruben Parra-Cardona, Michigan State University, East Lansing, MI

*myEpi: Applications in e-technology-enhanced life history research*

Georgiy Bobashev, Center for Data Science RTI International, Research Triangle Park, NC

### **Workshop II**

**McArthur Ballroom 4  
7:00 - 9:00 PM**

#### **TURNING ELECTRONIC HEALTH RECORDS INTO ACTIONABLE KNOWLEDGE IN ADDICTION RESEARCH**

Chairs: Yih-Ing Hser and Steven Sparenborg

*Prescription opioid use in an integrated health system*

Cynthia Campbell, Kaiser Permanente, Oakland, CA

*What can electronic health records tell us about the clinical course of patients with cannabis-use disorders treated in primary care settings*

Elizabeth Evans, Integrated Substance Abuse Program, UCLA, Los Angeles, CA

*Substance use disorders and hepatitis screening in the safety net population: A practice-based research network study*

Traci R. Rieckmann, OHSU and UCLA ISAP, Portland, OR

*Schizophrenia and affective psychosis in patients with addiction*

Fung-Chang Sung, China Medical University, Taichung, Taiwan

*Electronic health records and addiction research: Opportunities and challenges*

Yih-Ing Hser, Integrated Substance Abuse Program, UCLA, Los Angeles, CA

### **Workshop III**

**McArthur Ballroom 5/6**

**7:00 - 9:00 PM**

#### **CLINICAL OUTCOMES AND COST EVALUATION IN CLINICAL TRIALS: FROM ABSTINENCE TO DOLLARS AND CENTS**

Chairs: Sterling McPherson and Susan K. Mikulich-Gilbertson

*What should I do when my substance use outcome is not normal?*

Susan K. Mikulich-Gilbertson, University of Colorado Anschutz Medical Center, Aurora, CO

*Much ado about 'Missing'? : The importance of missing data sensitivity analyses to evaluate treatment effects*

Sterling McPherson, Washington State University, Spokane, WA

*Economic evaluation methods for randomized clinical trials*

Sean M. Murphy, Washington State University, Spokane, WA

*Examining measurement invariance across treatment groups, gender, and time in clinical trials*

Celestina Barbosa-Leiker, Washington State University, College of Nursing, Spokane, WA

### **Workshop IV**

**AZ Biltmore Ballroom**

**7:00 - 9:00 PM**

#### **NAVIGATING KEY STAGES OF A CAREER IN ADDICTION SCIENCE**

Chairs: Denise C. Vidot and Cristina B. Bares

*Navigating the pre-doctoral stage*

Denise C. Vidot, University of Miami Miller School of Medicine, Miami, FL

*Navigating the post-doctoral stage*

Thomas J. White, University of Vermont College of Medicine, Burlington, VT

*Navigating the early career stage and NIH funding*

Cristina B. Bares, Virginia Commonwealth University School of Social Work, Richmond, VA

## Media Forum

McArthur Ballroom 4  
8:00 - 9:30 AM

### WHAT'S HOT: 2015 ORAL ABSTRACT NOMINATIONS

Chairs: Bertha K. Madras and Anna Rose Childress

*Introduction to each speaker*

Anna Rose Childress, University of Pennsylvania, Philadelphia, PA

*Introduction to media and format*

Bertha K. Madras, Harvard Medical School, Southborough, MA

#### MARIJUANA: CHILDREN AT RISK

*Trends in use of and attitudes toward marijuana among youth before and after decriminalization: The case of California 2007-2013. Authors: L.A. Johnston, P. O'Malley, J. Bachman, J. Schulenberg, M. Patrick*

Richard Miech, University of Michigan, Ann Arbor, MI

*Surveying lactation professionals regarding breastfeeding and marijuana use*

Cecilia Bergeria, University of Vermont, Burlington, VT

*Maternal age and trajectories of marijuana use over 17 years. Authors: L. Goldschmidt, N. Day, M. Cornelius*

Natacha De Genna, University of Pittsburgh School of Medicine, Pittsburgh, PA

*California Federal Judge rules that marijuana should not be rescheduled from Schedule I (no current medical use) to Schedule II (medical use)*

Bertha K. Madras, Mclean Hospital, Belmont, MD

#### OPIOIDS: PRESCRIBING, DEATH AND RESCUE

*Mortality and guideline-concordant long-term opioid therapy for pain. Authors: J. Goulet, W. Becker, S. Crystal, E. Edelman, K. Gordon, R. Kerns, D. Rimland, M. Skanderson, A. Justice and D. Feillin*

J. R. Gaither, Yale, New Haven, CT

*Prescription opioid death rates are greater for females than males. Authors: M.C. LeLait, S.G. Severtson, B. Bucher-Bartelson and R.C. Dart*

J. Iwanicki, Rocky Mountain Poison and Drug Center, Denver, CO

*Implementing routine emergency department naloxone rescue kits for patients at risk of opioid overdose. Authors: J. Ellison, E. Koppelman, P. Mitchell, J. Feldman, E. Bernstein and A. Walley*

Mari-Lynn Drainoni, Boston University, Boston, MA

#### E-CIGARETTES: USE PATTERNS

*Use patterns, perceptions of relative harm, and gender effects in dual users of electronic and tobacco cigarettes Authors: O. Rass, L.R. Pacek, P.S. Johnson and M.W. Johnson*

Matthew W. Johnson, Johns Hopkins University, Baltimore, MD

*Use of electronic cigarettes among smokers in addiction treatment. Authors: T.Le, B. Tajima, B. Andrews, E. Passalacqua and J. Guydish*

Noah Gubner, USCF, San Francisco, CA

---

# Monday, June 15, 2015

---

## ALCOHOL: TELEHEALTH IN TREATMENT

*Impact of telehealth in-home-messaging devices on alcohol use in dually diagnosed veterans*

Authors: S. Martino and M. Gebregziabher

Elizabeth J. Santa Ana, Charleston VA Medical Center, Charleston, SC

## FAMILIES AT RISK

*Effects of parental alcohol vs. tobacco and marijuana use on early adolescent onset of alcohol use*

Authors: S.S. Tobero and K.C. Pears

Deborah Capaldi, Oregon Social Learning Center, Eugene, OR

## Symposium III

**McArthur Ballroom 1/2**

**10:00 - 12:00 PM**

### POSTTRAUMATIC STRESS AND SUBSTANCE USE DISORDERS: TREATMENT INITIATIVES AND CHALLENGES

Chairs: Anka Vujanovic and Joy Schmitz

- 10:00 *Combining treatments for PTSD and alcohol with antidepressants and CBT*  
Denise Hien, University of NY & Columbia University College of Physicians and Surgeons, New York, NY
- 10:25 *Use of mobile technologies to enhance substance abuse outcomes among individuals with posttraumatic stress disorder*  
Eric Dedert, Durham VA and Duke University Medical Centers, Durham, NC
- 10:50 *Treatment of PTSD and substance use disorders: An integrated model using prolonged exposure*  
Sudie E. Back, Medical University of South Carolina, Charleston, SC
- 11:15 *A novel integrated cognitive-behavioral treatment for posttraumatic stress and substance use disorders: Overview and preliminary results*  
Anka Vujanovic, University of Texas Health Science, Houston, TX
- 11:40 *DISCUSSANT: Treating addiction in the context of trauma*  
Dace Svikis, Virginia Commonwealth University, Richmond, VA

## Symposium IV

**McArthur Ballroom 4**

**10:00 - 12:00 PM**

### EMERGING EVIDENCE ON OPIOID-RELATED OVERDOSE RISK AND INTERVENTION

Chairs: Howard Chilcoat and Nabarun Dasgupta

- 10:00 *Risk of opioid overdose death in North Carolina by type of opioid and other controlled substances prescribed*  
Nabarun Dasgupta, University of North Carolina, Raleigh, NC
- 10:25 *Comparison of risk factors for opioid overdose in the United Kingdom and the United States: Role of opioid dosage strength, multiple opioids, and age*  
Paul Coplan, Purdue Pharma, Stamford, CT
- 10:50 *Opioid overdoses: A mixed-methods analysis of intentional vs. unintentional events*  
Carla Green, Center for Health Research, Kaiser Permanente Northwest, Portland, OR

- 11:15 *Project Lazarus: Effective community-based strategy for intervention and prevention of prescription opioid misuse and overdose*  
Fred W. Brason, Project Lazarus, Moravian Falls, NC
- 11:40 *DISCUSSANT: Implications for practice and prevention*  
Wilson Compton, National Institute on Drug Abuse, Bethesda, MD

### Oral Communications 3

McArthur Ballroom 5/6  
10:00 - 12:00 PM

#### **MEN/WOMEN ADDICTIONS: SEX DIFFERENCES**

Chairs: Jennifer W. Tidey and Sarah A. Kromrey

- 10:00 *Taurine effectively inhibits cocaine preference in male and female rats: Candidate for SUD treatment*  
K. Salas-Ramirez<sup>1</sup>, K. Uribe<sup>2</sup>, E. Friedman<sup>3</sup>, S. Banerjee<sup>1</sup>, <sup>1</sup>Physiology, Pharmacology and Neuroscience, The City College of New York, New York, NY, <sup>2</sup>Biology, The City College of New York, New York, NY, <sup>3</sup>Physiology, Pharmacology and Neuroscience, The City College of New York, New York, NY
- 10:15 *Cocaine self-administration in male and female monkeys, treatment with progesterone and enriched environment*  
M. E. Carroll, M. Collins, B. Dougen, Psychiatry, University of Minnesota, Minneapolis, MN
- 10:30 *Influence of reproductive hormones on social rank and vulnerability to cocaine reinforcement in female cynomolgus monkeys*  
S. Kromrey, P. W. Czoty, M. A. Nader, Physiology & Pharmacology, Wake Forest Univ School of Medicine, Winston-Salem, NC
- 10:45 *Gender differences in craving and internalizing symptoms in methamphetamine dependence*  
E. E. Hartwell<sup>1,2</sup>, L. A. Ray<sup>1</sup>, <sup>1</sup>Psychology, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 11:00 *Smoking topography in men and women with and without current depression: Findings from a 10-site clinical trial*  
J. W. Tidey<sup>1</sup>, A. Strasser<sup>2</sup>, E. Donny<sup>3</sup>, D. Hatsukami<sup>4</sup>, <sup>1</sup>Center for Alcohol & Addictions Studies, Brown University, Providence, RI, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>University of Minnesota Medical School, Minneapolis, MN
- 11:15 *Gender differences in cannabis withdrawal symptoms among treatment-seeking cannabis users*  
E. S. Herrmann<sup>1</sup>, E. Weerts<sup>1</sup>, R. Vandrey<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Johns Hopkins University, Baltimore, MD
- 11:30 *Prescription opioid death rates are greater for females than males*  
J. L. Iwanicki, M. C. Le Lait, S. G. Severtson, B. Bucher-Bartelson, R. C. Dart, RADARS® System, RMPDC, DHHA, Denver, CO
- 11:45 *Gender differences in history of sexual and physical abuse in relation to addiction severity*  
J. E. Korte<sup>1</sup>, T. Killeen<sup>1</sup>, S. Sonne<sup>1</sup>, L. Haynes<sup>1</sup>, A. Malek<sup>1</sup>, K. T. Brady<sup>1,2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H. Johnson VA Medical Center, Charleston, SC

**Oral Communications 4****AZ Biltmore Ballroom  
10:00 - 12:00 PM****MODERN ALCHEMY: MEDICATIONS DEVELOPMENT**

Chairs: Bronwyn M. Kivell and Ryan K. Lanier

- 10:00 *Kappa opioid agonist Mesyl Sal B attenuates behavioral sensitization to cocaine with few side-effects*  
B. M. Kivell<sup>1,2</sup>, A. Culverhouse<sup>1,2</sup>, A. Morani<sup>1</sup>, T. E. Prisinzano<sup>3</sup>, <sup>1</sup>School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand, <sup>2</sup>Centre for Biodiscovery, Wellington, New Zealand, <sup>3</sup>Medicinal Chemistry, University of Kansas, Lawrence, KS
- 10:15 *In vivo* evaluation of novel serotonin 5-HT<sub>2C</sub> receptor positive allosteric modulator CYD-1-79  
C. E. McAllister<sup>1</sup>, R. M. Hartley<sup>1</sup>, G. Zhang<sup>1</sup>, R. G. Fox<sup>1</sup>, N. C. Anastasio<sup>1,2</sup>, C. Wild<sup>1</sup>, J. Zhou<sup>1,2</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX
- 10:30 *Effects of the trace amine associated receptor 1 agonist RO5263397 on behavioral indices of methamphetamine in rats*  
J. Li<sup>1</sup>, L. Jing<sup>1</sup>, Y. Zhang<sup>2</sup>, <sup>1</sup>Pharmacology and Toxicology, University at Buffalo, Buffalo, NY, <sup>2</sup>Research Triangle Institute, Research Triangle Park, NC
- 10:30 *Systemic and intraaccumbens mGluR2/3 agonism attenuate ethanol-reinforced appetitive responding*  
K. A. Windisch<sup>2,1</sup>, C. L. Czachowski<sup>2</sup>, <sup>1</sup>Rockefeller University, Indianapolis, IN, <sup>2</sup>Psychology, IUPUI, Indianapolis, IN
- 10:45 *Effects of varenicline and GZ-793A on methamphetamine and food self-administration under a multiple schedule of reinforcement in rats*  
D. J. Stairs<sup>1</sup>, M. Kangiser<sup>1</sup>, M. N. Pfaff<sup>1</sup>, S. Ewin<sup>1</sup>, L. P. Dwoskin<sup>2</sup>, <sup>1</sup>Psychology, Creighton University, Omaha, NE, <sup>2</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY
- 11:00 *The angiotensin receptor blocker candesartan attenuates the subjective effects of methamphetamine in humans*  
C. N. Haile<sup>3</sup>, C. D. Verrico<sup>1</sup>, D. G. Thompson-Lake<sup>3</sup>, J. J. Mahoney<sup>2</sup>, T. Kosten<sup>1</sup>, R. De La Garza<sup>1</sup>, T. F. Newton<sup>1</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Baylor College of Medicine, Pearland, TX, <sup>3</sup>Psychiatry, Baylor College of Medicine, Houston, TX
- 11:15 *Varenicline versus nicotine patch plus brief advice for sober smokers in substance treatment*  
D. Rohsenow<sup>1</sup>, J. W. Tidey<sup>1,2</sup>, R. A. Martin<sup>1</sup>, S. Colby<sup>1</sup>, P. M. Monti<sup>1</sup>, <sup>1</sup>Center for Alcohol & Addictions Studies, Brown University, Providence, RI, <sup>2</sup>Providence Veterans Affairs Medical Center, Providence, RI
- 11:30 *Effects of an anatabine and yerba maté lozenge on craving in smokeless tobacco users and heavy smokers*  
R. K. Lanier, A. Cohen, K. Gibson, M. Varga, C. Wright, Rock Creek Pharmaceuticals, Inc., Sarasota, FL, FL

**Please be advised that no photographing of presentations or data is permitted.  
Badges must be worn at all times and are required for admission into all events  
and sessions.**



## Poster Session I

(Lunch)

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Frank Lloyd Wright Ballroom  
12:00 - 2:00 PM

Set-up time begins Sunday 3:00 PM

Must be removed at 2:00 PM Monday

### FOOD

- 1 *The validity of DSM-5 criteria for substance-related and addictive disorders adapted for “Food Addiction”*  
L. R. Reis<sup>2</sup>, M. C. Rosa<sup>1</sup>, F. H. P. Kessler<sup>1</sup>, E. Ferreira e Ferreira<sup>2</sup>, F. P. Pechansky<sup>1</sup>,  
<sup>1</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil,  
<sup>2</sup>Department of Social and Preventive Dentistry, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, Belo Horizonte, Brazil
- 2 *Overlap between food addiction and DSM-5 eating disorders in a treatment seeking sample*  
M. C. Rosa<sup>2,1</sup>, J. Collombat<sup>2</sup>, C. M. Denis<sup>3,2</sup>, J. Alexandre<sup>2</sup>, F. Serre<sup>2</sup>, M. Auriacombe<sup>2</sup>,  
M. Fatseas<sup>2</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, <sup>3</sup>University of Pennsylvania, Philadelphia, PA
- 3 *Measuring “craving” in food addiction: Type, frequency, intensity*  
M. Fatseas<sup>1</sup>, J. Collombat<sup>1</sup>, M. C. Rosa<sup>1,2</sup>, C. M. Denis<sup>3,1</sup>, J. Alexandre<sup>1</sup>, R. Debrabant<sup>1</sup>,  
F. Serre<sup>1</sup>, M. Auriacombe<sup>1</sup>, <sup>1</sup>Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>3</sup>University of Pennsylvania, Philadelphia, PA
- 4 *Validity of the eating section for the modified Addiction Severity Index*  
M. Auriacombe<sup>3</sup>, C. M. Denis<sup>3,4</sup>, M. C. Rosa<sup>3,2</sup>, J. Collombat<sup>3</sup>, F. Serre<sup>3</sup>, J. Daulouede<sup>1,3</sup>,  
M. Fatseas<sup>3</sup>, <sup>1</sup>BIZIA, Bayonne, France, <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>3</sup>Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, <sup>4</sup>University of Pennsylvania, Philadelphia, PA
- 5 *Topiramate effect on weight gain during methadone maintenance*  
A. Umbricht<sup>1</sup>, J. R. Schroeder<sup>2</sup>, D. G. Antoine<sup>1</sup>, D. A. Tompkins<sup>1</sup>, C. Barnhouser<sup>1</sup>,  
E. C. Strain<sup>1</sup>, G. Bigelow<sup>1</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD,  
<sup>2</sup>Schroeder Statistical Consulting, Ellicott City, MD
- 6 *Associations between isomeric serum methadone levels, total sugar intake, and orexin-A*  
D. G. Antoine<sup>1</sup>, E. C. Strain<sup>1</sup>, A. Umbricht<sup>2</sup>, <sup>1</sup>Behavioral Pharmacology Research Unit, Johns Hopkins Bayview, Baltimore, MD, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD
- 7 *Examining different choice procedures to study cocaine vs. food reward*  
J. J. Chow<sup>1</sup>, J. S. Beckmann<sup>2</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY,  
<sup>2</sup>Psychology, University of Kentucky, Lexington, KY
- 8 *The role of serotonin 2A (5-HT<sub>2A</sub>) and 2C (5-HT<sub>2C</sub>) receptors in the association between binge eating and impulsive action*  
S. J. Stutz<sup>1</sup>, N. C. Anastasio<sup>1,2</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX

- 9 *Aversive effects of drugs: A comparison of conditioned taste and place avoidance*  
J. K. Gore-Langton, S. M. Flax, R. Pomfrey, B. B. Wetzell, A. L. Riley, Psychopharmacology Laboratory, American University, Washington, DC
- 10 *An assessment of MDPV-induced place preference in adult Sprague-Dawley rats*  
H. E. King<sup>1</sup>, B. B. Wetzell<sup>2</sup>, K. Rice<sup>3</sup>, A. L. Riley<sup>1</sup>, <sup>1</sup>Psychology, American University, Washington, DC, <sup>2</sup>Psychopharmacology Laboratory, American University, Washington, DC, <sup>3</sup>Chemical Biology Research Branch, NIDA, Bethesda, MD

### STIMULANTS - ANIMALS

- 11 *The effects of estrous cycling on cocaine self-administration in socially housed male-female dyads*  
R. Lacy, M. Feinstein, J. C. Strickland, M. A. Smith, Department of Psychology, Davidson College, Davidson, NC
- 12 *A computation opponent process model describes and predicts cocaine self-administration among naïve rats*  
G. Bobashev<sup>1</sup>, N. Seider<sup>2</sup>, S. Ahmed<sup>3</sup>, <sup>1</sup>RTI International, Durham, NC, <sup>2</sup>Psychology, UNC Chapel Hill, Chapel Hill, NC, <sup>3</sup>University of Bordeaux, Bordeaux, France
- 13 *Comparison of cocaine reinforcement in lean and obese Zucker rats: Dose-sensitivity and reinstatement of extinguished operant responding*  
D. Townsend<sup>1</sup>, K. Freeman<sup>2</sup>, <sup>1</sup>Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Dept. of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS
- 14 *CaMKII inhibition affects cocaine-cue memory processes to attenuate reinstatement*  
M. T. Rich<sup>1</sup>, M. M. Torregrossa<sup>2</sup>, <sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 15 *CamKII and  $\beta$ -actin are activated both in striatum and hippocampus in opioid-induced conditioned place preference*  
J. M. Andersen, F. Boix Escolan, Division of Forensic Sciences, Norwegian Institute of Public Health, Oslo, Norway
- 16 *Serotonin (5-HT) 5-HT<sub>2C</sub> receptor (5-HT<sub>2C</sub>R) agonist lorcaserin suppresses cocaine or oxycodone cue reactivity*  
R. G. Fox<sup>1</sup>, S. J. Stutz<sup>1</sup>, S. Comer<sup>2</sup>, M. Haney<sup>2</sup>, N. C. Anastasio<sup>1,3</sup>, F. G. Moeller<sup>4</sup>, K. A. Cunningham<sup>1,3</sup>, <sup>1</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Div on Substance Abuse Dept of Psychiatry, Columbia University Medical Center, New York, NY, <sup>3</sup>Dept Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, <sup>4</sup>Dept of Psychiatry, Virginia Commonwealth University School of Medicine, Richmond, VA
- 17 *Novel bivalent serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor ligands demonstrate distinct activities in vitro and in vivo*  
R. M. Hartley<sup>1</sup>, S. Gilbertson<sup>1,2</sup>, Y. Chen<sup>2</sup>, N. C. Anastasio<sup>1,3</sup>, R. G. Fox<sup>1</sup>, S. J. Stutz<sup>1</sup>, C. Watson<sup>1,4</sup>, K. A. Cunningham<sup>1,3</sup>, <sup>1</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Department of Chemistry, University of Houston, Houston, TX, <sup>3</sup>Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, <sup>4</sup>Biochemistry & Molecular Biology, University of Texas Medical Branch, Galveston, TX



- 18 *Disruption of serotonin 5-HT<sub>2C</sub> receptor (5-HT<sub>2C</sub>R) interaction with protein phosphatase and tensin homologue (PTEN) results in distinct patterns of cortical phosphorylated extracellular-signal regulated kinase<sub>1/2</sub> (pERK<sub>1/2</sub>)*  
C. Soto<sup>1</sup>, N. C. Anastasio<sup>1</sup>, S. E. Swinford-Jackson<sup>1</sup>, R. G. Fox<sup>1</sup>, H. C. Du<sup>2</sup>, S. Gilbertson<sup>2</sup>, K. A. Cunningham<sup>1</sup>, <sup>1</sup>Center Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Dept. Chem, University of Houston, Houston, TX
- 19 *Serotonin 5-HT<sub>2C</sub> receptors in the ventral subiculum regulate cocaine-evoked hyperactivity in rats*  
H. Neelakantan<sup>1</sup>, S. J. Stutz<sup>1</sup>, M. J. Bubar<sup>1</sup>, R. M. Sears<sup>3</sup>, R. J. DiLeone<sup>3</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Center Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Dept. Pharm, University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Dept. Psychiatry, Yale University, New Haven, CT
- 20 *Chemokines and CXCR4: Role in cocaine dependence and relapse*  
J. K. Kim<sup>1</sup>, S. H. Ramirez<sup>2</sup>, S. Rawls<sup>1</sup>, <sup>1</sup>Pharmacology, CSAR, and <sup>2</sup>Pathology, Temple University, Philadelphia, PA
- 21 *Effects of l-methamphetamine on the discriminative stimulus and reinforcing effects of cocaine*  
S. Kohut<sup>1</sup>, B. Blough<sup>2</sup>, J. Bergman<sup>1</sup>, <sup>1</sup>McLean Hospital/Harvard Medical School, Belmont, MA, <sup>2</sup>Research Triangle Institute, Research Triangle Park, NC
- 22 *Cocaine-cue extinction learning in rats: Impact of cocaine training dose and modulation by environmental enrichment*  
J. M. Gauthier<sup>1</sup>, R. D. Spealman<sup>2</sup>, K. M. Kantak<sup>1</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>Harvard Medical School, Boston, MA
- 23 *Attenuating effect of environmental enrichment and abstinence on cardiac and renal toxicity induced by ketamine and methamphetamine self-administration in rats*  
Y. Liu<sup>1</sup>, P. Li<sup>2</sup>, S. Li<sup>2</sup>, W. Zhou<sup>2,3</sup>, <sup>1</sup>Ningbo University, Ningbo, China, <sup>2</sup>School of Medicine, Ningbo University, Ningbo, China, <sup>3</sup>Ningbo Addiction Research and Treatment Center, Ningbo, China
- 24 *GSK3B silencing in the NAc produces addiction- and depression-like phenotypes opposite of environmental enrichment and alters neuronal excitability*  
E. J. Crofton, M. N. Nenov, Y. Zhang, X. Fan, D. Li, F. Laezza, T. A. Green, University of Texas Medical Branch, Galveston, TX
- 25 *Modeling anhedonia in serine racemase knockout mice: Implications for co-morbid substance abuse and schizophrenia*  
M. Puhl, R. Donahue, S. Landino, W. Carlezon, J. Coyle, Psychiatry, Harvard Medical School/McLean Hospital, Belmont, MA
- 26 *Simultaneous determination of the effects of methamphetamine on GABA, glutamate and monoamines by microdialysis in the prefrontal cortex and hippocampus of rats*  
H. L. Rowley, L. Pinder, R. Kulkarni, S. Cheetham, D. J. Heal, RenaSci Ltd, Nottingham, United Kingdom
- 27 *Pramipexole alters GSK-3 $\beta$  signaling and AMPA receptor trafficking in limbic brain structures*  
S. Grasso<sup>1,3</sup>, A. Persons<sup>1,3</sup>, S. E. Tedford<sup>1,3</sup>, A. Newman<sup>2</sup>, C. Napier<sup>1,4,3</sup>, <sup>1</sup>Pharmacology, Rush University, Chicago, IL, <sup>2</sup>NIDH, Baltimore, MD, <sup>3</sup>Center for Compulsive Behavior and Addiction, Rush University, Chicago, IL, <sup>4</sup>Psychiatry, Rush University, Chicago, IL
- 28 *Retinoic acid signaling in the nucleus accumbens: A novel mechanism controlling addiction-related behavior*  
Y. Zhang, E. Crofton, D. Li, X. Fan, T. Green, University of Texas Medical Branch, Galveston, TX

- 29 *Proteomics analyses: Peroxisome proliferator-activated receptor gamma agonist for chronic cocaine administration in rodents*  
N. S. Tannu<sup>1</sup>, J. Schmitz<sup>2</sup>, S. D. Lane<sup>1</sup>, C. Green<sup>4</sup>, K. A. Cunningham<sup>3</sup>, R. Suchting<sup>4</sup>, J. Herrera<sup>4</sup>, P. A. Narayana<sup>4</sup>, <sup>1</sup>Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, TX, <sup>2</sup>University of Texas Houston, Houston, TX, <sup>3</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>4</sup>The University of Texas Medical School at Houston, Houston, TX
- 30 *The effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor*  
Y. Zhang<sup>1</sup>, D. A. Perrey<sup>1</sup>, N. A. German<sup>1</sup>, A. M. Decker<sup>1</sup>, D. Thorn<sup>2</sup>, J. Li<sup>2</sup>, B. P. Gilmour<sup>1</sup>, B. F. Thomas<sup>1</sup>, D. L. Harris<sup>1</sup>, S. P. Runyon<sup>1</sup>, <sup>1</sup>Research Triangle Institute, Research Triangle Park, NC, <sup>2</sup>Pharmacology and Toxicology, University at Buffalo, Buffalo, NY
- 31 *Oral JPC-077 and JPC-141, vesicular monoamine transporter-2 inhibitors, reduce methamphetamine self-administration and methamphetamine-induced reinstatement in rats*  
A. Wilson<sup>1</sup>, J. Nickell<sup>1</sup>, J. P. Culver<sup>1</sup>, V. Janganati<sup>2</sup>, G. Zheng<sup>2</sup>, P. A. Crooks<sup>2</sup>, L. P. Dwoskin<sup>1</sup>, M. T. Bardo<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Arkansas for Medical Science, Little Rock, AR
- 32 *Identification of novel allosteric dopamine transporter ligands with nanomolar potency*  
R. B. Rothman<sup>1</sup>, J. S. Partilla<sup>1</sup>, S. K. Saini<sup>2</sup>, O. Moukha-Chafiq<sup>2</sup>, V. Pathak<sup>2</sup>, M. H. Baumann<sup>1</sup>, S. Ananthan<sup>2</sup>, <sup>1</sup>IRP, NIDA, NIH, Baltimore, MD, <sup>2</sup>Southern Research Institute, Birmingham, AL
- 33 *Drug scheduling of stimulants: Dopamine transporter effects, brain occupancy and abuse liability*  
B. K. Madras<sup>1,5</sup>, A. J. Fischman<sup>4</sup>, P. C. Meltzer<sup>2</sup>, A. A. Bonab<sup>3</sup>, <sup>1</sup>Psychiatry, Harvard Medical School, Southborough, MA, <sup>2</sup>Organix Inc, Woburn, MA, <sup>3</sup>Radiology, Massachusetts General Hospital, Boston, MA, <sup>4</sup>Nuclear Medicine, Shriners Hospital for Children, Boston, MA, <sup>5</sup>Alcohol and Drug Abuse, McLean Hospital, Belmont, MA
- 34 *The effect of chronic concurrent intake of alcohol and cocaine on neural stem cell survival and differentiation*  
E. McGrath<sup>1,3,4</sup>, P. Wu<sup>4</sup>, J. Gao<sup>4</sup>, T. Dunn<sup>4</sup>, J. Allende-labastida<sup>4</sup>, K. A. Cunningham<sup>3</sup>, K. Dineley<sup>2</sup>, B. Kaphalia<sup>5</sup>, L. Wang<sup>4</sup>, Y. Hao<sup>4</sup>, <sup>1</sup>Institute of Translational Sciences, UTMB, Galveston, TX, <sup>2</sup>Neurology, University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>4</sup>Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, <sup>5</sup>Pathology, University of Texas Medical Branch, Galveston, TX

### IMPULSIVITY

- 35 *Strength from recovery: Former drug-dependent individuals discount the future less than current users and controls*  
A. Quisenberry<sup>1</sup>, M. N. Koffarnus<sup>2</sup>, C. Franck<sup>4</sup>, W. K. Bickel<sup>3</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>3</sup>Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>4</sup>Statistics, Virginia Tech, Roanoke, VA
- 36 *Temporally rapid, pharmacological state-dependent heroin delay discounting modulated by drug-use impulsivity*  
J. J. Stoltman, E. A. Woodcock, J. J. Lister, L. H. Lundahl, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

- 37 *Mediational pathways among attentional impulsivity, heroin use consequences, mood, and stress level*  
H. H. Reid, L. H. Lundahl, J. J. Lister, M. K. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI
- 38 *Impulsiveness and sex trading for drugs, money, both, or neither*  
S. Clingan, D. G. Fisher, G. L. Reynolds, Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA
- 39 *Effects of working memory training regimen on learning acquisition and score asymptote in alcohol dependents*  
S. E. Snider<sup>1</sup>, C. Franck<sup>2</sup>, M. N. Koffarnus<sup>1</sup>, S. LaConte<sup>3</sup>, W. K. Bickel<sup>1</sup>, <sup>1</sup>Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Department of Statistics, Virginia Polytechnic Institute and State University, Blacksburg, VA, <sup>3</sup>Virginia Tech Carilion Research Institute, Roanoke, VA
- 40 *Age of cigarette smoking onset is associated with impulsive responding on a smoking Go/NoGo task*  
Y. Mashhoon, S. Farmer, J. Betts, S. Lukas, Behavioral Psychopharmacology Research Lab, McLean Hospital, Belmont, MA
- 41 *Behavioral laboratory measures of impulsivity and decision-making in cigarette smokers*  
D. Ramesh<sup>1,2</sup>, W. Ahn<sup>1</sup>, L. A. Keyser-Marcus<sup>1</sup>, F. Moeller<sup>1</sup>, <sup>1</sup>Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA
- 42 *Impulsivity and marijuana demand among frequent marijuana users*  
E. Aston<sup>1</sup>, J. Metrik<sup>1,2</sup>, C. W. Kahler<sup>1</sup>, J. MacKillop<sup>3,1</sup>, <sup>1</sup>Center for Alcohol and Addiction Studies, Brown University, Providence, RI, <sup>2</sup>Providence VA Medical Center, Providence, RI, <sup>3</sup>Peter Boris Centre for Addictions Research, McMaster University, Hamilton, ON, Canada
- 43 *Dopamine, time perception, and future time perspective*  
J. Mitchell, D. Weinstein, A. Kayser, Neurology, UCSF, San Francisco, CA
- 44 *Dynamic causal modeling in humans offers a novel approach to delineate prefrontal-striatal serotonergic drivers of impulsivity in rats*  
A. E. Price<sup>1</sup>, H. Neelakantan<sup>1</sup>, L. Ma<sup>2</sup>, J. L. Steinberg<sup>3</sup>, S. D. Lane<sup>4</sup>, J. M. Bjork<sup>3</sup>, P. A. Narayana<sup>5</sup>, T. Kosten<sup>6</sup>, A. Bechara<sup>7</sup>, N. C. Anastasio<sup>1,8</sup>, F. Moeller<sup>3,9</sup>, K. A. Cunningham<sup>1,8</sup>, <sup>1</sup>Center Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Dept Radiology and <sup>3</sup>Dept Psych, Virginia Commonwealth University, Richmond, VA, <sup>4</sup>Dept Psych & Behav Sci and <sup>5</sup>Dept Diag & Intervent Img, University of Texas Health Science Center, Houston, TX, <sup>6</sup>Dept Psych, Baylor College of Medicine, Houston, TX, <sup>7</sup>Dept Psych, University of Southern California, Los Angeles, CA, <sup>8</sup>Dept Pharm, University of Texas Medical Branch, Galveston, TX, <sup>9</sup>Dept Pharm, Virginia Commonwealth University, Richmond, VA
- 45 *Treating impulsivity for cocaine and food in female and male rats by repurposing therapeutics*  
J. R. Smethells, M. E. Carroll, University of Minnesota, St. Paul, MN

**OPIOIDS**

- 46 *Are DSM-5 pharmaceutical opioid use disorder continua consistent across chronic pain and injecting drug use samples?*  
R. Bruno<sup>1,2</sup>, A. Peacock<sup>1</sup>, G. Campbell<sup>2</sup>, B. Larance<sup>2</sup>, N. Lintzeris<sup>2</sup>, S. Nielsen<sup>2</sup>, W. Hall<sup>2</sup>, M. Cohen<sup>2</sup>, L. Degenhardt<sup>2</sup>, <sup>1</sup>University of Tasmania, Hobart, TAS, Australia, <sup>2</sup>National Drug and Alcohol Research Centre, Sydney, NSW, Australia

- 47 *A novel oral oxycodone maintenance procedure for human laboratory studies*  
M. A. Coe, P. A. Nuzzo, M. R. Lofwall, S. L. Walsh, University of Kentucky College of Medicine, Lexington, KY
- 48 *Inspection time as a general measure of cognitive impairment following acute opioid exposure*  
S. Kershaw<sup>1</sup>, M. Dry<sup>2</sup>, C. Della Vedova<sup>1</sup>, I. Majumder<sup>1,3</sup>, M. Ward<sup>1</sup>, P. Williamson<sup>4</sup>, J. White<sup>1</sup>,  
<sup>1</sup>Pharmacy & Medical Sciences, University of South Australia, Adelaide, SA, Australia, <sup>2</sup>Psychology, University of Adelaide, Adelaide, SA, Australia, <sup>3</sup>Rural & Remote Mental Health Services, Country Health South Australia, Adelaide, SA, Australia, <sup>4</sup>Drug & Alcohol Services South Australia, Adelaide, SA, Australia
- 49 *Evidence for anhedonia in early recovery from prescription opiate addiction: Affect-modulated startle response suggests blunted hedonic responses to natural reward cues*  
A. S. Huhn, J. Harris, R. E. Meyer, E. Bixler, S. Bunce, Psychiatry, Penn State Hershey Medical Center, Hershey, PA
- 50 *Chronic pain, craving and recent opioid use among patients treated for opioid use disorders*  
M. C. Lira<sup>2</sup>, D. M. Cheng<sup>3</sup>, M. R. Winter<sup>3</sup>, J. M. Liebschutz<sup>2</sup>, D. Alford<sup>2</sup>, R. R. Edwards<sup>1</sup>, J. Samet<sup>2</sup>, J. I. Tsui<sup>4</sup>, <sup>1</sup>Brigham and Women's Hospital, Chestnut Hill, MA, <sup>2</sup>BU School of Medicine, Boston, MA, <sup>3</sup>BU School of Public Health, Boston, MA, <sup>4</sup>UW School of Medicine, Seattle, WA
- 51 *Evaluation of remifentanyl and morphine as reinforcers in a rat intravenous self-administration procedure*  
D. J. Heal<sup>2</sup>, S. Smith<sup>2</sup>, J. Gosden<sup>2</sup>, E. Johnson<sup>2</sup>, M. Hallam<sup>2</sup>, R. Dean<sup>1</sup>, M. S. Todtenkopf<sup>1</sup>,  
<sup>1</sup>Life Sciences, Alkermes, Inc., Cambridge, MA, <sup>2</sup>RenaSci Ltd, Nottingham, United Kingdom
- 52 *Suppression of acute up-regulation of phosphorylated extracellular-regulated kinase by mu-opioid receptor agonist in ventral tegmental area related to resistance of rewarding effect under bone cancer model mice*  
A. Nakamura, SHIONOGI & CO., LTD., Toyonaka, Japan
- 53 *Influence of stereochemistry in the macrocyclic tetrapeptide CJ-15,208 on antinociceptive efficacy and opioid receptor selectivity*  
S. O. Eans<sup>1</sup>, M. Ganno<sup>1</sup>, E. Mizrachi<sup>1</sup>, S. Senadheera<sup>2</sup>, J. Aldrich<sup>2,3</sup>, J. P. McLaughlin<sup>1</sup>, <sup>1</sup>Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, <sup>2</sup>Medicinal Chemistry, University of Kansas, Lawrence, KS, <sup>3</sup>Medicinal Chemistry, University of Florida, Gainesville, FL
- 54 *Simultaneous PET/MRI of neurovascular coupling to the  $\mu$ -opioid receptor occupancy*  
H. Wey<sup>1</sup>, J. M. Hooker<sup>1</sup>, M. S. Placzek<sup>1,2</sup>, B. R. Rosen<sup>1</sup>, J. B. Mandeville<sup>1</sup>, <sup>1</sup>Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Brain Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA

### HIV I

- 55 *ASSIST in HIV/AIDS service settings: Comparison of self-screening and peer-support screening method*  
G. M. Le<sup>1</sup>, H. Nguyen<sup>1</sup>, H. Tran<sup>1</sup>, G. Bart<sup>2</sup>, T. R. Rieckmann<sup>3</sup>, H. Tran<sup>1</sup>, K. Darfler<sup>4</sup>, R. Rawson<sup>4</sup>, <sup>1</sup>Hanoi Medical University, Hanoi, Viet Nam, <sup>2</sup>Medicine, Hennepin County Medical Center, Minneapolis, MN, <sup>3</sup>Public Health, OHSU, Portland, OR, <sup>4</sup>UCLA ISAP, Los Angeles, CA



- 56 *Alcohol and drug use among patients of HIV services in Hanoi, Vietnam*  
G. Bart<sup>2</sup>, G. M. Le<sup>1</sup>, H. Nguyen<sup>1</sup>, H. Tran<sup>1</sup>, T. R. Rieckmann<sup>3</sup>, S. Nguyen<sup>1</sup>, K. Darfler<sup>4</sup>, R. Rawson<sup>4</sup>, <sup>1</sup>Hanoi Medical University, Hanoi, Viet Nam, <sup>2</sup>Medicine, Hennepin County Medical Center, Minneapolis, MN, <sup>3</sup>Public Health, OHSU, Portland, OR, <sup>4</sup>UCLA ISAP, Los Angeles, CA
- 57 *A 6-month follow-up of the integrated treatment for opiate addiction and HIV in Vietnam*  
C. M. Denis<sup>4</sup>, D. Metzger<sup>4</sup>, L. Huang<sup>6</sup>, V. Trias<sup>6</sup>, M. Auriacombe<sup>3</sup>, G. Raguin<sup>6</sup>, S. Mai Thi Hoai<sup>5</sup>, G. Le Truong<sup>5</sup>, J. Daulouede<sup>1</sup>, C. P. O'Brien<sup>2</sup>, <sup>1</sup>BIZIA, Bayonne, France, <sup>2</sup>U Penn, Phila, PA, <sup>3</sup>Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, <sup>4</sup>University of Pennsylvania, Philadelphia, PA, <sup>5</sup>HCMC AIDS Committee, Ho Chi Minh City, Viet Nam, <sup>6</sup>ESTHER, Paris, France
- 58 *Verbal memory is impaired among HIV+ female, but not HIV+ male cocaine users*  
E. Martin<sup>1</sup>, R. Gonzalez<sup>2</sup>, J. Vassileva<sup>3</sup>, P. Maki<sup>4</sup>, <sup>1</sup>Psychiatry, Rush University Medical Center, Chicago, IL, <sup>2</sup>Psychology, Florida International University, Miami, FL, <sup>3</sup>Psychiatry, Virginia Commonwealth University, Richmond, VA, <sup>4</sup>Psychiatry, University of Illinois, Chicago, IL
- 59 *Risky decision-making in HIV-infected and non-infected methamphetamine users*  
P. T. Korthuis<sup>2</sup>, D. Schwartz<sup>1</sup>, V. Wilson<sup>1</sup>, D. Ha<sup>1</sup>, B. Tremblay<sup>1</sup>, L. Dennis<sup>1</sup>, R. Lisowski<sup>1</sup>, S. Bielavitz<sup>1</sup>, W. Hoffman<sup>1</sup>, <sup>1</sup>OHSU, Portland, OR, <sup>2</sup>HIV Program, Oregon Health & Science University, Portland, OR
- 60 *Overexpression of GRP78 confers protection against neurocognitive impairment in HIV-infected polydrug users*  
N. Boukli, M. Rodriguez, S. Lopez, M. Rivera, K. Narvaez, L. Cubano, E. Rios, Microbiology and Immunology, Universidad Central Del Caribe, Bayamon, PR
- 61 *Do prescribed opioids impact CD4 count restoration among HIV+ patients initiating antiretroviral therapy?*  
E. J. Edelman<sup>1</sup>, J. Tate<sup>1</sup>, K. S. Gordon<sup>2</sup>, W. Becker<sup>2,1</sup>, K. Bryant<sup>5</sup>, K. Crothers<sup>6</sup>, J. R. Gaither<sup>1</sup>, C. Gibert<sup>7</sup>, A. J. Gordon<sup>3</sup>, B. D. Marshall<sup>4</sup>, M. Rodriguez-Barradas<sup>8</sup>, J. Samet<sup>9</sup>, M. Skanderson<sup>2</sup>, A. Justice<sup>1,2</sup>, D. A. Fiellin<sup>1</sup>, <sup>1</sup>Yale, New Haven, CT, <sup>2</sup>VA CT, West Haven, CT, <sup>3</sup>Univ. of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Brown, Providence, RI, <sup>5</sup>NIAAA, Bethesda, MD, <sup>6</sup>Univ. of Washington, Seattle, WA, <sup>7</sup>DC VAMC, Washington, DC, <sup>8</sup>MED VAMC and Baylor, Houston, TX, <sup>9</sup>Boston University, Boston, MA
- 62 *Marijuana use, heavy drinking, and cognitive dysfunction in people with HIV infection and substance dependence*  
S. A. Lorkiewicz<sup>1</sup>, A. S. Ventura<sup>2</sup>, T. Heeren<sup>2</sup>, M. R. Winter<sup>2</sup>, A. Walley<sup>1,3</sup>, M. Sullivan<sup>1,3</sup>, J. Samet<sup>1,2,3</sup>, R. Saitz<sup>1,2,3</sup>, <sup>1</sup>School of Medicine, Boston University, Boston, MA, <sup>2</sup>School of Public Health, Boston University, Boston, MA, <sup>3</sup>Boston Medical Center, Boston, MA
- 63 *Behavioral economic analysis of marijuana consumption, diversion, and medical certification demand in HIV+ patients*  
M. K. Greenwald, L. H. Lundahl, Psychiatry, Wayne State University, Detroit, MI
- 64 *Marijuana use and undetectable HIV viral load in persons living with HIV in Florida*  
R. Cook<sup>3</sup>, Z. Zhou<sup>3</sup>, C. Okafor<sup>3</sup>, C. Cook<sup>1</sup>, L. Burrell<sup>2</sup>, N. E. Whitehead<sup>2</sup>, J. Harman<sup>4</sup>, <sup>1</sup>College of Nursing, University of Florida, Gainesville, FL, <sup>2</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL, <sup>3</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>4</sup>Health Services Research Management and Policy, University of Florida, Gainesville, FL

- 65 *Prize contingency management for smoking cessation among people living with HIV/AIDS: Preliminary analysis*  
D. M. Ledgerwood<sup>1</sup>, L. H. Lundahl<sup>1</sup>, M. Greenwald<sup>1</sup>, C. L. Arfken<sup>1</sup>, M. E. Tancer<sup>1</sup>, J. A. Cohn<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, <sup>2</sup>Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
- 66 *Low threshold methadone protects against HIV incidence in a Canadian setting*  
K. Ahamad<sup>1,2</sup>, K. Hayashi<sup>2</sup>, P. Nguyen<sup>2</sup>, S. Dobrer<sup>2</sup>, T. Kerr<sup>2,1</sup>, J. Montaner<sup>2</sup>, E. Wood<sup>2,1</sup>, <sup>1</sup>University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 67 *The relationship between African-American women's health discussion networks & HIV risk behaviors*  
C. B. Oser<sup>1</sup>, K. Eddens<sup>1</sup>, E. Pullen<sup>1</sup>, B. Perry<sup>2</sup>, R. Crosby<sup>1</sup>, <sup>1</sup>Univ of Kentucky, Lexington, KY, <sup>2</sup>Indiana University, Bloomington, IN
- 68 *Psychosocial syndemic affecting women living with and at-risk for HIV*  
A. Batchelder<sup>1</sup>, A. W. Carrico<sup>1</sup>, A. Palma<sup>2</sup>, E. Schoenbaum<sup>3</sup>, J. Gonzalez<sup>3</sup>, <sup>1</sup>University of California - San Francisco, San Francisco, CA, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Yeshiva University, Bronx, NY
- 69 *Comprehensive women-centered treatment for substance use in Georgia: Initial examination of drug use and HIV risk*  
I. Kirtadze<sup>2</sup>, D. Otiashvili<sup>2</sup>, K. O'Grady<sup>5</sup>, W. Zule<sup>3</sup>, E. Krupitsky<sup>4</sup>, W. Wechsberg<sup>6</sup>, H. E. Jones<sup>1</sup>, <sup>1</sup>OB/GYN, UNC Chapel Hill, Chapel Hill, NC, <sup>2</sup>Addiction Research Center, Union Alternative Georgia, Tbilisi, Georgia, <sup>3</sup>RTI International, Research Triangle Park, NC, Durham, NC, <sup>4</sup>Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, St. Petersburg, Russian Federation, <sup>5</sup>Department of Psychology, University of Maryland, College Park, MD, Baltimore, MD, <sup>6</sup>RTI International, Durham, NC
- 70 *The evolution of illicit opioid use among HIV-infected opioid users in Russia (2004-2014)*  
E. Blokhina<sup>2</sup>, E. Krupitsky<sup>2,4</sup>, D. M. Cheng<sup>1</sup>, C. Bridden<sup>3</sup>, A. Walley<sup>1</sup>, O. Toussova<sup>2</sup>, T. Yaroslavtseva<sup>2</sup>, N. Gnatienco<sup>3</sup>, L. Forman<sup>1</sup>, J. Samet<sup>1,3</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>First Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>3</sup>Boston Medical Center, Boston, MA, <sup>4</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation
- 71 *Factors associated with participation in HIV case management intervention among Russian drug users*  
O. Toussova<sup>4</sup>, D. M. Cheng<sup>3</sup>, E. Blokhina<sup>4</sup>, C. Bridden<sup>1</sup>, N. Gnatienco<sup>1</sup>, E. Quinn<sup>3</sup>, A. Raj<sup>6</sup>, T. K. Kiriazova<sup>5</sup>, K. Lunze<sup>3</sup>, A. Y. Walley<sup>2</sup>, E. Krupitsky<sup>7</sup>, J. Samet<sup>3</sup>, <sup>1</sup>Boston Medical Center, Boston, MA, <sup>2</sup>General Internal Medicine, Boston Univ, Boston, MA, <sup>3</sup>Boston University, Boston, MA, <sup>4</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, <sup>5</sup>NGO "Future Without AIDS", Odessa, Ukraine, <sup>6</sup>UCSD, San Diego, CA, <sup>7</sup>Bechterev Research Psychoneurological Institute, St. Petersburg, Russian Federation
- 72 *Implementation of case management to link HIV-infected Russian addiction patients to HIV service*  
K. Lunze<sup>1</sup>, T. K. Kiriazova<sup>2</sup>, E. Blokhina<sup>3</sup>, N. Gnatienco<sup>4</sup>, L. A. Wulach<sup>4</sup>, C. Curnyn<sup>4</sup>, N. Bushara<sup>3</sup>, C. Bridden<sup>4</sup>, E. Krupitsky<sup>3</sup>, A. Raj<sup>5</sup>, A. Gifford<sup>1</sup>, J. Samet<sup>1</sup>, <sup>1</sup>Boston University, Boston, MA, <sup>2</sup>NGO "Future Without AIDS", Odessa, Ukraine, <sup>3</sup>First Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>4</sup>Boston Medical Center, Boston, MA, <sup>5</sup>UCSD, San Diego, CA

- 73 *Food insecurity and HIV drug and sex risk behaviors among Russians living with HIV*  
B. Idrisov<sup>1</sup>, K. Lunze<sup>3</sup>, D. M. Cheng<sup>3</sup>, E. Blokhina<sup>2</sup>, N. Gnatienco<sup>3</sup>, G. Patts<sup>3</sup>, A. Tyurina<sup>2</sup>,  
C. Bridden<sup>3</sup>, C. Chaisson<sup>3</sup>, M. Larson<sup>4</sup>, E. Krupitsky<sup>2</sup>, J. H. Samet<sup>3</sup>, <sup>1</sup>Bashkir State Medical  
University, Ufa, Russian Federation, <sup>2</sup>First Pavlov State Medical University, St. Petersburg,  
Russian Federation, <sup>3</sup>Boston University, Boston, MA, <sup>4</sup>Brandeis University, Waltham, MA
- 74 *HIV-related stigma and substance use in a Russian cohort of HIV+ risky drinkers*  
J. Samet<sup>1</sup>, K. Lunze<sup>1</sup>, D. M. Cheng<sup>1</sup>, D. Lioznov<sup>3</sup>, E. Quinn<sup>1</sup>, C. Bridden<sup>1</sup>, C. Chaisson<sup>1</sup>,  
A. Y. Walley<sup>1</sup>, E. Krupitsky<sup>3</sup>, A. Raj<sup>4</sup>, E. J. Edelman<sup>2</sup>, <sup>1</sup>Boston University, Boston, MA,  
<sup>2</sup>Yale, New Haven, CT, <sup>3</sup>First St. Petersburg Pavlov State Medical U, St. Petersburg, Russian  
Federation, <sup>4</sup>UCSD, San Diego, CA

**TECHNOLOGY**

- 75 *Can persons with a history of multiple addiction treatment episodes and chronic relapse benefit from technology-delivered behavior therapy?*  
S. J. Kim, L. A. Marsch, Psychiatry, Dartmouth College, Lebanon, NH
- 76 *Integrating text messaging in a safety-net office-based buprenorphine program: A feasibility study*  
B. Tofighi<sup>2</sup>, E. Grossman<sup>2</sup>, S. Bereket<sup>2</sup>, Y. Aphinyanaphongs<sup>2</sup>, J. D. Lee<sup>1</sup>, <sup>1</sup>Population Health,  
New York University, New York, NY, <sup>2</sup>Population Health, New York University School of  
Medicine, New York City, NY
- 77 *Utilization of an electronic information system to evaluate and enhance practice at a medication-assisted opioid treatment program*  
M. Lin, L. S. Brown, S. Kritz, R. Zavala, B. Louie, START Treatment & Recovery Centers,  
Brooklyn, NY
- 78 *Ambulatory field measurement of heart rate in opioid/cocaine users*  
K. L. Preston<sup>1</sup>, A. Kennedy<sup>1</sup>, M. L. Jobes<sup>1</sup>, K. A. Phillips<sup>1</sup>, D. Agage<sup>1</sup>, M. Tyburski<sup>1</sup>,  
S. Kumar<sup>2</sup>, D. Epstein<sup>1</sup>, <sup>1</sup>NIDA IRP, Baltimore, MD, <sup>2</sup>U Memphis, Memphis, TN
- 79 *ALERRT™ visual analog scale: Assessing “work” requirements associated with tampering of abuse-deterrent opioid formulations*  
E. J. Cone, A. R. Buchhalter, D. W. Wang, J. Henningfield, PinneyAssociates, Inc.,  
Bethesda, MD
- 80 *Remotely monitoring smoking and relapse in adolescents and emerging adults*  
E. A. McClure<sup>1</sup>, M. J. Carpenter<sup>1</sup>, F. A. Treiber<sup>2</sup>, K. M. Gray<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral  
Sciences, Medical University of South Carolina, Charleston, SC, <sup>2</sup>College of Nursing, Medical  
University of South Carolina, Charleston, SC
- 81 *Patient attitudes toward technology-assisted treatment during hospital-based dual-diagnosis treatment*  
A. S. Hammond<sup>1</sup>, E. C. Strain<sup>2</sup>, J. Hsu<sup>1</sup>, D. G. Antoine<sup>2</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences,  
Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Behavioral Pharmacology  
Research Unit, Johns Hopkins University School of Medicine, Bayview Campus,  
Baltimore, MD
- 82 *Facebook as a locating and tracking strategy among rural drug-using women*  
M. F. Dickson<sup>1</sup>, M. Staton-Tindall<sup>2</sup>, C. Leukefeld<sup>3</sup>, M. Webster<sup>3</sup>, C. B. Oser<sup>4</sup>, <sup>1</sup>Center on  
Drug and Alcohol Research, University of Kentucky, Lexington, KY, <sup>2</sup>College of Social  
Work, University of Kentucky, Lexington, KY, <sup>3</sup>Behavioral Science, University of Kentucky,  
Lexington, KY, <sup>4</sup>Sociology, University of Kentucky, Lexington, KY

- 83 *Using Facebook ad sampling to efficiently survey cannabis vaporizer use*  
B. S. Crosier<sup>1</sup>, D. C. Lee<sup>2</sup>, A. J. Budney<sup>2</sup>, <sup>1</sup>Center for Technology and Behavioral Health, Dartmouth College, West Windsor, VT, <sup>2</sup>Geisel School of Medicine, Dartmouth College, Lebanon, NH
- 84 *“Time for dabs”: Analyzing Twitter data on butane hash oil use*  
R. Daniulaityte<sup>2</sup>, R. Carlson<sup>2</sup>, F. Golroo<sup>3</sup>, S. Wijeratne<sup>3</sup>, E. W. Boyer<sup>4</sup>, S. S. Martins<sup>1</sup>, R. W. Nahhas<sup>2</sup>, A. P. Sheth<sup>3</sup>, <sup>1</sup>Epidemiology, Columbia University, New York City, NY, <sup>2</sup>Community Health, Wright State University, Dayton, OH, <sup>3</sup>Kno.e.sis, Department of Computer Science, Wright State University, Dayton, OH, <sup>4</sup>University of Massachusetts Medical School, Boston, MA
- 85 *A smartphone application for managing cannabis use*  
S. Rooke, L. Webb, L. Albertella, J. Copeland, National Cannabis Prevention and Information Centre, UNSW Medicine, Sydney, NSW, Australia
- 86 *Content analysis of cannabis smartphone applications*  
D. Ramo<sup>1</sup>, L. Popova<sup>2</sup>, S. Zhao<sup>1</sup>, K. Chavez<sup>4</sup>, R. Grana Mayne<sup>3</sup>, <sup>1</sup>Psychiatry, UC San Francisco, San Francisco, CA, <sup>2</sup>Center for Tobacco Control Research and Education, UC San Francisco, San Francisco, CA, <sup>3</sup>Tobacco Control Research Branch, National Cancer Institute, Rockville, MD, <sup>4</sup>Semel Institute for Neuroscience & Human Behavior, UCLA, Los Angeles, CA
- 87 *6- and 9-month recovery trajectories among youth who participated in an aftercare pilot study*  
R. Gonzales-Castaneda<sup>1,2</sup>, A. Ang<sup>1</sup>, S. B. Douglas<sup>2</sup>, M. Hernandez<sup>3</sup>, A. McKeown<sup>2</sup>, S. Davidson<sup>2</sup>, G. Kim<sup>2</sup>, K. Abts<sup>2</sup>, J. Welch<sup>2</sup>, C. Nuzum<sup>2</sup>, B. Bagwell<sup>2</sup>, A. Guillen<sup>2</sup>, <sup>1</sup>ISAP, UCLA, Los Angeles, CA, <sup>2</sup>Psychology, APU, Alta Loma, CA, <sup>3</sup>Psychology, APU, Azusa, CA
- 88 *Theory-based text-messaging to reduce meth and sex risks among MSM*  
C. J. Reback<sup>1,2</sup>, J. B. Fletcher<sup>1</sup>, <sup>1</sup>Friends Research Institute, Los Angeles, CA, <sup>2</sup>ISAP, UCLA, Los Angeles, CA
- 89 *Contrasting trajectories of intervention-related self-monitoring in HIV primary care patients*  
E. Delker<sup>1</sup>, D. Cannizzaro<sup>1</sup>, D. S. Hasin<sup>2,1</sup>, E. Aharonovich<sup>1,2</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Columbia University, New York, NY
- 90 *Feasibility of web-based treatment delivery for cocaine use disorder: Profile of Internet access by active cocaine users*  
F. P. Wagner<sup>1</sup>, J. C. Strickland<sup>2</sup>, W. W. Stoops<sup>1,2,3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 91 *BSAFER: A web intervention for women in the ED with drug use and IPV*  
E. Choo<sup>1</sup>, C. Zlotnick<sup>2</sup>, D. Strong<sup>3</sup>, M. Mello<sup>1</sup>, <sup>1</sup>Department of Emergency Medicine, Brown University, Providence, RI, <sup>2</sup>Psychiatry and Human Behavior, Brown University, Providence, RI, <sup>3</sup>Department of Family and Preventive Medicine, UCSD, San Diego, CA
- 92 *Scientific evaluation on substance abuse research through Web of Science over the 2008-2012 period*  
D. Melero-Fuentes<sup>1</sup>, R. Aguilar-Moya<sup>2</sup>, J. Valderrama-Zurián<sup>3</sup>, F. Bueno-Cañigral<sup>4</sup>, R. Aleixandre-Benavent<sup>5</sup>, J. Pérez-de-los-Cobos<sup>6</sup>, <sup>1</sup>INDOTEI, Universidad Católica de Valencia, Godella, Spain, <sup>2</sup>Departamento de Ciencias de la Educación, Universidad Católica de Valencia, Godella, Spain, <sup>3</sup>Universitat de València, Valencia, Spain, <sup>4</sup>Plan Municipal de Drogodependencias, Ayuntamiento de Valencia, Valencia, Spain, <sup>5</sup>INGENIO, Spanish Research Council-CSIC, Valencia, Spain, <sup>6</sup>Servicio de Psiquiatría, Hospital de la Santa Creu i Santa Pau, Barcelona, Spain



- 93 *Consumption of anabolic steroids in athletes: A bibliometric approach (2006-2012)*  
R. Aleixandre-Agulló<sup>1</sup>, F. Bueno-Cañigral<sup>2</sup>, J. Valderrama-Zurián<sup>3</sup>, D. Melero-Fuentes<sup>1</sup>,  
R. Aleixandre-Benavent<sup>4</sup>, J. Pérez-de-los-Cobos<sup>5</sup>, <sup>1</sup>INDOTEI, Universidad Católica de  
Valencia, Godella, Spain, <sup>2</sup>Plan Municipal de Drogodependencias, Ayuntamiento de Valencia,  
Valencia, Spain, <sup>3</sup>Universitat de València, Valencia, Spain, <sup>4</sup>INGENIO, Spanish Research  
Council-CSIC, Valencia, Spain, <sup>5</sup>Servicio de Psiquiatría, Hospital de la Santa Creu i Santa  
Pau, Barcelona, Spain

### CRIMINAL JUSTICE

- 94 *Substance use and offenses among juvenile offenders*  
C. G. Leukefeld<sup>1</sup>, M. Staton-Tindall<sup>3</sup>, M. F. Dickson<sup>3</sup>, M. Webster<sup>1</sup>, C. B. Oser<sup>2</sup>,  
H. K. Knudsen<sup>1</sup>, E. Pullen<sup>1</sup>, J. R. Havens<sup>4</sup>, <sup>1</sup>Behavioral Science, Univ of Kentucky,  
Lexington, KY, <sup>2</sup>Sociology, Univ of Kentucky, Lexington, KY, <sup>3</sup>Center on Drug and Alcohol  
Research, University of Kentucky, Lexington, KY
- 95 *Identifying and addressing unmet medical needs: A call to broaden the scope of drug courts*  
K. L. Dugosh, D. Festinger, Section on Law and Ethics, Treatment Research Institute,  
Philadelphia, PA
- 96 *Sex, drugs, and violence: An analysis of women in drug court*  
A. Acheampong<sup>2</sup>, C. W. Striley<sup>3</sup>, D. O. Fakunle<sup>1</sup>, L. Cottler<sup>3</sup>, <sup>1</sup>Mental Health, Johns Hopkins  
Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>University of Florida, Gainesville, FL,  
<sup>3</sup>Epidemiology, University of Florida, Gainesville, FL
- 97 *Predictors of HIV risk among ex-offenders entering Sober Living Recovery Residences for drug  
problems*  
D. L. Polcin<sup>1</sup>, T. Nemoto<sup>2</sup>, R. Korcha<sup>1</sup>, A. Mericle<sup>1</sup>, E. Mahoney<sup>1</sup>, <sup>1</sup>Alcohol Research Group,  
Emeryville, CA, <sup>2</sup>Public Health Institute, Oakland, CA
- 98 *Moved to Thursday, Poster Session IV, Poster 137*
- 99 *Meeting the HIV and hepatitis C needs of female drug court participants in the context of their  
trauma*  
D. Morse<sup>1</sup>, C. Cerulli<sup>1</sup>, P. Bedell<sup>1</sup>, J. L. Wilson<sup>1</sup>, H. Amaro<sup>2</sup>, <sup>1</sup>Psychiatry, University of  
Rochester School of Medicine, Rochester, NY, <sup>2</sup>Social Work and Preventive Medicine,  
University of Southern California, Los Angeles, CA
- 100 *Healthcare utilization and insurance status of substance using ex-offenders in primary care*  
J. E. Chambers<sup>1</sup>, A. C. Brooks<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, J. Lauby<sup>2</sup>, D. Metzger<sup>1,3</sup>, K. C. Kirby<sup>1</sup>,  
<sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Public Health Management Corporation,  
Philadelphia, PA, <sup>3</sup>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA

### PREVENTION

- 101 *Criminal arrests among drug-using assault-injured youth seeking ED care: A prospective  
cohort study*  
R. M. Cunningham<sup>1</sup>, P. M. Carter<sup>1</sup>, M. Zimmerman<sup>1</sup>, F. Blow<sup>1</sup>, M. A. Walton<sup>1</sup>, <sup>1</sup>Univ. of  
Michigan, Ann Arbor, MI
- 102 *Event-level analysis of antecedents to firearm violence among drug-using ED youth*  
P. M. Carter<sup>1</sup>, M. A. Walton<sup>1</sup>, Q. Epstein-Ngo<sup>1</sup>, E. A. Austic<sup>1</sup>, M. Zimmerman<sup>1</sup>, F. Blow<sup>1</sup>,  
S. Chermack<sup>1</sup>, A. Buu<sup>2</sup>, R. M. Cunningham<sup>1</sup>, <sup>1</sup>Univ. of Michigan, Ann Arbor, MI, <sup>2</sup>Indiana  
University, Bloomington, IN
- 103 *Lifetime victimization and sexual relationship power among substance-abusing African-  
American women*  
C. Ahuama-Jonas, K. Burlew, University of Cincinnati, Taylor Mill, KY

- 104 *The risks of gang association among drug-using women in Cape Town, South Africa*  
T. Carney<sup>2</sup>, B. Myers<sup>1,3</sup>, F. Browne<sup>4</sup>, P. Wechsberg<sup>4,5,6</sup>, D. Kline<sup>4</sup>, <sup>1</sup>Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa, <sup>2</sup>Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa, <sup>3</sup>Psychiatry and Mental Health, University of Cape Town, Rondebosch, South Africa, <sup>4</sup>Research Triangle Institute International, Raleigh/Durham, NC, <sup>5</sup>Psychology in the Public Interest, North Carolina State University, Raleigh, NC, <sup>6</sup>Psychiatry and Behavioral Sciences, Duke University, Durham, NC
- 105 *Testing differential implementation feasibility and initial efficacy in a culturally adapted parenting intervention for Latino/a immigrants*  
R. Parra-Cardona, D. Bybee, Michigan State University, East Lansing, MI
- 106 *Parents as interventionists to address adolescent drug abuse*  
K. Winters, <sup>1</sup>University of Minnesota Medical School, Minneapolis, MN, <sup>2</sup>Treatment Research Institute, Philadelphia, PA
- 107 *Prevalence and correlates of drug use in women patients of community health centers in Tijuana, Mexico and Los Angeles, USA*  
M. Arroyo<sup>1</sup>, G. Natera<sup>1</sup>, L. Gelberg<sup>2</sup>, R. Andersen<sup>3</sup>, M. Rico<sup>2</sup>, <sup>1</sup>National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico, <sup>2</sup>Family Medicine; Public Health, UCLA, Los Angeles, CA, <sup>3</sup>UCLA School of Public Health, Los Angeles, CA
- 108 *Comparing attitudes toward addressing patient drug use among health professionals in training*  
J. A. Johnson<sup>6</sup>, U. Kelly<sup>1</sup>, A. Tindol<sup>3</sup>, D. Macmillan<sup>2</sup>, F. Payne<sup>3</sup>, S. Chalmers<sup>4</sup>, S. Shellenberger<sup>3</sup>, K. Le<sup>5</sup>, P. Seale<sup>3</sup>, <sup>1</sup>Emory Univ., Atlanta, GA, <sup>2</sup>Georgia College & State Univ., Milledgeville, GA, <sup>3</sup>Mercer Univ., Macon, GA, <sup>4</sup>Univ. of North Georgia, Dahlonega, GA, <sup>5</sup>Wake Forest Univ., Winston-Salem, NC, <sup>6</sup>Georgia Regents Univ., Augusta, GA
- 109 *Adolescent input on a web-based prescription opioid abuse prevention tool*  
S. K. Moore<sup>1</sup>, L. A. Marsch<sup>2</sup>, M. Grabinski<sup>3</sup>, S. Semino<sup>4</sup>, <sup>1</sup>Capital Health Medical Center, Hopewell, NJ, <sup>2</sup>Center for Technology and Behavioral Health, Dartmouth College, Hanover, NH, <sup>3</sup>HealthSim, LLC, New York, NY, <sup>4</sup>NY Public Library, New York, NY
- 110 *Exploring the feasibility to quantify prescription drug misuse and abuse: Focus group findings*  
D. S. Varma<sup>1</sup>, L. Hoffer<sup>2</sup>, L. Cottler<sup>1</sup>, <sup>1</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>2</sup>Anthropology, Case Western Reserve University, Cleveland, OH
- 111 *Perceptions among healthcare professionals of prescription drug misuse*  
A. Porath-Waller, S. Geregthy, P. Robeson, Canadian Centre on Substance Abuse, Ottawa, ON, Canada
- 112 *Predictors of transition to opioid dependence among illicit pharmaceutical opioid users*  
R. Carlson<sup>2</sup>, R. Nahhas<sup>2</sup>, S. S. Martins<sup>1</sup>, R. Daniulaityte<sup>2</sup>, <sup>1</sup>Epidemiology, Columbia University, New York City, NY, <sup>2</sup>Community Health, Wright State University, Dayton, OH
- 113 *Patterns of opioid use and co-morbidity in non-treatment-seeking individuals with opioid use disorder*  
J. M. Manubay, S. Comer, S. Mogali, J. D. Jones, V. Metz, G. Madera, R. Luba, J. Vogelman, M. A. Sullivan, Columbia University NYSPI, New York, NY
- 114 *A randomized clinical trial of a behavioral intervention to reduce opioid overdose risk behavior*  
A. S. Bohnert<sup>1,3</sup>, F. Blow<sup>1,3</sup>, R. Cunningham<sup>1</sup>, L. Thomas<sup>1</sup>, M. K. Greenwald<sup>2</sup>, S. Chermack<sup>1,3</sup>, E. E. Bonar<sup>1</sup>, M. Walton<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Psychiatry, Wayne State University, Detroit, MI, <sup>3</sup>VA Center for Clinical Management Research, Ann Arbor, MI

- 115 *Non-fatal overdose among recent veterans: Lessons learned from a mixed methods analysis*  
A. S. Bennett<sup>1</sup>, L. Elliott<sup>1</sup>, A. Golub<sup>2</sup>, E. R. Pouget<sup>2</sup>, A. Rosenblum<sup>3</sup>, P. Britton<sup>4</sup>, <sup>1</sup>National Development and Research Institutes, New York City, NY, <sup>2</sup>NDRI, Burlington, VT, <sup>3</sup>Institute for Treatment and Services Research, National Development and Research Institutes, Inc., New York, NY, <sup>4</sup>Center of Excellence for Suicide Prevention Canandaigua VAMC University of Rochester Medical Center, Rochester, NY
- 116 *Overdose education and naloxone for patients prescribed opioids in primary care: A qualitative study*  
I. A. Binswanger<sup>1,3</sup>, S. Koester<sup>2</sup>, S. Mueller<sup>1</sup>, E. Gardner<sup>3</sup>, K. Goddard<sup>4</sup>, J. Glanz<sup>4,5</sup>, <sup>1</sup>Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, <sup>2</sup>University of Colorado Denver, Denver, CO, <sup>3</sup>Denver Health, Denver, CO, <sup>4</sup>Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, <sup>5</sup>Colorado School of Public Health, Aurora, CO
- 117 *Screening and brief intervention for low risk drug use in primary care: A pilot randomized trial*  
S. Meli<sup>1</sup>, T. Palfai<sup>2</sup>, D. M. Cheng<sup>3</sup>, D. Alford<sup>4</sup>, J. Bernstein<sup>1</sup>, J. Samet<sup>4</sup>, R. Saitz<sup>1</sup>, <sup>1</sup>Community Health Sciences, Boston University, Boston, MA, <sup>2</sup>Psychological and Brain Sciences, Boston University, Boston, MA, <sup>3</sup>Biostatistics, Boston University, Boston, MA, <sup>4</sup>Medicine, Boston University, Boston, MA
- 118 *Participation in the binational QUIT trial for reducing problem drug use among patients of community health centers in East Los Angeles and Tijuana: The role of cross-border migration*  
M. Vahidi<sup>1</sup>, G. Natera<sup>3</sup>, M. Rico<sup>1</sup>, M. Arroyo<sup>3</sup>, R. Andersen<sup>4</sup>, J. Yacenda<sup>1</sup>, L. Gelberg<sup>2</sup>, <sup>1</sup>Family Medicine, UCLA, Woodland Hills, CA, <sup>2</sup>Family Medicine; Public Health, UCLA, Los Angeles, CA, <sup>3</sup>National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico, <sup>4</sup>UCLA School of Public Health, Los Angeles, CA
- 119 *Cannabis, Lord Shiva and holy men: Cannabis use among sadhus in Nepal*  
J. Copeland<sup>2</sup>, S. Acharaya<sup>1</sup>, J. Howard<sup>2</sup>, <sup>1</sup>Ministry of Health and Population, Kathmandu, Nepal, <sup>2</sup>National Cannabis Prevention and Information Centre, University of NSW, Sydney, NSW, Australia
- 120 *Moderators of electronic screening and brief intervention for marijuana among students in a health center: eCHECKUP TO GO bolsters efforts of those who are already trying to change*  
T. Palfai<sup>1</sup>, R. Saitz<sup>2</sup>, M. R. Winter<sup>3</sup>, <sup>1</sup>Psychological and Brain Sciences, Boston University, Boston, MA, <sup>2</sup>Community Health Sciences, Boston University and Boston Medical Center, Boston, MA, <sup>3</sup>Data Coordinating Center, Boston University, Boston, MA
- 121 *Evaluating the documentation of risky substance use in federally qualified health centers*  
A. Reddy<sup>1</sup>, M. Vahidi<sup>2</sup>, N. Cox<sup>1</sup>, H. Alden<sup>1</sup>, R. Andersen<sup>4</sup>, L. Gelberg<sup>3</sup>, <sup>1</sup>Department of Family Medicine, UCLA, Los Angeles, CA, <sup>2</sup>Family Medicine, UCLA, Woodland Hills, CA, <sup>3</sup>Family Medicine; Public Health, UCLA, Los Angeles, CA, <sup>4</sup>UCLA School of Public Health, Los Angeles, CA
- 122 *Underreporting of risky drug use among prime care patients in federally qualified health centers*  
M. Vahidi<sup>1</sup>, C. Bone<sup>1</sup>, R. Andersen<sup>3</sup>, J. Yacenda<sup>1</sup>, L. Gelberg<sup>2</sup>, <sup>1</sup>Family Medicine, UCLA, Woodland Hills, CA, <sup>2</sup>Family Medicine; Public Health, UCLA, Los Angeles, CA, <sup>3</sup>UCLA School of Public Health, Los Angeles, CA
- 123 *Reporting errors on combined use of caffeine and alcohol questions in a qualitative questionnaire*  
K. M. Polak<sup>2</sup>, D. Svikis<sup>1</sup>, L. Hancock<sup>2</sup>, D. Pomm<sup>2</sup>, <sup>1</sup>Virginia Commonwealth Univ., Richmond, VA, <sup>2</sup>Psychology, Virginia Commonwealth University, Henrico, VA

- 124 *Effects of cultural congruity on alcohol use severity among Hispanic emerging adults in college*  
M. Cano<sup>1</sup>, E. Vaughan<sup>3</sup>, M. de Dios<sup>4</sup>, Y. Castro<sup>2</sup>, A. Roncancio<sup>5</sup>, L. Ojeda<sup>6</sup>, <sup>1</sup>Epidemiology, Florida International University, Miami, FL, <sup>2</sup>School of Social Work, University of Texas at Austin, Austin, TX, <sup>3</sup>Indiana University, Bloomington, IN, <sup>4</sup>MD Anderson Cancer Center, Houston, TX, <sup>5</sup>UT Health Science Center, Houston, TX, <sup>6</sup>Texas A&M University, College Station, TX
- 125 *Correlates of specific personality and alcohol use with nonmedical use of prescription stimulants in college students*  
S. Bierma<sup>1</sup>, S. J. Lookatch<sup>2</sup>, K. Ritter<sup>1</sup>, G. Kurdziel<sup>2</sup>, T. Moore<sup>1</sup>, E. C. Katz<sup>3</sup>, <sup>1</sup>University of Tennessee, Knoxville, TN, <sup>2</sup>Department of Psychology, University of Tennessee, Knoxville, TN, <sup>3</sup>Towson University, Towson, MD

### POLICY

- 126 *Impacts of drinking-age legislation on arrests for alcohol-impaired driving among young people in Canada, 2009-2012*  
R. C. Callaghan<sup>1</sup>, J. Gatley<sup>1</sup>, M. Sanches<sup>2</sup>, <sup>1</sup>Northern Medical Program, University of Northern British Columbia, Prince George, BC, Canada, <sup>2</sup>Biostatistical Consulting Unit, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 127 *How are private health plans providing drug and alcohol services in an age of parity and health reform?*  
C. M. Horgan, M. Stewart, S. Reif, D. W. Garnick, D. Hodgkin, E. L. Merrick, A. Quinn, Brandeis University, Waltham, MA
- 128 *Hospital discharges for marijuana dependence over time in Colorado*  
J. M. Davis, K. Suleta, K. F. Corsi, R. Booth, University of Colorado Denver, Denver, CO
- 129 *“Smoking pot helps me focus”: A qualitative analysis of Internet forum discussions of ADHD and cannabis use*  
J. T. Mitchell, M. Sweitzer, A. Tunno, C. Hagmann, S. H. Kollins, J. McClernon, Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
- 130 *Medical marijuana laws and annual opioid analgesic sales in the United States*  
J. H. Kim<sup>2</sup>, J. Santaella<sup>1</sup>, M. Cerda<sup>1</sup>, S. S. Martins<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York City, NY, <sup>2</sup>Epidemiology, Mailman School of Public Health, New York, NY
- 131 *The spatial-temporal relationship of policing in areas with high drug activity*  
T. Gaines<sup>1</sup>, D. Werb<sup>1</sup>, J. Arredondo<sup>1</sup>, V. M. Alaniz<sup>3</sup>, L. Beletsky<sup>2</sup>, <sup>1</sup>Medicine, University of California San Diego, La Jolla, CA, <sup>2</sup>School of Law, Northeastern University, Boston, MA, <sup>3</sup>Tijuana Police Department, Tijuana, Mexico
- 132 *Scaling up SBIRT: Statewide implementation in the Oregon Health Plan*  
D. McCarty<sup>1</sup>, T. R. Rieckmann<sup>1</sup>, S. Renfro<sup>2</sup>, J. McConnell<sup>2</sup>, <sup>1</sup>Public Health, OHSU, Portland, OR, <sup>2</sup>Center for Health Systems Effectiveness, Oregon Health & Science University, Portland, OR
- 133 *A pre-post comparison in healthcare service utilization among heroin-using women in the methadone maintenance treatment in Taiwan*  
Y. Lien<sup>2</sup>, H. H. Yeh<sup>1</sup>, S. Fang<sup>2</sup>, C. Chen<sup>2</sup>, <sup>1</sup>Epidemiology, Michigan State University, East Lansing, MI, <sup>2</sup>Institute of Public Health, National Yang-Ming University, Taipei, Taiwan
- 134 *Impact of prescription monitoring on care of opioid-dependent patients*  
H. Hansen<sup>1,2</sup>, S. Mendoza<sup>4</sup>, E. V. Nunes<sup>3</sup>, J. Rotrosen<sup>4</sup>, <sup>1</sup>Psychiatry and Anthropology, New York University, New York, NY, <sup>2</sup>Statistics and Services Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, <sup>3</sup>Psychiatry, Columbia University, New York, NY, <sup>4</sup>Psychiatry, NYU, New York, NY



- 135 *Naloxone distribution to drug users in California and opioid-related overdose death rates*  
P. J. Davidson<sup>1</sup>, E. Wheeler<sup>2</sup>, J. Proudfoot<sup>3</sup>, R. Xu<sup>3</sup>, K. D. Wagner<sup>1</sup>, <sup>1</sup>Medicine, University of California San Diego, La Jolla, CA, <sup>2</sup>Harm Reduction Coalition, Oakland, CA, <sup>3</sup>Clinical & Translational Research Institute, University of California, San Diego, La Jolla, CA
- 136 *Factors associated with illicit methadone injecting in a Canadian setting*  
D. Tucker<sup>1</sup>, M. Milloy<sup>1,2</sup>, K. Hayashi<sup>1,2</sup>, R. Lung<sup>1</sup>, P. Nguyen<sup>1</sup>, T. Kerr<sup>1,2</sup>, E. Wood<sup>1,2</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, BC, Canada, <sup>2</sup>Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- 137 *Limitations to participation in opioid maintenance treatment in Europe*  
L. Brandt<sup>1</sup>, A. Unger<sup>2</sup>, L. Moser<sup>1</sup>, G. Fischer<sup>2,1</sup>, R. Jagsch<sup>3</sup>, <sup>1</sup>Center for Public Health and <sup>2</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Faculty for Psychology, University of Vienna, Vienna, Austria
- 138 *Access to buprenorphine treatment: Is the patient limit a barrier?*  
H. K. Knudsen<sup>1</sup>, M. R. Lofwall<sup>2</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Behavioral Science & Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY
- 139 *U.S. federal cocaine essential ("precursor") chemical regulation impacts on U.S. cocaine availability: An intervention time series analysis with temporal replication*  
J. K. Cunningham<sup>1</sup>, R. C. Callaghan<sup>2</sup>, L. Liu<sup>3</sup>, <sup>1</sup>Family and Community Medicine, University of Arizona, Tucson, AZ, <sup>2</sup>Northern Medical Program, University of Northern British Columbia, Prince George, BC, Canada, <sup>3</sup>Economics, National Taiwan University, Taipei, Taiwan
- 140 *Crack users with conduct disorder have more association with violence, trauma and psychiatric comorbidities*  
M. P. Pachado<sup>1</sup>, D. S. Souza<sup>4</sup>, J. N. Scherer<sup>5</sup>, F. P. Pechansky<sup>3</sup>, F. Kessler<sup>3</sup>, S. Faller<sup>2</sup>, <sup>1</sup>Psychiatric Dept, Center for Drug and Alcohol Research, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research (CPAD) - Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil, <sup>3</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>4</sup>Psychiatric Dept, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>5</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- 141 *Brazilian crack/cocaine inpatients show more legal and family social problems than outpatients*  
D. S. Souza, J. N. Scherer, M. P. Pachado, S. Halpern, L. von Diemen, F. P. Pechansky, F. Kessler, Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil
- 142 *The impacts of graphic warning labels in an addiction treatment population*  
B. Tajima, D. Garina, T. Le, A. Batchelder, J. Guydish, University of California San Francisco, San Francisco, CA
- 143 *Reactions to the FDA proposed graphic warning labels among smokers in addiction treatment centers*  
T. Le, B. Tajima, E. Passalacqua, J. Guydish, Philip R. Lee Institute for Health Policy Studies, UCSF, San Francisco, CA
- 144 *State-level tobacco-related norms and policies show differential effects on cigarette smoking in population subgroups*  
D. Shmulewitz, M. Stohl, K. M. Keyes, Q. Brown, D. Hasin, Columbia University, New York, NY

- 145 *Assessing the cost-effectiveness of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness*  
S. M. Murphy<sup>1,2</sup>, M. G. McDonell<sup>3</sup>, S. McPherson<sup>2</sup>, D. Srebnik<sup>4</sup>, J. M. Roll<sup>2</sup>, R. Ries<sup>3</sup>, <sup>1</sup>Health Policy & Administration, Washington State University, Spokane, WA, <sup>2</sup>Program of Excellence in Addictions Research (PEAR), Washington State University, Spokane, WA, <sup>3</sup>Medical School, University of Washington, Seattle, WA, <sup>4</sup>King County Mental Health, Seattle, WA

### Symposium V

McArthur Ballroom 1/2  
2:00 - 4:00 PM

#### CANNABIDIOL AND DRUGS OF ABUSE: PRECLINICAL AND CLINICAL STUDIES OF CANNABIDIOL AND COCAINE, ETHANOL, OPIOIDS AND CANNABINOIDS

Chairs: Margaret Haney and Yasmin L. Hurd

- 2:00 *Cannabidiol: Long-lasting amelioration of vulnerability states associated with relapse risk as determined in animal models of drug seeking, anxiety, and impulsivity*  
Friedbert Weiss, The Scripps Research Institute, La Jolla, CA
- 2:25 *Study to test the safety and efficacy of cannabidiol as a treatment intervention for opioid relapse*  
Didier Jutras-Aswad, University of Montreal, Montreal, QC, Canada
- 2:50 *The interactions of cannabidiol and delta-9-tetrahydrocannabinol in healthy humans*  
Mohini Ranganathan, Yale School of Medicine, New Haven, CT
- 3:15 *Influence of oral cannabidiol on the subjective, reinforcing and cardiovascular effects of smoked marijuana*  
Margaret Haney, Columbia University Medical Center, New York, NY
- 3:40 *DISCUSSANT: Preclinical and clinical experience testing cannabidiol for opioid dependence*  
Yasmin Hurd, Mount Sinai Hospital, New York, NY

### Oral Communications 5

Grand Ballroom  
2:00 - 4:00 PM

#### MAINTAINING ABSTINENCE: TREATMENTS FOR OPIOID DEPENDENCE

Chairs: Mark A. Smith and Andrew Rosenblum

- 2:00 *The effects of strength training on heroin self-administration*  
M. A. Smith, G. Fronk, S. Bills, R. Lacy, Davidson College, Davidson, NC
- 2:15 *Casein kinase-1 inhibitors as a novel treatment for substance use disorders*  
D. B. Horton<sup>1</sup>, E. Dunn-Sims<sup>1</sup>, T. T. Wager<sup>3</sup>, C. Chang<sup>2</sup>, A. Doran<sup>2</sup>, A. Rosado<sup>1</sup>, A. N. Mead<sup>1</sup>, <sup>1</sup>Global Safety Pharmacology, DSRD, Pfizer, Inc, Groton, CT, <sup>2</sup>PDM - NCE, Pfizer, Inc., Groton, CT, <sup>3</sup>Neuroscience Research Unit, Pfizer, Inc., Cambridge, MA
- 2:30 *Hapten selection for heroin vaccines*  
G. R. Matyas<sup>2</sup>, F. Li<sup>1,3</sup>, J. Antoline<sup>1,3</sup>, R. Jalah<sup>4</sup>, O. Torres<sup>4</sup>, Z. Beck<sup>4</sup>, A. Jacobson<sup>1,3</sup>, C. Alving<sup>2</sup>, K. Rice<sup>1,3</sup>, <sup>1</sup>Drug Design and Synthesis Section, National Institute on Drug Abuse, NIH, Bethesda, MD, <sup>2</sup>US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, <sup>3</sup>National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, <sup>4</sup>US Military HIV Research Program, Herny M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD

- 2:45 *Effects of ibudilast on the reinforcing, subjective and analgesic effects of oxycodone – preliminary results*  
V. Metz, J. D. Jones, M. A. Sullivan, S. Mogali, J. M. Manubay, B. Vaughan, S. D. Comer, Psychiatry, Columbia University and NYSPI, New York, NY
- 3:00 *Reducing the cost of free time: Treatment success in a randomized trial of clonidine as adjunct to buprenorphine maintenance is associated with more leisure activities in the clonidine condition*  
W. J. Kowalczyk, M. A. Furnari, K. A. Phillips, M. L. Jobes, U. Ghitzza, D. Epstein, K. L. Preston, NIDA, NIH, Bethesda, MD
- 3:15 *Extended-release naltrexone for opioid relapse prevention among opioid-dependent, criminal justice-involved adults*  
J. D. Lee<sup>1</sup>, P. D. Friedmann<sup>2</sup>, T. W. Kinlock<sup>3</sup>, E. V. Nunes<sup>4</sup>, M. S. Gordon<sup>3</sup>, C. P. O'Brien<sup>5</sup>, <sup>1</sup>Population Health, New York University, New York, NY, <sup>2</sup>Medicine, Rhode Island Hospital, Providence, RI, <sup>3</sup>Friends Research Institute, Baltimore, MD, <sup>4</sup>Columbia University, New York, NY, <sup>5</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 3:30 *Reduction in prescription opioid misuse among enrollees into opioid treatment programs*  
A. Rosenblum, C. Fong, H. Matusow, ITSR, National Development and Research Institutes, New York, NY
- 3:45 *Implementing routine emergency department naloxone rescue kits for patients at risk of opioid overdose*  
M. Drainoni<sup>3,2</sup>, J. Ellison<sup>3</sup>, E. Koppelman<sup>3</sup>, P. Mitchell<sup>2,1</sup>, J. Feldman<sup>2,1</sup>, E. Bernstein<sup>2,1</sup>, A. Walley<sup>2,1</sup>, <sup>1</sup>Boston Medical Center, Boston, MA, <sup>2</sup>Medicine, Boston Univ, Boston, MA, <sup>3</sup>Public Health, Boston Univ, Boston, MA

## Oral Communications 6

McArthur Ballroom 4  
2:00 - 4:00 PM

### ADLERESCENTS: ADOLESCENT DRUG ABUSE

Chairs: Richard Miech and Chloe J. Jordan

- 2:00 *Trends in use of and attitudes toward marijuana among youth before and after decriminalization: The case of California 2007-2013*  
R. Miech, L. A. Johnston, P. O'Malley, J. Bachman, J. Schulenberg, M. Patrick, University of Michigan, Ann Arbor, MI
- 2:15 *Adolescent d-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects during adolescence and cocaine abuse risk during adulthood*  
C. J. Jordan<sup>1</sup>, D. M. Taylor<sup>1</sup>, S. Jeon<sup>1</sup>, B. M. Baskin<sup>1</sup>, L. P. Dwoskin<sup>2</sup>, K. M. Kantak<sup>1</sup>, <sup>1</sup>Psychological & Brain Sciences, Boston University, Boston, MA, <sup>2</sup>Pharmaceutical Sciences, University of Kentucky, Lexington, KY
- 2:30 *Amphetamine exposure during adolescence alters anxiety- and depression-like behaviors and prefrontal cortex dopamine receptor expression in adulthood*  
S. Kang<sup>2</sup>, M. Wu<sup>1</sup>, R. Galvez<sup>1,2</sup>, J. M. Gulley<sup>1,2</sup>, <sup>1</sup>Psychology Department, University of Illinois, Urbana-Champaign, Champaign, IL, <sup>2</sup>Neuroscience program, University of Illinois, Urbana-Champaign, Champaign, IL

- 2:45 *Adaptive reward learning is intact in young adults with remitted substance use and depressive disorders*  
S. A. Langenecker<sup>2</sup>, N. A. Crane<sup>3</sup>, S. DelDonno<sup>2</sup>, L. Gabriel<sup>2</sup>, J. Gowins<sup>2</sup>, C. Nagel<sup>2</sup>, B. Mickey<sup>4</sup>, J. Zubieta<sup>4</sup>, R. Mermelstein<sup>3</sup>, E. Martin<sup>1</sup>, <sup>1</sup>Psychiatry, Rush University Medical Center, Chicago, IL, <sup>2</sup>Psychiatry and Psychology, The University of Illinois at Chicago, Chicago, IL, <sup>3</sup>Psychology, University of Illinois at Chicago, Chicago, IL, <sup>4</sup>Psychiatry, The University of Michigan, Ann Arbor, MI
- 3:00 *Adolescent C57Bl/6J mice self-administer more oxycodone than adult mice in an extended-access paradigm (4hrs)*  
S. P. Rahm, A. Ho, M. Kreek, Y. Zhang, The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University, New York, NY
- 3:15 *Effects of environmental enrichment on microRNA-221 expression and ERK phosphorylation in the rat prefrontal cortex following nicotine-induced sensitization or nicotine self-administration*  
J. Zhu<sup>1,2</sup>, A. M. Gomez<sup>1</sup>, W. Sun<sup>1</sup>, D. Altomare<sup>1</sup>, K. E. Creek<sup>1</sup>, S. B. Harrod<sup>2</sup>, <sup>1</sup>Dept. of Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC, <sup>2</sup>Psychology, University of South Carolina, Columbia, SC
- 3:30 *Effects of withdrawal from chronic nicotine on emotional and cognitive behaviors in adult and adolescent mice*  
P. A. Nucero<sup>2</sup>, E. Holliday<sup>1</sup>, M. G. Kutlu<sup>1</sup>, T. Gould<sup>1</sup>, E. Unterwald<sup>2</sup>, <sup>1</sup>Psychology, Temple University, Philadelphia, PA, <sup>2</sup>Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA
- 3:45 *Effects of parental alcohol vs. tobacco and marijuana use on early adolescent onset of alcohol use*  
D. Capaldi<sup>2</sup>, S. S. Tiberio<sup>2</sup>, D. C. Kerr<sup>1,2</sup>, K. C. Pears<sup>2</sup>, <sup>1</sup>School of Psychological Science, Oregon State University, Corvallis, OR, <sup>2</sup>Oregon Social Learning Center, Eugene, OR

## Oral Communications 7

McArthur Ballroom 5/6  
2:00 - 4:00 PM

### MARTY'S AMINES: MONOAMINES

Chairs: Ronald Cowan and Sarah E. Swinford-Jackson

- 2:00 *Combined enhancement of acetylcholine and monoamines causes persistent reductions in cocaine reward*  
K. Grasing, F. Yang, H. Xu, Kansas City VA Medical Center, Kansas City, MO
- 2:15 *Drug-seeking following extinction of MDMA self-administration: Role of dopamine and serotonin*  
S. Schenk, Psychology, Victoria University Wellington, Wellington, New Zealand
- 2:30 *Subjective responses to acute cocaine are moderated by variants of the serotonergic system*  
D. A. Nielsen<sup>1</sup>, S. C. Hamon<sup>2</sup>, M. H. Harding<sup>1</sup>, E. M. Nielsen<sup>1</sup>, T. Kosten<sup>1</sup>, T. F. Newton<sup>1</sup>, R. De La Garza<sup>1</sup>, <sup>1</sup>Psychiatry, Baylor College of Medicine, Houston, TX, <sup>2</sup>Statistical and Genetic Consulting LLC, Darien, CT, Darien, CT
- 2:45 *Neuropharmacology of replacement analogs of the designer drug 3,4-methylenedioxymethcathinone*  
M. H. Baumann, O. Dillon-Carter, M. O. Bukhari, R. B. Rothman, J. S. Partilla, IRP, NIDA, NIH, Baltimore, MD
- 3:00 *Effects of the 5-HT1B receptor agonist CP 94253 on methamphetamine self-administration*  
R. Garcia, N. Pentkowski, J. Venault, K. Leslie, J. Bonadonna, A. Cotter, M. F. Olive, J. L. Neisewander, School of Life Sciences, Arizona State University, Tempe, AZ



- 3:15 *Ceftriaxone attenuates acute cocaine evoked motor activity and dopaminergic neurotransmission in the dorsal and ventral striatum*  
J. L. Barr<sup>1</sup>, B. A. Rassmussen<sup>1</sup>, C. S. Tallarida<sup>1</sup>, J. L. Scholl<sup>2</sup>, G. L. Forster<sup>2</sup>, E. Unterwald<sup>1</sup>, S. Rawls<sup>1</sup>, <sup>1</sup>Pharmacology and Center for Substance Abuse Research, Temple University, Philadelphia, PA, <sup>2</sup>Center for Brain and Behavior Research, The University of South Dakota, Vermillion, SD
- 3:30 *Differential modulation of cocaine-related behaviors consequent to knockdown of serotonin 5-HT<sub>2C</sub> receptor in the nucleus accumbens shell vs. ventral tegmental area*  
S. E. Swinford-Jackson<sup>1</sup>, N. C. Anastasio<sup>1,2</sup>, S. J. Stutz<sup>1</sup>, R. G. Fox<sup>1</sup>, K. A. Cunningham<sup>1,2</sup>, <sup>1</sup>Center Addiction Res, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Dept. Pharmacology, University of Texas Medical Branch, Galveston, TX
- 3:45 *Increased cortical excitability in human MDMA users*  
R. Cowan<sup>1</sup>, M. Dietrich<sup>1</sup>, J. Kim<sup>2</sup>, D. Zald<sup>2</sup>, <sup>1</sup>Psychiatric Neuroimaging Program, Vanderbilt University, Nashville, TN, <sup>2</sup>Psychology, Vanderbilt University, Nashville, TN

### **Marian W. Fischman Memorial Award Lecture**

**McArthur Ballroom 4  
4:30 - 5:30 PM**

*Presentation of the Marian W. Fischman Award to Kathleen Brady*

Introduction by Sudie Back

*Stress and addictions*  
Kathleen T. Brady

### **Pre- and Post Doctoral Trainees Networking Event**

**Gold  
5:30 - 7:00 PM**

### **Workshop V**

**McArthur Ballroom 1/2  
7:00 - 9:00 PM**

#### **THE CASE FOR RESCHEDULING PSILOCYBIN AS A TREATMENT MEDICATION: REGULATORY RATIONALE, ABUSE LIABILITY, SAFETY, AND TREATMENT EFFICACY**

Chairs: Roland R. Griffiths and Matthew W. Johnson

*Psilocybin: Efficacy in treatment of psychological distress in cancer patients and eight-factor analysis of abuse liability under the Controlled Substances Act*

Roland R. Griffiths, Johns Hopkins University School of Medicine, Baltimore, MD

*National household survey data on suicide-associated correlates of psilocybin use*

Peter S. Hendricks, University of Alabama at Birmingham, Birmingham, AL

*Psilocybin treatment of tobacco and other addictions*

Matthew W. Johnson, Johns Hopkins University, Baltimore, MD

*Can there be a role for psilocybin as a medical intervention?*

H. Westley Clark, Center for Substance Abuse Treatment, Santa Clara, CA

## Workshop VI

McArthur Ballroom 4  
7:00 - 9:00 PM

### USE OF SBIRT TO ADDRESS ADOLESCENT DRUG ABUSE

Chairs: Ken Winters and Michael L. Dennis

*Efficacy study of a SBIRT program in a school setting*

Ken Winters, University of Minnesota, Minneapolis, MN

*Adolescent SBIRT implementation in pediatric primary care: Patient outcomes in a randomized trial in an integrated health care delivery system*

Stacy Sterling, Kaiser Permanente Division of Research, Oakland, CA

*A small, randomized comparison of two SBIRT models for increasing treatment engagement among treatment-referred adolescents*

Douglas C. Smith, University of Illinois at Urbana-Champaign, Chicago, IL

*Brief alcohol interventions for adolescents and young adults: A systematic review and meta-analysis*

Emily Tanner-Smith, Vanderbilt University, Nashville, TN

*Implications of SBIRT in health service delivery*

Michael L. Dennis, Chestnut Health Systems, Normal, IL

## Workshop VII

McArthur Ballroom 5/6  
7:00 - 9:00 PM

### SUBSTANCE ABUSE TREATMENT CLINICAL TRIALS: DOES GENDER MATTER?

Chairs: Shelly F. Greenfield and Carmen Rosa

*Stimulant reduction intervention using dosed exercise: Gender differences and treatment acceptability*

Therese Killeen, Medical University of South Carolina, Charleston, SC

*Gender differences in response to a 12-step engagement intervention: Results of a national drug abuse treatment clinical trials network study*

Mary Hatch-Maillette, University of Washington, Seattle, WA

*Web-based psychosocial treatment for outpatient substance abuse treatment seekers: Gender differences in acceptability and treatment outcomes*

Aimee Campbell, Columbia University College Medical Center, New York, NY

*Gender differences in accessing substance abuse treatment following an emergency department SBIRT intervention*

Audrey Brooks, University of Arizona, Tucson, AZ

*DISCUSSANT: Recent results in the NIDA clinical trials network: Does gender matter?*

Shelly F. Greenfield, Harvard Medical School, Boston, MA

**Workshop VIII**

**Grand Ballroom**

**7:00 - 9:00 PM**

**INTERVENTION 2.0: USING SOCIAL DIGITAL TOOLS TO REACH  
DIFFICULT-TO-TREAT SUBSTANCE USERS**

Chairs: Danielle Ramo and Suzette Glasner-Edwards

*Mobile phone technology targeting relapse prevention and medication adherence among HIV+ substance users*

Suzette Glasner-Edwards, University of California Los Angeles Integrated Substance Abuse Programs, Los Angeles, CA

*Integrating online monitoring, treatment and social networking into managing binge drinking and depression in young Australians*

Frances Kay-Lambkin, University of New South Wales National Drug, Randwick, NSW, Australia

*Using social media to recruit parents to a family program to prevent teen drug use*

Sabrina Oesterle, University of Washington, Seattle, WA

*One-year outcomes from a smoking cessation intervention on Facebook*

Danielle Ramo, University of California San Francisco, San Francisco, CA

*DISCUSSANT:*

Alan J. Budney, Geisel School of Medicine at Dartmouth, Lebanon, NH

**Please be advised that no photographing of presentations or data is permitted.  
Badges must be worn at all times and are required for admission into all events  
and sessions.**

**Basic Science**

- 100 *Characterization of the lethality and biological safety profiles on rodents of a 10-valent opiate vaccine, the M-TT vaccine*  
A. Benito, J. Hernandez-Calderon, R. Acevedo, S. Jacinto, D. Meneses, R. Hernandez-Miramontes, E. Ramos-Ochoa, S. Jacinto, S. Barbosa, J. Calva, M. Matus, A. Flores, A. Salazar. National Institute of Psychiatry, Ramón de la Fuente, Mexico
- 101 *Haloperidol and ketanserin prevent psychosis-like behaviors induced by toluene in rats*  
S. Cruz, M. Rivera-García, C. López-Rubalcava. Cinvestav, Mexico
- 102 *Kappa opioid receptor agonist 16-bromosalvinorin A reduces cocaine-seeking in rats*  
A. Ewald<sup>1</sup>, J. Miller<sup>1</sup>, T. Prisinzano<sup>2</sup>, B. Kivell<sup>1</sup>. <sup>1</sup>Centre for Biodiscovery, Victoria University of Wellington, New Zealand; <sup>2</sup>Department of Medicinal Chemistry, The University of Kansas, United States
- 103 *Abuse liability evaluation of mephedrone in humans*  
M. Farré<sup>1,2</sup>, C. Pérez-Mañá<sup>1,2</sup>, J. Mateus<sup>1,2</sup>, M. Pujadas<sup>1</sup>, F. Fonseca<sup>1</sup>, M. Torrens<sup>1,2</sup>, R. de la Torre<sup>1,3</sup>, E. Papaseit<sup>1,2</sup>. <sup>1</sup>Hospital del Mar Medical Research Institute-IMIM and Drug Addiction Unit, Parc de Salut Mar, Spain; <sup>2</sup>Universidad Autónoma de Barcelona, Spain; <sup>3</sup>Universidad Pompeu Fabra, Spain
- 104 *Evaluation of dried urine spot method for detection of cotinine among tobacco users*  
R. Jain, R. Quraishi, A. Verma. National Drug Dependence Treatment Center, All India Institute of Medical Sciences, India
- 105 *Heterogeneity of heroin dependence and genetic polymorphism of dopamine system*  
A. O. Kibitov, V. M. Brodyansky, N. A. Chuprova. National Research Centre on Addictions, Russia
- 106 *Kappa opioid receptor agonist Mesyl Sal B attenuates behavioral sensitization to cocaine with fewer aversive side effects*  
B. M. Kivell<sup>1</sup>, A. S. Morani<sup>1</sup>, A. Culverhouse<sup>1</sup>, T. E. Prisinzano<sup>2</sup>. <sup>1</sup>School of Biological Science, Centre for Biodiscovery, Victoria University of Wellington, New Zealand; <sup>2</sup>Department of Medicinal Chemistry, The University of Kansas, United States
- 107 *Decreased thalamocortical connectivity in chronic ketamine users: Implications for schizophrenia*  
Y. Liao<sup>1</sup>, M. Song<sup>2</sup>, J. Tang<sup>1</sup>, J. Liu<sup>3</sup>, M. Yang<sup>1,4,5</sup>, M. Ma<sup>6</sup>, X. Wang<sup>1</sup>, Q. Deng<sup>1</sup>, H. Chen<sup>1</sup>, X. Xiang<sup>1</sup>, T. Liu<sup>1</sup>, X. Chen<sup>1</sup>, W. Hao<sup>1</sup>. <sup>1</sup>Mental Health Institute, the Second Xiangya Hospital of Central South University, China; <sup>2</sup>Brainnetome Center and National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, China; <sup>3</sup>The People's Hospital of Hunan Province, China; <sup>4</sup>Department of Addiction Medicine, Hunan Brain Hospital, China; <sup>5</sup>School of Public Health, Central South University, China; <sup>6</sup>The Kangda Voluntary Drug Rehabilitation Centers in Hunan Province, China
- 108 *The M-TT vaccine preserves its immunogenic efficacy to trigger humoral immune responses in compromised opiate-immunodepressed rodents*  
S. Martiñon, R. Hernandez-Miramontes, R. Acevedo, E. Ramos-Ochoa, J. Hernandez-Calderon, S. Jacinto, J-C. Calva, M. Matus, B. Anton. National Institute of Psychiatry, Ramón de la Fuente, Mexico

- 109 *Development of a combination heroin-HIV vaccine*  
G. R. Matyas<sup>1</sup>, R. Jalah<sup>2</sup>, O. B. Torres<sup>2</sup>, F. Li<sup>3,4</sup>, J. F. G. Antoline<sup>3,4</sup>, Z. Beck<sup>2</sup>, A. E. Jacobson<sup>3,4</sup>, K. C. Rice<sup>3,4</sup>, C. R. Alving<sup>1</sup>. <sup>1</sup>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States; <sup>2</sup>U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States; <sup>3</sup>National Institute on Drug Abuse, National Institutes of Health (NIH), United States; <sup>4</sup>National Institute on Alcohol Abuse and Alcoholism, NIH, United States
- 110 *Association between crack addiction and the intron 8 variable number of tandem repeats polymorphism of the DAT1 gene*  
D. Müller<sup>1</sup>, A. R. Stolf<sup>2</sup>, G. C. Akutagava-Martins<sup>1</sup>, L. S. P. Guimaraes<sup>2</sup>, F. H. P. Kessler<sup>2</sup>, F. Pechansky<sup>2</sup>, T. Roman<sup>1</sup>. <sup>1</sup>Department of Genetics, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil
- 111 *Reacquisition of cocaine-conditioned place preference and its inhibition by previous social interaction preferentially affect D1-medium spiny neurons in the accumbens corridor*  
J. M. Prast<sup>1</sup>, A. Schardl<sup>1</sup>, C. Schwarzer<sup>1</sup>, G. Dechant<sup>1</sup>, A. Saria<sup>1</sup>, G. Zernig<sup>1,2</sup>. <sup>1</sup>Innsbruck Medical University, Austria; <sup>2</sup>Leopold-Franzens University of Innsbruck, Austria
- 112 *Effect of nalbuphine on plasma corticosterone levels and opiate withdrawals*  
R. Raghav, R. Jain, T. S. Roy, A. Dhawan, P. Kumar. National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India
- 113 *Cannabis users show increased susceptibility to false memories*  
J. Riba<sup>1</sup>, F. Sampedro<sup>2</sup>, A. Rodríguez-Pujadas<sup>1</sup>, S. Martínez-Horta<sup>1</sup>, J. Kulisevsky<sup>1</sup>, J. Pérez de los Cobos<sup>3</sup>, A. Rodríguez-Fornells<sup>2</sup>, M. Valle<sup>1</sup>. <sup>1</sup>Human Neuropsychopharmacology Group, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Spain; <sup>2</sup>Universidad de Barcelona, Spain; <sup>3</sup>Hospital de la Santa Creu i Sant Pau, Spain
- 114 *Overexpression of GRP78 confers protection against neurocognitive impairment in HIV-infected polydrug users*  
M. Rodriguez, S. Lopez, M. Rivera, K. Narvaez, L. Cubano, E. Rios, N. Boukli. Universidad Central del Caribe Medical School, United States
- 115 *Role of DJ1 gene in cocaine addiction and HIV-associated cognitive impairment*  
U. Roy, V. Atluri, M. Agudelo, M. Nair. Herbert Wertheim College of Medicine, Florida International University, United States
- 116 *Khat synergizes gentamicin-induced nephrotoxicity in rats: Drug of abuse beyond addiction*  
Z. S. Sabe<sup>1</sup>, E. Engidawork<sup>2</sup>. <sup>1</sup>College of Medicine and Health Sciences, University of Gondar, Ethiopia; <sup>2</sup>College of Medicine and Health Sciences, Addis Ababa University, Ethiopia
- 117 *Immunopharmacological characterization of combination use of two structurally related tetanus toxoid-based morphine vaccines*  
A. Salazar, J. Hernandez-Calderon, S. Barbosa, R. Hernandez-Miramontes, R. Acevedo, E. Ramos-Ochoa, S. Jacinto, J. Calva, D. Meneses, I. Feregrino Marta, C. Martinez, M. Matus, A. Flores, S. Martiñon, A. Benito. National Institute of Psychiatry, Ramón de la Fuente, Mexico
- 118 *Effects of khat (Catha edulis Forsk) on electrophysiologic properties of the heart and of lung function indices*  
Y. M. Sewiye. Jimma University, Ethiopia

- 119 *Clinical characteristics and genotype frequencies of the dopamine transporter gene (DAT1/SLC6A3) 3'UTR variable number of tandem repeats in crack cocaine users*  
A. R. Stolf<sup>1</sup>, G. C. Akutagava-Martins<sup>2</sup>, D. Müller<sup>2</sup>, L. S. P. Guimaraes<sup>1</sup>, F. Pechansky<sup>1</sup>, T. Roman<sup>2</sup>, F. H. P. Kessler<sup>1</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Department of Genetics, Federal University of Rio Grande do Sul, Brazil
- 120 *Effect of hapten density on the induction of antibodies to heroin hapten-protein conjugates*  
O. B. Torres<sup>1,2</sup>, R. Jalah<sup>1,2</sup>, F. Li<sup>3,4</sup>, J. F. G. Antoline<sup>3,4</sup>, Z. Beck<sup>1,2</sup>, A. E. Jacobson<sup>3,4</sup>, C. R. Alving<sup>1</sup>, K. C. Rice<sup>3,4</sup>, G. R. Matyas<sup>1</sup>. <sup>1</sup>U.S. Military HIV Research Program, Walter Reed Army Institute of Research, United States; <sup>2</sup>U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States; <sup>3</sup>National Institute on Drug Abuse, National Institutes of Health (NIH), United States; <sup>4</sup>National Institute on Alcohol Abuse and Alcoholism, NIH, United States
- 121 *Assessment of Oxidative DNA damage biomarker 8-hydroxy-2'-deoxyguanosine among adolescent inhalant users*  
A. Verma<sup>1</sup>, R. Jain<sup>1</sup>, A. Dhawan<sup>1</sup>, R. Lakshmy<sup>2</sup>. <sup>1</sup>National Drug Dependence Treatment Center, All India Institute of Medical Sciences, India; <sup>2</sup>Department of Cardiac Biochemistry, All India Institute of Medical Sciences, India
- 122 *VTA glutamate neurons that co-release GABA can be excitatory or inhibitory*  
V. Zell, J. H. Yoo, N. Guterrez-Reed, K. Fife, T. S. Hnasko. University of California San Diego, United States

**Epidemiology**

- 200 *Screening substance use among college and faculty students in Bucharest*  
A. O. Abagiu, M. I. Maftai, A. Atomoaie, I. T. Niculescu. National Institute for Infectious Diseases Prof. Dr. Matei Bals, Romania
- 201 *Differences in tobacco use, attitude, and knowledge among young Jordanians*  
M. Abdoh<sup>1</sup>, R. M. Jones<sup>2</sup>. <sup>1</sup>Humphrey Fellowship Program, Virginia Commonwealth University, United States; <sup>2</sup>School of Medicine and Massey Cancer Center, Virginia Commonwealth University, United States
- 202 *Low threshold methadone protects against HIV incidence in a Canadian setting*  
K. Ahamad<sup>1,2</sup>, K. Hayashi<sup>2</sup>, P. Nguyen<sup>2</sup>, S. Dobrer<sup>2</sup>, T. Kerr<sup>1,2</sup>, J. Montaner<sup>2</sup>, E. Wood<sup>1,2</sup>. <sup>1</sup>University of British Columbia, Canada; <sup>2</sup>British Columbia Centre for Excellence in HIV/AIDS, Canada
- 203 *Effect of Gaza 2014 war on use of smoking, tramadol, and psychoactive drugs among university students*  
M. F. Afifi<sup>1</sup>, M. Sakka<sup>2</sup>, M. Shehada<sup>1</sup>, R. Afifi<sup>1</sup>. <sup>1</sup>Substance Abuse Research Center, Palestinian Territories; <sup>2</sup>Al-Azhar University, Palestinian Territories
- 204 *Findings from the Inaugural Iraqi Community Epidemiological Workgroup on Substance Use*  
N. Al Hemiary<sup>1</sup>, A. Abutiheen<sup>2</sup>, E. Abdulrazzaq<sup>3</sup>, M. Al-Hachami<sup>1</sup>, R. Dabbagh<sup>4</sup>, A. Hasson<sup>4</sup>, V. Antonini<sup>4</sup>, R. Rawson<sup>4</sup>. <sup>1</sup>College of Medicine, University of Baghdad, Iraq; <sup>2</sup>College of Medicine, Karbala University, Iraq; <sup>3</sup>Ministry of Health, Iraq; <sup>4</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States
- 205 *Age of first use and drug dependence: Data from 617 consecutively ascertained subjects*  
S. Bacciardi<sup>1,2</sup>, A. G. I. Maremmanni<sup>1,2</sup>, E. Butelman<sup>2</sup>, B. Ray<sup>2</sup>, E. Ducat<sup>2</sup>, M. J. Kreek<sup>2</sup>. <sup>1</sup>“VP Dole” Dual Diagnosis Unit, Santa Chiara University Hospital of Pisa, Italy; <sup>2</sup>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, United States



- 206 *Size estimation of injecting drug users in Sri Lanka*  
A. I. Bandara. National Dangerous Drugs Control Board (retired), Sri Lanka
- 207 *Second online survey on drug use in college students at a private university in El Salvador*  
F. Bautista Pérez. Universidad Evangélica de El Salvador, El Salvador
- 208 *The use of new psychoactive substances in Belgium: A worrying phenomenon*  
P. Blanckaert<sup>1</sup>, T. Windelinckx<sup>2</sup>, K. Maudens<sup>3</sup>. <sup>1</sup>Belgian Early Warning System Drugs, Belgium; <sup>2</sup>Free Clinic Needle Exchange–Antwerp, Belgium; <sup>3</sup>Toxicological Center, Antwerp University, Belgium
- 209 *Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the Pain and Opioids IN Treatment (POINT) cohort*  
G. Campbell<sup>1</sup>, S. Nielsen<sup>1,2</sup>, B. Larance<sup>1</sup>, R. Bruno<sup>1,3</sup>, R. Mattick<sup>1</sup>, W. Hall<sup>4</sup>, N. Lintzeris<sup>2,5</sup>, M. Cohen<sup>6</sup>, K. Smith<sup>1</sup>, L. Degenhardt<sup>1,7,8,9</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales (UNSW), Australia; <sup>2</sup>School of Medicine, University of Tasmania, Australia; <sup>3</sup>The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services, Australia; <sup>4</sup>St. Vincent’s Clinical School, UNSW Medicine, Australia; <sup>5</sup>Sydney Medical School, Sydney University, Australia; <sup>6</sup>Black Dog Institute, UNSW, Australia; <sup>7</sup>Centre for Youth Substance Abuse Research, University of Queensland, Australia; <sup>8</sup>National Addiction Centre, King’s College London, England; <sup>9</sup>School of Population and Global Health, University of Melbourne, Australia
- 210 *Characteristics of pregnant women who smoke in Guadalajara, Mexico*  
O. Campollo<sup>1,2</sup>, F. Hernandez Mora<sup>2</sup>, E. Angulo<sup>2</sup>, A. Guzman<sup>2</sup>, A. Munguía<sup>2</sup>, M. García<sup>2</sup>, J. K. Cunningham<sup>3</sup>. <sup>1</sup>Center of Studies on Alcohol and Addictions, CUCS, Universidad de Guadalajara, Mexico; <sup>2</sup>Hospital Civil de Guadalajara, Mexico; <sup>3</sup>Department of Family and Community Medicine, University of Arizona, United States
- 211 *Dimensional and categorical phenotypes of opioid use disorder criteria among frequent nonmedical prescription opioid users: Investigating sociodemographic, psychiatric, and source correlates*  
J. M. Castaldelli-Maia<sup>1,2,3</sup>, L. H. Andrade<sup>1</sup>, K. M. Keyes<sup>4</sup>, M. Cerdá<sup>4</sup>, D. J. Pilowsky<sup>4,5</sup>, S. S. Martins<sup>4</sup>. <sup>1</sup>Section of Psychiatric Epidemiology, Department and Institute of Psychiatry, University of São Paulo Medical School, Brazil; <sup>2</sup>Interdisciplinary Group of Studies on Alcohol and Drugs, Department and Institute of Psychiatry, University of São Paulo Medical School, Brazil; <sup>3</sup>Department of Neuroscience, Medical School, Fundação do ABC, Brazil; <sup>4</sup>Department of Epidemiology, Mailman School of Public Health, Columbia University, United States; <sup>5</sup>New York State Psychiatric Institute, United States
- 212 *Study of socio-demographic profile and correlates of injection drug use among children in India*  
B. Chatterjee, A. Dhawan, A. Chopra, R. Bhargawa, R. D. Pattanayak. National Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of Medical Sciences, India
- 213 *New epidemiological evidence on coca leaf chewing and a dependence syndrome in 2008*  
V. Cruz<sup>1,2,3</sup>, J. C. Anthony<sup>1,2</sup>. <sup>1</sup>Department of Epidemiology, Michigan State University, United States; <sup>2</sup>School of Public Health, Cayetano Heredia University, Peru; <sup>3</sup>Peruvian National Institute of Mental Health, Peru

- 214 *Substance use and adherence among HIV-infected persons receiving antiretroviral therapy in Latin America*  
R. B. De Boni<sup>1</sup>, B. E. Shepherd<sup>2</sup>, B. Grinsztejn<sup>1</sup>, C. Cesar<sup>3</sup>, C. Cortés<sup>4</sup>, D. Padgett<sup>5</sup>, E. Gotuzzo<sup>6</sup>, F. Belaunzarán<sup>7</sup>, S. Duda<sup>2</sup>, C. McGowan<sup>2</sup>, The Caribbean, Central and South America Network for HIV Research (CCASAnet)<sup>8</sup>. <sup>1</sup>Instituto de Pesquisa Clínica Evandro Chagas - Fundação Oswaldo Cruz, Brazil; <sup>2</sup>Vanderbilt University, United States; <sup>3</sup>Fundación Huésped, Argentina; <sup>4</sup>Fundación Arriaran, Chile; <sup>5</sup>Instituto Hondureño de Seguridad Social and Hospital Escuela, Tegucigalpa, Honduras; <sup>6</sup>Universidad Peruana Cayetano Heredia, Lima; <sup>7</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico; <sup>8</sup>CCASAnet, Vanderbilt University, United States
- 215 *Experience of adjunctive cannabis use for chronic noncancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study*  
L. Degenhardt<sup>1,2</sup>, N. Lintzeris<sup>3,4</sup>, G. Campbell<sup>1</sup>, R. Bruno<sup>1,5</sup>, M. Cohen<sup>6</sup>, M. Farrell<sup>1</sup>, W. Hall<sup>7,8</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>School of Population and Global Health, University of Melbourne, Australia; <sup>3</sup>Discipline of Addiction Medicine, University of Sydney (UNSW), Australia; <sup>4</sup>The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services, Australia; <sup>5</sup>School of Medicine, University of Tasmania, Australia; <sup>6</sup>St. Vincent's Clinical School, UNSW Medicine, Australia; <sup>7</sup>Centre for Youth Substance Abuse Research, University of Queensland, Australia; <sup>8</sup>National Addiction Centre, King's College London, England
- 216 *Increase in prevalence of marijuana use among university students in Bolivia, Colombia, Ecuador, and Peru*  
M. Demarco<sup>1</sup>, M. Hynes<sup>1</sup>, J. C. Araneda<sup>2</sup>, F. Cumsille<sup>1</sup>. <sup>1</sup>Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, Organization of American States, United States; <sup>2</sup>Global Synthetics Monitoring: Analyses, Reporting and Trends Programme (SMART)-Latin America, United Nations Office on Drugs and Crime, Switzerland
- 217 *Study of socio-demographic profiles and correlates of inhalant use among children in India*  
A. Dhawan, B. Chatterjee, A. Chopra, R. Bhargawa, R. D. Pattanayak. National Drug Dependence Treatment Centre and Department of Psychiatry, All India Institute of Medical Sciences, India
- 218 *Three rounds of integrated bio-behavioral surveillance confirm declining HIV prevalence among people who inject drugs (PWID) in Ukraine*  
K. Dumchev<sup>1</sup>, T. Salyuk<sup>2</sup>, Y. Sazonova<sup>2</sup>. <sup>1</sup>Institute on Public Health Policy, Ukraine; <sup>2</sup>International HIV/AIDS Alliance-Ukraine, Ukraine
- 219 *Use patterns of tobacco and nicotine-containing products among college students in the United States*  
O. El-Shahawy<sup>1</sup>, S. Cho<sup>2</sup>, A. McGann<sup>3</sup>, K. Hill<sup>3</sup>. <sup>1</sup>School of Medicine, Virginia Commonwealth University, United States; <sup>2</sup>Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, United States; <sup>3</sup>Wellness Resource Center, Virginia Commonwealth University, United States
- 220 *Aspects of substance abuse among adolescents detained in a juvenile delinquency institution in Upper Egypt*  
A. A. Elkoussi<sup>1</sup>, T. S. Bakheet<sup>2</sup>, S. H. Bakheet<sup>2</sup>. <sup>1</sup>Department of Pharmacology, College of Medicine, Assiut University, Egypt; <sup>2</sup>Department of Sociology, College of Arts, Assiut University, Egypt



- 221 *Mortality and cannabis detection in a cohort of patients with opiate, cocaine, and alcohol dependence*  
D. Fuster<sup>1,2</sup>, A. Sanvisens<sup>1,2</sup>, P. Zuluaga<sup>1,2</sup>, J. Tor<sup>1,2</sup>, I. Rivas<sup>3</sup>, R. Muga<sup>1,2</sup>. <sup>1</sup>Internal Medicine Service. Hospital Germans Trias i Pujol, Spain; <sup>2</sup>Universitat Autònoma de Barcelona, Spain; <sup>3</sup>Municipal Centre for Substance Abuse Treatment, Centro Delta, IMSP, Spain
- 222 *Mixed drug intake and its dosage as a predictor of mental health status, Bahir-Dar, North West Ethiopia*  
A. G. Gebresilus. College of Education and Behavioral Studies, Addis Ababa University, Ethiopia
- 223 *ASSIST in HIV/AIDS service settings: Comparison of self-screening and peer-support screening method*  
L. M. Giang<sup>1</sup>, H. Nguyen<sup>1</sup>, H. Tran<sup>1</sup>, G. Bart<sup>2</sup>, T. Rieckmann<sup>3</sup>, H. Tran<sup>1</sup>, K. Darfler<sup>4</sup>, R. Rawson<sup>4</sup>. <sup>1</sup>Hanoi Medical University, Viet Nam; <sup>2</sup>Department of Medicine, Hennepin County Medical Center, United States; <sup>3</sup>School of Public Health, Oregon Health & Science University, United States; <sup>4</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States
- 224 *Occupational and demographic factors associated with drug use among female sex workers in Burma (Myanmar)*  
K. Hail-Jares<sup>1</sup>, S. Choi<sup>1</sup>, J. Huang<sup>1</sup>, L. Duo<sup>2</sup>, Z. Luo<sup>2</sup>. <sup>1</sup>Department of International Health, School of Nursing and Health Studies, Georgetown University, United States; <sup>2</sup>Yundi Harm Reduction Network, China
- 225 *Naloxone in Egypt—availability and challenges*  
W. Hassan<sup>1,2</sup>, R. Naguib<sup>1</sup>. <sup>1</sup>Institute of Psychiatry, Ain Shams University, Egypt; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 226 *Drug use trends among Israeli school dropouts based on gender and country of origin status: A 10-year study (2004–2013)*  
R. Isralowitz, A. Reznik. Regional Alcohol and Drug Abuse Research Center, Spitzer Department of Social Work, Ben Gurion University, Israel
- 227 *Piloting of ASSIST screening tool for identification of alcohol, tobacco, and drug use in pregnancy in two cities of Ukraine*  
T. Kiriazova<sup>1</sup>, T. Tarasova<sup>2</sup>, O. Makarenko<sup>1</sup>, O. Zeziulin<sup>1</sup>, V. Martsinovskaya<sup>3</sup>, S. Dvoriak<sup>1</sup>. <sup>1</sup>Ukrainian Institute on Public Health Policy, Ukraine; <sup>2</sup>UNICEF, Ukraine; <sup>3</sup>Ukrainian Center for Socially Dangerous Disease Control, Ministry of Health, Ukraine
- 228 *Transition from heroin use to dependence and treatment seeking among an opioid-dependent sample*  
B. Larance<sup>1</sup>, E. Cama<sup>1</sup>, N. Gisev<sup>1</sup>, E. Nelson<sup>2</sup>, L. Degenhardt<sup>1</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>Washington University in St. Louis, United States
- 229 *Diagnosis of hepatitis C virus infection after entry to opioid substitution therapy: A 15-year observational cohort study*  
S. Larney<sup>1</sup>, J. Grebely<sup>2</sup>, M. Falster<sup>3,4</sup>, A. Swart<sup>4</sup>, J. Amin<sup>2</sup>, L. Degenhardt<sup>1</sup>, L. Burns<sup>1</sup>, C. M. Vajdic<sup>4</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales (UNSW), Australia; <sup>2</sup>The Kirby Institute, UNSW, Australia; <sup>3</sup>Centre for Health Research, University of Western Sydney, Australia; <sup>4</sup>Prince of Wales Clinical School, UNSW, Australia
- 230 *Risk of schizophrenia in marijuana users: Findings from a nationwide sample of drug users in Chile*  
N. Libuy, V. Angel, C. Ibáñez. Department of Psychiatry and Mental Health North, Clinical Hospital, University of Chile, Chile

- 231 *A pre-post comparison in health care service utilization among heroin-using women in methadone maintenance treatment in Taiwan*  
Y-T. Lien<sup>1,2</sup>, H-H. Yeh<sup>3</sup>, S-Y. Fang<sup>1,2</sup>, C-Y. Chen<sup>1,2</sup>. <sup>1</sup>Institute of Public Health, National Yang-Ming University, Taiwan; <sup>2</sup>Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan; <sup>3</sup>Department of Epidemiology and Biostatistics, Michigan State University, United States
- 232 *Performance of lay outreach workers in a needle exchange program in China*  
W. Liu<sup>1,2</sup>, H. Li<sup>3</sup>, L. Duo<sup>4</sup>, Z. Luo<sup>2</sup>, J. Yang<sup>2</sup>, H. Xue<sup>2</sup>, L. Yang<sup>2</sup>, Z. K. Hail-Jares<sup>5</sup>, J. Huang<sup>5</sup>. <sup>1</sup>School of Public Health, Kunming Medical University, China; <sup>2</sup>Kunming Yundi Behavior and Health Research Center, China; <sup>3</sup>Yunnan Provincial Center for Disease Prevention and Control, China; <sup>4</sup>Second People's Hospital of Yunnan Province, China; <sup>5</sup>Department of International Health, Georgetown University, United States
- 233 *Gender differences in methamphetamine use in a Mexico-U.S. border city*  
O. Loza<sup>1</sup>, J. Ferreira-Pinto<sup>1</sup>, R. Ramos<sup>2</sup>, M. E. Ramos Rodriguez<sup>3</sup>. <sup>1</sup>University of Texas-El Paso, United States; <sup>2</sup>Alliance Border Collaboratives, United States; <sup>3</sup>Instituto Nacional de Psiquiatría, Ramón de la Fuente Muñiz, México
- 234 *Substance-related disorders among patients with human immunodeficiency virus: An analytical study*  
S. T. Mahmud. Bogra Anti-Drug Society, Bangladesh
- 235 *Psychiatric diagnoses in a cohort of normal volunteers and drug-dependent subjects: Comparative data from 617 consecutive subjects*  
A. G. I. Maremmani<sup>1,2</sup>, S. Bacciardi<sup>1,2</sup>, E. Butelman<sup>2</sup>, B. Ray<sup>2</sup>, E. Ducat<sup>2</sup>, M. J. Kreek<sup>2</sup>. <sup>1</sup>“VP Dole” Dual Diagnosis Unit, Santa Chiara University Hospital of Pisa, Italy; <sup>2</sup>Laboratory of the Biology of Addictive Diseases, The Rockefeller University, United States
- 236 *Application of outreach strategies to international collaborative research*  
H. V. McCoy<sup>1</sup>, A. J. M. Bengoa<sup>2</sup>, A. J. Mendez<sup>2</sup>, J. M. Shultz<sup>2</sup>, D. C. McBride<sup>3</sup>, R. Achi<sup>4</sup>, S. Lai<sup>5</sup>, M. Zhao<sup>6</sup>, J. Cordova<sup>1</sup>. <sup>1</sup>Florida International University, United States; <sup>2</sup>University of Miami, United States; <sup>3</sup>Andrews University, United States; <sup>4</sup>University of Costa Rica, Costa Rica; <sup>5</sup>Johns Hopkins University, United States; <sup>6</sup>Shanghai Mental Health Center, China
- 237 *Pathways from Gini (index) and neighborhood characteristics to children's drug use: Multinational study*  
K. Miyamoto<sup>1,2</sup>. <sup>1</sup>School of Medicine, University of Tokyo, Japan; <sup>2</sup>School of Public Health, Drexel University, United States
- 238 *Drug abuse in Afghanistan also includes problems with children under 15*  
A. S. Momand<sup>1,2</sup>. <sup>1</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; <sup>2</sup>Drug Demand Reduction Consultant, Afghanistan
- 239 *Predictors of early relapse in adolescent crack users after hospital discharge*  
H. Moura<sup>1</sup>, R. Rosa<sup>1</sup>, F. Kessler<sup>1</sup>, T. G. Pianca<sup>1</sup>, L. Guimarães<sup>1</sup>, P. Ferronato<sup>1</sup>, E. Pagnussat<sup>2</sup>, F. Pechansky<sup>1</sup>, L. von Diemen<sup>1</sup>. <sup>1</sup>Center for Drug and Alcohol Research Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Pontifical Catholic University of Rio Grande do Sul, Brazil
- 240 *Sex-specific disease outcomes of HIV-positive patients in a methadone treatment program with access to cART*  
R. Muga<sup>1,2</sup>, I. Rivas<sup>3</sup>, E. Faure<sup>3</sup>, D. Fuster<sup>1,2</sup>, P. Zuluaga<sup>1,2</sup>, J. L. García-Medina<sup>1,4</sup>, J. Tor<sup>1,2</sup>, A. Sanvisens<sup>1</sup>. <sup>1</sup>Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Spain; <sup>2</sup>Universitat Autònoma de Barcelona, Spain; <sup>3</sup>Municipal Center for Substance Abuse Treatment, Centro Delta, IMSP, Spain; <sup>4</sup>Escuela Superior de Medicina, Instituto Politécnico Nacional, México

- 241 *Measuring stigma associated with opioid drug use*  
T. Mukherjee<sup>1</sup>, J. Wickersham<sup>2</sup>, V. Earnshaw<sup>2</sup>, F. L. Altice<sup>1,2,3</sup>, A. B. Kamarulzaman<sup>2,3</sup>.  
<sup>1</sup>School of Public Health, Yale University, United States; <sup>2</sup>School of Medicine, Section of Infectious Diseases, AIDS Program, Yale University, United States; <sup>3</sup>Universiti of Malaya, Centre of Excellence for Research in AIDS, Malaysia
- 242 *Effect of negative affect regulation and impulsivity on food addiction in a sample of Egyptian females*  
R. Naguib, A. Omar, A. ElRasheed, H. Azzam, D. ElSerafi. University of Ain Shams, Egypt
- 243 *Substance abuse prevalence in Karachi and services by Drug Free Pakistan Foundation*  
F. Naveed<sup>1,2</sup>. <sup>1</sup>Drug Free Pakistan Foundation, Pakistan; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 244 *Internalizing and externalizing disorders as risk factors for the increase of cannabis use and the onset and stability of cannabis use disorders: A systematic review of cohort studies from the general population*  
M. Neumann<sup>1</sup>, S. Behrendt<sup>1</sup>, A. Perkonig<sup>2</sup>, G. Bühringer<sup>1</sup>. <sup>1</sup>Addiction Research Unit, Institute for Clinical Psychology and Psychotherapy, Dresden University of Technology, Germany; <sup>2</sup>Psychopathology and Clinical Intervention Unit, Department of Psychology, University of Zurich, Switzerland
- 245 *Substance dependence criteria, not substance use, associated with HIV virologic control*  
S. Nolan<sup>1</sup>, A. Y. Walley<sup>2</sup>, T. C. Heeren<sup>2</sup>, G. J. Patts<sup>2</sup>, A. S. Ventura<sup>2</sup>, M. Sullivan<sup>2</sup>, J. H. Samet<sup>2</sup>, R. Saitz<sup>2</sup>. <sup>1</sup>Department of Medicine, University of British Columbia, Canada; <sup>2</sup>Boston University, United States
- 246 *Use of substance “h” (heroin) among students in Ecuador: Findings from qualitative research in five school systems in Guayaquil and two school systems in Santa Elena*  
D. Oceña<sup>1</sup>, J. Paspuel<sup>1</sup>, S. Almeida<sup>1</sup>, P. Jacobs<sup>2</sup>. <sup>1</sup>National Observatory, Consejo Nacional de Sustancias Estupefacientes y Psicotrópicas del Ecuador, Ecuador; <sup>2</sup>The Catholic University de Santiago in Guayaquil, Ecuador
- 247 *Illicit drug use in Nigeria: Recent findings from the National Survey on Alcohol and Drug Use*  
A. Ogunwale, T. A. Adamson, A. O. Ogunlesi, A. O. Akinhanmi, P. O. Onifade, E. B. Somoye. Neuropsychiatric Hospital, Nigeria
- 248 *Use of marijuana and expression of antisocial behavior among young people in urban Nigeria*  
M. O. Onoja<sup>1</sup>; K. A. Raphael<sup>2</sup>; A. Okoh<sup>3</sup>; J. A. Ocheh<sup>4</sup>. <sup>1</sup>National Primary Health Care Development Agency, Nigeria; <sup>2</sup>Dunamis Christian Academy, Nigeria; <sup>3</sup>Paths Educational Centre, Nigeria; <sup>4</sup>Young People’s Home, Nigeria
- 249 *Pattern of psychoactive substance use among long-distance commercial drivers in Calabar metropolis, Cross River State*  
T. Onyuku. Federal Neuropsychiatric Hospital–Calabar Cross River State, Nigeria
- 250 *Drug use and injection practices in Tajikistan: Qualitative study in Kulob and Khorog*  
D. Otiashvili<sup>1</sup>, A. Latypov<sup>2</sup>, U. Ibragimov<sup>3</sup>, I. Kirtadze<sup>1</sup>, W. Zule<sup>4</sup>. <sup>1</sup>Addiction Research Center, Alternative Georgia, Georgia; <sup>2</sup>Management Sciences for Health, Leadership, Management and Governance, Ukraine; <sup>3</sup>Laney Graduate School, Emory University, United States; <sup>4</sup>RTI International, United States
- 251 *Crack users with conduct disorder have greater association with violence, trauma, and psychiatric comorbidities*  
M. P. Pachado, D. S. Souza, J. N. Scherer, F. Pechansky, F. H. P. Kessler, S. Faller. Center for Alcohol and Drugs Research, Federal University of Rio Grande do Sul, Brazil

- 252 *Cocaine base paste use in South America: Review of epidemiological and toxicological aspects.*  
A. Pascale<sup>1</sup>, M. Hynes<sup>2</sup>, F. Cumsille<sup>2</sup>, C. B. Bares<sup>3</sup>. <sup>1</sup>Red Latinoamericana de Investigadores en Drogas (REDLA) Network, Uruguay; <sup>2</sup>Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, Organization of American States, United States; <sup>3</sup>School of Social Work, Virginia Commonwealth University, United States
- 253 *Comparison of DUI prevalences among fatal, nonfatal, and roadside samples of Brazilian drivers*  
F. P. Pechansky, L. Von Diemen, A. O. Sordi. Center for Drug and Alcohol Studies, Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Brazil; Secretariat for Drug and Alcohol Policies (SENAD) Collaborating Center on Alcohol and Drugs, Brazil
- 254 *Transition from first substance use to crack cocaine: Predictors of faster addiction progression and clinical characteristics in crack cocaine adolescent users*  
T. G. Pianca<sup>1</sup>, R. L. Rosa<sup>2</sup>, A. P. de Assis Begnis<sup>3</sup>, P. B. Ferronato<sup>1</sup>, M. C. Jensen<sup>3</sup>, L. A. P. Rohde<sup>1</sup>, F. Pechansky<sup>1</sup>, C. M. Szobot<sup>1</sup>. <sup>1</sup>Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil; <sup>2</sup>Hospital Psiquiátrico São Pedro, Brazil; <sup>3</sup>Universidade Luterana do Brasil, Brazil
- 255 *Methamphetamine use among Iranian patients in methadone maintenance treatment: Is this a threat?*  
S. R. Radfar<sup>1,2</sup>, U. S. Warda<sup>1</sup>, R. Rawson<sup>1</sup>. <sup>1</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, United States; <sup>2</sup>Thought, Culture and Health (ROOZBEH) Institute, Iran
- 256 *Association of alcohol use with drug use and weapon carrying among Thai adolescents*  
O. Saiphoklang<sup>1,2</sup>, K. Wongboonsin<sup>1,2</sup>, P. Wongboonsin<sup>1</sup>, U. Perngarn<sup>1</sup>, L. B. Cottler<sup>1,2</sup>. <sup>1</sup>College of Population Studies, College of Public Health Sciences, Chulalongkorn University, Thailand; <sup>2</sup>Substance Abuse Training Center in Public Health, University of Florida, United States
- 257 *HIV-related stigma and substance use in a Russian cohort of HIV-infected risky drinkers*  
J. H. Samet<sup>1</sup>, K. Lunze<sup>1</sup>, D. M. Cheng<sup>1</sup>, D. Lioznov<sup>2</sup>, E. Quinn<sup>1</sup>, C. Bridden<sup>1</sup>, C. Chaisson<sup>1</sup>, A. Y. Walley<sup>1</sup>, E. Krupitsky<sup>2</sup>, A. Raj<sup>3</sup>, E. J. Edelman<sup>4</sup>. <sup>1</sup>Boston University, United States; <sup>2</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>3</sup>University of California, San Diego, United States; <sup>4</sup>Yale University, United States
- 258 *Adolescent substance use and specificity of association with educational outcomes in young adulthood*  
E. Silins<sup>1</sup>, L. J. Horwood<sup>2</sup>, D. Fergusson<sup>2</sup>, G. Patton<sup>3</sup>, C. Olsson<sup>4</sup>, D. Hutchinson<sup>1</sup>, L. Degenhardt<sup>1</sup>, R. Mattick<sup>1</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>Christchurch Health and Development Study, Department of Psychological Medicine, University of Otago, New Zealand; <sup>3</sup>Centre for Adolescent Health, Murdoch Children's Research Institute, University of Melbourne, Australia; <sup>4</sup>Department of Paediatrics, and School of Psychological Sciences, University of Melbourne, Australia
- 259 *Users' knowledge about risks of benzodiazepine dependence in Kosovo*  
Z. Tahiri<sup>1,2</sup>, F. Berisha<sup>1</sup>, I. Rrahmani<sup>3</sup>. <sup>1</sup>Medical University of Tirana, Mexico; <sup>2</sup>Main Family Medicine Center, Mexico; <sup>3</sup>Regional Hospital of Gjiilan, Mexico
- 260 *"We need more than condoms": Community mobilization of substance-using female sex workers in Tijuana, Mexico*  
L. A. Urada<sup>1</sup>, E. Reed<sup>1</sup>, T. Gaines<sup>1</sup>, C. Magis-Rodriguez<sup>2</sup>, K. Meckel-Parker<sup>1</sup>, P. Gonzalez-Zuniga<sup>1</sup>, K. C. Brouwer<sup>1</sup>. <sup>1</sup>Department of Medicine, Division of Global Public Health, University of California, San Diego; <sup>2</sup>Concorcio de Investigacion sobre HIV/AIDS and TB, Mexico



- 261 *Cross-sectional and prospective relation of cannabis potency, dosing, and smoking behavior with cannabis dependence: An ecological study*  
P. Van der Pol, N. Liebrechts, T. Brunt, J. van Amsterdam, R. de Graaf, D. J. Korf, W. van den Brink, M. van Laar. The Trimbos Institute, Netherlands Institute of Mental Health and Addiction, The Netherlands; Bongier Institute of Criminology, Academic Medical Centre, University of Amsterdam, The Netherlands
- 262 *Adaptation of a risk and protective factor survey for substance use among 9th and 10th grade students in Burma (Myanmar)*  
N. Wan<sup>1</sup>, W. L. Kliewer<sup>2</sup>. <sup>1</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; <sup>2</sup>Department of Psychology, Virginia Commonwealth University, United States
- 263 *Substance abuse in Iraq “psychiatrists’ experience”*  
R. I. Yasein, V. Hussein. Ministry of Health-Kurdistan, Iraq
- 264 *U.S. national estimates of parenting level and risk of newly incident drug use: 2002–2013*  
H-H. Yeh<sup>1</sup>, J. C. Anthony<sup>2</sup>, R. B. Seedall<sup>2</sup>. <sup>1</sup>Department of Epidemiology, Michigan State University, United States; <sup>2</sup>Department of Family, Consumer, and Human Development, Utah State University, United States
- 265 *A rapidly changing recreational drug market: Findings from the Canadian Community Epidemiology Network on Drug Use*  
M. M. Young<sup>1,2</sup>, T. Pirie<sup>1</sup>, S. Hosein<sup>3</sup>. <sup>1</sup>Canadian Centre on Substance Abuse, Canada; <sup>2</sup>Carleton University, Canada; <sup>3</sup>University of Calgary, Canada
- 266 *Substance use dynamics and emergence of new drugs in Ukraine*  
O. Zeziulin<sup>1</sup>, K. Dumchev<sup>1</sup>, O. Varetskaya<sup>2</sup>, T. Salyuk<sup>2</sup>. <sup>1</sup>Ukrainian Institute on Public Health Policy, Ukraine; <sup>2</sup>International HIV Alliance–Ukraine, Ukraine

**Other**

- 300 *Consumption of anabolic steroids in athletes: A bibliometric approach (2006–2012)*  
R. Aleixandre-Agulló<sup>1</sup>, F. Bueno-Cañigral<sup>2</sup>, J. C. Valderrama-Zurián<sup>3</sup>, D. Melero-Fuentes<sup>1</sup>, R. Aleixandre-Benavent<sup>4</sup>, J. C. Pérez-de-los-Cobos<sup>5</sup>. <sup>1</sup>Instituto de Documentación y Tecnologías de la Información, Universidad Católica de Valencia, Spain; <sup>2</sup>Plan Municipal de Drogodependencias, Ayuntamiento de Valencia, Spain; <sup>3</sup>Departamento de Historia de la Ciencia y Documentación, Universitat de València, Spain; <sup>4</sup>Instituto de Gestión de la Innovación y del Conocimiento, Spanish Research Council-CSIC, Spain; <sup>5</sup>Servicio de Psiquiatría, Hospital de la Santa Creu i Santa Pau, Spain
- 301 *Review of narcotics law in the process of the national reform movement in Burma (Myanmar)*  
N. P. E. Kham<sup>1</sup>, E. Jensema<sup>2</sup>, R. L. Balster<sup>1</sup>. <sup>1</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; <sup>2</sup>Transnational Institute, The Netherlands
- 302 *The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University*  
J. R. Koch, R. L. Balster, A. Breland, L. D. Hedges. Virginia Commonwealth University, United States
- 303 *The VCU Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: A follow-up assessment*  
O. Leonchuk<sup>1</sup>, J. R. Koch<sup>2</sup>, R. L. Balster<sup>2</sup>, A. Breland<sup>2</sup>. <sup>1</sup>North Carolina State University, United States; <sup>2</sup>Virginia Commonwealth University, United States



- 304 *Long-acting reversible contraception (LARC) use and implemental barriers in the Song District, Sarawak, Malaysia*  
J-L. Lim<sup>1,2</sup>, C. Z. F. Chua<sup>3</sup>. <sup>1</sup>Ministry of Health, Malaysia; <sup>2</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; <sup>3</sup>Klinik Kesihatan Song, Malaysia
- 305 *International collaboration improves the impact of addiction research articles: A bibliometric analysis*  
J. McCormally. International Programme in Addiction Studies, Virginia Commonwealth University, United States
- 306 *Scientific evaluation on substance abuse research through Web of Science over the 2008–2012 period*  
D. Melero-Fuentes<sup>1</sup>, R. Aguilar-Moya<sup>2</sup>, J. C. Valderrama-Zurián<sup>3</sup>, F. Bueno-Cañigral<sup>4</sup>, R. Aleixandre-Benavent<sup>5</sup>, J. C. Pérez-de-los-Cobos<sup>6</sup>. <sup>1</sup>Instituto de Documentación y Tecnologías de la Información, Universidad Católica de Valencia, Spain; <sup>2</sup>Departamento de Ciencias de la Educación, Universidad Católica de Valencia, Spain; <sup>3</sup>Departamento de Historia de la Ciencia y Documentación, Universitat de València, Spain; <sup>4</sup>Plan Municipal de Drogodependencias, Ayuntamiento de Valencia, Spain; <sup>5</sup>Instituto de Gestión de la Innovación y del Conocimiento, Spanish Research Council-CSIC, Spain; <sup>6</sup>Servicio de Psiquiatría, Hospital de la Santa Creu i Santa Pau, Spain
- 307 *The “War on Drugs” in West Africa: An appraisal by participants at a human rights and drug policy training–Ghana*  
O. O. Umoh. University of Uyo, Nigeria
- 308 *Creating capacity across continents through distance education: A multimethod assessment of the International Programme in Addiction Studies, Master’s in Addiction Studies*  
A. Williams<sup>1</sup>, L. Cathers<sup>2</sup>, M. Loos<sup>2</sup>, R. Balster<sup>2</sup>, K. Dyer<sup>1</sup>, J. Strang<sup>1</sup>, F. Buisman-Pijlman<sup>3</sup>, G. Kandler<sup>1</sup>, A. Salem<sup>3</sup>. <sup>1</sup>King’s College London, United Kingdom; <sup>2</sup>Virginia Commonwealth University, United States; <sup>3</sup>University of Adelaide, Australia

**Prevention**

- 400 *Cannabis, Lord Shiva, and holy men: Cannabis use among sadhus in Nepal*  
S. L. Acharya<sup>1</sup>, J. Howard<sup>2</sup>, S. B. Pant<sup>3</sup>, J. Copeland<sup>2</sup>. <sup>1</sup>Ministry of Health and Population, Nepal; <sup>2</sup>National Cannabis Prevention and Information Centre, University of New South Wales Medicine, Australia; <sup>3</sup>Saarathi OST Program, Tribuvan University, Nepal
- 401 *Content analysis of evaluation of effectiveness in prevention programs on drug abuse*  
R. Aleixandre-Benavent<sup>1</sup>, D. Ribeiro-Schneider<sup>2</sup>, F. Bissoli-Neto<sup>2</sup>, M. Bolaños-Pizarro<sup>1</sup>, F. Bueno-Cañigral<sup>3</sup>, J. C. Pérez-de-los-Cobos<sup>4</sup>. <sup>1</sup>Unidad de Información e Investigación Social y Sanitaria, IHMC López Piñero, CSIC-Universidad de Valencia, Spain; <sup>2</sup>Núcleo de Pesquisas em Psicologia Clínica, Departamento de Psicologia, Universidade Federal de Santa Catarina, Brazil; <sup>3</sup>Plan Municipal de Drogodependencias, Concejalía de Sanidad y Consumo, Ayuntamiento de Valencia, Spain; <sup>4</sup>Servicio de Psiquiatría, Hospital de la Santa Creu i Santa Pau, Spain
- 402 *Adolescents’ and parents’ perceptions of substance use and factors influencing substance use: A qualitative study in Abu Dhabi, United Arab Emirates*  
L. Alhyas, N. Al-Ozaibi, H. Elarabi, A. Elkashef, S. Wanigaratne, A. Almarzouqi, A. Alhosani, H. Al-Ghaferi. National Rehabilitation Centre, United Arab Emirates
- 403 *Together, marginalized youths can make a difference in HIV response*  
Y. Aung. Hubert H. Humphrey Fellow, Virginia Commonwealth University, United States

- 404 *Socio-demographic and drug use profiles of persons who inject drugs (PWID) across different HIV prevention service utilization patterns in Ukraine*  
I. Barska<sup>1</sup>, M. Samko<sup>1</sup>, Dumchev<sup>2</sup>. <sup>1</sup>International HIV/AIDS Alliance–Ukraine, Ukraine; <sup>2</sup>Ukrainian Institute on Public Health Policy, Ukraine
- 405 *At risk and at home: Young women who have left school early*  
T. Carney<sup>1</sup>, B. Myers<sup>1,2</sup>, K. Johnson<sup>1</sup>, F. A. Browne<sup>3</sup>, T. Kline<sup>3</sup>, I. Doherty<sup>3</sup>, W. M. Wechsberg<sup>3-6</sup>. <sup>1</sup>Alcohol, Tobacco and Other Drug Abuse Research Unit, South African Medical Research Council, South Africa; <sup>2</sup>Department of Psychiatry and Mental Health, University of Cape Town, South Africa; <sup>3</sup>RTI International, United States; <sup>4</sup>Health, Policy and Administration, Gillings School of Global Public Health, The University of North Carolina, Chapel Hill, United States; <sup>5</sup>Psychology in the Public Interest, North Carolina State University, United States; <sup>6</sup>Psychiatry and Behavioral Sciences, School of Medicine, Duke University, United States
- 406 *Peak versus off-peak effects of cannabis: Impacts on driving performance*  
G. Gaffney<sup>1,2</sup>, G. Milavetz<sup>1,3</sup>, T. Brown<sup>1</sup>, A. Spurgin<sup>1,3</sup>, R. J. Johnson<sup>4</sup>. <sup>1</sup>National Advanced Driving Simulator, University of Iowa, United States; <sup>2</sup>Carver College of Medicine, University of Iowa, United States; <sup>3</sup>College of Pharmacy, University of Iowa, United States; <sup>4</sup>Advanced Brain Monitoring–San Diego, United States
- 407 *Can peers be more important than friends in predicting adolescents' drug use?*  
A. Gardikiotis<sup>1</sup>, W. D. Crano<sup>2</sup>. <sup>1</sup>Aristotle University of Thessaloniki, Greece; <sup>2</sup>Claremont Graduate University, United States
- 408 *Substance use disorders among adolescent girls in Paraguay and its potential consequences on their offspring*  
E. G. Gonzalez Willim. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 409 *National Drug Facts Week campaign in Egypt in collaboration with NIDA*  
A. Hammad<sup>1</sup>, M. Elkhoully<sup>1</sup>, M. Hussein<sup>1</sup>, H. Hassan<sup>2</sup>, W. Ebrahim<sup>3,4</sup>, M. ElHamshary<sup>4,5</sup>. <sup>1</sup>Abbasiya Mental Hospital, Egypt; <sup>2</sup>National Research Center, Egypt; <sup>3</sup>AinShams University, Egypt; <sup>4</sup>Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; <sup>5</sup>Psychological Medicine Hospital, Egypt
- 410 *Food insecurity and HIV drug and sex risk behaviors among Russians living with HIV*  
B. Idrisov<sup>1</sup>, K. Lunze<sup>2</sup>, D. M. Cheng<sup>2</sup>, E. Blokhina<sup>3</sup>, N. Gnatenko<sup>2</sup>, G. Patts<sup>2</sup>, A. Tyurina<sup>3</sup>, C. Bridden<sup>2</sup>, C. Chaisson<sup>2</sup>, M. J. Larson<sup>4</sup>, E. Krupitsky<sup>3</sup>, J. H. Samet<sup>2</sup>. <sup>1</sup>Bashkir State Medical University, Russia; <sup>2</sup>Boston University, United States; <sup>3</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>4</sup>Brandeis University, United States
- 411 *Ambiguous roles of police in harm minimization in Nepal*  
C. K. Jha, D. M. Donovan. Alcohol and Drug Abuse Institute, University of Washington, United States
- 412 *Family and socio-cultural practices influencing the onset and continuation of alcohol and drug use among youth polytechnic students in Kirinyaga County, Kenya*  
T. K. Kinai. Kenyatta University, Kenya
- 413 *Reduce substance use and road accidents among commercial drivers in Greater Accra Region, Ghana*  
S. Koomson. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States

- 414 *Validation of self-reported risk practices among persons who inject drugs in Ukraine: Findings from the ethnographic study*  
V. Kushakov, I. Sazonova, T. Salyuk. ICF “International HIV/AIDS Alliance–Ukraine,” Ukraine
- 415 *Adapting keepin’ it REAL for Mexico: The effects on trajectories of substance use behaviors*  
F. Marsiglia<sup>1</sup>, S. Kulis<sup>1</sup>, B. Nuño-Gutierrez<sup>2</sup>, J. Booth<sup>3</sup>, S. Ayers<sup>1</sup>. <sup>1</sup>Southwest Interdisciplinary Research Center, Arizona State University, United States; <sup>2</sup>Mexican Social Security Institute, Mexico; <sup>3</sup>School of Social Work, University of Pittsburgh, United States
- 416 *Peer educator program among injecting drug users associated with lower incidence of HIV, HVC, and HVB infection*  
R. Myint<sup>1</sup>, L. A. Swe<sup>2</sup>. <sup>1</sup>Myanmar Anti Narcotic Association, Burma (Myanmar); <sup>2</sup>Community-Based Self-Help Group, Burma (Myanmar)
- 417 *HIV testing uptake among methadone maintenance treatment patients and testing referrals for their sexual partners*  
L. Nguyen<sup>1</sup>, B. X. Tran<sup>2</sup>. <sup>1</sup>School of Public Health, Harvard University, United States; <sup>2</sup>Bloomberg School of Public Health, Johns Hopkins University, United States
- 418 *Substance use among secondary school students in Calabar, Nigeria: A study in advance of establishing a school-based prevention program*  
U. C. Onukogu<sup>1</sup>, E. E. Ekpe<sup>1</sup>, B. Edet<sup>1</sup>, C. A. Anya<sup>2</sup>. <sup>1</sup>Federal Neuro Psychiatric Hospital, Calabar, Nigeria; <sup>2</sup>Federal University Zamfara, Nigeria
- 419 *Introduction of a tamper-resistant formulation of controlled-release oxycodone: A prospective cohort study*  
A. Peacock<sup>1</sup>, L. Degenhardt<sup>2</sup>, B. Larance<sup>2</sup>, E. Cama<sup>2</sup>, N. Lintzeris<sup>3</sup>, R. Ali<sup>4</sup>, R. Bruno<sup>1</sup>. <sup>1</sup>School of Medicine, University of Tasmania, Australia; <sup>2</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>3</sup>Sydney Medical School, Sydney University, Australia; <sup>4</sup>University of Adelaide, Australia
- 420 *From zero to demand: Moving Guatemala City public schools toward substance abuse prevention for adolescents*  
M. Porta<sup>1</sup>, P. Dustman<sup>2</sup>, J. Booth<sup>3</sup>. <sup>1</sup>Uyumcap Organization, Guatemala City, Guatemala; <sup>2</sup>Southwest Interdisciplinary Research Center, Arizona State University, United States; <sup>3</sup>School of Social Work, University of Pittsburgh, United States
- 421 *HIV risks due to substance abuse—the case of Nepal*  
M. B. Poudyal-Chhetri. Nepal Center for Disaster Management, Nepal
- 422 *Risk and protective factors for recreational and hard drug use among Malaysian adolescent and young adults*  
M. Razali<sup>1</sup>, W. Kliewer<sup>2</sup>. <sup>1</sup>Sultan Idris Education University, Malaysia; <sup>2</sup>Virginia Commonwealth University, United States
- 423 *Evaluation of “Choice-8” effect a year after implementing the substance abuse prevention program*  
V. Ryabukha. Prevention Center, “Choice,” Ukraine
- 424 *Risky injection practices among persons who inject drugs (PWID) in smaller Ukrainian cities: An overlooked at-risk population of PWID*  
T. Salyuk, I. Sazonova. ICF “International HIV/AIDS Alliance–Ukraine,” Ukraine
- 425 *Evaluation of impact of HIV prevention programs for persons who inject drugs on HIV seroconversion by using a cohort study design.*  
M. Samko<sup>1</sup>, J. Barska<sup>1</sup>, Dumchev<sup>2</sup>. <sup>1</sup>ICF “International HIV/AIDS Alliance–Ukraine,” Ukraine; <sup>2</sup>Ukrainian Institute on Public Health Policy, Ukraine

- 426 *A critical analysis of the falling age of initiation among injecting drug users and the programmatic response in Manipur, India*  
K. K. Shimray. Royal Tropical Institute, Vrije Universiteit, The Netherlands
- 427 *Factors associated with participation in HIV case management intervention among Russian drug users*  
O. Toussova<sup>1</sup>, D. M. Cheng<sup>2</sup>, E. Blokhina<sup>1</sup>, C. Bridden<sup>3</sup>, N. Gnatienco<sup>3</sup>, E. Quinn<sup>2</sup>, A. Raj<sup>4</sup>, T. Kiriazova<sup>5</sup>, K. Lunze<sup>2</sup>, A. Y. Walley<sup>2,3</sup>, E. M. Krupitsky<sup>1,6</sup>, J. H. Samet<sup>2,3</sup>. <sup>1</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>2</sup>Boston University, United States; <sup>3</sup>Boston Medical Center, United States; <sup>4</sup>University of California, San Diego, United States; <sup>5</sup>Future without AIDS—Odessa, Ukraine; <sup>6</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia
- 428 *Familias unidas for high-risk adolescents: Cultural adaptation of a U.S. drug and HIV prevention intervention in Ecuador—preliminary results of phase I (pilot) testing*  
G. Valenzuela<sup>1</sup>, A. Quevedo<sup>1</sup>, C. Condo<sup>1</sup>, M. Albán<sup>1</sup>, G. Prado<sup>2</sup>, Y. Estrada<sup>2</sup>, M. Tapia<sup>2</sup>, M. Velazquez<sup>2</sup>, P. Jacobs<sup>1</sup>. <sup>1</sup>The Catholic University de Santiago, Ecuador; <sup>2</sup>University of Miami, United States
- 429 *Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia*  
A. Vijay<sup>1</sup>, A. R. Bazazi<sup>1,2</sup>, A. Kamarulzaman<sup>1,3</sup>, F. L. Altice<sup>1,2,3</sup>. <sup>1</sup>AIDS Program, Section of Infectious Diseases, Department of Medicine, School of Medicine, Yale University, United States; <sup>2</sup>School of Public Health, Yale University, United States; <sup>3</sup>Centre of Excellence for Research in AIDS (CERiA), Universiti of Malaya, Malaysia
- 430 *Family functioning and self-esteem among substance abusers in two substance abuse treatment centres, Kuala Lumpur*  
S. Wahab<sup>1</sup>, E. C. Lau<sup>2</sup>, A. M. Zahidi<sup>2</sup>, N. M. Ishak<sup>2</sup>, A. Tsutsumi<sup>3</sup>, S. E. Haque<sup>3</sup>, N. A. Muhammad<sup>4</sup>, M. Mazlan<sup>5</sup>. <sup>1</sup>Department of Psychiatry, Universiti Kebangsaan Malaysia Medical Centre, Malaysia; <sup>2</sup>PERMATApintar™, National Gifted Centre, Universiti Kebangsaan, Malaysia; <sup>3</sup>International Institute for Global Health, United Nations University, Malaysia; <sup>4</sup>Institute for Medical Research, Malaysia; <sup>5</sup>Substance Abuse Research Centre, Malaysia
- 431 *Methamphetamine use and risk behavior in Cape Town adolescents*  
E. H. Weybright<sup>1</sup>, L. Wegner<sup>2</sup>, P. Bediako<sup>3</sup>, L. L. Caldwell<sup>4</sup>, E. A. Smith<sup>5</sup>. <sup>1</sup>Human Development, Washington State University, United States; <sup>2</sup>Occupational Therapy, University of the Western Cape, South Africa; <sup>3</sup>Health Policy and Administration, Pennsylvania State University, United States; <sup>4</sup>Recreation, Park, and Tourism Management, Pennsylvania State University, United States; <sup>5</sup>Prevention Research Center, Pennsylvania State University, United States

**Treatment**

- 500 *An alternative to incarceration of drug users: A comparative study of Ghana and the United States*  
D. Amankwaah. Narcotics Control Board, Ghana
- 501 *The evolution of illicit opioid use among HIV-infected opioid users in Russia (2004–2014)*  
E. Blokhina<sup>1</sup>, E. M. Krupitsky<sup>1,2</sup>, D. M. Cheng<sup>3</sup>, C. Bridden<sup>4</sup>, A. Y. Walley<sup>3</sup>, O. Toussova<sup>1</sup>, T. Yaroslavtseva<sup>1</sup>, N. Gnatienco<sup>4</sup>, L. Forman<sup>3</sup>, J. H. Samet<sup>3,4</sup>. <sup>1</sup>First St. Petersburg Pavlov State Medical University, Russia; <sup>2</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; <sup>3</sup>Boston University, United States; <sup>4</sup>Boston Medical Center, United States

- 502 *Limitations to participation in opioid maintenance treatment in Europe*  
L. Brandt<sup>1</sup>, A. Unger<sup>2</sup>, L. Moser<sup>1</sup>, G. Fischer<sup>1,2</sup>, R. Jagsch<sup>3</sup>. <sup>1</sup>Center for Public Health, Medical University of Vienna, Austria; <sup>2</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria; <sup>3</sup>Faculty of Psychology, University of Vienna, Austria
- 503 *Evaluation of cognitive functioning of co-occurring opiate and amphetamine-type stimulant use disorders in Malaysia*  
W-T. Chooi<sup>1</sup>, N. M. Zaharim<sup>1</sup>, A. Desrosiers<sup>2</sup>, I. Ahmad<sup>1</sup>, M. A. M. Yasin<sup>1</sup>, S. Z. Syed-Jaapar<sup>1</sup>, R. S. Schottenfeld<sup>2</sup>, B. K. Vicknasingam<sup>1</sup>, M. C. Chawarski<sup>2</sup>. <sup>1</sup>Universiti Sains, Malaysia; <sup>2</sup>School of Medicine, Yale University, United States
- 504 *A comparison of outcomes and costs in three modalities of opioid dependence treatment in Ukraine*  
V. Chtenguelov<sup>1</sup>, S. Dvoriak<sup>2</sup>, G. Prib<sup>3</sup>. <sup>1</sup>Department of Social Work and Applied Psychology, Academy of Labor, Social Relations and Tourism, Ukraine; <sup>2</sup>Ukrainian Institute on Public Health Policy, Ukraine; <sup>3</sup>Department of Psychology, Institute of Professional Training for Public Employment Service, Ukraine
- 505 *Illicit drug users age 60 and older in Western Rio de Janeiro, Brazil: Trajectory, added risks, and experiences*  
J. Da Silva, M. Rodrigues, J. Santos. Anna Nery School of Nursing, Federal University of Rio de Janeiro, Brazil
- 506 *Screening, brief intervention, and referral to treatment (SBIRT) implementation in primary care centers in Brazil: Innovative technology-building relationships*  
F. De Conto, S. A. L. Saraiva, R. de Cerqueira Campos, J. Zepeda. Florianopolis Department of Mental Health and Primary Care, Brazil
- 507 *A 6-month follow-up of an integrated treatment program for opiate addiction and HIV in Vietnam*  
C. Denis<sup>1</sup>, D. Metzger<sup>1</sup>, L. Huang<sup>2</sup>, V. Trias<sup>2</sup>, M. Auriacombe<sup>3</sup>, G. Raguin<sup>2</sup>, S. Mai Thi Hoai<sup>4</sup>, G. Le Truong<sup>4</sup>, J-P. Daulouède<sup>2,3,5</sup>, C. O'Brien<sup>1</sup>. <sup>1</sup>Center for Studies of Addiction, University of Pennsylvania, United States; <sup>2</sup>Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau—ESTHER, France; <sup>3</sup>USR3413, CNRS, Someil-Attention-Neuropsychiatrie (SANPsy), University of Bordeaux, France; <sup>4</sup>Ho Chi Minh City AIDS Committee, Vietnam; <sup>5</sup>Bizia Addiction Clinic, France
- 508 *HIV status, mental health, and quality of life among opiate-using adults in Russia*  
A. Desrosiers<sup>1</sup>, E. Blokhina<sup>2</sup>, E. Krupitsky<sup>2</sup>, E. Zvartau<sup>2</sup>, R. Schottenfeld<sup>1</sup>, M. Chawarski<sup>1</sup>. <sup>1</sup>Department of Psychiatry, School of Medicine, Yale University, United States; <sup>2</sup>First Pavlov State Medical University, St. Petersburg, Russia
- 509 *Development of treatment capacity of addicted women in the context of attachment-based therapy*  
P. Dolezalova. Clinic of Addictology, Charles University in Prague, National Institut of Mental Health, Czech Republic
- 510 *International addiction medicine: A certification exam and new textbook*  
N. El-Guebaly. University of Calgary, Canada
- 511 *Psychometric properties of the Spanish-language version of the University of Rhode Island Change Assessment (URICA) scale*  
J. Fernández-Monragón, A. Pérez-López, L. Villalobos-Gallegos, L. Larios-Chávez, R. Marín-Navarrete. Ramón de la Fuente Muñiz National Institute of Psychiatry, México



- 512 *Provision of prescription drugs by the Social Security health care system in Peru from 2005 to 2014*  
F. Fiestas<sup>1</sup>, V. Dongo<sup>1</sup>, K. Hoffman<sup>2,3</sup>, J. Ponce<sup>2,3</sup>, D. McCarty<sup>4</sup>. <sup>1</sup>Seguro Social de Salud (ESSALUD), Perú; <sup>2</sup>Universidad Antonio Ruiz de Montoya, Perú; <sup>3</sup>International Center for Advanced Research and Applied Science, Perú; <sup>4</sup>Oregon Health & Science University, United States
- 513 *Retention in a methadone maintenance treatment program: Impact of comorbidity*  
F. Fonseca<sup>1,2</sup>, C. Castillo<sup>1,2</sup>, D. Martínez-Sanvisens<sup>1,2</sup>, P. Rossi<sup>1,2</sup>, A. Roquer<sup>1</sup>, M. Farré<sup>2,3</sup>, M. Torrents<sup>1,2,3</sup>. <sup>1</sup>Institut de Neuropsiquiatria I Addiccions–Parc de Salut Mar, Spain; <sup>2</sup>Institut Hospital del Mar d’Investigacions Mèdiques, Spain; <sup>3</sup>Psychiatry and Pharmacology Departments, Autonomous University of Barcelona, Spain
- 514 *International standards in the treatment of drug use disorders*  
G. Gilberto<sup>1</sup>, I. Koutsenok<sup>2</sup>, E. Saenz<sup>2</sup>, A. Busse<sup>2</sup>. <sup>1</sup>Drug Prevention and Health Branch, United Nations Office on Drugs and Crime (UNODC), Austria; <sup>2</sup>Prevention Treatment and Rehabilitation Section, UNODC, Austria
- 515 *Implementation of the Matrix Model in Cape Town, South Africa: Evaluating treatment engagement and relapse outcomes*  
H. Gouse<sup>1</sup>, J. Magidson<sup>2</sup>, W. Burnhams<sup>1</sup>, J. E. Remmert<sup>2</sup>, J. Joska<sup>1</sup>, A. W. Carrico<sup>4</sup>. <sup>1</sup>University of Cape Town, South Africa; <sup>2</sup>Massachusetts General Hospital, United States; <sup>3</sup>Harvard Medical School, United States; <sup>4</sup>University of California, San Francisco, United States
- 516 *Applicability of evidence-based treatment program for offenders under community corrections*  
A. Hetti-Arachchige. Department of Community Based Corrections, Ministry of Rehabilitation and Prison Reform, Sri Lanka
- 517 *Ensuring continuity of opioid substitution treatment (OST), HIV, and TB treatment for OST patients from annexed Crimea and occupied territory (Donetsk, Luhansk) of Ukraine*  
Z. Islam, S. Filippovych, T. Tretskaya, A. Shost, Y. Morenets. ICF “International HIV/AIDS Alliance–Ukraine, Ukraine
- 518 *Changes in P300 event-related potentials vary with changes in craving among methamphetamine-dependent patients followed at 3 and 6 months after cessation*  
H. Jiang<sup>1</sup>, W. Zhuang<sup>1</sup>, H. Cheng<sup>1</sup>, C. Li<sup>1</sup>, J. Du<sup>1</sup>, H. Sun<sup>1</sup>, Z. Chen<sup>1</sup>, D. Xu<sup>2</sup>, J. Wang<sup>1</sup>, M. Zhao<sup>1</sup>. <sup>1</sup>Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, China; <sup>2</sup>Shanghai Bureau of Drug Administration, China
- 519 *Effectiveness of psycho-educational group therapy to motivate change among addicts in the early stages of change*  
M. R. Jusoh<sup>1</sup>, M. H. Abd. Halim<sup>2</sup>. <sup>1</sup>National Antidrug Agency, Malaysia; <sup>2</sup>Universiti Sains Islam Malaysia
- 520 *Comprehensive women-centered treatment for substance use in Georgia: Initial examination of drug use and HIV risk*  
I. Kirtadze<sup>1</sup>, D. Otiashvili<sup>1</sup>, K. O’Grady<sup>2</sup>, W. Zule<sup>3</sup>, E. Krupitsky<sup>4</sup>, W. Wechsberg<sup>3</sup>, H. E. Jones<sup>5</sup>. <sup>1</sup>Addiction Research Center, Alternative Georgia, Georgia; <sup>2</sup>Department of Psychology, University of Maryland, United States; <sup>3</sup>RTI International, United States; <sup>4</sup>Department of Addictions, Bekhterev Research Psychoneurological Institute, St. Petersburg, Russia; <sup>5</sup>University of North Carolina (UNC) Horizons, Department of Obstetrics and Gynecology, UNC at Chapel Hill, United States

- 521 *Alcohol screening among opioid agonist patients in a primary care and opioid treatment program*  
J. Klimas<sup>1,2</sup>, J. Muench<sup>3</sup>, K. Wiest<sup>4</sup>, R. Croff<sup>5</sup>, T. Rieckman<sup>5</sup>, D. McCarty<sup>5</sup>. <sup>1</sup>School of Medicine and Medical Science, University College Dublin, Ireland; <sup>2</sup>Addiction & Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, Canada; <sup>3</sup>Department of Family Medicine, Oregon Health & Science University (OHSU), United States; <sup>4</sup>Comprehensive Options for Drug Abusers, Inc., United States; <sup>5</sup>Department of Public Health and Preventive Medicine, OHSU, United States
- 522 *Anhedonia, depression, anxiety, and craving for opiates in opiate addicts stabilized on oral naltrexone and long-acting naltrexone implant*  
E. Krupitsky<sup>1,2</sup>, E. Zvartau<sup>2</sup>, E. Blokhina<sup>2</sup>, E. Verbitskaya<sup>2</sup>, V. Palatkin<sup>2</sup>, A. Tyurina<sup>2</sup>, T. Yaroslavtseva<sup>1</sup>, N. Bushara<sup>2</sup>, A. Pecoraro<sup>3</sup>, G. Woody<sup>3</sup>. <sup>1</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; <sup>2</sup>St. Petersburg Pavlov State Medical University, Russia; <sup>3</sup>University of Pennsylvania, Philadelphia, United States
- 523 *Changes of CD4 cell counts in patients with antiretroviral treatment and associated factors, including drug use at outpatient clinics in Hanoi*  
L. La<sup>1</sup>, T. Le<sup>1</sup>, D. Nguyen<sup>1</sup>, H. Nguyen<sup>1</sup>, H. Tran<sup>1</sup>, D. Cao<sup>1</sup>, N. Vu<sup>2</sup>, T. Do<sup>2</sup>, H. Le<sup>2</sup>, X. Le<sup>2</sup>, S. Nguyen<sup>3</sup>, H. Vu<sup>4</sup>. <sup>1</sup>Hanoi AIDS Center, Vietnam; <sup>2</sup>Hanoi School of Public Health, Vietnam; <sup>3</sup>Hanoi Medical School, Vietnam; <sup>4</sup>Substance Abuse and Mental Health Services Administration, U. S. Department of Health and Human Services, Vietnam
- 524 *Trends and gender differences in drug use patterns as reported by polydrug users seeking treatment in a therapeutic community in Israel (2011–2014)*  
M. Lawental<sup>1</sup>, E. Shahar<sup>2</sup>, A. Michael<sup>2</sup>, E. Lawental<sup>3</sup>. <sup>1</sup>University of Haifa, Israel; <sup>2</sup>Ha'Derech TC, Israel; <sup>3</sup>Tel-Hai Academic College, Israel
- 525 *Incremental cost-effectiveness of a voucher-based contingency management protocol added to cognitive behavioral treatment for smoking cessation*  
C. López-Núñez, F. Alonso-Pérez, S. Weidberg, I. Pericot-Valverde, R. Secades-Villa. Department of Psychology, University of Oviedo, Spain
- 526 *Compulsory addiction treatment and subsequent hospitalizations: A Swedish registry-based study*  
L. Lundgren<sup>1,2</sup>, D. McCarty<sup>3</sup>, M. Padyab<sup>1</sup>. <sup>1</sup>Umea University, Sweden; <sup>2</sup>Boston University, United States; <sup>3</sup>Oregon Health & Sciences University, United States
- 527 *Implementation of case management to link HIV-infected Russian addiction patients to HIV services*  
K. Lunze<sup>1</sup>, T. Kiriazova<sup>2</sup>, E. Blokhina<sup>3</sup>, N. Gnatienco<sup>1</sup>, L. Wulach<sup>1</sup>, C. Curnyn<sup>1</sup>, N. Bushara<sup>3</sup>, C. Bridden<sup>1</sup>, E. Krupitsky<sup>3</sup>, A. Raj<sup>4</sup>, A. Gifford<sup>1</sup>, J. H. Samet<sup>1</sup>. <sup>1</sup>Boston University, United States; <sup>2</sup>Future without AIDS, Ukraine; <sup>3</sup>First Pavlov State Medical University, Russia; <sup>4</sup>University of California, San Diego, United States
- 528 *Effects of cytidine 5'-diphosphocholine administration on gray matter volumes in methamphetamine dependents*  
I. K. Lyoo<sup>1,2,3</sup>, S. Yoon<sup>1</sup>, Y. H. Sung<sup>4</sup>, J. Hwang<sup>5</sup>, J. E. Kim<sup>1,3</sup>, E. Namgung<sup>1,3</sup>, S. Oh<sup>1,3</sup>, S. Moon<sup>1,2</sup>, S. Kim<sup>1,3</sup>, S. Yu<sup>1,3</sup>, P. F. Renshaw<sup>4</sup>. <sup>1</sup>Ewha Brain Institute, Ewha W. University, South Korea; <sup>2</sup>Graduate School of Pharmaceutical Sciences, Ewha W. University, South Korea; <sup>3</sup>Brain and Cognitive Sciences, Ewha W. University, South Korea; <sup>4</sup>The Brain Institute, University of Utah, United States; <sup>5</sup>Department of Psychiatry, Soonchunhyang University, South Korea

- 529 *Vocalized truths: Participation of Iranian drug-using women in a qualitative study*  
E. Merghati-Khoii<sup>1</sup>, Kate Dolan<sup>2</sup>, Threse Kileen<sup>3</sup>, Faribal Yaddollahi<sup>4</sup>. <sup>1</sup>Iranian National Center of Addiction Studies, Tehran University of Medical Sciences, Iran; <sup>2</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>3</sup>Clinical Neuroscience Division, Medical University of South Carolina, United States; <sup>4</sup>School of Public Health, Iran University of Medical Sciences, Iran
- 530 *Cognition and impulsiveness in adults with attention-deficit/hyperactivity disorder (ADHD) with and without cocaine and/or crack dependence*  
C. S. Miguel<sup>1</sup>, P. A. Martins<sup>2</sup>, M. Klein<sup>1</sup>, N. A. Moleda<sup>3</sup>, P. J. Cunha<sup>4,5</sup>, M. A. Gobbo<sup>1</sup>, T. Chaim<sup>4</sup>, T. M. Alves<sup>1</sup>, M. A. Silva<sup>1</sup>, M. R. Louzã<sup>1,2</sup>. <sup>1</sup>Adult ADHD Research Program (PRODATH), Institute of Psychiatry (ISP), Faculty of Medicine, University of São Paulo (USP), Brazil; <sup>2</sup>Early Psychosis Evaluation and Intervention Program (ASAS), ISP, Faculty of Medicine, USP, Brazil; <sup>3</sup>Universidade Prebisteriana Mackenzie, Brazil; <sup>4</sup>Laboratory of Neuroimaging (LIM-21), Faculty of Medicine, USP, Brazil; <sup>5</sup>Interdisciplinary Group of Studies on Alcohol and Drugs (GREA), Faculty of Medicine, USP, Brazil
- 531 *Considerations about psychotropic drugs and their repercussions in physicians' prescription habits*  
F. J. Montero-Bancalero<sup>1</sup>, E. Moreno-San-Pedro<sup>2</sup>, J. Gómez-Bujedo<sup>2</sup>. <sup>1</sup>University of Osuna, Spain; <sup>2</sup>University of Huelva, Spain
- 532 *Addressing substance use within primary health care settings in South Africa: Opportunities and challenges*  
B. Myers<sup>1</sup>, K. Sorsdahl<sup>2</sup>. <sup>1</sup>Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, South Africa; <sup>2</sup>Alan J. Flisher Centre for Public Mental Health, University of Cape Town, South Africa
- 533 *Adult antisocial behaviors in methadone patients with and without comorbid alcohol use disorder*  
E. Ngjelina, A. Edwards, D. Pomm, K. Polak, C. Wagner, K. Kendler, D. Svikis. Virginia Commonwealth University, United States
- 534 *An Australian cohort of pharmaceutical opioid users in treatment*  
S. Nielsen<sup>1,2</sup>, B. Larance<sup>1</sup>, N. Lintzeris<sup>2,3</sup>, S. Holliday<sup>4</sup>, M. Vanderhaven<sup>1</sup>, G. Lattas<sup>1</sup>, A. Hordern<sup>1</sup>, A. Dunlop<sup>4,5</sup>, P. Haber<sup>3,6</sup>, B. Murnion<sup>3,6</sup>, C. Silsbury<sup>7</sup>, J. Johnson<sup>8</sup>, A. Demirko<sup>2,9</sup>, C. Sadler<sup>4,5,9</sup>, N. Phung<sup>7</sup>, L. Burns<sup>1</sup>, R. Mattick<sup>1</sup>, G. Campbell<sup>1</sup>, M. Farrell<sup>1</sup>, M. Cohen<sup>10,11</sup>, R. Bruno<sup>12</sup>, M. Hardy<sup>13</sup>, A. Brown<sup>4</sup>, J. Houseman<sup>13</sup>, L. Degenhardt<sup>1</sup>. <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Australia; <sup>2</sup>The Langton Centre, South East Sydney Local Health District Drug and Alcohol Services, Australia; <sup>3</sup>Discipline of Addiction Medicine, University of Sydney, Australia; <sup>4</sup>Drug and Alcohol Clinical Services, Hunter New England Local Health District, Australia; <sup>5</sup>University of Newcastle, Australia; <sup>6</sup>Royal Prince Alfred Hospital, Australia; <sup>7</sup>Drug Health Service, Western Sydney Local Health District, Australia; <sup>8</sup>University Centre for Rural Health, Australia; <sup>9</sup>Cavalry Mater Hospital, Australia; <sup>10</sup>University of New South Wales, Australia; <sup>11</sup>St Vincent's Hospital, Australia; <sup>12</sup>University of Tasmania, Australia; <sup>13</sup>Drug and Alcohol Services, Northern Sydney Local Health District, Australia
- 535 *Does cue exposure treatment improve outcomes in smoking cessation treatment? A controlled trial*  
I. Pericot-Valverde, O. García-Rodríguez, C. López-Núñez, S. Weidberg-López, R. Secades-Villa. University of Oviedo, Spain

- 536 *Early mortality after entering a methadone treatment program in Badalona, Spain*  
I. Rivas<sup>1</sup>, A. Sanvisens<sup>2</sup>, E. Faure<sup>1</sup>, D. Fuster<sup>2</sup>, T. Muñoz<sup>1</sup>, R. Manoli<sup>1</sup>, R. Muga<sup>2</sup>. <sup>1</sup>Municipal Center for Substance Abuse Treatment, IMSP, Spain; <sup>2</sup>Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain
- 537 *Overlap between food addiction and DSM-5 eating disorders in a treatment-seeking sample*  
M. C. Rosa<sup>1,2</sup>, J. Collombat<sup>2</sup>, C. M. Denis<sup>2,3</sup>, J. Alexandre<sup>2</sup>, F. Serre<sup>2</sup>, M. Auriacombe<sup>2</sup>, M. Fatseas<sup>2</sup>. <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Brazil; <sup>2</sup>Addiction Psychiatry, USR3413, CNRS, Université Bordeaux, France; <sup>3</sup>University of Pennsylvania, United States
- 538 *Higher levels of brain-derived neurotrophic factor associated with inpatient treatment adherence of crack cocaine users*  
J. N. Scherer, S. Schuch, F. Ornell, A. A. O. Sordi, F. H. P. Kessler, L. von Diemen, F. Pechansky. Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Hospital de Clínicas of Porto Alegre, Brazil
- 539 *Electronic tool for opioid substitution treatment (OST) data collection, processing, and analysis based on the data management platform "SYREX"*  
A. Shost, Z. Islam, S. Filippovych, V. Kolomiets. ICF "International HIV/AIDS Alliance–Ukraine," Ukraine
- 540 *HIV/AIDS and opioid use: Current situation in Indonesia*  
Z. Syarif<sup>1</sup>, R. Sarasvita<sup>2</sup>, M. Chawarski<sup>3</sup>. <sup>1</sup>Psychiatry Department, University of Indonesia, Indonesia; <sup>2</sup>National Narcotics Board (BNN), Indonesia; <sup>3</sup>Psychiatry Department, School of Medicine, Yale University, United States
- 541 *Guidelines for establishment and licensing of treatment and rehabilitation centers in Ghana*  
F. K. Torkornoo. Demand Reduction Division, Narcotics Control Board, Ghana
- 542 *Opioid substitution treatment in Spain: 20 years of experience in harm reduction programs*  
M. Torrens<sup>1,2,3</sup>, F. Fonseca<sup>1,2</sup>, C. Castillo<sup>1,2</sup>, A. Domingo-Salvany<sup>2</sup>. <sup>1</sup>Institut de Neuropsiquiatria i Addiccions–Parc de Salut Mar, Spain; <sup>2</sup>Institut Hospital del Mar d'Investigacions Mèdiques, Spain; <sup>3</sup>Psychiatry Department, Autonomous University of Barcelona, Spain
- 543 *Patient preference and willingness to pay for stand-alone, integrative, and satellite models of dispensing methadone for the treatment of opioid dependence in Vietnam*  
B. X. Tran<sup>1,2</sup>, C. A. Latkin<sup>2</sup>. <sup>1</sup>Institute for Preventive Medicine and Public Health, Hanoi Medical University, Vietnam; <sup>2</sup>Bloomberg School of Public Health, Johns Hopkins University, United States
- 544 *Effects of fixed or self-titrated dosages of Sativex on cannabis users*  
J. M. Trigo<sup>1</sup>, D. Lagzdins<sup>1</sup>, J. Rehm<sup>2</sup>, P. Selby<sup>3</sup>, I. Gamaledin<sup>1</sup>, B. Fischer<sup>2,4</sup>, A. J. Barnes<sup>1</sup>, M. Huestis<sup>5</sup>, B. Le Foll<sup>1,3</sup>. <sup>1</sup>Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Canada; <sup>2</sup>Social and Epidemiological Research, CAMH, Canada; <sup>3</sup>Ambulatory Care and Structured Treatments, CAMH; <sup>4</sup>Faculty of Health Sciences, Simon Fraser University, Canada; <sup>5</sup>National Institute on Drug Abuse, National Institutes of Health, United States
- 545 *Factors associated with illicit methadone injecting in a Canadian setting*  
D. Tucker<sup>1</sup>, M-J. Milloy<sup>1,2</sup>, K. Hayashi<sup>1,2</sup>, R. Lung<sup>1</sup>, P. Nguyen<sup>1</sup>, T. Kerr<sup>1,2</sup>, E. Wood<sup>1,2</sup>. <sup>1</sup>British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Canada; <sup>2</sup>Department of Medicine, University of British Columbia, Canada

- 546 *Cannabidiol attenuates the increased susceptibility to false memories produced by tetrahydrocannabinol*  
M. Valle<sup>1</sup>, L. C. Martial<sup>1</sup>, M. Garrido<sup>1</sup>, A. Rodríguez-Fornells<sup>2</sup>, M. Punes<sup>1</sup>, R. M. Antonijoan<sup>3</sup>, J. Claramunt<sup>1</sup>, D. Martínez<sup>1</sup>, M. González<sup>1</sup>, M. Martínez<sup>1</sup>, J. Pérez de los Cobos<sup>3</sup>, J. Riba<sup>1</sup>.  
<sup>1</sup>Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Spain; <sup>2</sup>Universidad de Barcelona, Spain; <sup>3</sup>Hospital de la Santa Creu i Sant Pau, Spain
- 547 *Aripiprazole and risperidone in treatment of methamphetamine-associated psychosis in China: A pilot randomized study*  
G. Wang<sup>1</sup>, Y. Zhang<sup>2</sup>, S. Zhang<sup>2</sup>, H. Chen<sup>2</sup>, Z. Xu<sup>2</sup>, W. Hao<sup>1</sup>, M. C. Chawarski<sup>3</sup>. <sup>1</sup>Mental Health Center, The Second Xiangya Hospital, China; <sup>2</sup>Wuhan Mental Health Center, China; <sup>3</sup>Department of Psychiatry, School of Medicine, Yale University, United States
- 548 *Take-home naloxone training: Comparing the effects on knowledge and attitudes between family members and drug users*  
A. V. Williams, J. Marsden, J. Strang. Institute of Psychiatry, Psychology and Neuroscience, Department of Addictions, King's College London, United Kingdom
- 549 *Cognitive impairments and psychological well-being of methamphetamine addicts*  
N. Zhong, H. Jiang, J. Du, Y. Zhao, C. Li, W. Zhuang, X. Li, W. Wang, M. Zhao. Shanghai Mental Health Center, School of Medicine, Shanghai Jiaotong University, China



**CPDD/INRC Plenary**

**AZ Biltmore Ballroom  
8:00 - 9:00 AM**

*Drug abuse and addiction research: progress, priorities and challenges*  
Nora Volkow, Director, National Institute on Drug Abuse

**INRC Session 1**

**Grand Ballroom  
9:00 - 10:00 AM**

**ADDICTION TO PRESCRIPTION OPIOIDS**

Chair: Fred Nyberg

*Prescription opioid abuse and dependence in Scandinavian Countries*  
Thomas Clausen, University of Oslo, Norway, Sweden

*Addiction and diversion of prescription opioids in Europe*  
Gabriele Fischer, Medical University of Vienna, Norway, Sweden

*Nonmedical prescription opioid use in North America*  
Pauline Voon, St. Paul's Hospital, Vancouver, BC, Canada

**Policy Forum**

**AZ Biltmore Ballroom  
9:30 - 11:30 AM**

Chairs: William L. Dewey and Martin Y. Iguchi

*Introduction:*  
William L. Dewey, VCU, Richmond, VA

*Speaker: Update from Capitol Hill*  
Ed Long, Van Scoyoc Associates, Washington, DC

*Overdose prevention: Community-driven policy change*  
Fred Wells Brason, II, Project Lazarus, Moravian Falls, NC

**Poster Session II  
(Lunch)**

**Frank Lloyd Wright Ballroom  
11:30 - 1:30 PM**

**Odd-numbered posters manned first hour;  
Even-numbered, second hour**

**Set-up time begins Monday 3:00 PM**

**Must be removed at 2:00 PM Tuesday**

**GENETICS**

- 1 *Functional and behavioral consequences of DRD4 genetic variation in macaques*  
E. J. Vallender<sup>2,4</sup>, L. M. Ogawa<sup>3,4</sup>, L. J. Lynch<sup>4</sup>, J. L. Schimmel<sup>4</sup>, G. M. Miller<sup>1,4</sup>,  
<sup>1</sup>Pharmaceutical Sciences, Northeastern University, Boston, MA, <sup>2</sup>Psychiatry and Human Behavior, University of Mississippi Medical School, Jackson, MS, <sup>3</sup>Yale University, New Haven, CT, <sup>4</sup>New England Primate Research Center, Harvard Medical School, Southborough, MA

- 2 *Clinical characteristics and genotype frequencies of the dopamine transporter gene (DAT1/SLC6A3) 3'UTR variable number of tandem repeats in crack-cocaine users*  
A. R. Stolf<sup>3</sup>, G. Akutagava-Martins<sup>2</sup>, D. Müller<sup>2</sup>, L. Guimarães<sup>3</sup>, F. P. Pechansky<sup>1</sup>, T. Roman<sup>2</sup>, F. Kessler<sup>3</sup>, <sup>1</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>2</sup>Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>3</sup>Center for Drug and Alcohol Research, UFRGS, Porto Alegre, Brazil
- 3 *Dopaminergic genetic variation moderates effect of nicotine on cigarette reward self-report*  
P. T. Harrell<sup>1</sup>, H. Lin<sup>1,2</sup>, J. Y. Park<sup>1,2</sup>, D. J. Drobles<sup>1,2</sup>, D. E. Evans<sup>1,2</sup>, <sup>1</sup>Moffitt Cancer Center, Tampa, FL, <sup>2</sup>University of South Florida, Tampa, FL
- 4 *A non-parametric method finds genetic etiology of nicotine dependence differs in males and females*  
Q. Lu<sup>1</sup>, C. Wei<sup>2</sup>, R. C. Elston<sup>3</sup>, O. Vsevolozhskaya<sup>1</sup>, <sup>1</sup>Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, <sup>2</sup>Department of Biostatistics and Epidemiology, University of North Texas Health Science Center, Fort Worth, TX, <sup>3</sup>Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
- 5 *Intrinsic clustering of treatment outcome in recovery from opioid use disorder: Results from Starting Treatment with Agonist Replacement Therapies*  
S. Luo<sup>1</sup>, J. Goldsmith<sup>1</sup>, R. Crist<sup>3</sup>, W. Berritini<sup>3</sup>, A. Saxon<sup>4</sup>, W. Ling<sup>2</sup>, M. P. Hillhouse<sup>2</sup>, E. V. Nunes<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Veterans Affairs Puget Sound Health Care System, Seattle, WA

**SEX DIFFERENCES**

- 6 *Sex difference in behavioral effects of the THC agonist CP55,940*  
H. T. French<sup>1,2</sup>, A. Klambatsen<sup>1,2</sup>, C. Chan<sup>2</sup>, S. Jenab<sup>1,2</sup>, V. Quinones-Jenab<sup>1,2</sup>, <sup>1</sup>Psychology, Graduate Center of the City University of New York, New York, NY, <sup>2</sup>Psychology, Hunter College CUNY, New York, NY
- 7 *Sex differences in dopamine and serotonin activation of brain pathways in adolescent rats exposed to social partners or amphetamine*  
V. G. Weiss<sup>1</sup>, R. S. Hofford<sup>1</sup>, J. R. Yates<sup>2</sup>, M. T. Bardo<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Northern Kentucky University, Newport, KY
- 8 *Sex differences in reinstatement of cocaine-seeking in rats after acute treatment of progesterone and atomoxetine*  
N. Swalve<sup>1</sup>, N. Zlebnik<sup>1</sup>, H. Veglahn<sup>1</sup>, M. E. Carroll<sup>2</sup>, <sup>1</sup>Psychiatry, Univ of Minnesota, Minneapolis, MN, <sup>2</sup>University of Minnesota, Mahtomedi, MN
- 9 *Age and gender effects on subjective drug effect of d-amphetamine*  
R. Pang<sup>1</sup>, M. Kirkpatrick<sup>3</sup>, N. Goldenson<sup>1</sup>, C. Guillot<sup>1</sup>, A. Leventhal<sup>1</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>Department of Preventive Medicine, University of Southern California, Azusa, CA, <sup>3</sup>Preventive Medicine, University of Southern California, Los Angeles, CA
- 10 *Gender differences in associations between neurocognitive impairment and cocaine use among high-risk cocaine-dependent methadone-maintained patients*  
R. Shrestha<sup>1</sup>, T. B. Huedo-Medina<sup>2</sup>, M. Copenhaver<sup>2</sup>, <sup>1</sup>Community Medicine & Health Care, University of Connecticut Health Center, Farmington, CT, <sup>2</sup>Allied Health Sciences, University of Connecticut, Storrs, CT

- 11 *Sex differences in intrinsic connectivity during fMRI Stroop in cocaine-dependent and healthy comparison subjects*  
M. R. Mitchell<sup>1</sup>, E. E. DeVito<sup>1</sup>, I. Balodis<sup>1</sup>, C. Lacadie<sup>2</sup>, D. Scheinost<sup>3</sup>, R. Constable<sup>2</sup>, R. Malison<sup>1</sup>, K. M. Carroll<sup>1</sup>, M. N. Potenza<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, <sup>3</sup>Biomedical Engineering, Yale University School of Medicine, New Haven, CT
- 12 *Gender differences in Stroop performance following guanfacine versus placebo in early abstinent cocaine-dependent men and women*  
V. Milivojevic<sup>1</sup>, N. Jayaram-Lindstrom<sup>2</sup>, R. Sinha<sup>1</sup>, H. C. Fox<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Karolinska Institute, Solna, Sweden
- 13 *Impact of yohimbine and cocaine-cues on executive function in cocaine-dependent men and women*  
M. Moran-Santa Maria<sup>1</sup>, K. T. Brady<sup>2,3</sup>, A. McRae-Clark<sup>2</sup>, J. Prisciandaro<sup>2</sup>, N. Baker<sup>4</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, MUSC, Charleston, SC, <sup>2</sup>Psychiatry, Medical University of South Carolina, Charleston, SC, <sup>3</sup>Ralph H Johnson VAMC, Charleston, SC, <sup>4</sup>Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC
- 14 *Gender differences in methamphetamine use in a Mexico-U.S. border city*  
O. Loza<sup>1</sup>, J. Ferreira-Pinto<sup>3</sup>, R. Ramos<sup>2</sup>, M. Ramos Rodriguez<sup>4</sup>, <sup>1</sup>Public Health Sciences, UT El Paso, El Paso, TX, <sup>2</sup>Alliance of Border Collaboratives (ABC), El Paso, TX, <sup>3</sup>UTEP College of Health Sciences, El Paso, TX, <sup>4</sup>Programa Compañeros, A.C., Ciudad Juárez, Mexico
- 15 *The Israeli club drug culture: A qualitative examination of gender differences in substance use and sexual risk behaviors*  
M. Lawental<sup>1</sup>, S. P. Kurtz<sup>3</sup>, M. E. Buttram<sup>2</sup>, <sup>1</sup>School of Social Work, University of Haifa, Haifa, Israel, <sup>2</sup>Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, <sup>3</sup>ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
- 16 *Risk of sexual abuse among ecstasy users differs by gender and other drug use*  
S. R. Khan<sup>2</sup>, C. W. Striley<sup>2</sup>, J. Copeland<sup>3</sup>, S. P. Kurtz<sup>1</sup>, L. Cottler<sup>2</sup>, <sup>1</sup>ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>3</sup>NCPIC, University of NSW, Sydney, NSW, Australia
- 17 *Substance use outcomes of girls with ADHD in a 10-year follow-up of a prospective longitudinal study*  
K. Belendiuk<sup>1</sup>, S. Hinshaw<sup>1,2</sup>, <sup>1</sup>University of California, Berkeley, CA, <sup>2</sup>University of California, San Francisco, CA
- 18 *Liability for violence in young women*  
M. D. Reynolds, S. P. Knopf, L. Kirisci, R. E. Tarter, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
- 19 *Prevalence and correlates of spousal sexual violence against married women in India*  
V. Murugan, Social Work, Washington University St. Louis, Ladue, MO
- 20 *Gender differences among MST survivors on chronic opioid therapy*  
S. Lin, D. Plott, Mental Healthcare Line, Cincinnati VAMC, Cincinnati, OH
- 21 *Gender differences in mortality among treated opioid-dependent patients*  
E. Evans<sup>2</sup>, L. Li<sup>2</sup>, J. Min<sup>1</sup>, D. Y. Huang<sup>2</sup>, D. Urada<sup>2</sup>, Y. Hser<sup>2</sup>, B. Nosyk<sup>1</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>2</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA

- 22 *Sex differences in alcohol use disorders and risky drinking among chronic non-cancer pain patients receiving opioid therapy*  
B. Larance<sup>1</sup>, A. Peacock<sup>2</sup>, G. Campbell<sup>1</sup>, R. Bruno<sup>2</sup>, N. Lintzeris<sup>3</sup>, M. Cohen<sup>1</sup>, S. Nielsen<sup>1</sup>, W. Hall<sup>4</sup>, R. P. Mattick<sup>1</sup>, L. Degenhardt<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>School of Psychology, University of Tasmania, Hobart, TAS, Australia, <sup>3</sup>Langton Centre, South Eastern Sydney and Illawarra Local Health District, Sydney, NSW, Australia, <sup>4</sup>University of Queensland, Brisbane, QLD, Australia
- 23 *The gendered risk environment for injection drug use: An event specific analysis of injection risk behavior*  
P. Janulis, Department of Epidemiology and Biostatistics, Michigan State University, Lansing, MI
- 24 *Medical and mental health needs of lesbian, gay, and bisexual clients in substance abuse treatment*  
A. Flentje<sup>1</sup>, N. Livingston<sup>2</sup>, J. Roley<sup>3</sup>, J. Sorensen<sup>1</sup>, <sup>1</sup>University of California, San Francisco, San Francisco, CA, <sup>2</sup>University of Montana, Missoula, MT, <sup>3</sup>Drexel University, Philadelphia, PA

#### PHARMACOKINETICS

- 25 *Heroin metabolism in blood and not in brain is critical to its acute effects*  
F. Boix Escolan, J. M. Andersen, I. Bogen, A. Gottås, J. G. Mørland, Division for Forensic Sciences, Norwegian Institute of Public Health, Oslo, Norway
- 26 *Do they really inject heroin? A study on the possible changes in opioid content during heroin preparation for intravenous injection*  
J. G. Mørland, J. M. Andersen, I. Bogen, R. Karinen, G. Brochman, E. L. Øiestad, V. Vindenes, F. Boix Escolan, Division of Forensic Sciences, Norwegian Institute of Public Health, Oslo, Norway
- 27 *Pharmacokinetics of bupropion sustained release in pregnancy and postpartum at steady state*  
V. M. Fokina<sup>1,3</sup>, X. Wang<sup>1</sup>, E. Rytting<sup>1</sup>, M. S. Ahmed<sup>1</sup>, C. Oncken<sup>2</sup>, G. Hankins<sup>1</sup>, T. Nanovskaya<sup>1</sup>, <sup>1</sup>OB&GYN, UTMB, Galveston, TX, <sup>2</sup>Medicine, University of Connecticut Health Center, Farmington, CT, <sup>3</sup>Pharmacology & Toxicology, UTMB, Galveston, TX
- 28 *Modulation of buprenorphine partial agonism by the opioid antagonist samidorphan: A mechanistic PK/PD model*  
R. Turncliff, W. I. Li, Translational Medicine, Alkermes, Inc., Waltham, MA
- 29 *Oral human abuse potential of Oxycodone DETERx: An abuse-deterrent, extended-release formulation in recreational opioid users*  
E. A. Kopecky, A. B. Fleming, M. O'Connor, R. K. Varanasi, Collegium Pharmaceutical, Inc., Canton, MA
- 30 *Single-center, randomized, double-blind crossover study evaluation of the abuse potential, PK, and safety of crushed and intranasally administered immediate release oxycodone tablets in recreational opioid users*  
S. Colucci<sup>1</sup>, S. Harris<sup>1</sup>, K. Friedman<sup>1</sup>, M. Shram<sup>2</sup>, <sup>1</sup>Purdue Pharma L.P., Stamford, CT, <sup>2</sup>Alteos Research Partners, Toronto, ON, Canada
- 31 *Impact of CYP2D6 phenotype on response to methamphetamine in healthy volunteers*  
A. Oliveto<sup>1</sup>, B. Gurley<sup>2</sup>, H. Hendrickson<sup>2</sup>, W. B. Gentry<sup>2</sup>, J. D. Thostenson<sup>2</sup>, M. J. Mancino<sup>1</sup>, <sup>1</sup>Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR

- 32 *The role of carbonyl reductases in biotransformation of bupropion and 4-methylnitrozamino-1-(3-pyridyl)-1-butanone by human placenta*  
T. Nanovskaya<sup>1</sup>, V. M. Fokina<sup>1,2</sup>, X. Wang<sup>1</sup>, C. Oncken<sup>3</sup>, M. S. Ahmed<sup>1</sup>, G. Hankins<sup>1</sup>,  
<sup>1</sup>OB&GYN, UTMB, Galveston, TX, <sup>2</sup>Pharmacology & Toxicology, UTMB, Galveston, TX,  
<sup>3</sup>Medicine, University of Connecticut Health Center, Farmington, TX
- 33 *Does electronic cigarette liquid nicotine concentration and user experience influence plasma nicotine concentration?*  
C. Ramoa, T. Spindle, K. Osei, B. Kilgalen, A. Breland, T. Eissenberg, Psychology, VCU,  
Richmond, VA
- 34 *Physical and self-reported response and the pharmacokinetics of e-cigarettes compared to cigarettes in substance-abusing participants*  
O. Brooks<sup>1</sup>, C. Lederhos<sup>1</sup>, A. Lamp<sup>1</sup>, D. Howell<sup>1</sup>, J. White<sup>1</sup>, J. Padowski<sup>2</sup>, M. Layton<sup>1</sup>,  
D. Moody<sup>3</sup>, J. M. Roll<sup>1</sup>, S. McPherson<sup>1</sup>, <sup>1</sup>Program of Excellence in Addictions Research  
(PEAR), Washington State University, Spokane, WA, <sup>2</sup>Washington State University,  
Spokane, WA, <sup>3</sup>University of Utah, Salt Lake City, UT
- 35 *Nicotine dependence, nicotine metabolism, and the extent of compensation in response to reduced nicotine content cigarettes*  
K. Ross<sup>1</sup>, F. Bandiera<sup>2</sup>, S. Taghavi<sup>3</sup>, K. Delucchi<sup>1</sup>, R. Tyndale<sup>3</sup>, N. Benowitz<sup>1</sup>, <sup>1</sup>Center for  
Tobacco Control, Research, & Education, University of California, San Francisco, San  
Francisco, CA, <sup>2</sup>University of Texas, Dallas, Dallas, TX, <sup>3</sup>University of Toronto, Toronto, ON,  
Canada
- 36 *Financial incentives promote smoking abstinence among patients with pulmonary disease*  
A. C. Meyer, J. M. Streck, T. A. Ochalek, B. Hruska, C. C. Teneback, A. E. Dixon,  
S. C. Sigmon, University of Vermont, Burlington, VT
- 37 *Migration and time to first tobacco cigarette after waking*  
W. Xue<sup>1</sup>, J. C. Anthony<sup>2</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Epidemiology and  
Biostatistics, Michigan State University, East Lansing, MI

#### NICOTINE TREATMENT

- 38 *Smoking and cardiac rehabilitation program completion*  
D. Gaalema<sup>1</sup>, A. Cutler<sup>1</sup>, S. T. Higgins<sup>1</sup>, P. Savage<sup>2</sup>, P. Ades<sup>1,2</sup>, <sup>1</sup>University of Vermont,  
Burlington, VT, <sup>2</sup>University of Vermont Medical Center, Burlington, VT
- 39 *Cigarette craving is associated with blunted reward processing in nicotine-dependent smokers*  
A. L. Peechatka<sup>1,2</sup>, A. E. Whitton<sup>1</sup>, S. L. Farmer<sup>1</sup>, D. A. Pizzagalli<sup>1</sup>, A. Janes<sup>1</sup>, <sup>1</sup>McLean  
Hospital/ Harvard Medical School, Belmont, MA, <sup>2</sup>Psychology, Suffolk University,  
Boston, MA
- 40 *Does craving intensity influence cue exposure reports? An Ecological Momentary Assessment study in patients with alcohol, tobacco, cannabis and heroin use disorder*  
F. Serre<sup>1</sup>, M. Fatseas<sup>1</sup>, J. Swendsen<sup>2</sup>, M. Auriacombe<sup>1</sup>, <sup>1</sup>Addiction Psychiatry (CNRS USR  
3413), Universite Bordeaux, Bordeaux, France, <sup>2</sup>CNRS UMR 5284 INCIA Univ. Bordeaux,  
Bordeaux, France
- 41 *Cigarette smoking trajectories among comorbid cocaine-dependent and attention deficit/hyperactivity-disorder individuals treated with extended-release mixed amphetamine salts*  
B. Sou<sup>1</sup>, A. Glass<sup>2</sup>, D. J. Brooks<sup>3</sup>, A. Mahony<sup>5</sup>, J. J. Mairani<sup>3</sup>, J. Grabowski<sup>4</sup>, F. R. Levin<sup>3</sup>, <sup>1</sup>The  
Sophie Davis School of Biomedical Education, New York, NY, <sup>2</sup>Biostatistics, New York State  
Psychiatric Institute, New York, NY, <sup>3</sup>New York State Psychiatric Institute, New York, NY,  
<sup>4</sup>Psychiatry, University of Minnesota, Minneapolis, MN, <sup>5</sup>New York State Psychiatric  
Institute, New York, NY



- 42 *Does cue exposure treatment improve outcomes in smoking cessation treatment? A controlled trial*  
I. Pericot-Valverde<sup>1</sup>, O. Garcia-Rodriguez<sup>1</sup>, C. López-Núñez<sup>2</sup>, S. Weidberg<sup>1</sup>, R. Secades-Villa<sup>2</sup>, <sup>1</sup>Psychology, University of Oviedo, Oviedo, Spain, <sup>2</sup>University of Oviedo, Oviedo, Spain
- 43 *Episodic future thinking reduces delay discounting in cigarette smokers*  
J. S. Stein<sup>1</sup>, T. O. Daniel<sup>2</sup>, L. H. Epstein<sup>2</sup>, W. K. Bickel<sup>1</sup>, <sup>1</sup>Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Department of Pediatrics, University at Buffalo, Buffalo, NY
- 44 *Treating smokers in substance treatment with contingent vouchers, nicotine replacement and brief advice adapted for sobriety settings*  
R. A. Martin<sup>1</sup>, D. Rohsenow<sup>1,2</sup>, J. W. Tidey<sup>1</sup>, S. Colby<sup>1</sup>, P. Monti<sup>1</sup>, <sup>1</sup>Center for Alcohol and Addiction Studies, Brown University, Providence, RI, <sup>2</sup>Providence Veterans Affairs Medical Center, Providence, RI
- 45 *Incremental cost-effectiveness of a voucher-based CM protocol added to a CBT for smoking cessation*  
C. López-Núñez<sup>1</sup>, F. Alonso Pérez<sup>2</sup>, S. E. Weidberg<sup>1</sup>, I. Pericot-Valverde<sup>1</sup>, R. Secades-Villa<sup>1</sup>, <sup>1</sup>Psychology, University of Oviedo, Oviedo, Spain, <sup>2</sup>Psychology, University of Oviedo, Oviedo, Asturias, Spain
- 46 *Smoking status on day 3 of a quit attempt predicts future smoking outcomes*  
B. Hruska<sup>1</sup>, A. C. Meyer<sup>2</sup>, S. C. Sigmon<sup>2</sup>, <sup>1</sup>Psychiatry, The University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT
- 47 *A comparison of the behavioral effects of electronic and tobacco cigarettes following 24-hr tobacco deprivation*  
A. Harvanko<sup>1,2</sup>, C. A. Martin<sup>3</sup>, J. S. Fogel<sup>2,1</sup>, J. Lile<sup>1,2,3</sup>, T. H. Kelly<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 48 *WITHDRAWN*
- 49 *Treatment expectations predict quit attempts, reduction in cigarettes per day, and readiness to quit in smokers who were not ready to quit*  
E. M. Klemperer, J. Hughes, Psychiatry, University of Vermont, Burlington, VT
- 50 *A tobacco cessation readiness group increases initiation of quitting in residential treatment patients*  
J. Guydish<sup>1</sup>, V. Gruber<sup>1</sup>, T. Le<sup>1</sup>, B. Tajima<sup>1</sup>, B. Andrews<sup>1</sup>, H. Leo<sup>2</sup>, J. Tsoh<sup>1</sup>, <sup>1</sup>University of California San Francisco, San Francisco, CA, <sup>2</sup>Yale University, New Haven, CT
- 51 *The role of smoking-specific experiential avoidance in the relation between perceived stress and tobacco use among treatment-seeking smokers*  
L. Garey<sup>1</sup>, M. J. Zvolensky<sup>1</sup>, N. B. Schmidt<sup>2</sup>, <sup>1</sup>Department of Psychology, University of Houston, Houston, TX, <sup>2</sup>Department of Psychology, Florida State University, Tallahassee, FL
- 52 *Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts*  
A. P. Garcia-Romeu<sup>1</sup>, T. Noorani<sup>3</sup>, R. R. Griffiths<sup>2</sup>, M. W. Johnson<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Departments of Psychiatry and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

- 53 *Validation of the revised Mystical Experiences Questionnaire in experimental sessions with psilocybin*  
F. S. Barrett<sup>2</sup>, M. W. Johnson<sup>2</sup>, R. R. Griffiths<sup>2,1</sup>, <sup>1</sup>Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 54 *The brain mind connection: Effect of trait mindfulness on responses to real-time fMRI feedback in nicotine-dependent smokers*  
K. Hartwell<sup>1,2</sup>, M. Canterberry<sup>1</sup>, X. Li<sup>1</sup>, M. Moran-Santa Maria<sup>1</sup>, C. A. Hanlon<sup>1</sup>, M. George<sup>1,2</sup>, K. T. Brady<sup>1,2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Ralph H Johnson VAMC, Charleston, SC
- 55 *Acceptance as a relevant mindfulness facet for cigarette smokers*  
C. Vinci<sup>2</sup>, M. R. Peltier<sup>1</sup>, C. A. Spears<sup>3</sup>, A. L. Copeland<sup>1</sup>, <sup>1</sup>Louisiana State University, Baton Rouge, LA, <sup>2</sup>UT MD Anderson Cancer Center, Houston, TX, <sup>3</sup>The Catholic University of America, Washington, D.C., DC
- 56 *Smoking cessation intervention on Facebook: Which content generates the best engagement?*  
J. Thrull<sup>1</sup>, A. B. Klein<sup>1,2</sup>, D. Ramo<sup>1</sup>, <sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>University of California, Berkeley, Berkeley, CA
- 57 *Association between tobacco smoking and death by suicide: A competing risks hazard analysis in a large twin cohort with 35-year follow up*  
A. Evins<sup>1,2</sup>, T. Korhonen<sup>3,4,5</sup>, T. H. Kinnunen<sup>2,6</sup>, J. Kaprio<sup>3,5,7</sup>, <sup>1</sup>Psychiatry, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>Public Health, University of Helsinki, Helsinki, Finland, <sup>4</sup>Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, <sup>5</sup>National Institute for Health and Welfare, Helsinki, Finland, <sup>6</sup>Behavioral Science Consulting, Hopkinton, MA, <sup>7</sup>Institute for Molecular Medicine (FIMM), University of Helsinki, Helsinki, Finland

**PRESCRIPTION OPIOIDS**

- 58 *Using behavioral economics to predict opioid use during prescription opioid dependence treatment*  
M. Worley<sup>1</sup>, S. Shoptaw<sup>1</sup>, W. K. Bickel<sup>2</sup>, W. Ling<sup>3</sup>, <sup>1</sup>University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>3</sup>UCLA, Integrated Substance Abuse, Los Angeles, CA
- 59 *Correlates of prescription opioid legitimacy estimations among community pharmacists in Tennessee*  
N. E. Hagemeyer<sup>1</sup>, A. Alamian<sup>2</sup>, M. M. Murawski<sup>3</sup>, R. P. Pack<sup>4</sup>, <sup>1</sup>Pharmacy Practice, East Tennessee State University, Johnson City, TN, <sup>2</sup>Biostatistics and Epidemiology, East Tennessee State University, Johnson City, TN, <sup>3</sup>Pharmacy Administration, Purdue University, West Lafayette, IN, <sup>4</sup>Community and Behavioral Health, East Tennessee State University, Johnson City, TN
- 60 *Opioid prescribing practices of members of the National Dental Practice-Based Research Network*  
J. L. McCauley<sup>1</sup>, V. V. Gordan<sup>2</sup>, J. L. Riley<sup>2</sup>, R. B. Fillingim<sup>2</sup>, S. K. Makhija<sup>3</sup>, K. T. Brady<sup>1</sup>, N. Dental PBRN Collaborative Group<sup>3</sup>, <sup>1</sup>Psychiatry, Medical University of South Carolina, Charleston, SC, <sup>2</sup>University of Florida, Gainesville, FL, <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL
- 61 *Trends in prescription opioid misuse among young adult multidrug users in Miami, 2006-2014*  
M. E. Buttram<sup>1</sup>, S. P. Kurtz<sup>2</sup>, <sup>1</sup>Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, <sup>2</sup>ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL

- 62 *Potential determinants of unique and co-occurring major depression and nonmedical use of prescription opioids*  
D. S. Fink<sup>1</sup>, R. Hu<sup>1</sup>, M. Cerda<sup>1</sup>, K. Keyes<sup>1</sup>, B. D. Marshall<sup>2</sup>, S. Galea<sup>1</sup>, S. S. Martins<sup>1</sup>,  
<sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>Epidemiology, Brown University,  
Providence, RI
- 63 *Preliminary reliability and validity of an opioid overdose risk behavior scale in a community-based sample of recent veterans*  
E. R. Pouget, A. S. Bennett, L. Elliott, A. Golub, A. Rosenblum, NDRI, New York City, NY
- 64 *An online national survey and the Crime Survey for England and Wales: Are the data comparable?*  
J. L. Green<sup>1</sup>, P. I. Dargan<sup>2</sup>, D. M. Wood<sup>2</sup>, A. C. Besharat<sup>1</sup>, E. M. Martinez<sup>1</sup>, R. C. Dart<sup>1</sup>,  
<sup>1</sup>Rocky Mountain Poison & Drug Center, Denver, CO, <sup>2</sup>Guy's and St. Thomas' NHS  
Foundation Trust and King's Health Partners, London, United Kingdom
- 65 *Changes in abuse prevalence of prescription opioids and heroin across six years in the ASI-MV network for different patient subgroups*  
S. F. Butler<sup>1</sup>, T. A. Cassidy<sup>1</sup>, S. H. Budman<sup>1</sup>, <sup>1</sup>Inflexxion, Inc, Newton, MA
- 66 *Evaluation of relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users*  
K. Schoedel<sup>3</sup>, L. Rabinovich-Guilatt<sup>1</sup>, M. Gasior<sup>1</sup>, R. Malamut<sup>1</sup>, Y. Ma<sup>1</sup>, L. Webster<sup>2</sup>,  
M. Bond<sup>1</sup>, <sup>1</sup>Teva, Frazer, PA, <sup>2</sup>PRA Health Sciences, Salt Lake City, UT, <sup>3</sup>Altreos Research  
Partners, Toronto, NU, Canada
- 67 *Evaluation of the abuse potential of an hydrocodone extended-release bitartrate tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users*  
M. Bond<sup>1</sup>, M. Darwish<sup>2</sup>, Y. Ma<sup>1</sup>, L. Webster<sup>3</sup>, <sup>1</sup>Teva, Frazer, PA, <sup>2</sup>Sci-Med Bridge,  
Malvern, PA, <sup>3</sup>PRA, Salt Lake City, UT
- 68 *Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study*  
R. Weiss<sup>1,2</sup>, J. S. Potter<sup>3,1,2</sup>, M. L. Griffin<sup>1,2</sup>, S. Provost<sup>1</sup>, G. Fitzmaurice<sup>1,2,4</sup>, K. McDermott<sup>1</sup>,  
E. Srisarajivakul<sup>1</sup>, D. Dodd<sup>1</sup>, J. A. Dreifuss<sup>1,2</sup>, K. McHugh<sup>1,2</sup>, K. M. Carroll<sup>5</sup>, <sup>1</sup>McLean  
Hospital, Belmont, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>UT Health Science Center,  
San Antonio, TX, <sup>4</sup>Department of Biostatistics, Harvard School of Public Health, Boston, MA,  
<sup>5</sup>Psychiatry, Yale University School of Medicine, West Haven, CT

**PROGRAM DESCRIPTION**

- 69 *Opioid substitution treatment in Spain: 20 years of experience in harm reduction programs*  
M. Torrens<sup>1,2,3</sup>, F. Fonseca<sup>1,2</sup>, C. Castillo<sup>1,2</sup>, A. Domingo-Salvany<sup>2</sup>, <sup>1</sup>INAD- Parc de Salut Mar,  
Barcelona, Spain, <sup>2</sup>IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona,  
Spain, <sup>3</sup>Psychiatry Department, Autonomous University of Barcelona, Barcelona, Spain
- 70 *Regulatory challenges in evaluating the abuse-deterrent properties of novel opioid products*  
S. N. Calderon<sup>3,1</sup>, M. Klein<sup>2,1</sup>, J. M. Tolliver<sup>3,1</sup>, <sup>1</sup>CDER/CSS, Food and Drug Administration,  
Silver Spring, MD, <sup>2</sup>CDER, FDA, Silver Spring, MD, <sup>3</sup>FDA, HHS, Silver Spring, MD
- 71 *Curbing the rising heroin epidemic in Colombia: Methadone-assisted treatment programs*  
G. Gonzalez<sup>1,2,3</sup>, L. Giraldo<sup>4</sup>, G. DiGirolamo<sup>1,5</sup>, M. Romero-Gonzalez<sup>1,3</sup>, <sup>1</sup>Division of Addiction  
Psychiatry, University of Massachusetts, Worcester, MA, <sup>2</sup>VA Central Western Massachusetts  
Healthcare System, Northampton, MA, <sup>3</sup>Mayu of New England, New Haven, CT, <sup>4</sup>ESE  
Hospital CARISMA, Medellin, Colombia, <sup>5</sup>College of the Holy Cross, Worcester, MA

- 72 *Women's Intervention to Stop HIV/HCV (WISH)*  
M. Staton-Tindall<sup>5</sup>, M. Webster<sup>3</sup>, C. Leukefeld<sup>2</sup>, J. R. Havens<sup>4</sup>, C. B. Oser<sup>1</sup>, <sup>1</sup>Sociology, Univ of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, Lexington, LA, <sup>3</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>4</sup>Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, <sup>5</sup>Social Work, University of Kentucky, Lexington, KY
- 73 *A tribal community-wide intervention for addiction*  
B. Gillette<sup>1</sup>, A. A. Forcehimes<sup>3,2</sup>, K. Venner<sup>4</sup>, <sup>1</sup>Circle of Life, Three Affiliated Tribes, New Town, ND, <sup>2</sup>Train for Change, Inc., Carson City, NV, <sup>3</sup>Psychiatry, University of New Mexico, Albuquerque, NM, <sup>4</sup>Psychology, University of New Mexico, Albuquerque, NM
- 74 *Multi-Component Tobacco-Free Workplace Program in community mental health settings: The role of providers' training in tobacco dependence treatment*  
V. Correa Fernández<sup>2</sup>, L. R. Reitzel<sup>1</sup>, W. T. Wilson<sup>3</sup>, B. A. Kyburz<sup>3</sup>, T. Stacey<sup>3</sup>, J. Garza<sup>1</sup>, C. Lam<sup>2</sup>, <sup>1</sup>University of Houston, Houston, TX, <sup>2</sup>UT MD Anderson Cancer Center, Houston, TX, <sup>3</sup>Austin Travis County Integral Care, Austin, TX
- 75 *A computerized system for entering and summarizing Timeline Followback information on multiple substances*  
S. K. McWilliams, C. Thurstone, P. D. Riggs, S. K. Mikulich-Gilbertson, Univ. of Colorado, Aurora, CO
- 76 *Using cellphone technology to monitor and increase dosing adherence*  
M. Oyama<sup>1</sup>, M. P. Hillhouse<sup>1</sup>, C. Thomas<sup>1</sup>, J. Annon<sup>1</sup>, A. Hasson<sup>1</sup>, L. Mooney<sup>1</sup>, R. Walker<sup>2</sup>, L. Chang<sup>3</sup>, S. Sparenborg<sup>4</sup>, W. Ling<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>UT Southwestern Medical Center, Dallas, TX, <sup>3</sup>University of Hawaii, Honolulu, HI, <sup>4</sup>Center for the Clinical Trials Network, National Institute on Drug Abuse, Bethesda, MD
- 77 *The Parent's Modular Toolkit: Development of an online CRAFT program for parents of emerging adults with SUD*  
E. Bresani<sup>1</sup>, K. C. Kirby<sup>1,2</sup>, R. J. Meyers<sup>3</sup>, T. Case<sup>1</sup>, T. G. Miller<sup>1</sup>, D. Festinger<sup>1</sup>, B. Serna<sup>3</sup>, S. Grasso<sup>1</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Robert J. Meyers, Ph.D. & Associates, Albuquerque, NM
- 78 *A new study methodology: ADAPT, The short, staged trial*  
J. Annon<sup>1</sup>, M. Hillhouse<sup>1</sup>, C. Thomas<sup>1</sup>, L. Mooney<sup>1</sup>, A. Hasson<sup>1</sup>, R. Walker<sup>2</sup>, L. Chang<sup>3</sup>, S. Sparenborg<sup>4</sup>, R. Lindblad<sup>5</sup>, P. VanVeldhuisen<sup>5</sup>, W. Ling<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>UT Southwestern, Dallas, TX, <sup>3</sup>University of Hawaii, Honolulu, HI, <sup>4</sup>National Institute on Drug Abuse, Bethesda, MD, <sup>5</sup>EMMES Corp., Rockville, MD
- 79 *International standards on the treatment of drug use disorders*  
A. Busse<sup>2</sup>, G. Gerra<sup>1</sup>, I. Koutsenok<sup>2</sup>, E. Saenz<sup>2</sup>, <sup>1</sup>Drug Prevention and Health Branch, UNODC, Vienna, Austria, <sup>2</sup>Prevention, Treatment and Rehabilitation Section (PTRS), United Nations Office on Drugs and Crime (UNODC), Vienna, Austria
- 80 *Current drug scheduling reviews of synthetic cathinones by the U.S. Drug Enforcement Administration*  
C. Prioleau, S. R. Tella, M. Walker, S. Ghosland, L. Fang, J. Trecki, A. S. Bale, A. R. Polk, D. Willenbring, L. L. Wong, T. L. Boos, Office of Diversion Control, Drug Enforcement Administration, Springfield, VA
- 81 *Early Career Award in Chemistry of Drug Abuse and Addiction*  
K. J. Bough, R. Rapaka, D. A. White, J. Rutter, National Institute on Drug Abuse, Rockville, MD



## STIMULANTS - HUMANS

- 82 *Learning of fine motor skills is not impaired in individuals with a history of illicit stimulant use*  
G. Todd, V. Pearson-Dennett, S. C. Flavel, M. Haberfield, H. Edwards, J. White, School of Pharmacy and Medical Sciences and Sansom Institute, University of South Australia, Adelaide, SA, Australia
- 83 *Hand function is altered in individuals with a history of illicit stimulant use*  
V. Pearson-Dennett<sup>1</sup>, S. C. Flavel<sup>1</sup>, R. A. Wilcox<sup>2</sup>, D. Thewlis<sup>4</sup>, A. Vogel<sup>3</sup>, J. White<sup>1</sup>, G. Todd<sup>1</sup>, <sup>1</sup>School of Pharmacy & Medical Sciences, Sansom Institute, University of South Australia, Adelaide, SA, Australia, <sup>2</sup>Department of Neurology, Flinders Medical Centre, Adelaide, SA, Australia, <sup>3</sup>Speech Neuroscience Unit, University of Melbourne, Melbourne, VIC, Australia, <sup>4</sup>School of Health Sciences, Sansom Institute, University of South Australia, Adelaide, SA, Australia
- 84 *The brain structural changes associated with stages of cocaine abstinence*  
Y. Hser<sup>1</sup>, Q. He<sup>2</sup>, M. Schulte<sup>1</sup>, A. Bechara<sup>2</sup>, <sup>1</sup>UCLA, La, CA, <sup>2</sup>USC, La, CA
- 85 *Emotional traits predict individual differences in amphetamine-induced positive mood*  
M. Kirkpatrick<sup>1</sup>, N. Goldenson<sup>1</sup>, C. W. Kahler<sup>3</sup>, H. de Wit<sup>2</sup>, R. Swift<sup>3</sup>, J. McGeary<sup>3</sup>, A. Leventhal<sup>1</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>University of Chicago, Chicago, IL, <sup>3</sup>Brown University, Providence, RI
- 86 *Neuropsychological effects of placebo stimulants in college students*  
S. J. Lookatch<sup>2</sup>, T. Moore<sup>1</sup>, E. C. Katz<sup>1</sup>, <sup>1</sup>Psychology, University of Tennessee, Knoxville, TN, <sup>2</sup>Psychology, Towson University, Towson, MD
- 87 *Personality risk for crack cocaine initiation*  
W. C. Pedersen<sup>1</sup>, D. G. Fisher<sup>2</sup>, G. L. Reynolds<sup>2</sup>, A. J. Roberts<sup>1</sup>, J. Davis<sup>3</sup>, <sup>1</sup>Psychology, California State University, Long Beach, CA, <sup>2</sup>Center for Behavioral Research & Services, California State University, Long Beach, Long Beach, CA, <sup>3</sup>Sociology, California State University, Long Beach, CA
- 88 *Changes in P300 event-related potentials vary with changes in craving among methamphetamine-dependent patients followed at 3 and 6 months after cessation*  
H. Jiang, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Shanghai Mental Health Center, Shanghai Jiao Tong University School Of Medicine, Shanghai, China
- 89 *Methylphenidate for methamphetamine use disorders in participants with and without ADHD*  
A. Ang, M. Hillhouse, J. Jenkins, S. Reed, W. Ling, UCLA, Los Angeles, CA
- 90 *Varenicline for the treatment of methamphetamine dependence*  
M. Briones<sup>1</sup>, M. Worley<sup>1</sup>, D. DeYoung<sup>1</sup>, A. Swanson<sup>2</sup>, K. G. Heinzerling<sup>1</sup>, S. Shoptaw<sup>1</sup>, <sup>1</sup>Department of Family Medicine, UCLA, Los Angeles, CA, <sup>2</sup>Stanford University, Stanford, CA
- 91 *The acquisition of coping skills from computerized cognitive behavioral therapy for substance use disorders: It's all where you start*  
B. D. Kiluk, E. E. DeVito, M. Buck, C. Nich, K. M. Carroll, Psychiatry, Yale School of Medicine, West Haven, CT
- 92 *Laboratory drug administration does not increase use in the natural ecology immediately following study discharge*  
K. R. Marks<sup>1,3</sup>, A. Lemons III<sup>1</sup>, W. W. Stoops<sup>1,3,2</sup>, J. A. Lile<sup>1,3,2</sup>, C. R. Rush<sup>1,3,2</sup>, <sup>1</sup>Behav. Science, Univ. Kentucky, Lexington, KY, <sup>2</sup>Psychiatry, Univ. Kentucky, Lexington, KY, <sup>3</sup>Psychology, Univ. Kentucky, Lexington, KY



- 93 *Alternative endpoints based on health outcomes in stimulant users trials*  
J. May<sup>1</sup>, P. VanVeldhuisen<sup>1</sup>, C. Allen<sup>1</sup>, R. Lindblad<sup>1</sup>, L. Hu<sup>1</sup>, B. Tai<sup>3</sup>, A. J. Rush<sup>2</sup>, <sup>1</sup>The EMMES Corporation, Rockville, MD, <sup>2</sup>Duke University, Durham, NC, <sup>3</sup>NIDA CCTN, Bethesda, MD
- 94 *Higher levels of BDNF are associated with inpatient treatment adherence of crack-cocaine users*  
J. N. Scherer, S. Schuch, F. Ornell, A. O. Sordi, F. H. Kessler, L. von Diemen, F. P. Pechansky, Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil
- 95 *Efficacy and tolerability of doxazosin in psychostimulant-dependent patients*  
M. J. Mancino<sup>1</sup>, J. McGaugh<sup>1</sup>, J. D. Thostenson<sup>2</sup>, J. Guise<sup>1</sup>, T. Kosten<sup>3</sup>, A. Oliveto<sup>1</sup>, <sup>1</sup>Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR, <sup>3</sup>Psychiatry, Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX
- 96 *Treatment satisfaction in the CTN Cocaine Use Reduction with Buprenorphine study*  
C. Thomas, M. Hillhouse, A. Ang, J. Annon, L. Mooney, A. Hasson, W. Ling, UCLA, Los Angeles, CA
- 97 *Opioid use severity and treatment outcomes in cocaine-dependent participants with a history of opioid abuse/dependence*  
M. P. Hillhouse<sup>1</sup>, A. Ang<sup>1</sup>, C. Thomas<sup>1</sup>, S. Nielsen<sup>5</sup>, R. Walker<sup>4</sup>, J. Potter<sup>2</sup>, G. Brigham<sup>3</sup>, S. Stout<sup>6</sup>, M. Weimer<sup>7</sup>, T. Winhusen<sup>8</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>UT Health Science Center, San Antonio, TX, <sup>3</sup>ADAPT, Roseburg, OR, <sup>4</sup>UT Southwestern, Dallas, TX, <sup>5</sup>U of New South Wales, Sydney, NSW, Australia, <sup>6</sup>Atlanta VA, Atlanta, GA, <sup>7</sup>Portland VA, Portland, OR, <sup>8</sup>U of Cincinnati, Cincinnati, OH
- 98 *Influence of bupirone maintenance on the pharmacodynamic effects of cocaine and sexual risk taking in cocaine users*  
B. L. Bolin<sup>1</sup>, J. A. Lile<sup>1,2,3</sup>, K. R. Marks<sup>2</sup>, C. R. Rush<sup>1,2,3</sup>, W. W. Stoops<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY
- 99 *Contingency management vs. non-contingent rewards: Intervention response patterns among stimulant-using MSM*  
J. B. Fletcher<sup>1</sup>, R. J. Landovitz<sup>3</sup>, C. J. Reback<sup>1,2</sup>, <sup>1</sup>Friends Research Institute, Inc., Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>3</sup>Center for Clinical AIDS Research & Education, UCLA, Los Angeles, CA
- 100 *Making the most of mindfulness: Which specific mindfulness deficits might be targeted to optimize addiction treatment?*  
J. Ury, D. Flack, E. Dakwar, NYSPI, New York City, NY
- 101 *Failure to get into drug treatment*  
L. D'Anna<sup>1</sup>, D. G. Fisher<sup>2</sup>, G. L. Reynolds<sup>2</sup>, D. Hosmer<sup>3</sup>, K. Hardan-Khalil<sup>4</sup>, <sup>1</sup>Center for Health Equity, California State University, Long Beach, CA, <sup>2</sup>Center for Behavioral Research & Services, California State University, Long Beach, Long Beach, CA, <sup>3</sup>Department of Mathematics and Statistics, University of Vermont, Stowe, VT, <sup>4</sup>School of Nursing, California State University, Long Beach, CA

**ADOLESCENT I**

- 102 *Amphetamine exposure during adolescence alters behavior, dopamine receptors and medial prefrontal cortex function in adulthood*  
J. M. Gulley, L. Sherrill, Psychology and Neuroscience, University of Illinois, Urbana-Champaign, Champaign, IL
- 103 *Energy drink compounds differentially affect anxiety, locomotion, depression and cognition in adolescent and adult female rats*  
K. Chauhan<sup>1</sup>, S. Perez<sup>2</sup>, M. Chrisphonte<sup>1</sup>, M. Evelyn<sup>1</sup>, M. Guzman<sup>1</sup>, D. Woo<sup>1</sup>, U. Akpara<sup>1</sup>, H. Saleh<sup>1</sup>, A. Alexander-Street<sup>2</sup>, K. Salas-Ramirez<sup>1</sup>, <sup>1</sup>Physiology, Pharmacology and Neuroscience, The City College of New York, New York, NY, <sup>2</sup>Biology, Lehman College, CUNY, Bronx, NY
- 104 *Dysregulation in the cholinergic system after adolescent nicotine is reversed by dietary choline*  
E. Holliday, C. Oliver, T. Gould, Psychology, Temple University, Philadelphia, PA
- 105 *A test of the aversive versus the rewarding effects of nicotine in rats neonatally treated with quinpirole*  
S. Kirby, E. D. Cummins, D. J. Peterson, L. Kassem, R. W. Brown, Psychology, East Tennessee State University, Johnson City, TN
- 106 *The role of the  $\alpha 7$  and  $\alpha 4\beta 2$  nicotinic receptors in nicotine sensitization and neural plasticity of adolescent rats neonatally treated with quinpirole*  
D. J. Peterson, C. M. Bardo, E. D. Cummins, R. W. Brown, Psychology, East Tennessee State University, Johnson City, TN
- 107 *Genetic and environmental influences on initiation and heaviness of smoking from adolescence to adulthood*  
C. B. Bares, K. S. Kendler, H. Maes, Virginia Commonwealth University, Richmond, VA
- 108 *Predictors of early relapse in adolescent crack users after hospital discharge*  
H. F. Moura<sup>1</sup>, R. L. Rosa<sup>1</sup>, F. H. Kessler<sup>1</sup>, T. G. Pianca<sup>1</sup>, L. S. Guimarães<sup>3</sup>, P. B. Ferronato<sup>1</sup>, E. Pagnussat<sup>4</sup>, F. P. Pechansky<sup>2</sup>, L. von Diemen<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>2</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>3</sup>CPAD, Porto Alegre, Brazil, <sup>4</sup>Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
- 109 *Predictors of e-cigarette use among adolescents*  
S. Krishnan-Sarin<sup>2</sup>, G. Kong<sup>2</sup>, D. R. Camenga<sup>1</sup>, D. A. Cavallo<sup>2</sup>, P. Simon<sup>2</sup>, C. Connell<sup>2</sup>, R. Wu<sup>2</sup>, M. E. Morean<sup>2</sup>, <sup>1</sup>Pediatrics, Yale School of Medicine, New Haven, CT, <sup>2</sup>Department of Psychiatry, Yale University School of Medicine, New Haven, CT
- 110 *The impact of e-cigarette advertisements on e-cigarette initiation among middle and high school students*  
K. M. Gutierrez, D. R. Camenga, G. Kong, D. A. Cavallo, P. Simon, R. Wu, C. Connell, S. Krishnan-Sarin, Yale University, New Haven, CT
- 111 *Socioeconomic disparities in electronic cigarette use among adolescents*  
P. Simon, D. R. Camenga, G. Kong, D. A. Cavallo, C. Connell, K. M. Gutierrez, S. Krishnan-Sarin, Yale School of Medicine, New Haven, CT
- 112 *Factors contributing to tobacco use and cessation in Hispanic adolescents*  
S. E. Gomez Luna<sup>1</sup>, D. A. Cavallo<sup>2</sup>, G. Kong<sup>2</sup>, J. Knight<sup>3</sup>, S. Krishnan-Sarin<sup>2</sup>, <sup>1</sup>School of Medicine, Yale, New Haven, CT, <sup>2</sup>Psychiatry, Yale University, New Haven, CT, <sup>3</sup>School of Medicine, Harvard, Boston, MA

- 113 *Is cannabis smoking harmful? A microscope view discloses patterned maturation of youthful risk perceptions*  
M. Chandra, S. M. Hughes, J. C. Anthony, Department of Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 114 *Negative affect mediates relations between anxiety sensitivity and substance use problems in adolescents*  
C. Guillot<sup>1</sup>, R. Pang<sup>1</sup>, M. Kirkpatrick<sup>1</sup>, A. Leventhal<sup>2</sup>, <sup>1</sup>Department of Preventive Medicine, University of Southern California, Azusa, CA, <sup>2</sup>Departments of Preventive Medicine and Psychology, University of Southern California, Los Angeles, CA
- 115 *Relationship between changes in cannabis use and anxiety among adolescents*  
J. C. Duperrouzel, J. M. Ross, R. Gonzalez, Psychology, Florida International University, Miami, FL
- 116 *Moderating effects of decision-making on cannabis use and body mass index among adolescents*  
J. M. Ross, P. Graziano, J. C. Duperrouzel, I. Gonzalez, R. Gonzalez, Psychology, Florida International University, Miami, FL
- 117 *School context and marijuana use among Maryland high school students*  
E. Parker<sup>1</sup>, R. M. Johnson<sup>1</sup>, S. Lindstrom Johnson<sup>2</sup>, C. Bradshaw<sup>3,4</sup>, <sup>1</sup>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, <sup>3</sup>Curry School of Education, University of Virginia, Charlottesville, VA, <sup>4</sup>Johns Hopkins Center for the Prevention of Youth Violence, Baltimore, MD
- 118 *Cannabis smoking clusters within secondary schools: Results from the United States Monitoring the Future Study 1976-2013*  
M. A. Parker, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 119 *Adolescent substance use and specificity of association with educational attainment in young adulthood*  
E. Silins<sup>1</sup>, L. J. Horwood<sup>2</sup>, D. Fergusson<sup>2</sup>, G. Patton<sup>3</sup>, C. Olsson<sup>3</sup>, D. Hutchinson<sup>1</sup>, L. Degenhardt<sup>1</sup>, R. P. Mattick<sup>1</sup>, <sup>1</sup>University of NSW, Sydney, NSW, Australia, <sup>2</sup>University of Otago, Christchurch, New Zealand, <sup>3</sup>University of Melbourne, Parkville, VIC, Australia
- 120 *Developing a multidimensional measure of marijuana-specific communication with friends*  
J. A. Kam, Communication, UC Santa Barbara, Santa Barbara, CA
- 121 *Identifying treatment response subgroups for adolescent cannabis use disorders*  
S. F. Babbin, C. Stanger, A. J. Budney, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH

**EPIDEMIOLOGY I**

- 122 *Are early-onset users of inhalants at excess risk of developing inhalants dependence soon after onset of inhalant use: Estimates for the United States, 2002-2011*  
R. Brosig, J. C. Anthony, Michigan State University, Rochester, MI
- 123 *A rapidly changing recreational drug market: Findings from the Canadian Community Epidemiology Network on Drug Use*  
M. M. Young, Canadian Centre on Substance Abuse, Ottawa, ON, Canada

- 124 *Novel psychoactive substance use in the European Union*  
S. P. Novak<sup>1</sup>, A. Hakansson<sup>2</sup>, J. Reimer<sup>5</sup>, J. Martinez-Raga<sup>4</sup>, J. Lorvick<sup>3</sup>, <sup>1</sup>Behavioral Epidemiology, RTI International, Research Triangle Park, NC, <sup>2</sup>Division of Psychiatry, U of Lund, Lund, Sweden, <sup>3</sup>RTI International, RTI, San Francisco, CA, <sup>4</sup>Teaching Unit of Psychiatry and Psychological Medicine, U of Valencia, Valencia, Spain, <sup>5</sup>Centre for Interdisciplinary Addiction Research, Hamburg Medical, Hamburg, Germany
- 125 *The use of new psychoactive substances amongst a sample of regular psychostimulant users, 2010-2014*  
R. Sutherland<sup>2</sup>, L. Burns<sup>1</sup>, <sup>1</sup>NDARC, UNSW, Sydney, NSW, Australia, <sup>2</sup>National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- 126 *Patterns of performance and image-enhancing drug use among men accessing needle and syringe programs in Sydney, Australia*  
R. Rowe, I. Berger, Drug and Alcohol Multicultural Education Centre, Sydney, NSW, Australia
- 127 *Combined and independent relationships between current marijuana and cigarette use and cardiometabolic disease risk among United States emerging adults: Results from the National Health and Nutrition Examination Surveys 2007-2012*  
D. C. Vidot<sup>1</sup>, G. Prado<sup>1</sup>, K. Arheart<sup>1</sup>, W. Hlaing<sup>1</sup>, A. Acheampong<sup>2</sup>, S. Messiah<sup>1</sup>, <sup>1</sup>University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>University of Florida, Gainesville, FL
- 128 *Marijuana use trajectories during college predict health outcomes nine years post-matriculation*  
A. M. Arria<sup>1</sup>, K. M. Caldeira<sup>1</sup>, B. A. Bugbee<sup>1</sup>, K. B. Vincent<sup>1</sup>, K. E. O'Grady<sup>2</sup>, <sup>1</sup>Univ. of Maryland School of Public Health, College Park, MD, <sup>2</sup>Dept. of Psychology, Univ. of Maryland, College Park, MD
- 129 *Up in Smoke?: Marijuana initiation and prevalence trends in Colorado: 2008 to 2014*  
T. A. Cassidy, T. Green, P. Garg, S. F. Butler, Inflexxion, Inc., Newton, MA
- 130 *Are medical marijuana users different than recreational marijuana users?*  
S. S. Martins<sup>2</sup>, J. Santaella<sup>1</sup>, L. R. Pacek<sup>3</sup>, K. Keyes<sup>2</sup>, M. Cerda<sup>2</sup>, D. S. Hasin<sup>2</sup>, S. Galea<sup>2</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Epidemiology, Columbia University, New York City, NY, <sup>3</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD
- 131 *Characteristics and consequences of adults who use cannabis as their first drug*  
B. J. Fairman, R. M. Johnson, C. M. Furr-Holden, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 132 *Associations between age and cannabis use problems among medical cannabis patients*  
K. Bohnert<sup>1,2</sup>, M. A. Ilgen<sup>1,2</sup>, <sup>1</sup>Psychiatry, University of Michigan, Ann Arbor, MI, <sup>2</sup>VA Ann Arbor, Ann Arbor, MI
- 133 *Estimated probability of becoming a case of drug dependence in relation to duration of drug-taking experience: A functional approach*  
O. Vsevolozhskaya<sup>2</sup>, J. C. Anthony<sup>1</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 134 *Cannabis smoking, cardiometabolic health, and cardiovascular disease: United States NHANES, 2005-2010*  
O. Alshaarawy, J. C. Anthony, Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

- 135 *Is marijuana use associated with less opioid use among people who inject drugs?*  
A. Kral<sup>1</sup>, L. Wenger<sup>1</sup>, S. P. Novak<sup>2</sup>, K. F. Corsi<sup>3</sup>, R. Bluthenthal<sup>4</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>Behavioral Epidemiology, RTI International, Research Triangle Park, NC, <sup>3</sup>Psychiatry, University of Colorado Denver, Denver, CO, <sup>4</sup>Preventive Medicine, University of Southern California, Los Angeles, CA
- 136 *Parallel development of longitudinal tobacco smoking and alcohol consumption: The Amsterdam Growth and Health Longitudinal Study*  
C. Lederhos, O. Brooks, A. Lamp, C. Barbosa-Leiker, T. Hoekstra, S. Murphy, M. Layton, J. Roll, S. McPherson, Program of Excellence in Addictions Research (PEAR), Washington State University, Spokane, WA
- 137 *Perceived approval of substance use in soldiers vs. civilians*  
G. G. Homish, D. Homish, K. Cummings, S. A. Cercone, E. Read, R. Daws, D. Saltino, Community Health & Health Behavior, State University of New York at Buffalo, Buffalo, NY
- 138 *E-cigarettes in Baltimore alcohol outlets: Geographic and demographic correlates of availability*  
D. O. Fakunle, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 139 *Cigarette smoking and food insecurity in socioeconomically disadvantaged young adults*  
J. E. Kim, J. Tsoh, Psychiatry, University of California San Francisco, San Francisco, CA
- 140 *Mental health among smokers in the U.S. from 2008 to 2013: Diverging trends by socioeconomic status*  
R. Goodwin<sup>1,2</sup>, M. Wall<sup>3</sup>, M. Hu<sup>3</sup>, M. J. Zvolensky<sup>4</sup>, D. S. Hasin<sup>2</sup>, <sup>1</sup>Psychology, City University of New York, Queens, NY, <sup>2</sup>Epidemiology, Columbia University, New York, NY, <sup>3</sup>Biostatistics, Columbia University, New York, NY, <sup>4</sup>Psychology, University of Houston, Houston, TX
- 141 *Cigarette smoking and risk of substance use and substance use disorder relapse among adults in recovery*  
A. H. Weinberger<sup>2</sup>, J. Platt<sup>3</sup>, S. Galea<sup>3</sup>, R. Goodwin<sup>1,3</sup>, <sup>1</sup>Psychology, City University of New York, Queens, NY, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>3</sup>Epidemiology, Columbia University, New York, NY
- 142 *An epidemiological test of the Kandel-Kandel hypothesis of Sept 2014: U.S. 2002-13*  
K. Alcover, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 143 *Crack, powdered cocaine, both or neither: A generalized logit analysis of a community-based sample*  
G. L. Reynolds<sup>1,2</sup>, D. G. Fisher<sup>1</sup>, E. Erlyana<sup>2</sup>, <sup>1</sup>Center for Behavioral Research and Services, California State University, Long Beach, Long Beach, CA, <sup>2</sup>Health Care Administration, California State University, Long Beach, Long Beach, CA
- 144 *Social rank and cocaine dependence: Estimates for the United States, 2005-2013*  
A. M. Mohammed, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 145 *Estimated rapid transition from first stimulant use until onset of stimulant dependence: Larger for methamphetamine users?*  
O. J. Santiago Rivera<sup>1</sup>, J. C. Anthony<sup>2</sup>, <sup>1</sup>Epidemiology, Michigan State University, Okemos, MI, <sup>2</sup>Epidemiology and Biostatistics, Michigan State University, East Lansing, MI



- 146 *Prevalence and correlates of simultaneous heroin and methamphetamine injection in two parallel cohorts of PWID in San Diego, CA, and Tijuana, BC, Mexico*  
M. C. Meacham<sup>1,2</sup>, R. Armenta<sup>1,2</sup>, R. Garfein<sup>1</sup>, J. Cuevas-Mota<sup>1</sup>, P. Gonzalez Moreno-Zuniga<sup>1</sup>, S. Strathdee<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>San Diego State University, San Diego, CA
- 147 *Characteristics and predictors of naloxone utilization in a community-based overdose prevention program*  
P. O. Coffin<sup>1,2</sup>, C. Rowe<sup>1</sup>, G. Santos<sup>1</sup>, E. Vittinghoff<sup>3</sup>, E. Wheeler<sup>4</sup>, <sup>1</sup>Substance Use Research, San Francisco Department of Public Health, San Francisco, CA, <sup>2</sup>HIV/AIDS, University of California San Francisco, San Francisco, CA, <sup>3</sup>University of California San Francisco, San Francisco, CA, <sup>4</sup>Harm Reduction Coalition, Oakland, CA

## **Symposium VI**

**AZ Biltmore Ballroom  
1:30 - 3:30 PM**

### **MINDFULNESS-BASED APPROACHES: FROM NEUROBIOLOGICAL MECHANISMS TO TREATMENT**

Chairs: David Shurtleff and Emmeline Edwards

- 1:30 *Neurobiological mechanisms of mindfulness meditation*  
Judson Brewer, University of Massachusetts Medical School, New Haven, MA
- 1:55 *Pharmacological facilitation of mindfulness training*  
Elias Dakwar, New York State Psychiatric Institute, New York, NY
- 2:20 *Applying yoga to smoking cessation interventions*  
Beth Bock, Miriam Hospital, Providence, RI
- 2:45 *Mindfulness-based relapse prevention: Theoretical and empirical foundations for treatment of addictive behaviors*  
Sarah Bowen, University of Washington, Portland, OR
- 3:10 *DISCUSSANT:*  
David Shurtleff, National Institutes of Health, Bethesda, MD

## **Symposium VII**

**McArthur Ballroom 1/2  
1:30 - 3:30 PM**

### **BEHAVIORAL ECONOMICS OF HEALTH DISPARITIES IN ADDICTION**

Chairs: Adam Leventhal and Stephen T. Higgins

- 1:30 *Behavioral economic sources of disparities in addiction*  
Adam Leventhal, University of Southern California Keck School of Medicine, Los Angeles, CA
- 1:55 *The behavioral economics of tobacco use among people with serious mental illness*  
Jennifer W. Tidey, Brown University, Providence, RI
- 2:20 *Behavioral economics: Improving outcomes among disadvantaged women and infants*  
Stephen T. Higgins, University of Vermont, Burlington, VT
- 2:45 *Behavioral economic incentives for drug abstinence in low-income adults at risk for HIV*  
Kenneth Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

3:10 *DISCUSSANT: Therapeutic opportunities for health disparities: Change and the limits of change*

Warren K. Bickel, Virginia Tech Carilion Research Institute, Roanoke, VA

## **Oral Communications 8**

**McArthur Ballroom 4**

**1:30 - 3:30 PM**

### **MOMMAS WHO ABUSE: PERINATAL DRUG ABUSE**

Chairs: Sarah H. Heil and Sarah A. Cercone

1:30 *Correspondence between self-reported and biochemical measures of cigarette smoking in pregnant women*

S. H. Heil, L. J. Solomon, J. M. Skelly, I. M. Bernstein, S. T. Higgins, Vermont Center on Behavior and Health, University of Vermont, Burlington, VT

1:45 *Individual characteristics and social process in influencing maternal smoking behavior: A longitudinal analysis of a national birth cohort*

W. Liu, E. Mumford, Public Health, NORC at University of Chicago, Bethesda, MD

2:00 *Prenatal tobacco exposure predicts child's internalizing behavior*

S. A. Cercone<sup>1</sup>, G. G. Homish<sup>1</sup>, R. D. Eiden<sup>2</sup>, J. L. Derrick<sup>2</sup>, <sup>1</sup>Community Health & Health Behavior, State University of New York at Buffalo, Buffalo, NY, <sup>2</sup>Research Institute on Addictions, Buffalo, NY

2:15 *Second-hand smoke exposure during pregnancy and anxiety disorder in children at age 11-13*

J. Liu, H. Liu, W. Liu, School of Nursing, University of Pennsylvania, Philadelphia, PA

2:30 *Hospital admissions for alcohol use disorders in pregnancy*

C. L. Breen<sup>1</sup>, F. Xu<sup>2</sup>, L. Burns<sup>1</sup>, <sup>1</sup>NDARC, UNSW, Sydney, NSW, Australia, <sup>2</sup>UNSW, Simpson Centre for Health Services Research, Sydney, NSW, Australia

2:45 *Prevalence and predictors of antenatal alcohol use prior to awareness of pregnancy*

C. McCormack<sup>1</sup>, D. Hutchinson<sup>1</sup>, L. Burns<sup>1</sup>, J. Wilson<sup>1</sup>, E. Elliott<sup>2</sup>, S. Allsop<sup>3</sup>, J. Najman<sup>4</sup>, C. Olsson<sup>5</sup>, S. Jacobs<sup>6</sup>, A. Bartu<sup>7</sup>, R. P. Mattick<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia, <sup>3</sup>National Drug Research Institute, Curtin University of Technology, Perth, WA, Australia, <sup>4</sup>Queensland Alcohol and Drug Research Education Centre, University of Queensland, Brisbane, QLD, Australia, <sup>5</sup>Centre for Social and Early Emotional Development, Deakin University, Melbourne, VIC, Australia, <sup>6</sup>Department of Obstetrics, Royal Prince Alfred Hospital, Sydney, NSW, Australia, <sup>7</sup>School of Nursing and Midwifery, Curtin University, Perth, WA, Australia

3:00 *Prevalence of heavy fetal alcohol exposure during pregnancy in Canada: A population-based meconium study*

K. Delano<sup>1,2</sup>, E. Pope<sup>2,3</sup>, B. Kapur<sup>2</sup>, G. Koren<sup>1,2</sup>, <sup>1</sup>Pharmacology and Toxicology, The University of Toronto, Toronto, ON, Canada, <sup>2</sup>Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, Canada, <sup>3</sup>Health Sciences, McMaster University, Hamilton, ON, Canada

3:15 *Maternal age and trajectories of marijuana use over 17 years*

N. De Genna<sup>1</sup>, L. Goldschmidt<sup>2</sup>, N. Day<sup>1</sup>, M. Cornelius<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>Western Psychiatric Institute and Clinic (WPIC), University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA

**Oral Communications 9****McArthur Ballroom 5/6  
1:30 - 3:30 PM****MISTY ASPIRATIONS: VAPING**

Chairs: Olga Rass and Michael A. Taffe

- 1:30 *Use patterns, perceptions of relative harm, and gender effects in dual users of electronic and tobacco cigarettes*  
O. Rass, L. R. Pacek, P. S. Johnson, M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 1:45 *Use of electronic cigarettes among smokers in addiction treatment*  
N. R. Gubner<sup>1</sup>, T. Le<sup>2</sup>, B. Tajima<sup>2</sup>, B. Andrews<sup>2</sup>, E. Passalacqua<sup>2</sup>, J. Guydish<sup>2</sup>, <sup>1</sup>CTCRE, UCSF, San Francisco, CA, <sup>2</sup>IHPS, UCSF, San Francisco, CA
- 2:00 *Predictors of youth use of e-cigarettes for smoking cessation*  
D. R. Camenga, G. Kong, D. A. Cavallo, C. Connell, K. M. Gutierrez, P. Simon, S. Krishnan-Sarin, Yale School of Medicine, New Haven, CT
- 2:15 *Informing the regulation of e-cigarettes to restrict youth access*  
G. Kong<sup>2</sup>, D. A. Cavallo<sup>2</sup>, M. E. Morean<sup>3</sup>, D. R. Camenga<sup>1</sup>, S. Krishnan-Sarin<sup>2</sup>, <sup>1</sup>Pediatrics, Yale School of Medicine, New Haven, CT, <sup>2</sup>Psychiatry, Yale University, New Haven, CT, <sup>3</sup>Oberlin College, Oberlin, OH
- 2:30 *ECIG-induced suppression of nicotine/tobacco abstinence symptoms*  
A. A. Lopez, M. Hiler, T. Ratner, K. Pettaway, A. Breland, T. Eissenberg, Psychology, Virginia Commonwealth University, Richmond, VA
- 2:45 *Efficacy of electronic cigarettes for smoking cessation in veterans*  
J. Eisenhofer<sup>1</sup>, T. Makanjuola<sup>1</sup>, V. Martinez<sup>1</sup>, D. G. Thompson-Lake<sup>1</sup>, C. Rodgman<sup>2</sup>, D. S. DeBrule<sup>2</sup>, D. P. Graham<sup>2</sup>, R. De La Garza, II<sup>1</sup>, <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Michael E. DeBakey VA Medical Center, Houston, TX
- 3:00 *Development and validation of a device for the intrapulmonary delivery of  $\Delta^9$ -tetrahydrocannabinol to rats*  
M. A. Taffe, S. M. Aarde, M. Cole, CNAD, The Scripps Research Institute, La Jolla, CA
- 3:15 *Characterizing vaporizer use among cannabis users*  
D. C. Lee<sup>2</sup>, B. S. Crosier<sup>1</sup>, A. J. Budney<sup>2</sup>, <sup>1</sup>Center for Technology and Behavioral Health, Dartmouth College, West Windsor, VT, <sup>2</sup>Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH

**Please be advised that no photographing of presentations or data is permitted.  
Badges must be worn at all times and are required for admission into all events  
and sessions.**

## **Symposium VIII**

**McArthur Ballroom 1/2  
3:45 - 4:45 PM**

### **USING TRANSLATIONAL RESEARCH TO DEVELOP INTERVENTIONS FOR STIMULANT USE DISORDERS: NONHUMAN PRIMATE, HUMAN LABORATORY AND CLINICAL TRIAL FINDINGS**

Chairs: William W. Stoops and Paul W. Czoty

- 3:45 *Enhancing the predictive validity of laboratory animal drug self-administration procedures by incorporating clinically relevant variables*  
Paul W. Czoty, Wake Forest School of Medicine, Winston-Salem, NC
- 4:10 *Utility and predictive validity of human laboratory drug self-administration measures for stimulant treatment development*  
William W. Stoops, University of Kentucky, Lexington, KY
- 4:35 *Are new clinical trial designs needed for the successful translation of research into an effective medication for stimulant dependence?*  
Keith Heinzerling, University of California-Los Angeles, Los Angeles, CA

## **Oral Communications 10**

**McArthur Ballroom 5/6  
3:45 - 4:45 PM**

### **MALLEABLE AGE: INFANTS AND CHILDREN**

Chairs: Loretta Finnegan and Jillian Hardee

- 3:45 *Surveying lactation professionals regarding breastfeeding and marijuana use*  
C. L. Bergeria<sup>3,2</sup>, S. H. Heil<sup>3,1,2</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Psychology, University of Vermont, Burlington, VT, <sup>3</sup>Vermont Center on Behavior and Health, Burlington, VT
- 4:00 *Gender differences in the development of emotion circuitry in youth at risk for substance abuse: A longitudinal fMRI study*  
J. Hardee, L. M. Cope, R. Zucker, M. Heitzeg, Psychiatry, University of Michigan, Ann Arbor, MI
- 4:15 *Drug- and alcohol-exposed pregnancies: Maternal and infant outcomes*  
M. Tuten<sup>1</sup>, S. Moore<sup>1</sup>, H. Fitzsimons<sup>2</sup>, M. Velez<sup>3</sup>, M. S. Chisolm<sup>2</sup>, L. Jansson<sup>3</sup>, H. E. Jones<sup>4</sup>, <sup>1</sup>School of Social Work, UMB, Baltimore, MD, <sup>2</sup>Psychiatry and Behavioral Sciences, JHU, Baltimore, MD, <sup>3</sup>Pediatrics, JHU, Baltimore, MD, <sup>4</sup>OB/GYN, UNC Chapel Hill, Chapel Hill, NC
- 4:30 *Gender differences in associations between childhood sexual abuse and illicit drug use in adulthood*  
S. Gao<sup>1</sup>, J. D. Scheidell<sup>2</sup>, T. Champion<sup>1</sup>, K. Vaddiparti<sup>1</sup>, S. McGorray<sup>1</sup>, M. R. Khan<sup>2</sup>, <sup>1</sup>Colleges of Public Health & Health Professions and Medicine, University of Florida, Gainesville, FL, <sup>2</sup>Population Health, New York University, New York, NY

**Oral Communications 11****AZ Biltmore Ballroom  
3:45 - 5:45 PM****MANAGING AGONY: OPIOIDS AND PAIN**

Chairs: Silvia L. Cruz and Kate McHugh

- 3:45 *Adolescent oxycodone self administration alters subsequent antinociceptive effect of oxycodone in C57Bl/6J mice in adulthood*  
J. H. Altschuler, K. Niikura, E. Butelman, M. Kreek, Y. Zhang, Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY
- 4:00 *Morphine and fentanyl chronic effects on lipopolysaccharide response and  $\mu$  opioid receptor localization in mast cells*  
S. L. Cruz, L. Molina, C. Gonzalez-Espinosa, Farmacobiología, Centro de Investigación y de Estudios Avanzados del IPN, Tlalpan, Mexico
- 4:15 *Inflammatory cytokines and pain in patients with opioid use disorders*  
J. I. Tsui<sup>2</sup>, M. C. Lira<sup>1</sup>, D. M. Cheng<sup>3</sup>, M. R. Winter<sup>3</sup>, R. R. Edwards<sup>4</sup>, J. Mao<sup>5</sup>, J. Samet<sup>1</sup>,  
<sup>1</sup>BU School of Medicine, Boston, MA, <sup>2</sup>UW School of Medicine, Seattle, WA, <sup>3</sup>BU School of Public Health, Boston, MA, <sup>4</sup>Brigham and Women's Hospital, Chestnut Hill, MA, <sup>5</sup>Mass General Hospital, Boston, MA
- 4:30 *Mortality and guideline-concordant long-term opioid therapy for pain*  
J. R. Gaither<sup>1</sup>, J. Goulet<sup>1,2</sup>, W. Becker<sup>1,2</sup>, S. Crystal<sup>3</sup>, E. Edelman<sup>1</sup>, K. Gordon<sup>2</sup>, R. Kerns<sup>1,2</sup>,  
D. Rimland<sup>4</sup>, M. Skanderson<sup>2</sup>, A. Justice<sup>1,2</sup>, D. Fiellin<sup>1</sup>, <sup>1</sup>Yale, New Haven, CT, <sup>2</sup>VAHCS, West Haven, CT, <sup>3</sup>Rutgers, New Brunswick, NJ, <sup>4</sup>Emory, Atlanta, GA
- 4:45 *Predictors for high dose chronic opioid therapy*  
D. Plott, S. Miller, MHCL, VHACIN, Cincinnati, OH
- 5:00 *Distress intolerance and prescription opioid abuse in chronic pain patients*  
K. McHugh<sup>1,3</sup>, R. R. Edwards<sup>2,3</sup>, R. N. Jamison<sup>2,3</sup>, M. C. Cornelius<sup>2</sup>, R. Weiss<sup>3,1</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Harvard Medical School, Boston, MA
- 5:15 *Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the Pain and Opioids In Treatment cohort*  
G. Campbell<sup>2</sup>, S. Nielsen<sup>2</sup>, B. Larance<sup>2</sup>, R. Bruno<sup>3</sup>, R. Mattick<sup>2</sup>, W. Hall<sup>4</sup>, N. Lintzeris<sup>1</sup>,  
M. Cohen<sup>2</sup>, K. Smith<sup>2</sup>, L. Degenhardt<sup>2</sup>, <sup>1</sup>Langton Centre, Sydney, NSW, Australia, <sup>2</sup>National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, <sup>3</sup>School of Psychology, University of Tasmania, Hobart, TAS, Australia, <sup>4</sup>University of Queensland, Brisbane, QLD, Australia
- 5:30 *Examining DSM and ICD definitions of pharmaceutical opioid dependence in people taking opioids for chronic pain: Findings from the Pain and Opioids IN Treatment study*  
L. Degenhardt<sup>2</sup>, R. Bruno<sup>4</sup>, N. Lintzeris<sup>1</sup>, W. Hall<sup>5</sup>, S. Nielsen<sup>2</sup>, B. Larance<sup>3</sup>, M. Cohen<sup>3</sup>,  
G. Campbell<sup>2</sup>, <sup>1</sup>Langton Centre, Sydney, NSW, Australia, <sup>2</sup>National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, <sup>3</sup>University of New South Wales, Sydney, NSW, Australia, <sup>4</sup>School of Medicine, University of Tasmania, Hobart, TAS, Australia, <sup>5</sup>Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, QLD, Australia



## **Oral Communications 12**

**McArthur Ballroom 1/2  
5:00 - 6:00 PM**

### **MECHANISMS OF ADDICTION**

Chairs: Cassandra D. Gipson and Aron Lichtman

- 5:00 *The kappa opioid receptor agonist 16-bromosalvinorin A reduces cocaine seeking in rats*  
A. Ewald<sup>2</sup>, J. Miller<sup>2</sup>, T. E. Prisinzano<sup>1</sup>, B. M. Kivell<sup>2</sup>, <sup>1</sup>Medicinal Chemistry, The University of Kansas, Lawrence, KS, <sup>2</sup>Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand
- 5:15 *Disruption of cortical n-methyl-d-aspartate receptor tone governs impulsive action*  
C. Krebs, N. C. Anastasio, C. Wood, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX
- 5:30 *N-Acetylcysteine inhibits nicotine relapse-associated synaptic plasticity and restores glial glutamate transport in nicotine-withdrawn animals*  
C. D. Gipson, S. Spencer, N. Stankeviciute, N. Allen, C. Garcia-Keller, P. W. Kalivas, Neurosciences, Medical University of South Carolina, Charleston, SC
- 5:45 *Dual blockade of endocannabinoid hydrolyzing enzymes reveal a CB<sub>1</sub> receptor-mediated interoceptive stimulus*  
R. Owens<sup>1</sup>, P. Beardsley<sup>1</sup>, B. Cravatt<sup>3</sup>, A. Lichtman<sup>2</sup>, <sup>1</sup>VCU, Richmond, VA, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>The Scripps Research Institute, La Jolla, CA

## **Symposium IX**

**McArthur Ballroom 5/6  
5:00 - 6:00 PM**

### **NEW PERSPECTIVES ON GENETICS AND METABOLOMICS OF NICOTINE DEPENDENCE AND SMOKING CESSATION: IMPLICATIONS FOR NICOTINE DEPENDENCE TREATMENT**

Chair: Joni Rutter

- 5:00 *Genomic contributions to nicotine dependence: A meta-analysis*  
Xiangning Chen, Virginia Commonwealth University, Richmond, VA
- 5:20 *Genetically variable pharmacokinetic influences on nicotine dependence: Implications for smoking cessation*  
Meghan Chenoweth, University of Toronto, Toronto, ON, Canada
- 5:40 *Use of genomic and metabolomic data to increase smoking cessation success*  
Li-Shiun Chen, Washington University School of Medicine, St. Louis, MO

## **Symposium X**

**McArthur Ballroom 4  
5:00 - 6:00 PM**

### **THE INTERPLAY OF PHARMACOKINETICS AND PHARMACODYNAMICS IN ABUSE POTENTIAL: MODELING MADNESS?**

Chairs: Megan Shram and Sharon L. Walsh

- 5:00 *Pharmacokinetic and dynamic factors in abuse potential: Historical perspectives from research on opioids, stimulants and nicotine*  
Jack Henningfield, The Johns Hopkins University School of Medicine, Bethesda, MD

5:20 *Drug metabolism within the brain alters drug response and abuse liability: Examples from propofol, codeine and nicotine in an animal model*

Rachel Tyndale, University of Toronto, Toronto, ON, Canada

5:40 *Use of PK-PD modeling to evaluate the impact of formulation on a subject's drug experience: Can we predict abuse potential?*

Megan Shram, University of Toronto, Toronto, ON, Canada

## **Workshop IX**

**McArthur Ballroom 1/2**

**7:00 - 9:00 PM**

### **THE INTERTWINING EPIDEMICS OF DRUG USE AND HIV/AIDS: THE HIV/AIDS WORKGROUP**

Chairs: Adam W. Carrico and Don C. Des Jarlais

*Gender-specific HIV prevention interventions for women who use alcohol and other drugs: The evolution of the science and future directions*

Wendee Wechsberg, Research Triangle Institute, Research Triangle Park, NC

*Providing ART to HIV-seropositive persons who use drugs: Progress in New York City, prospects for "ending the epidemic"*

Don C. Des Jarlais, Beth Israel Medical Center, New York, NY

*Risk and protective factors associated with ARV adherence among aging, indigent, substance abusing people living with HIV*

Maria A. Levi-Minzi, Nova Southeastern University, Miami, FL

*Injection risk behavior and HIV and HCV prevalence among young opioid injectors in New York City*

Pedro Mateu-Gelabert, National Development and Research Institutes, New York, NY

*Longitudinal associations between the dissolution of committed partnerships that occurs during incarceration and post-release HIV risk among African-American men released from prison in North Carolina*

Maria R. Khan, New York University, New York, NY

*Two-year trajectories of HIV sexual risk behaviors among adolescents and emerging adults who use drugs*

Erin E. Bonar, University of Michigan, Ann Arbor, MI

*Development and factor analysis of a comprehensive behavioral risk assessment for infectious diseases*

Evan S. Herrmann, Johns Hopkins University, Baltimore, MD

*Theory-based text-messaging to reduce methamphetamine use and sex risks among men who have sex with men*

Cathy J. Reback, Friends Research Institute, Los Angeles, CA

*Modifying effects of HIV-status on correlates of smoking and vaping among men who have sex with men in San Francisco*

Glenn-Milo Santos, University of California, San Francisco, San Francisco, CA

*Substance use and delayed HIV testing among young black men who have sex with men*

Adam W. Carrico, University of California, San Francisco, San Francisco, CA

## **Workshop X**

**AZ Biltmore Ballroom  
7:00 - 9:00 PM**

### **MARIJUANA LAWS: THE CHANGING LEGAL LANDSCAPE AND ITS CONSEQUENCES**

Chair: Marsha Lopez

*Medical marijuana laws and U.S. adolescent marijuana use: Results over 20 years*  
Deborah S. Hasin, Columbia University, New York, NY

*Adolescent substance use and related risk factors in the context of changes in marijuana-related legislation in Washington and other states*  
Katarina Guttmanova, University of Washington, Seattle, WA

*Science in the Federal courthouse: Marijuana rescheduling in a court case in California*  
Bertha Madras, Harvard Medical School, Belmont, MA

*Health conditions and patterns of marijuana use among young adult medical marijuana patients in Los Angeles*  
Stephen Lankenau, Drexel University School of Public Health, Philadelphia, PA

*Examining length of time between waking and first use of marijuana for the day in adult medical marijuana patients*  
Mark Ilgen, University of Michigan, Ann Arbor, MI

*DISCUSSANT: Legalizing and regulating marijuana: Should we be worried?*  
Priscilla Hunt, Rand Corporation, Santa Monica, CA

## **Workshop XI**

**McArthur Ballroom 4  
7:00 - 9:00 PM**

### **21ST ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP**

Chairs: Kelly E. Dunn and Diann Gaalema

Open to all meeting attendees. For description, see back of book.

## **Workshop XII**

**McArthur Ballroom 5/6  
7:00 - 9:00 PM**

### **CULTURALLY ADAPTED SUBSTANCE ABUSE TREATMENTS FOR RACIAL/ETHNIC MINORITIES: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS**

Chairs: Kathleen Burlew and Carmen L. Masson

*The research and practice of culturally adapting substance abuse treatments for Latino adolescents*

Jason Burrow-Sanchez, University of Utah, Salt Lake City, UT

*Considerations in the treatment of API: Counselor and patient perspectives*  
Martin Y. Iguchi, Georgetown University, Washington, DC

*How improving substance use treatment with racial/ethnic minorities can inform treatment for all*  
Kamilla Venner, University of New Mexico, Albuquerque, Mexico

### **Grant-Writing Workshop (Pre-Registrants Only)**

**AZ Biltmore Ballroom  
8:00 - 12:00 PM**

### **Town Hall Industry/Academia Forum**

**McArthur Ballroom 4  
8:00 - 10:00 AM**

#### **EVALUATION OF SOCIETAL AND ECONOMIC BURDEN OF PRESCRIPTION OPIOID ABUSE**

Chairs: Beatriz Rocha and Beatrice Setnik

*FDA's perspective on prescription drug abuse*

Michael Klein, Food and Drug Administration, Silver Spring, MD

*Societal impact of Rx opioid abuse from poison center and emergency medicine*

Richard C. Dart, Rocky Mountain Poison and Drug Center - A Division of Denver Health, Denver, CO

*An industry perspective on reducing the abuse of opioid medications*

J. David Haddox, Purdue Pharma L.P., Stamford, CT

*Abuse of prescription medicines: The primary care perspective*

William McCarberg, American Academy in Pain Medicine, Poway, CA

*Big data, crowdsourcing and harm reduction*

Nabarun Dasgupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

### **2015 Outreach Event**

**UMOM New Day Center  
9:00 - 12:00 PM**

Organized by Colleen Hanlon

### **Animals in Research Forum**

**McArthur Ballroom 1/2  
10:00 - 12:00 PM**

Chairs: Marilyn E. Carroll and Bert Weiss

*Animal Forum*

*Defending scientific research in an age of extremism*

J. David Jentsch, UCLA, Los Angeles, CA

*The use of both female and male animals in NIH-funded research*

Cora Lee Wetherington, NIDA, Bethesda, MD

**Please be advised that no photographing of presentations or data is permitted.  
Badges must be worn at all times and are required for admission into all events  
and sessions.**

## Poster Session III

(Lunch)

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Frank Lloyd Wright Ballroom  
12:00 - 2:00 PM

Set-up time begins Tuesday 3:00 PM

Must be removed at 2:00 PM Wednesday

### CLUB DRUGS

- 1 *Repeated exposure to the 5-HT<sub>1B/1A</sub> agonist, RU 24969, facilitates the acquisition of MDMA self-administration*  
D. Aronsen, N. Bukholt, S. Schenk, Psychology, Victoria University of Wellington, Wellington, New Zealand
- 2 *The differential role of DA and 5-HT in the discriminative stimulus properties of high vs. low doses of  $\pm$ 3,4-methylenedioxymethamphetamine*  
J. Webster, S. Schenk, D. Harper, Psychology, Victoria University of Wellington, Wellington, New Zealand
- 3 *Abuse liability evaluation of mephedrone in humans*  
M. Farre<sup>1</sup>, C. Pérez-Mañá<sup>1</sup>, J. Mateus<sup>1</sup>, M. Pujadas<sup>1</sup>, F. Fonseca<sup>2</sup>, M. Torrens<sup>2</sup>, R. De la Torre<sup>3</sup>, E. Papaseit<sup>1</sup>, <sup>1</sup>Human Pharmacology and Neurosciences, IMIM-UAB, Barcelona, Spain, <sup>2</sup>Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain, <sup>3</sup>Human Pharmacology and Neurosciences, IMIM-UPF, Barcelona, Spain
- 4 *Recent trend of drug-arrested charges and hospital visits in Taiwan: 2009-2013*  
J. Hsu<sup>1</sup>, C. Yu<sup>1</sup>, S. Lee<sup>1</sup>, W. Tsay<sup>1</sup>, C. Chen<sup>2</sup>, <sup>1</sup>Food and Drug Administration, Ministry of Health and Welfare, Taipei, Taiwan, <sup>2</sup>Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan
- 5 *Decreased thalamocortical connectivity in chronic ketamine users*  
Y. Liao, J. Tang, Mental Health Institute, the Second Xiangya Hospital, Central South University, Changsha, China
- 6 *Comparative phenomenology of psilocybin experiences in research and non-research settings*  
T. M. Carbonaro<sup>2</sup>, M. Klinedinst<sup>2</sup>, M. W. Johnson<sup>2</sup>, R. R. Griffiths<sup>1</sup>, <sup>1</sup>Departments of Psychiatry and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 7 *Correlates between Brazilian club drug users men who have sex with men, psychiatric vulnerabilities and multiple sexual partners*  
L. S. Remy<sup>2</sup>, H. Surratt<sup>1</sup>, S. Kutz<sup>1</sup>, F. P. Pechansky<sup>2</sup>, <sup>1</sup>Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, <sup>2</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil
- 8 *Prevalence and patterns of the use of novel psychoactive substances, “kiken drugs”, among younger adults at dance parties in Japan*  
T. Shimane<sup>1</sup>, K. Wada<sup>1</sup>, Y. Hidaka<sup>2</sup>, M. Funada<sup>1</sup>, <sup>1</sup>Drug Dependence Research, NIMH, NCNP, Kodaira, Japan, <sup>2</sup>Takarazuka University School of Nursing, Osaka, Japan



### PSYCHIATRIC COMORBIDITY

- 9 *Aripiprazole and risperidone in treatment of methamphetamine associated psychosis in China: A pilot randomized study*  
G. Wang<sup>1</sup>, Y. Zhang<sup>3</sup>, S. Zhang<sup>3</sup>, H. Chen<sup>3</sup>, Z. Xu<sup>3</sup>, W. Hao<sup>1</sup>, M. C. Chawarski<sup>2</sup>, <sup>1</sup>Mental Health Center, The Second Xiangya Hospital, Changsha, China, <sup>2</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>3</sup>Wuhan Mental Health Center, Wuhan, China
- 10 *Psychiatric symptoms and treatment outcomes in cocaine-dependent adults treated with buprenorphine and long-acting naltrexone*  
L. Mooney<sup>1</sup>, M. P. Hillhouse<sup>2</sup>, C. Thomas<sup>1</sup>, A. Ang<sup>1</sup>, A. Hasson<sup>1</sup>, J. Annon<sup>1</sup>, S. Reed<sup>1</sup>, W. Ling<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA
- 11 *Mindfulness-based relapse prevention improves stimulant use among adults with major depression and generalized anxiety disorder*  
S. Glasner-Edwards<sup>3</sup>, L. Mooney<sup>1</sup>, A. Ang<sup>1</sup>, H. Chokron Garneau<sup>3</sup>, E. E. Hartwell<sup>3</sup>, M. Brecht<sup>2</sup>, R. Rawson<sup>1</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>3</sup>Psychiatry, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 12 *Mirtazapine pilot trial in comorbid MDD/SUD: Long-term follow-up results*  
J. R. Cornelius<sup>1</sup>, A. Douaihy<sup>1</sup>, D. Daley<sup>1</sup>, T. Chung<sup>1</sup>, M. A. Wesesky<sup>1</sup>, D. S. Wood<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 13 *The interrelationship of culture and depression in the barrio*  
Y. Villarreal<sup>1</sup>, T. Luis<sup>2</sup>, P. Bordnick<sup>2</sup>, <sup>1</sup>Family & Community Medicine, University of Texas Medical School, Houston, TX, <sup>2</sup>Graduate College of Social Work, University of Houston, Houston, TX
- 14 *Anhedonia, depression, anxiety, and craving for opiates in opiate addicts stabilized on oral naltrexone and long-acting naltrexone implant*  
E. Krupitsky<sup>1</sup>, E. Zvartau<sup>1</sup>, E. Blokhina<sup>1</sup>, E. Verbitskaya<sup>1</sup>, V. Palatkin<sup>3</sup>, A. Tyurina<sup>2</sup>, T. Yaroslavtseva<sup>3</sup>, N. Bushara<sup>3</sup>, A. Pecoraro<sup>4</sup>, G. E. Woody<sup>4</sup>, <sup>1</sup>St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>2</sup>First Pavlov State Medical University, St. Petersburg, Russian Federation, <sup>3</sup>St. Petersburg Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, <sup>4</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 15 *Incentivizing attendance to prolonged exposure in methadone maintenance*  
J. M. Peirce<sup>1</sup>, R. L. Schacht<sup>2</sup>, R. K. Brooner<sup>1</sup>, V. L. King<sup>1</sup>, M. S. Kidorf<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Psychology, University of Maryland, Baltimore County, Baltimore, MD
- 16 *Factors associated with history of drug and psychiatric treatment among active heroin users*  
J. J. Atchison<sup>2</sup>, J. D. Jones<sup>1</sup>, S. D. Comer<sup>1</sup>, <sup>1</sup>Psychiatry, Columbia University and NYSPI, New York, NY, <sup>2</sup>Psychology, City College of New York, New York, NY
- 17 *The impact of co-morbid Borderline Personality Disorder and Substance Use Disorder on HPA axis reactivity to social stressors*  
R. Browne<sup>1</sup>, E. Fertuck<sup>1,2</sup>, B. Stanley<sup>2</sup>, <sup>1</sup>The City College of New York (CUNY), Jamaica, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY

- 18 *Gender influence on comorbidity and clinical features of cocaine-dependent patients*  
C. Roncero<sup>1,3,2</sup>, C. Daigre<sup>1,2</sup>, L. Grau-López<sup>1,2,3</sup>, E. Ros-Cucurull<sup>1,2,3</sup>, L. Rodriguez-Cintas<sup>1,2,3</sup>, C. Barral<sup>1,2,3</sup>, N. Martinez-Luna<sup>1,2,3</sup>, J. Pérez-Pazos<sup>1,2,3</sup>, A. Egido<sup>1,2</sup>, M. Prat<sup>1,2,3</sup>, J. Gonzalez<sup>5</sup>, A. Alfonso<sup>4</sup>, J. Alvarós<sup>1,2</sup>, N. Tarifa<sup>1,2</sup>, M. Casas<sup>2,3</sup>, <sup>1</sup>Outpatient Drug Clinic, ASPB, Barcelona, Spain, <sup>2</sup>Psychiatry, Hospital Vall Hebron, Barcelona, Spain, <sup>3</sup>Psychiatry, Universidad Autónoma de Barcelona, Barcelona, Spain, <sup>4</sup>Psychiatry, Universidad Nacional de asunción, Asunción, Paraguay, <sup>5</sup>Psychiatry, Centro de Investigaciones del SNC, Bogota, Colombia
- 19 *Comorbidity and functioning of substance-dependent women with sexual abuse history in the Stage II Women's Recovery Group therapy trial*  
D. E. Sugarman<sup>1,2</sup>, B. Iles<sup>2</sup>, S. F. Greenfield<sup>1,2</sup>, <sup>1</sup>Harvard Medical School/McLean Hospital, Belmont, MA, <sup>2</sup>Division of Alcohol and Drug Abuse; Division of Women's Mental Health, McLean Hospital, Belmont, MA
- 20 *Shared and distinct neural mechanisms of inhibitory control in individuals with a history of a substance use disorder and depression*  
N. A. Crane<sup>1</sup>, L. Gabriel<sup>1</sup>, K. K. Meyers<sup>2</sup>, A. L. Weldon<sup>1</sup>, M. T. Kassel<sup>1</sup>, R. J. Mermelstein<sup>1</sup>, J. Zubieta<sup>2</sup>, S. A. Langenecker<sup>1</sup>, <sup>1</sup>UIC, Chicago, IL, <sup>2</sup>UM, Ann Arbor, MI
- 21 *Patterns of behavioral health services provided in a 2012 national sample of U.S. outpatient substance use disorder treatment facilities: Implications for the treatment of co-occurring disorders*  
P. M. Mauro, C. M. Furr-Holden, R. Mojtabai, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 22 *Applying SBIRT to new settings: Preliminary findings of substance use disorder risk in community mental health settings*  
S. E. Spear<sup>2</sup>, M. Karno<sup>3</sup>, S. Glasner-Edwards<sup>3</sup>, R. Rawson<sup>3</sup>, R. Saitz<sup>1</sup>, B. Dominguez<sup>3</sup>, <sup>1</sup>Community Health Sciences, Boston University and Boston Medical Center, Boston, MA, <sup>2</sup>Health Sciences, California State University, Northridge, Northridge, CA, <sup>3</sup>Psychiatry, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 23 *Social support, cannabis misuse, and post-deployment depression in returning veterans*  
M. B. Benz<sup>1</sup>, J. Metrik<sup>1,2</sup>, B. Borsari<sup>1,2</sup>, <sup>1</sup>Behavioral and Social Sciences, Brown University, Providence, RI, <sup>2</sup>Providence VA Medical Center, Providence, RI
- 24 *Black-white disparities in risk for cannabis use and problems in women: The role of early tobacco use, trauma type and psychiatric pathology*  
K. B. Werner<sup>1</sup>, V. V. McCutcheon<sup>2</sup>, C. E. Sartor<sup>3</sup>, E. C. Nelson<sup>2</sup>, A. C. Heath<sup>2</sup>, K. K. Bucholz<sup>2</sup>, <sup>1</sup>Social Work, Washington University (WU), St. Louis, MO, <sup>2</sup>Psychiatry, WU School of Medicine, St. Louis, MO, <sup>3</sup>Psychiatry, Yale School of Medicine, West Haven, CT
- 25 *The impact of nicotine dose assignment on affect and depression during extended exposure to experimental Spectrum cigarettes: Findings from CENIC Project 1 Study 1*  
L. R. Pacek<sup>3</sup>, R. Vandrey<sup>2</sup>, J. W. Tidey<sup>1</sup>, D. J. Drobes<sup>5</sup>, J. Koopmeiners<sup>6</sup>, A. Umbricht<sup>4</sup>, D. Hatsukami<sup>7</sup>, E. Donny<sup>8</sup>, <sup>1</sup>Center for Alcohol & Addictions Studies, Brown University, Providence, RI, <sup>2</sup>Johns Hopkins University, Baltimore, MD, <sup>3</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, <sup>4</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>5</sup>Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, <sup>6</sup>Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, <sup>7</sup>Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, <sup>8</sup>Department of Psychology, University of Pittsburgh, Pittsburgh, PA

- 26 *Dimensional and categorical phenotypes using Tobacco Use Disorder criteria: Investigating socio-demographic, psychiatric and clinical correlates*  
J. M. Castaldelli-Maia<sup>1,2</sup>, L. H. Andrade<sup>1</sup>, A. Andrade<sup>1,2</sup>, S. S. Martins<sup>3</sup>, <sup>1</sup>Department of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil, <sup>2</sup>Department of Neuroscience, Fundação do ABC Medical School, Santo André, Brazil, <sup>3</sup>Epidemiology, Columbia University, New York City, NY
- 27 *Cigarette smoking and the onset and persistence of panic attacks during mid-adulthood in the United States: 1994-2005*  
J. Bakhshaie<sup>2</sup>, M. J. Zvolensky<sup>2</sup>, R. Goodwin<sup>1</sup>, <sup>1</sup>Queens College, City University of New York, Flushing, NY, <sup>2</sup>Psychology, University of Houston, Houston, TX

### ADOLESCENT II

- 28 *The relationship between risky substance use and friends' use of nicotine, alcohol, and other drugs in an adolescent sample*  
S. M. Kelly<sup>1</sup>, K. O'Grady<sup>2</sup>, J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, A. Kirk<sup>3</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Univ. of Maryland, College Park, MD, <sup>3</sup>Total Health Care, Baltimore, MD
- 29 *Transition from first substance use to crack-cocaine: Predictors of faster addiction progression, and clinical characteristics in crack-cocaine adolescents users*  
T. G. Pianca<sup>2</sup>, R. L. Rosa<sup>3</sup>, A. P. Begnis<sup>4</sup>, P. B. Ferronato<sup>5</sup>, M. Jensen<sup>4</sup>, F. P. Pechansky<sup>1</sup>, L. A. Rohde<sup>2</sup>, C. Szobot<sup>2</sup>, <sup>1</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>2</sup>Child & Adolescent Psychiatry Service, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, <sup>3</sup>Hospital Psiquiátrico São Pedro, Porto Alegre, Brazil, <sup>4</sup>ULBRA, Canoas, Brazil, <sup>5</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- 30 *Alcohol and tobacco use among Brazilian high school students: The role of psychiatric symptomatology*  
T. M. Fidalgo<sup>2</sup>, Z. M. Sanchez<sup>3</sup>, S. Caetano<sup>2</sup>, E. Carlini<sup>3</sup>, S. S. Martins<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York City, NY, <sup>2</sup>Psychiatry, Federal University of Sao Paulo, Santos, Brazil, <sup>3</sup>Preventive Medicine, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
- 31 *Association of alcohol use with drug use and weapon carrying among Thai adolescents*  
O. Saiphoklang<sup>1</sup>, K. Wongboonsin<sup>1</sup>, P. Wongboonsin<sup>1</sup>, U. Perngparn<sup>3</sup>, L. Cottler<sup>2</sup>, <sup>1</sup>College of Population Studies, Chulalongkorn University, Bangkok, Thailand, Patumwan, Thailand, <sup>2</sup>Epidemiology, University of Florida, Gainesville, FL, <sup>3</sup>College of Public Health Sciences, Chulalongkorn University, Patumwan, Thailand
- 32 *Effectiveness of suicide prevention programs with high-risk adolescent alcohol users*  
S. Fernández-Artamendi<sup>2</sup>, S. Al-Halabi<sup>2</sup>, P. Burón<sup>2</sup>, E. Díaz-Mesa<sup>2</sup>, M. Garrido<sup>2</sup>, G. Galván<sup>2</sup>, J. Rancaño<sup>2</sup>, R. Secades-Villa<sup>1</sup>, P. García-Portilla<sup>2</sup>, P. Sáiz<sup>2</sup>, J. Bobes<sup>2</sup>, <sup>1</sup>Addictive Behaviors Research Group, Department of Psychology, University of Oviedo, Oviedo, Spain, <sup>2</sup>Department of Psychiatry - University of Oviedo, Biomedical Networking Research Centre for Mental Health (CIBERSAM), Oviedo, Spain
- 33 *A prospective study of alcohol advertisement on alcohol experiences among adolescents in Taiwan*  
H. Huang<sup>1</sup>, K. Chen<sup>1</sup>, F. Tseng<sup>1</sup>, W. Chen<sup>2</sup>, C. Chen<sup>1,3</sup>, <sup>1</sup>Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, <sup>2</sup>College of Public Health, National Taiwan University, Taipei, Taiwan, <sup>3</sup>Center for Neuropsychiatric Research, National Health Research Institutes, ZuNan, Taiwan
- 34 *Reducing underage drinking through comprehensive community interventions: The Strategic Prevention Framework*  
K. D. Anderson-Carpenter, UCLA Integrated Substance Abuse Programs, Los Angeles, CA

- 35 *Underage drinking diversion: Characterizing risk with latent class analysis*  
N. Mendoza, E. Anthony, D. Row-Sepowitz, Arizona State University, Phoenix, AZ
- 36 *Adolescent substance use: Latent class and transition analysis*  
J. R. Temple<sup>2</sup>, H. Choi<sup>2</sup>, M. T. Schulte<sup>1</sup>, M. S. Ahmed<sup>3</sup>, T. Nanovskaya<sup>2</sup>, <sup>1</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>Ob/Gyn, UTMB Health, Galveston, TX, <sup>3</sup>OB/GYN Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, TX
- 37 *Daily patterns of substance use and sexual behavior among urban adolescents and emerging adults*  
E. E. Bonar<sup>3</sup>, M. Walton<sup>1</sup>, E. Austic<sup>1</sup>, F. Blow<sup>3</sup>, B. M. Booth<sup>2</sup>, A. Buu<sup>4</sup>, R. M. Cunningham<sup>1</sup>, <sup>1</sup>Univ Michigan, Ann Arbor, MI, <sup>2</sup>Psychiatry, Univ. Ark Med Sciences, Little Rock, AR, <sup>3</sup>Psychiatry, Building 16, University of Michigan; North Campus Research Complex, Ann Arbor, MI, <sup>4</sup>Indiana University, Bloomington, IN
- 38 *Gender differences in the longitudinal development of normative beliefs for tobacco, alcohol and marijuana use among middle and high school students*  
H. Petras<sup>1</sup>, Z. Sloboda<sup>2</sup>, <sup>1</sup>Health and Social Development, American Institutes for Research, Washington, DC, <sup>2</sup>Applied Prevention Science, Inc., Ontario, OH
- 39 *A gender-stratified analysis of adolescent substance use on violence trajectories*  
J. Lim, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 40 *Role of gender in age of initiation of nonmedical use of prescription drugs among youth 10 to 18 years*  
S. O. Lasopa, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 41 *Trajectories of nonmedical use of prescription opioids in adolescents in primary care*  
L. A. Lin<sup>2</sup>, M. Walton<sup>1</sup>, F. Blow<sup>2</sup>, <sup>1</sup>Univ Michigan, Ann Arbor, MI, <sup>2</sup>Department of Psychiatry, University of Michigan, Ann Arbor, MI
- 42 *Prevalence of nonmedical use of prescription opioids among adolescents in substance use treatment*  
A. Al-Tayyib<sup>1</sup>, P. Riggs<sup>2</sup>, S. Mikulich-Gilbertson<sup>2</sup>, C. Hopfer<sup>2</sup>, <sup>1</sup>Denver Public Health, Denver, CO, <sup>2</sup>University of Colorado School of Medicine, Aurora, CO
- 43 *Working memory predicts outcome for youth opioid addiction treatment*  
H. T. Vo<sup>1</sup>, M. J. Fishman<sup>1,2</sup>, G. Barnett<sup>1</sup>, <sup>1</sup>Research, Maryland Treatment Center, Baltimore, MD, <sup>2</sup>Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD
- 44 *Exploring the factor structure of a recovery assessment measure among substance-abusing young people*  
S. B. Douglas<sup>1</sup>, M. Hernandez<sup>1</sup>, R. Gonzales-Castaneda<sup>2,1</sup>, C. Yu<sup>1</sup>, <sup>1</sup>Psychology, Azusa Pacific University, Azusa, CA, <sup>2</sup>Integrated Substance Abuse Programs, Los Angeles, CA
- 45 *Randomized, controlled trial of CRAFT for parents of treatment-resistant adolescents and young adults: Interim results*  
K. C. Kirby<sup>1,2</sup>, K. Meyers<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, E. Bresani<sup>1</sup>, K. L. Dugosh<sup>1</sup>, K. Zentgraf<sup>1</sup>, D. Zaslav<sup>1</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 46 *United States national estimates of parenting level and risk of newly incident drug use: 2002-2013*  
H. H. Yeh<sup>1</sup>, J. C. Anthony<sup>1</sup>, R. Seedall<sup>2</sup>, <sup>1</sup>Epidemiology, Michigan State University, East Lansing, MI, <sup>2</sup>Dept of Family, Consumer, & Human Development, Utah State University, Logan, UT



- 47 *Sequences of substance use initiation among adolescent nonmedical users of prescription opioids and stimulants*  
E. A. Austic, S. E. McCabe, Q. Epstein-Ngo, P. T. Veliz, S. A. Stoddard, C. Boyd, University of Michigan, Ann Arbor, MI
- 48 *Do private practitioners provide quality care to adolescents with substance abuse disorders?*  
K. Meyers<sup>1</sup>, J. Cacciola<sup>1,2</sup>, S. Ward<sup>1</sup>, E. Bresani<sup>1</sup>, K. C. Kirby<sup>1,2</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA

### HIV II / HCV

- 49 *Compulsive sexual behavior, substance abuse, and sexual risk-taking among emerging adult gay and bisexual men in New York City: The P18 Cohort Study*  
E. D. Storholm<sup>1,2</sup>, D. D. Satre<sup>1</sup>, F. Kapadia<sup>2</sup>, P. N. Halkitis<sup>2</sup>, <sup>1</sup>Psychiatry, University of California, San Francisco, San Francisco, CA, <sup>2</sup>New York University, New York, NY
- 50 *Risky sexual behavior among OEF/OIF veterans with and without recent substance use*  
M. Rosen, A. C. Black, Psychiatry, Yale University, West Haven, CT
- 51 *Conflict, substance use and HIV*  
B. T. Kerridge, D. S. Hasin, Epidemiology, Columbia University, Gaithersburg, MD
- 52 *Attacks on PWIDs' dignity: Associations with behaviors*  
S. R. Friedman, Y. Jones, E. R. Pouget, M. R. Sandoval, Institute for Infectious Disease Research, National Development and Research Institutes, Inc, New York, NY
- 53 *The perceived stigma of substance abuse scale: Reliability and validity with substance-using people living with HIV*  
K. Stringer<sup>1</sup>, J. E. Schumacher<sup>2</sup>, J. M. Turan<sup>3</sup>, M. Mugavero<sup>4</sup>, M. C. Kempf<sup>5</sup>, E. Baker<sup>1</sup>, <sup>1</sup>Sociology, University of Alabama at Birmingham, Hoover, AL, <sup>2</sup>Dept of Medicine/Div of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Health Care Organization and Policy, University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>School of Medicine/Div. of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, <sup>5</sup>UAB School of Nursing/ Center for Nursing Research, University of Alabama at Birmingham, Birmingham, AL
- 54 *Substance use disorders treatment history among hospitalized HIV-infected substance users in 11 U.S. cities*  
J. A. Frimpong<sup>2</sup>, L. R. Metsch<sup>2</sup>, R. Duan<sup>3</sup>, D. F. Feaster<sup>3</sup>, K. Shiu<sup>2</sup>, T. Matheson<sup>7</sup>, E. DeMicco<sup>7</sup>, J. Sorensen<sup>1</sup>, R. Walker<sup>8</sup>, M. Drainoni<sup>4</sup>, S. Gaskin<sup>9</sup>, M. Stitzer<sup>5</sup>, R. Mandler<sup>6</sup>, E. Farber<sup>10</sup>, C. del Rio<sup>10</sup>, <sup>1</sup>University of California, San Francisco, San Francisco, CA, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>University of Miami, Miami, FL, <sup>4</sup>Boston University, Boston, MA, <sup>5</sup>Johns Hopkins University, Baltimore, MD, <sup>6</sup>National Institute of Drug Abuse, Bethesda, MD, <sup>7</sup>San Francisco Department of Public Health, San Francisco, CA, <sup>8</sup>UT Southwestern Medical Center, Dallas, TX, <sup>9</sup>University of Alabama, Tuscaloosa, AL, <sup>10</sup>Emory University, Atlanta, GA
- 55 *HealthCall: Technology use to reduce non-injection drug use in HIV primary care*  
E. Aharonovich<sup>2</sup>, D. S. Hasin<sup>1</sup>, M. Stohl<sup>3</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>Psychiatry, Columbia University Medical Center, New York, NY, <sup>3</sup>Psychiatry, New York State Psychiatric Institute, New York, NY
- 56 *An mHealth application for increasing HIV and hepatitis knowledge in waitlisted opioid abusers*  
T. A. Ochalek, A. C. Meyer, B. Hruska, J. M. Streck, S. C. Sigmon, University of Vermont, Burlington, VT



- 57 *Acceptability of a mobile-phone-based hepatitis C intervention*  
J. A. Levine<sup>1</sup>, S. Cohen<sup>1</sup>, P. Harkin<sup>2</sup>, J. Guydish<sup>1</sup>, J. Sorensen<sup>1</sup>, C. L. Masson<sup>1</sup>, <sup>1</sup>University of California, San Francisco, CA, <sup>2</sup>GLIDE Health Services, San Francisco, CA
- 58 *A 3-year follow-up of HCV infection in opioid use disorder patients in treatment*  
C. Duburque<sup>2</sup>, V. Canva<sup>3,4</sup>, M. Auriacombe<sup>1</sup>, P. Djomboue<sup>4,5</sup>, B. Hernout<sup>4,5</sup>, D. Lucidarme<sup>2,4</sup>, J. Harbonnier<sup>4,5</sup>, <sup>1</sup>Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, <sup>2</sup>CH Saint-Philibert, Lomme, Lomme, France, <sup>3</sup>CHRU, Lille, Lille, France, <sup>4</sup>Réseau Hépatite Nord-Pas de Calais, Lille, France, <sup>5</sup>Centre Boris Vian, Lille, Lille, France
- 59 *Risks associated with nonmedical prescription opioid use: Transition to heroin use and drug injection, overdose and hepatitis C*  
P. Mateu-Gelabert, H. Guarino, L. Jessell, C. Syckes, S. R. Friedman, Institute for Infectious Disease Research, National Development and Research Institutes, Inc, New York, NY
- 60 *Hepatitis C and associated risk behaviors in people who inject drugs*  
K. Butler, L. Burns, National Drug and Alcohol Research Centre, UNSW Australia, Sydney, NSW, Australia
- 61 *Opioid use trajectories, injection drug use and HCV risk among young adults from the former Soviet Union in NYC*  
H. Guarino<sup>1</sup>, L. A. Marsch<sup>3</sup>, S. Deren<sup>2</sup>, S. L. Straussner<sup>4</sup>, A. Teper<sup>1</sup>, <sup>1</sup>National Development & Research Institutes, New York, NY, <sup>2</sup>College of Nursing, New York University, New York, NY, <sup>3</sup>Psychiatry, Dartmouth College, Hanover, NH, <sup>4</sup>Silver School of Social Work, New York University, New York, NY
- 62 *Diagnosis of hepatitis C virus infection after entry to opioid substitution therapy*  
S. Larney<sup>3</sup>, J. Grebely<sup>4</sup>, M. Falster<sup>5</sup>, A. Swart<sup>6</sup>, J. Amin<sup>4</sup>, L. Degenhardt<sup>2</sup>, L. Burns<sup>1</sup>, C. Vajdic<sup>6</sup>, <sup>1</sup>NDARC, UNSW, Sydney, NSW, Australia, <sup>2</sup>National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, <sup>3</sup>National Drug and Alcohol Research Centre, University of New South Wales, Randwick, NSW, Australia, <sup>4</sup>The Kirby Institute, University of NSW, Sydney, NSW, Australia, <sup>5</sup>Centre for Health Research, University of Western Sydney, Sydney, NSW, Australia, <sup>6</sup>Prince of Wales Clinical School, University of NSW, Sydney, NSW, Australia

### OPIOID TREATMENT

- 63 *The cost-effectiveness of opioid agonist treatment in California's publicly funded drug treatment facilities*  
E. Krebs<sup>1</sup>, L. Li<sup>2</sup>, J. Min<sup>1</sup>, E. Evans<sup>2</sup>, R. Rawson<sup>2</sup>, Y. Hser<sup>2</sup>, B. Nosyk<sup>1</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>2</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 64 *Challenges to opioid treatment programs after Hurricane Sandy: Impact, preparedness, and recovery*  
H. Matusow<sup>1</sup>, E. Benoit<sup>2</sup>, A. Rosenblum<sup>1</sup>, <sup>1</sup>Institute for Treatment and Services Research, National Development and Research Institutes, Inc., New York, NY, <sup>2</sup>Institute for Special Populations Research, NDRI, New York, NY
- 65 *Counselors' views of providing patient-centered methadone treatment in a clinical trial*  
S. G. Mitchell<sup>1</sup>, L. Monico<sup>1</sup>, E. Lertch<sup>1</sup>, J. Gryczynski<sup>1</sup>, S. M. Kelly<sup>1</sup>, K. E. O'Grady<sup>2</sup>, J. H. Jaffe<sup>1</sup>, R. P. Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>University of Maryland, College Park, MD

- 66 *Health service use in a randomized clinical trial comparing three methods of emergency department interventions for opioid dependence*  
S. Busch, K. Hawk, D. Fiellin, P. O'Connor, M. Chawarski, P. Owens, M. Pantalon, S. Bernstein, G. D'Onofrio, Yale University, New Haven, CT
- 67 *A randomized clinical trial of emergency department initiated treatment for opioid dependence: Two- and six-month outcomes*  
G. D'Onofrio, P. O'Connor, M. Pantalon, M. Chawarski, S. Busch, P. Owens, S. Bernstein, D. Fiellin, Yale University, New Haven, CT
- 68 *Early mortality after entering a methadone treatment program in Badalona, Spain*  
I. Rivas<sup>1</sup>, A. Sanvisens<sup>2</sup>, E. Faure<sup>1</sup>, D. Fuster<sup>2</sup>, M. Trinidad<sup>1</sup>, M. Rubio<sup>1</sup>, R. Muga<sup>2</sup>, <sup>1</sup>Municipal Center for Substance Abuse Treatment, Badalona, Spain, <sup>2</sup>Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, Badalona, Spain
- 69 *Predictors of induction onto XR-NTX in patients with opioid use disorder*  
P. Mannelli, K. Peindl, L. Wu, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC
- 70 *Intranasal buprenorphine alone and in combination with naloxone: Reinforcing efficacy and abuse liability in physically dependent opioid abusers*  
S. L. Walsh<sup>2</sup>, P. A. Nuzzo<sup>2</sup>, C. Elayi<sup>1,3</sup>, M. R. Lofwall<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Department of Behavioral Science and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, <sup>3</sup>Internal Medicine, University of Kentucky, Lexington, KY
- 71 *Associations between buprenorphine treatment trajectories and clinical outcomes in a large Medicaid program*  
W. Lo-Ciganic<sup>1,3</sup>, W. F. Gellad<sup>3,2</sup>, A. J. Gordon<sup>3,2</sup>, G. Cochran<sup>3</sup>, J. M. Donohue<sup>3</sup>, <sup>1</sup>University of Arizona, Tucson, AZ, <sup>2</sup>VA Pittsburgh Healthcare System, Pittsburgh, PA, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA
- 72 *Determining menstrual phase in substance use research: A review with recommendations*  
A. M. Allen<sup>3</sup>, A. McRae-Clark<sup>2</sup>, M. E. Saladin<sup>1</sup>, K. M. Gray<sup>2</sup>, C. Wetherington<sup>4</sup>, S. A. McKee<sup>6</sup>, S. Allen<sup>5</sup>, <sup>1</sup>Health Sciences and Research, Med. Univ. of SC, Charleston, SC, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, <sup>3</sup>Family Medicine & Community Health, University of Minnesota, Minneapolis, MN, <sup>4</sup>NIDA, Bethesda, MD, <sup>5</sup>University of Minnesota, Minneapolis, MN, <sup>6</sup>Psychiatry, Yale, New Haven, CT
- 73 *Interim buprenorphine treatment: Leveraging technology to bridge waitlist delays*  
S. C. Sigmon<sup>1</sup>, A. C. Meyer<sup>1</sup>, B. Hruska<sup>1</sup>, T. Ochalek<sup>1</sup>, S. H. Heil<sup>1</sup>, S. T. Higgins<sup>1</sup>, R. P. Schwartz<sup>2</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Friends Research Institute, Baltimore, MD
- 74 *Impaired cognitive control in longer-term abstinent buprenorphine-assisted treatment opioid-dependent patients*  
G. DiGirolamo<sup>1,2</sup>, G. Gonzalez<sup>1</sup>, C. Hynes<sup>2</sup>, D. Smelson<sup>1</sup>, M. Romero-Gonzalez<sup>1</sup>, <sup>1</sup>Division of Addiction Psychiatry, University of Massachusetts, Worcester, MA, <sup>2</sup>Psychology, College of the Holy Cross, Worcester, MA
- 75 *Drug-free period from non-opioids before start of the treatment with methadone or buprenorphine for heroin-dependence improves efficacy*  
O. M. Hoffmann<sup>1</sup>, T. Ljungberg<sup>2</sup>, F. Frisell<sup>1</sup>, <sup>1</sup>Addiction Center, Psychiatric Clinic Eskilstuna, Stockholm, Sweden, <sup>2</sup>Center for Clinical Research, Psychiatric Clinic, Nyköping, Sweden

- 76 *Physician integration in formerly “drug-free” outpatient programs providing buprenorphine*  
L. Monico<sup>1</sup>, S. G. Mitchell<sup>1</sup>, J. Gryczynski<sup>1</sup>, R. P. Schwartz<sup>1</sup>, Y. Olsen<sup>2</sup>, K. E. O’Grady<sup>3</sup>,  
J. H. Jaffe<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>IBR Reach, Baltimore, MD,  
<sup>3</sup>University of Maryland, College Park, MD
- 77 *Testing the VACS Index as a measure of health outcomes associated with abstinence among patients receiving opioid agonist treatment*  
D. A. Fiellin<sup>1</sup>, K. McGinnis<sup>2</sup>, J. Tate<sup>1</sup>, A. Justice<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT,  
<sup>2</sup>Univ. of Pittsburgh, Pittsburgh, PA
- 78 *Health state transitions among prescribed opiate patients accessing pharmacological treatment for opioid dependence in California, 2006 - 2010*  
L. Li<sup>1</sup>, E. Evans<sup>1</sup>, J. Min<sup>2</sup>, L. Liu<sup>3</sup>, D. Y. Huang<sup>1</sup>, D. Urada<sup>1</sup>, E. Wood<sup>2,5</sup>, Y. Hser<sup>1</sup>, B. Nosyk<sup>2,4</sup>,  
<sup>1</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>2</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>3</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>4</sup>Simon Fraser University, Faculty of Health Sciences, Vancouver, BC, Canada, <sup>5</sup>Division of AIDS, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
- 79 *Estimation of life expectancy and the expected years of life loss among heroin users in the era of opiate substitution treatment in Taiwan*  
K. Chang<sup>1,2</sup>, C. Chen<sup>3</sup>, J. Wang<sup>2</sup>, T. Lu<sup>2</sup>, <sup>1</sup>General Psychiatry, Jianan Psychiatric Center, Ministry of Health & Welfare, Tainan, Taiwan, Tainan, Taiwan, <sup>2</sup>Department of Public Health, National Cheng Kung University, Tainan, Taiwan, Tainan, Taiwan, <sup>3</sup>Institute of Public Health & Department of Public Health, National Yang-Ming University, Taipei, Taiwan
- 80 *Does drug of choice matter in mHealth delivery? Comparison of methamphetamine- and heroin-dependent patients*  
M. T. Schulte<sup>1</sup>, Y. Hser<sup>2</sup>, <sup>1</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA,  
<sup>2</sup>Department of Psychiatry & Behavioral Sciences, UCLA, Los Angeles, CA
- 81 *Evaluating the effectiveness of telehealth-delivered opioid agonist therapy across Ontario, Canada*  
J. K. Eibl<sup>1</sup>, J. Daiter<sup>2</sup>, M. Varenbut<sup>2</sup>, D. Pellegrini<sup>1</sup>, D. C. Marsh<sup>1</sup>, <sup>1</sup>Northern Ontario School of Medicine, Sudbury, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 82 *Pilot evaluation of the “Tailored telephone intervention delivered by peers to prevent recurring opioid overdoses”*  
T. Winhusen, J. Theobald, D. Lewis, C. M. Wilder, M. Lyons, University of Cincinnati, Cincinnati, OH

### PERINATAL

- 83 *Constrained choices: The care-decision-making experience for pregnant opioid-dependent women*  
H. G. Howard, Social Work, Women & Infants Hospital, Lincoln, RI
- 84 *Postpartum contraceptive behavior of opioid-maintained pregnant women*  
H. S. Melbostad<sup>1,2</sup>, S. H. Heil<sup>1,3,2</sup>, <sup>1</sup>Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, <sup>2</sup>Psychological Sciences, University of Vermont, Burlington, VT,  
<sup>3</sup>Psychiatry, University of Vermont, Burlington, VT

- 85 *A SMART design: Response to reinforcement-based treatment intensity among pregnant, drug-dependent women*  
H. Fitzsimons<sup>1</sup>, M. Tuten<sup>2</sup>, K. O'Grady<sup>3</sup>, M. S. Chisolm<sup>1</sup>, H. E. Jones<sup>4</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, <sup>2</sup>School of Social Work, University of Maryland Baltimore, Baltimore, MD, <sup>3</sup>Psychology, University of Maryland, College Park, MD, <sup>4</sup>OB/GYN, UNC Chapel Hill, Chapel Hill, NC
- 86 *Correspondence between self-reported and biochemical measures of smoking in opioid-dependent pregnant women*  
C. A. Arger, S. T. Higgins, S. H. Heil, Vermont Center on Behavior and Health, Burlington, VT
- 87 *Effects of prenatal cocaine and nicotine on maternal white matter integrity in early postpartum*  
M. Leming, M. Styner, K. M. Grewen, Psychiatry, UNC, Chapel Hill, NC
- 88 *Characteristics of smoking pregnant women in Guadalajara, Mexico*  
O. Campollo<sup>1</sup>, F. Hernandez-Mora<sup>2</sup>, E. Angulo-C<sup>3</sup>, A. Guzman<sup>2</sup>, A. Munguia<sup>1</sup>, M. Garcia<sup>1</sup>, J. K. Cunningham<sup>4</sup>, <sup>1</sup>Center of Studies on Alcohol and Addictions, University of Guadalajara, Guadalajara, Mexico, <sup>2</sup>Obstetrics and Gynecology, AHCG, Guadalajara, Mexico, <sup>3</sup>Neonatology, AHCG, Gdl., Mexico, <sup>4</sup>Family and Community Medicine, University of Arizona, Tucson, AZ
- 89 *Pregnancy, tobacco use, and access to health care*  
Q. Brown<sup>1</sup>, K. Keyes<sup>1</sup>, D. S. Hasin<sup>1</sup>, O. Ravenell<sup>2</sup>, D. S. Fink<sup>1</sup>, S. S. Martins<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>Kraemer Women's Care, Columbia, SC
- 90 *Smoking and mental health from first prenatal visit to postpartum*  
V. H. Coleman-Cowger<sup>1,2</sup>, B. Koszowski<sup>1</sup>, K. Mark<sup>2</sup>, M. Terplan<sup>3</sup>, <sup>1</sup>Health & Analytics, Battelle, Baltimore, MD, <sup>2</sup>Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland, Baltimore, MD, <sup>3</sup>Behavioral Health System Baltimore, Baltimore, MD
- 91 *Perinatal attentional retraining intervention for smoking - A pilot study*  
D. W. Foster<sup>1</sup>, A. J. Waters<sup>2</sup>, A. Forray<sup>1</sup>, <sup>1</sup>Psychiatry, Yale School of Medicine, New Haven, CT, <sup>2</sup>Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD
- 92 *Psychiatric symptoms among pregnant and newly postpartum women receiving financial incentives for smoking cessation*  
I. A. Zvorsky<sup>1</sup>, A. A. Lopez<sup>3</sup>, T. J. White<sup>1</sup>, J. M. Skelly<sup>2</sup>, S. T. Higgins<sup>1</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Biostatistics, University of Vermont, Burlington, VT, <sup>3</sup>Psychology, Virginia Commonwealth University, Richmond, VA
- 93 *A comparison of meconium screening outcomes as an indicator of the impact of state-level relaxation of marijuana policy*  
J. T. Jones, A. Baldwin, I. Shu, Lab, United States Drug Testing Laboratories, Des Plaines, IL

### ALCOHOL

- 94 *Patient pre-treatment expectations and substance use treatment outcomes*  
K. Serafini<sup>2</sup>, S. Decker<sup>2,3</sup>, B. D. Kiluk<sup>1</sup>, L. Anez<sup>2</sup>, M. Paris<sup>2</sup>, T. Frankforter<sup>2</sup>, K. M. Carroll<sup>2</sup>, <sup>1</sup>Psychiatry, Yale School of Medicine, West Haven, CT, <sup>2</sup>Department of Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>3</sup>West Haven VA, West Haven, CT

- 95 *A longitudinal mediational study of the stability of alexithymia among alcohol treatment seekers*  
F. A. Thorberg<sup>1,3</sup>, R. M. Young<sup>4</sup>, K. Sullivan<sup>4</sup>, M. Lyvers<sup>2</sup>, J. Connor<sup>5</sup>, E. P. Noble<sup>7</sup>,  
E. London<sup>7</sup>, R. Tyssen<sup>3</sup>, G. Feeney<sup>6</sup>, <sup>1</sup>Natnl Centre Dual Diagnosis, Innlandet Hosp Trust,  
Hamar, Norway, <sup>2</sup>Bond University, Gold Coast, QLD, Australia, <sup>3</sup>University of Oslo, Oslo,  
Norway, <sup>4</sup>Queensland University of Technology, Brisbane, QLD, Australia, <sup>5</sup>University  
of Queensland, Brisbane, QLD, Australia, <sup>6</sup>Princess Alexandra Hospital, Brisbane, QLD,  
Australia, <sup>7</sup>University of California Los Angeles, Los Angeles, CA
- 96 *Alcohol screening and brief intervention among opioid agonist patients in a primary care and  
opioid treatment program*  
J. Klimas<sup>1</sup>, J. Muench<sup>3</sup>, K. Wiest<sup>5</sup>, R. Croff<sup>4</sup>, T. R. Rieckmann<sup>2</sup>, D. McCarty<sup>3</sup>, <sup>1</sup>BC Centre for  
Excellence in HIV/AIDS, Addiction & Urban Health Research Initiative, Vancouver, BC,  
Canada, <sup>2</sup>Public Health, OHSU, Portland, OR, <sup>3</sup>CB 669 PHPM, Oregon Health & Science  
Univ, Portland, OR, <sup>4</sup>Public Health & Preventive Medicine, Oregon Health & Science  
University, Portland, OR, <sup>5</sup>Coda, Portland, OR
- 97 *Heterogeneity of alcohol use treatment services: A latent class analysis*  
R. J. Evans-Polce, M. S. Schuler, The Methodology Center and Prevention Research Center,  
Pennsylvania State University, State College, PA
- 98 *Markers of inflammation and mortality in a cohort of alcohol-dependent patients*  
D. Fuster<sup>1</sup>, A. Sanvisens<sup>1</sup>, F. Bolao<sup>2</sup>, P. Zuluaga<sup>1</sup>, I. Rivas<sup>3</sup>, J. Tor<sup>1</sup>, R. Muga<sup>1</sup>, <sup>1</sup>Internal  
Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, <sup>2</sup>Internal Medicine,  
Hospital Bellvitge, L'Hospitalet de Llobregat, Spain, <sup>3</sup>IMSP Badalona, Municipal Centre for  
Substance Abuse Treatment (Centro Delta), Badalona, Spain
- 99 *Exposure to ethanol in Brazilian gasoline station attendants*  
R. P. Limberger<sup>4</sup>, B. T. Borille<sup>4</sup>, T. R. Fiorentin<sup>4</sup>, B. C. Coppe<sup>4</sup>, E. Comiran<sup>4</sup>, A. B. Jacques<sup>4</sup>,  
T. R. Sousa<sup>2</sup>, G. Pasa<sup>1</sup>, F. H. Kessler<sup>3</sup>, F. P. Pechansky<sup>3</sup>, S. M. Castro<sup>4</sup>, <sup>1</sup>Center for Drug  
and Alcohol Research - Federal University of Rio Grande do Sul - Hospital de Clinicas de  
Porto Alegre, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research, CPAD - Federal  
University of Rio Grande do Sul - UFRGS, Porto Alegre, Brazil, <sup>3</sup>Psychiatry, Center for Drug  
and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>4</sup>Pharmacy, Federal University of  
Rio Grande do Sul, Porto Alegre, Brazil
- 100 *Online feasibility study about HIV-negative male couples substance use with weekly ecological  
momentary diary assessments*  
J. W. Mitchell<sup>1</sup>, F. Davis<sup>1</sup>, Y. Pan<sup>2</sup>, D. J. Feaster<sup>1</sup>, <sup>1</sup>Public Health Sciences, University  
of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>University of Miami Miller School of  
Medicine, Miami, FL
- 101 *Personality and gambling characteristics of problem gamblers with and without alcohol  
dependence*  
J. J. Lister<sup>1</sup>, A. Milosevic<sup>2</sup>, D. M. Ledgerwood<sup>1</sup>, <sup>1</sup>Psychiatry, Wayne State School of Medicine,  
Detroit, MI, <sup>2</sup>Psychology, University of Windsor, Windsor, ON, Canada
- 102 *The moderating role of negative urgency in the relation between distress intolerance and  
alcohol drinking motives*  
M. Yang<sup>1</sup>, T. M. Leyro<sup>2</sup>, S. Moshier<sup>3</sup>, K. Szuhany<sup>3</sup>, M. W. Otto<sup>3</sup>, <sup>1</sup>Department of Psychology,  
Rutgers University, Highland Park, NJ, <sup>2</sup>Department of Psychology, Rutgers University,  
Piscataway, NJ, <sup>3</sup>Department of Psychological and Brain Sciences, Boston University,  
Boston, MA



- 103 *Exploring substance group differences on the simultaneous alcohol and tobacco expectancy questionnaire in a young adult community*  
R. S. Trim<sup>1,2</sup>, N. Doran<sup>1,2</sup>, C. Barnett<sup>1</sup>, <sup>1</sup>Psychiatry, UC-San Diego, San Diego, CA, <sup>2</sup>VA San Diego Healthcare System, San Diego, CA
- 104 *Prevalence, correlates, and substance use and psychiatric predictors of regularly drinking alcohol before sex among adults in the United States*  
N. R. Eaton<sup>3</sup>, R. G. Thompson<sup>2</sup>, M. Hu<sup>4</sup>, D. S. Hasin<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>Psychiatry, Columbia University, New York, NY, <sup>3</sup>Psychology, Stony Brook University, Stony Brook, NY, <sup>4</sup>Columbia University, New York, NY
- 105 *Geographic distance to nationwide professional treatment for alcohol use disorder in Mexico*  
C. Rafful<sup>3</sup>, R. Orozco<sup>1</sup>, S. Strathdee<sup>2</sup>, M. E. Medina-Mora<sup>4</sup>, <sup>1</sup>National Institute of Psychiatry, Mexico City, Mexico, <sup>2</sup>Univ of California San Diego, San Diego, CA, <sup>3</sup>Global Public Health, University of California San Diego, San Diego State University, San Diego, CA, <sup>4</sup>National Institute of Psychiatry, Mexico City, Mexico

**POLYDRUG ABUSE**

- 106 *Comparison of DWI prevalences among fatal, non-fatal and roadside samples of Brazilian drivers*  
F. P. Pechansky<sup>1</sup>, L. Von Diemen<sup>1</sup>, A. O. Sordi<sup>2</sup>, <sup>1</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>2</sup>Department of Psychiatry, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- 107 *Different patterns of drug use among crack and powder cocaine users in Brazil*  
M. P. Pachado<sup>1</sup>, D. S. Souza<sup>3</sup>, J. N. Scherer<sup>4</sup>, S. Halpern<sup>1</sup>, L. Von Diemen<sup>2</sup>, F. P. Pechansky<sup>2</sup>, F. Kessler<sup>2</sup>, <sup>1</sup>Psychiatric Dept, Center for Drug and Alcohol Research, Porto Alegre, Brazil, <sup>2</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>3</sup>Psychiatric Dept, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, <sup>4</sup>Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- 108 *Inhibitory processing in relation to age of first substance use and age of first regular substance use*  
A. L. Paz, J. Conniff, B. Gonzalez, M. Rosselli, Florida Atlantic University, Miami, FL
- 109 *Evaluation of cognitive functioning of individuals with co-occurring opiate and amphetamine-type stimulants use disorders in Malaysia*  
W. Chooi<sup>2</sup>, N. M. Zaharim<sup>2</sup>, A. Desrosiers<sup>1</sup>, I. Ahmad<sup>2</sup>, M. M. Yasin<sup>2</sup>, S. Z. Syed Jaapar<sup>2</sup>, R. S. Schottenfeld<sup>1</sup>, V. B. Kasinather<sup>2</sup>, M. C. Chawarski<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University School of Medicine, New Haven, CT, <sup>2</sup>Universiti Sains Malaysia, Penang, Malaysia
- 110 *Pilot study of atomoxetine for BUP/NX-maintained patients with co-occurring opioid and ATS use disorder*  
R. S. Schottenfeld<sup>1</sup>, M. C. Chawarski<sup>1</sup>, M. Sofuoglu<sup>1</sup>, W. Chooi<sup>2</sup>, N. M. Zaharim<sup>2</sup>, M. M. Yasin<sup>2</sup>, I. Ahmad<sup>2</sup>, S. Jaapar<sup>2</sup>, V. B. Kasinather<sup>2</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven & West Haven, CT, <sup>2</sup>Universiti Sains Malaysia, Penang & Kota Bharu, Malaysia
- 111 *Alexithymia level and response to computer-based training in cognitive behavioral therapy among cocaine-dependent methadone-maintained individuals*  
K. P. Morie<sup>1</sup>, C. Nich<sup>2</sup>, K. Hunkele<sup>2</sup>, M. N. Potenza<sup>2</sup>, K. M. Carroll<sup>2</sup>, <sup>1</sup>Diagnostic Radiology, Yale University, New Haven, CT, <sup>2</sup>Psychiatry, Yale University School of Medicine, West Haven, CT

- 112 *Efficacy of computer and therapist brief interventions for drug users*  
F. Blow<sup>3</sup>, A. S. Bohnert<sup>1</sup>, R. Ignacio<sup>3</sup>, K. Barry<sup>3</sup>, M. A. Ilgen<sup>3</sup>, B. M. Booth<sup>2</sup>, R. Cunningham<sup>1</sup>, M. Walton<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Psychiatry, Univ. Ark Med Sciences, Little Rock, AR, <sup>3</sup>Psychiatry, University of Michigan, Ann Arbor, MI
- 113 *Web-based treatment for substance use disorders: Differential effects by primary substance*  
G. Cochran<sup>1</sup>, M. L. Stitzer<sup>2</sup>, A. Campbell<sup>3</sup>, M. Hu<sup>4</sup>, R. Vandrey<sup>5</sup>, E. V. Nunes<sup>4</sup>, <sup>1</sup>Social Work, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Psychiatry, Johns Hopkins, Baltimore, MD, <sup>3</sup>Substance Abuse Division, New York State Psychiatric Institute, New York, NY, <sup>4</sup>Psychiatry, Columbia University, New York, NY, <sup>5</sup>Johns Hopkins University, Baltimore, MD
- 114 *Characterizing nicotine withdrawal in opioid-maintained smokers*  
J. M. Streck<sup>2</sup>, A. C. Meyer<sup>1</sup>, J. Bunn<sup>3</sup>, S. C. Sigmon<sup>1</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Psychology, University of Vermont, Burlington, VT, <sup>3</sup>Biostatistics, University of Vermont, Burlington, VT
- 115 *The longitudinal influence of multiple depressant use on nonfatal overdose among young people who inject drugs*  
E. Riley<sup>2</sup>, J. A. Hahn<sup>2</sup>, J. L. Evans<sup>2</sup>, A. Briceno<sup>2</sup>, P. J. Davidson<sup>1</sup>, P. J. Lum<sup>2</sup>, K. Page<sup>3</sup>, <sup>1</sup>Medicine, University of California, San Diego, La Jolla, CA, <sup>2</sup>Medicine, University of California, San Francisco, San Francisco, CA, <sup>3</sup>Epidemiology, University of New Mexico, Albuquerque, NM
- 116 *Self-reported drug use patterns for drug users presenting in emergency department*  
G. Sharma<sup>1</sup>, M. Bogenschutz<sup>2</sup>, <sup>1</sup>The EMMES Corporation, Rockville, MD, <sup>2</sup>University of NM, Albuquerque, NM
- 117 *What is the impact of “professional subjects” on medication efficacy trials?*  
D. McCann, NIDA/NIH, Bethesda, MD
- 118 *Problems of treatment demands related to substance dependency*  
V. Kirzhanova, E. Koshkina, K. Vyshynskiy, Federal Medical Research Centre for Psychiatry and Addictions, Moscow, Russian Federation
- 119 *Cautious use of race in analyses to predict retention in substance abuse treatment*  
A. Duncan<sup>1</sup>, R. Ahmed<sup>2</sup>, <sup>1</sup>IMPAQ International, Washington, DC, <sup>2</sup>University of Manitoba, Winnipeg, MB, Canada
- 120 *How do gender and race/ethnicity influence perceived barriers to help-seeking for substance use problems?*  
C. E. Grella<sup>1</sup>, A. Otiniano Verissimo<sup>2</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>California State University, San Bernardino, San Bernardino, CA
- 121 *Does urban size and region predict outpatient substance abuse treatment completion?*  
G. Stahler, J. Mennis, Geography & Urban Studies, Temple University, Philadelphia, PA
- 122 *Comprehensive women-centered treatment for substance use disorders in Georgia: Initial examination of sex risk*  
H. E. Jones<sup>2</sup>, I. Kirtadze<sup>3</sup>, D. Otiashvili<sup>3</sup>, W. Zule<sup>4</sup>, W. Wechsberg<sup>4</sup>, E. Krupitsky<sup>1</sup>, <sup>1</sup>KG Consulting, St. Petersburg, Russian Federation, <sup>2</sup>OB/GYN, UNC Chapel Hill, Chapel Hill, NC, <sup>3</sup>Addiction Research Center, Union Alternative Georgia, Tbilisi, Georgia, <sup>4</sup>RTI International, Rtp, NC
- 123 *Effects of non-pharmacological treatment of substance use in Medicare elderly with prostate cancer*  
S. Chhatre<sup>1</sup>, D. Metzger<sup>1</sup>, R. Jayadevappa<sup>2</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA

- 124 *Coping strategies as a mediator of Internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial*  
A. Levesque<sup>1</sup>, A. Campbell<sup>2,3</sup>, M. Pavlicova<sup>4,5</sup>, M. Hu<sup>3</sup>, E. V. Nunes<sup>3,2</sup>, <sup>1</sup>Mount Sinai Roosevelt Hospital, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY, <sup>3</sup>Department of Psychiatry, Columbia University Medical Center, New York, NY, <sup>4</sup>Department of Biostatistic, Mailman School of Public Health, New York, NY, <sup>5</sup>Columbia University, New York, NY
- 125 *Development of a prospective memory training program for substance use treatment*  
M. M. Sweeney, O. Rass, P. S. Johnson, M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD
- 126 *A behavioral economic demand model modification to improve versatility*  
M. N. Koffarnus<sup>1</sup>, C. T. Franck<sup>1</sup>, J. S. Stein<sup>1</sup>, W. K. Bickel<sup>2</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Virginia Tech, Roanoke, VA, <sup>2</sup>Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA
- 127 *Fidelity monitoring model for an MI-based brief intervention*  
A. A. Forcehimes<sup>2,3</sup>, M. Bogenschutz<sup>2,3</sup>, G. Sharma<sup>1</sup>, K. Wilson<sup>2</sup>, T. Moyers<sup>2</sup>, <sup>1</sup>NIDA Data & Statistics Center, The EMMES Corporation, Rockville, MD, <sup>2</sup>CASAA, University of New Mexico, Albuquerque, NM, <sup>3</sup>Psychiatry, University of New Mexico, Albuquerque, NM
- 128 *Expanded brief intervention in primary care results in reduced self-reported substance use at six-month follow-up: Preliminary results*  
R. B. Medvin<sup>1</sup>, A. C. Brooks<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, J. Lauby<sup>2</sup>, D. Metzger<sup>3,1</sup>, E. Byrne<sup>2</sup>, K. Favor<sup>4</sup>, K. C. Kirby<sup>1,3</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Public Health Management Corporation, Philadelphia, PA, <sup>3</sup>University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Lincoln University, Lincoln University, PA
- 129 *Evidence-based multimedia 12-Step facilitation toolkit durably improves counselor adherence in group counseling with minimal training*  
A. C. Brooks<sup>1</sup>, C. M. Carpenedo<sup>1</sup>, J. E. Chambers<sup>1</sup>, L. Benishek<sup>1</sup>, A. B. Laudet<sup>2</sup>, K. L. Dugosh<sup>1</sup>, D. Carise<sup>1</sup>, K. C. Kirby<sup>1</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>C-STAR, NDRI, New York, NY
- 130 *Health-related issues among people who inject drugs in Australia*  
J. Stafford, L. Burns, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- 131 *Does screening and brief intervention for drug use in primary care increase receipt of substance use disorder treatment?*  
T. W. Kim<sup>1,3</sup>, J. Bernstein<sup>1</sup>, D. M. Cheng<sup>1</sup>, J. Samet<sup>1,3</sup>, C. Lloyd-Travaglini<sup>1</sup>, T. Palfai<sup>2</sup>, J. German<sup>3</sup>, R. Saitz<sup>1,3</sup>, <sup>1</sup>Schools of Medicine and Public Health, Boston University, Boston, MA, <sup>2</sup>Department of Psychology, Boston University, Boston, MA, <sup>3</sup>Boston Medical Center, Boston, MA
- 132 *Incentives in public addiction treatment systems: Context and effects on access, retention, selection and outcomes*  
S. Reif, M. Stewart, C. M. Horgan, B. Mohr, M. Torres, M. T. Davis, D. Hodgkin, G. Ritter, A. Nguyen, Brandeis University, Waltham, MA

### LITERATURE REVIEW

- 133 *Screening, brief interventions and referral to treatment for substance use disorders in South African health services: Opportunities and challenges*  
B. Myers<sup>1,2</sup>, K. Sorsdahl<sup>2</sup>, <sup>1</sup>Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa, <sup>2</sup>Psychiatry, University of Cape Town, Cape Town, South Africa
- 134 *Contingency management in the treatment of substance use disorders: Trends in the literature*  
D. R. Davis<sup>2,1</sup>, A. N. Kurti<sup>1</sup>, S. T. Higgins<sup>1,2</sup>, <sup>1</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>2</sup>Psychology, University of Vermont, Burlington, VT
- 135 *Prescription monitoring programs: Best practice and Canadian program review*  
B. Sproule, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 136 *Current challenges in implementing prescription monitoring programs*  
S. Sarkar<sup>2</sup>, B. C. Ginsburg<sup>1</sup>, M. Pugh<sup>2</sup>, E. Finley<sup>2</sup>, D. McGeary<sup>2</sup>, V. Bebart<sup>2</sup>, A. Garcia<sup>2</sup>, J. S. Potter<sup>2</sup>, <sup>1</sup>Psychiatry and Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, <sup>2</sup>Psychiatry, UT Health Science Center, San Antonio, TX
- 137 *Assessing aberrant behaviors related to prescription drugs in the patient population: Recent studies, methodologies and findings*  
B. Setnik<sup>3</sup>, C. Kornegay<sup>4</sup>, M. Sokolowska<sup>2</sup>, C. L. Roland<sup>1</sup>, P. Geoffroy<sup>3</sup>, <sup>1</sup>Pfizer Inc, Cary, NC, <sup>2</sup>Grunenthal, Bedminster, NJ, <sup>3</sup>INC Research, Toronto, ON, Canada, <sup>4</sup>CDER/OSE/OPE, FDA, Silver Spring, MD
- 138 *More than meets the eye: What visual cortex reactivity to cues may tell us about neural processing in addiction*  
L. T. Dowdle, T. Naselaris, B. Froeliger, C. A. Hanlon, Medical University of South Carolina, Charleston, SC
- 139 *Reinforcing effects of very low nicotine content cigarettes: A review*  
T. J. White<sup>1,2</sup>, R. Redner<sup>1,2</sup>, S. T. Higgins<sup>1,2,3</sup>, <sup>1</sup>Vermont Center on Behavior & Health, University of Vermont, Burlington, VT, <sup>2</sup>Psychiatry, University of Vermont, Burlington, VT, <sup>3</sup>Psychology, University of Vermont, Burlington, VT
- 140 *Buprenorphine-assisted treatment of opioid-dependent adolescents: State of the science*  
J. Borodovsky<sup>1</sup>, L. A. Marsch<sup>1</sup>, S. K. Moore<sup>2</sup>, <sup>1</sup>Dartmouth College, Lebanon, NH, <sup>2</sup>Capital Health Medical Center, Hopewell, NJ
- 141 *Cocaine use and sexual risk among individuals with a severe mental illness: A narrative review*  
T. M. Bishop<sup>1</sup>, S. A. Maisto<sup>2</sup>, L. Ashrafioun<sup>1</sup>, <sup>1</sup>VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY, <sup>2</sup>Psychology, Syracuse University, Syracuse, NY
- 142 *N-acetylcysteine for cocaine addiction: A systematic review*  
M. N. Echevarria, T. M. Fidalgo, T. A. Reis, D. X. Silveira, V. S. Soares, G. R. Capatti, Psychiatry, Federal University of São Paulo, São Paulo, Brazil
- 143 *Poppers: A systematic review*  
B. Banducci Rahe<sup>2,3</sup>, T. M. Fidalgo<sup>1,2</sup>, D. Xavier da Silveira<sup>1,2</sup>, <sup>1</sup>Psychiatry, Federal University of Sao Paulo, Santos, Brazil, <sup>2</sup>Proad-Unifesp, Sao Paulo, Brazil, <sup>3</sup>Psiquiatria, Faculdade Santa Marcelina, São Paulo, Brazil

**Symposium XI**  
**CPDD/INRC Joint Symposium**

**AZ Biltmore Ballroom**  
**2:00 - 4:00 PM**

**NOVEL STRATEGIES FOR REDUCING OPIOID ABUSE**

Chairs: Sandra Comer and Paul Pentel

- 2:00 *Prospects for serotonin therapeutics in addictive disorders*  
Kathryn A. Cunningham, University of Texas Medical Branch, Galveston, TX
- 2:30 *Development of vaccines for opioid abuse*  
Marco Pravetoni, University of Minnesota, Minneapolis, MN
- 3:00 *Assessing the ability of glial inhibitors to alter the abuse liability of opioids using laboratory models in humans*  
Jermaine D. Jones, Columbia University, New York, NY
- 3:30 *Epidemiology on the impact of opioid abuse-deterrent medications on opioid abuse in the community*  
Ted Cicero, Washington University, St. Louis, MO

**Symposium XII**

**McArthur Ballroom 1/2**  
**2:00 - 4:00 PM**

**ENVIRONMENTAL AND SOCIAL INFLUENCES ON DRUG-TAKING:  
THE GOOD, THE BAD AND THE UGLY**

Chairs: Minda Lynch and Michael T. Bardo

- 2:00 *Differential effects of enrichment on stimulant reward in males and females*  
Sari Izenwasser, University of Miami Miller School of Medicine, Miami, FL
- 2:25 *Anti-craving effects of environmental enrichment: Generalization to different drugs of abuse*  
Marcello Solinas, University of Poitiers, Poitiers Cedex, France
- 2:50 *The influence of social learning on drug self-administration*  
Mark A. Smith, Davidson College, Davidson, NC
- 3:15 *Dyadic social interaction as an alternative reward to cocaine*  
Gerald Zernig, Medical University of Innsbruck, Innsbruck, ACT, Australia
- 3:40 *DISCUSSANT: The translational puzzle: Fitting the pieces*  
Michael T. Bardo, University of Kentucky, Lexington, KY

**Symposium XIII**

**McArthur Ballroom 4**  
**2:00 - 4:00 PM**

**CANNABIS USE IN YOUTH: NEUROCOGNITIVE EFFECTS,  
GENETIC MODERATORS, AND EPIGENETIC FINDINGS**

Chair: Krista Lisdahl

- 2:00 *Half baked? Exploring the impact of early onset marijuana use on brain structure and function*  
Staci A. Gruber, McLean Hospital - CCNC, Belmont, MA
- 2:25 *Endocannabinoid genetics moderate the impact of regular cannabis use on cognition and brain structure in adolescents and emerging adults*  
Krista Lisdahl, UW-Milwaukee, Milwaukee, WI



- 2:50 *Genetic modulators of marijuana's effects on brain morphometry*  
Francesca Filbey, University of Texas at Dallas, Dallas, TX
- 3:15 *Methylation patterns in adolescent cannabis use symptoms: A preliminary investigation*  
Sarah Feldstein Ewing, University of New Mexico, Albuquerque, NM
- 3:40 *DISCUSSANT: Cannabis science: Information needed to inform policy*  
Krista Lisdahl, UW-Milwaukee, Milwaukee, WI

### Oral Communications 13

McArthur Ballroom 5/6  
2:00 - 4:00 PM

#### MULTIPLE ADVERSITIES: COMORBIDITY

Chairs: Kristen D. Seay and Steven L. Batki

- 2:00 *A comparison of male and female caregivers: Caregiver depression as a mediator in the pathway from caregiver problematic drug use to child internalizing behaviors*  
K. D. Seay, College of Social Work, The University of South Carolina, Columbia, SC
- 2:15 *Retention in a methadone maintenance treatment: Impact of comorbidity*  
F. Fonseca<sup>2,3</sup>, C. Castillo<sup>2,3</sup>, D. Martinez-Sanvisens<sup>2,3</sup>, P. Rossi<sup>2,3</sup>, A. Roquer<sup>2</sup>, M. Farre<sup>3,1</sup>, M. Torrens<sup>2,3,4</sup>, <sup>1</sup>Human Pharmacology and Neurosciences, IMIM-UAB, Barcelona, Spain, <sup>2</sup>Institut de Neuropsiquiatria i Addiccions (INAD), Parc de Salut Mar, Barcelona, Spain, <sup>3</sup>IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain, <sup>4</sup>Psychiatry Department, Autonomous University of Barcelona, Barcelona, Spain
- 2:30 *Association between morningness/eveningness, addiction severity and psychiatric disorders among individuals with addictions*  
C. Kervran<sup>1</sup>, R. Debrabant<sup>2</sup>, J. Taillard<sup>2</sup>, P. Philip<sup>2</sup>, M. Auriacombe<sup>1</sup>, M. Fatseas<sup>1</sup>, <sup>1</sup>Addiction Psychiatry (CNRS USR 3413), Université Bordeaux, Bordeaux, France, <sup>2</sup>Sanpsy CNRS USR 3413, Sleep Research, Bordeaux, France
- 2:45 *Association between drug use and suicidal ideation and attempt among at-risk primary care patients*  
L. Ashrafioun<sup>2</sup>, W. R. Pigeon<sup>2</sup>, K. R. Conner<sup>2</sup>, T. M. Bishop<sup>2</sup>, S. Leong<sup>1</sup>, D. W. Oslin<sup>1</sup>, <sup>1</sup>Philadelphia VA, Philadelphia, PA, <sup>2</sup>VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
- 3:00 *A comparison of attempted suicide rates by methylphenidate exposure in adult and adolescent populations*  
E. M. McRae, M. C. Le Lait, N. West, R. C. Dart, RMPDC, Denver, CO
- 3:15 *Borderline personality disorder diagnosis, diagnostic criteria, and criterion count as predictors of regularly drinking alcohol before sex among adults in the United States*  
R. G. Thompson<sup>2</sup>, N. R. Eaton<sup>3</sup>, M. Hu<sup>4</sup>, D. S. Hasin<sup>1</sup>, <sup>1</sup>Epidemiology, Columbia University, New York, NY, <sup>2</sup>Psychiatry, Columbia University, New York, NY, <sup>3</sup>Psychology, Stony Brook University, Stony Brook, NY, <sup>4</sup>Columbia University, New York, NY
- 3:30 *ADHD and substance use disorders: Subtype and gender differences*  
H. Hurmic, R. Debrabant, C. Kervran, F. Serre, M. Auriacombe, M. Fatseas, Addiction Psychiatry (CNRS USR 3413), Université Bordeaux, Bordeaux, France
- 3:45 *Smoking and non-alcohol substance use in veterans with PTSD and alcohol use disorder*  
S. L. Batki<sup>1,2</sup>, D. Pennington<sup>2</sup>, B. Lasher<sup>2</sup>, E. Herbst<sup>2</sup>, E. Schrodek<sup>2</sup>, S. Yohannes<sup>2</sup>, J. McDonald<sup>2</sup>, B. Schmeling<sup>2</sup>, T. Wong<sup>2</sup>, <sup>1</sup>UCSF, San Francisco, CA, <sup>2</sup>SFVAMC, San Francisco, CA

---

**Wednesday, June 17, 2015**

---

**Late-Breaking Research**

**AZ Biltmore Ballroom  
4:15 - 5:15 PM**

**Business Meeting**  
**(MEMBERS ONLY)**

**AZ Biltmore Ballroom  
5:15 - 6:00 PM**

**DINNER AND DANCING**  
**BADGES MUST BE WORN FOR ADMISSION**

**McArthur Ballroom 1/2  
7:30 - 10:30 PM**

**Please be advised that no photographing of presentations or data is permitted.  
Badges must be worn at all times and are required for admission into all events  
and sessions.**

## Poster Session IV

(Breakfast)

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Frank Lloyd Wright Ballroom  
8:00 - 10:00 AM

Set-up time begins Wednesday 3:00 PM

Must be removed at 12:00 Noon Thursday

### BENZODIAZEPINE, INHALANTS

- 1 *Gender effects on zolpidem efficacy and safety*  
T. Roehrs<sup>1,2</sup>, T. Roth<sup>1,2</sup>, <sup>1</sup>Sleep Disorders Center, Henry Ford Health System, Detroit, MI, <sup>2</sup>Dept of Psychiatry, Wayne State University, School of Medicine, Detroit, MI
- 2 *WITHDRAWN*
- 3 *Reinstatement of drug-seeking behavior in rats trained to self-administer intravenous injections of midazolam*  
B. W. Gunter<sup>1</sup>, D. Platt<sup>1</sup>, D. Rueedi-bettschen<sup>1</sup>, K. Freeman<sup>1</sup>, J. Rowlett<sup>1,2</sup>, <sup>1</sup>Psychiatry and Human Behavior, Univ. Mississippi Medical Center, Jackson, MS, <sup>2</sup>Tulane National Primate Research Center, Covington, LA
- 4 *Problematic pregabalin and gabapentin use: Results from the Canada Vigilance Adverse Reaction Online Database*  
M. Zhang<sup>1,2</sup>, B. Sproule<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada
- 5 *Evidence for sedative effects of benzodiazepines involving unexpected GABA<sub>A</sub> receptor subtypes*  
J. Rowlett<sup>2,1,3</sup>, A. N. Duke<sup>4,1</sup>, D. Platt<sup>2,1</sup>, O. A. Namjoshi<sup>5</sup>, M. Poe<sup>6</sup>, P. Tiruveedhula<sup>6</sup>, J. Cook<sup>6</sup>, <sup>1</sup>NEPRC, Harvard Med Sch, Southborough, MA, <sup>2</sup>University of Mississippi Medical Center, Jackson, MS, <sup>3</sup>TNPRC, Tulane Univ, Covington, LA, <sup>4</sup>Wake Forest Medical Center, Winston-Salem, NC, <sup>5</sup>Discovery Sciences, RTI International, Research Triangle Park, NC, <sup>6</sup>University of Wisconsin-Milwaukee, Milwaukee, WI
- 6 *Oral midazolam consumption using a two-bottle choice procedure in C57BL/6J mice*  
M. E. Follett<sup>1</sup>, J. Rowlett<sup>1,2</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Tulane National Primate Research Center, Covington, LA
- 7 *Cardiovascular toxicity of single and repeated inhalation of “Kolla” – A locally abused Egyptian glue*  
A. A. Elkoussi, Pharmacology, Assiut College of Medicine, Assiut, Egypt

### ABUSE LIABILITY

- 8 *Designing a human abuse potential study for a drug with a novel mechanism of action*  
K. Bonson, M. Klein, Controlled Substance Staff, Food and Drug Administration, Silver Spring, MD
- 9 *Abuse potential of oral phendimetrazine in cocaine-dependent individuals*  
W. W. Stoops<sup>1,2,3</sup>, B. L. Bolin<sup>1</sup>, J. P. Sites<sup>4</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry, University of Kentucky, Lexington, KY, <sup>4</sup>College of Medicine, University of Kentucky, Lexington, KY

- 10 *Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users*  
K. S. Koblan<sup>1</sup>, S. S. Hopkins<sup>1</sup>, K. Sarma<sup>1</sup>, N. Senmartin<sup>1</sup>, N. Levy-Cooperman<sup>2</sup>, K. Schoedel<sup>2</sup>, A. Loebel<sup>1</sup>, <sup>1</sup>Sunovion Pharmaceuticals, Inc, Marlborough, MA, <sup>2</sup>Altreos Research Partners, Toronto, ON, Canada
- 11 *An exploratory human abuse potential assessment of centanafadine, a novel triple reuptake inhibitor*  
M. Shram<sup>1,3</sup>, K. Schoedel<sup>1</sup>, N. Chen<sup>4</sup>, D. Kelsh<sup>5</sup>, C. O'Brien<sup>2</sup>, B. Robertson<sup>2</sup>, T. Hsu<sup>2</sup>, <sup>1</sup>Altreos Research Partners, Inc., Toronto, ON, Canada, <sup>2</sup>Neurovance, Inc., Cambridge, MA, <sup>3</sup>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, <sup>4</sup>Alstat, Toronto, ON, Canada, <sup>5</sup>Vince and Associates Clinical Research, Overland Park, KS
- 12 *New epidemiological evidence on coca leaf chewing and a dependence syndrome in 2008*  
V. Cruz<sup>1,3,2</sup>, J. C. Anthony<sup>1,3</sup>, <sup>1</sup>Epidemiology, Michigan State University, East Lansing, MI, <sup>2</sup>Peruvian National Institute of Mental Health, Lima, Peru, <sup>3</sup>School of Public Health, Cayetano Heredia University, Lima, Peru
- 13 *Changes in the pain analgesic and heroin epidemiology*  
J. C. Maxwell, Addiction Research Institute, University of Texas at Austin, Austin, TX
- 14 *Abuse liability of controlled-release oxycodone formulations*  
B. Rafat<sup>1,2</sup>, A. Smith<sup>1</sup>, K. Farid Araki<sup>1</sup>, A. Furlan<sup>3,2</sup>, B. Sproule<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>University Health Network, Toronto, ON, Canada
- 15 *Individual difference in opioid response*  
K. E. Dunn<sup>3</sup>, B. Brands<sup>1,4</sup>, D. Marsh<sup>5,6</sup>, G. Bigelow<sup>2</sup>, <sup>1</sup>Health Canada, Toronto, ON, Canada, <sup>2</sup>Psychiatry & Behavioral Sciences, Johns Hopkins Medical School, Baltimore, MD, <sup>3</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>4</sup>University of Toronto, Toronto, ON, Canada, <sup>5</sup>Northern Ontario School of Medicine, Sudbury, ON, Canada, <sup>6</sup>Laurentian University, Sudbury, ON, Canada
- 16 *Subjective and objective evidence of low abuse potential of the peripherally acting kappa opioid, CR845, compared with pentazocine*  
J. W. Stauffer<sup>1</sup>, F. Menzaghi<sup>1</sup>, L. R. Webster<sup>2</sup>, R. H. Spencer<sup>1</sup>, N. E. Abrouk<sup>3</sup>, M. Lewis<sup>1</sup>, D. Chalmers<sup>1</sup>, <sup>1</sup>Cara Therapeutics, Shelton, CT, <sup>2</sup>PRA, Salt Lake City, UT, <sup>3</sup>Innovex, Mountain View, CA
- 17 *Prevalence of opioid misuse in cancer survivors in palliative medicine clinic at a tertiary cancer center*  
N. Moryl, A. Wiesenthal, T. Nikolova, Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
- 18 *Opioid therapy for chronic non-cancer pain: Does typology of risk predict aberrant behaviour?*  
A. Peacock<sup>1</sup>, L. Degenhardt<sup>3</sup>, N. Lintzeris<sup>2</sup>, B. Larance<sup>3</sup>, G. Campbell<sup>3</sup>, S. Nielsen<sup>3</sup>, M. Cohen<sup>3</sup>, R. Bruno<sup>1</sup>, <sup>1</sup>UTAS, Hobart, TAS, Australia, <sup>2</sup>Langton Centre, Sydney, NSW, Australia, <sup>3</sup>UNSW, Sydney, NSW, Australia
- 19 *The abuse liability of buprenorphine is blocked by samidorphan, a novel opioid modulator, in rats tested in the intracranial self-stimulation paradigm*  
M. S. Todtenkopf, K. O'Neill, D. Deaver, Life Sciences, Alkermes, Inc., Cambridge, MA
- 20 *Locomotor depression and THC-like discriminative stimulus effects of three novel synthetic cannabinoids: ADBICA, THJ-2201, and ADB-PINACA*  
S. Dolan, M. J. Forster, M. B. Gatch, Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX

### THC

- 21 *Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain*  
M. Funada, K. Tomiyama, K. Wada, Drug Dependence Research, NIMH, NCNP, Kodaira, Japan
- 22 *Cannabidiol and tetrahydrocannabinol interactions on antinociception in male and female rats*  
S. Britch, Psychology, Washington State University, Pullman, WA
- 23 *Effects of norbinaltorphimine pretreatment on THC-induced place and taste avoidance in Sprague-Dawley rats*  
S. M. Flax<sup>1</sup>, A. G. Wakeford<sup>1</sup>, K. Rice<sup>2,3</sup>, A. Riley<sup>1</sup>, <sup>1</sup>Psychology, American University, Washington, DC, <sup>2</sup>Chemical Biology and Research Branch, National Institute on Drug Abuse, Bethesda, MD, <sup>3</sup>National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD
- 24 *Multidimensional assessment of cue-elicited increases in incentive salience for marijuana*  
J. Metrik<sup>1</sup>, E. Aston<sup>1</sup>, C. W. Kahler<sup>1</sup>, D. Rohsenow<sup>1</sup>, J. McGeary<sup>1</sup>, V. Knopik<sup>1</sup>, J. MacKillop<sup>2</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>McMaster University, Hamilton, ON, Canada
- 25 *Magnitude and duration of cue-induced craving for marijuana in volunteers with cannabis use disorder*  
L. H. Lundahl<sup>2</sup>, M. Greenwald<sup>1</sup>, <sup>1</sup>Psychiatry, Wayne State University, Detroit, MI, <sup>2</sup>Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI
- 26 *Effects of repeated cue exposure on cannabis craving*  
J. S. Fogel<sup>2</sup>, T. H. Kelly<sup>2,1</sup>, A. M. Harvanko<sup>2</sup>, J. Lile<sup>1</sup>, <sup>1</sup>Behavioral Science, University of Kentucky, Lexington, KY, <sup>2</sup>Psychology, University of Kentucky, Lexington, KY
- 27 *Eye tracking measures of attentional bias to individually calibrated marijuana cues*  
J. H. Yoon, A. Vujanovic, M. Weaver, R. Suchting, C. Green, J. Schmitz, S. D. Lane, Psychiatry and Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX
- 28 *Cannabis use, schizotypy, and attentional inhibition*  
L. Albertella<sup>1</sup>, M. Le Pelley<sup>2</sup>, J. Copeland<sup>1</sup>, <sup>1</sup>National Cannabis Prevention and Information Centre, UNSW Medicine, Sydney, NSW, Australia, <sup>2</sup>Psychology, UNSW, Sydney, NSW, Australia
- 29 *ADHD and the risk of initiation of marijuana use among a national sample of youth 10 to 18 years of age*  
C. Okafor, S. O. Lasopa, C. W. Striley, R. Cook, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 30 *Methods for associating trajectories of comorbidities: ADHD and substance use*  
S. K. Mikulich-Gilbertson, B. D. Wagner, P. D. Riggs, S. K. McWilliams, G. O. Zerbe, Univ. of Colorado, Aurora, CO
- 31 *Mixed-amphetamine salts increase abstinence from marijuana in patients with co-occurring attention-deficit/hyperactivity disorder and cocaine dependence*  
D. Notzon<sup>3</sup>, J. J. Mariani<sup>2</sup>, M. Pavlicova<sup>1</sup>, A. Glass<sup>5</sup>, A. Mahony<sup>3</sup>, D. J. Brooks<sup>4</sup>, J. Grabowski<sup>6</sup>, F. R. Levin<sup>2</sup>, <sup>1</sup>Martina Pavlicova, Columbia University, New York, NY, <sup>2</sup>Psychiatry/Division on Substance Abuse, Columbia University/New York State Psychiatric Institute, New York, NY, <sup>3</sup>Division on Substance Abuse, NY State Psychiatric Institute, New York, NY, <sup>4</sup>Substance Abuse, NYSPI, New York, NY, <sup>5</sup>Biostatistics, New York State Psychiatric Institute, New York, NY, <sup>6</sup>Psychiatry, University of Minnesota, Minneapolis, MN



- 32 *Cannabidiol attenuates the increased susceptibility to false memories produced by tetrahydrocannabinol*  
M. Valle<sup>2</sup>, L. C. Martial<sup>2</sup>, M. Garrido<sup>2</sup>, A. Rodríguez-Fornells<sup>3</sup>, M. Punes<sup>4</sup>, R. M. Antonijoan<sup>1</sup>, J. Claramunt<sup>4</sup>, D. Martínez<sup>4</sup>, M. González<sup>4</sup>, M. Martínez<sup>4</sup>, J. Pérez de los Cobos<sup>1</sup>, J. Riba<sup>4</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>2</sup>Pharmacokinetic and pharmacodynamic modeling and simulation, Institut de Recerca HSCSP, Barcelona, Spain, <sup>3</sup>IDIBELL, Hospitalet de Llobregat, Spain, <sup>4</sup>Institut de Recerca HSCSP, Barcelona, Spain
- 33 *Examination of the behavioral effects of oral cannabidiol alone and in combination with smoked marijuana*  
S. Babalonis<sup>1</sup>, M. R. Lofwall<sup>1</sup>, P. A. Nuzzo<sup>1</sup>, C. Elayi<sup>2</sup>, R. J. Malcolm<sup>3</sup>, M. Haney<sup>4</sup>, S. L. Walsh<sup>1</sup>, <sup>1</sup>Behavioral Science and Center on Drug and Alcohol Research, Univ of Kentucky, Lexington, KY, <sup>2</sup>Internal Medicine, Univ of Kentucky, Lexington, KY, <sup>3</sup>Psychiatry and Behavioral Sciences, Medical Univ of South Carolina, Charleston, SC, <sup>4</sup>Psychiatry, Columbia University, New York, NY
- 34 *The point of a joint: A multivariate classification of marijuana use motives*  
A. Ketcherside, F. Filbey, Behavior and Brain Sciences, University of Texas at Dallas, Dallas, TX
- 35 *Acute effects of cannabis on young drivers' performance of driving-related skills*  
J. Burston<sup>2,1</sup>, R. Mann<sup>1,2</sup>, B. Le Foll<sup>1,2</sup>, G. Stoduto<sup>1</sup>, C. Wickens<sup>1,2</sup>, J. Pan<sup>2,1</sup>, M. A. Huestis<sup>3</sup>, B. Brands<sup>4,1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>IRP, Chemistry and Drug Metabolism, National Institute on Drug Abuse, Baltimore, MD, <sup>4</sup>Health Canada, Ottawa, ON, Canada
- 36 *Preliminary report on the residual effects of cannabis on young drivers' performance of driving-related skills*  
J. Pan<sup>2,1</sup>, R. Mann<sup>1</sup>, B. Brands<sup>3,1,2</sup>, G. Stoduto<sup>1</sup>, C. Wickens<sup>1</sup>, J. Burston<sup>2,1</sup>, M. A. Huestis<sup>4</sup>, B. Le Foll<sup>1,2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Health Canada, Ottawa, ON, Canada, <sup>4</sup>IRP, Chemistry and Metabolism, National Institute on Drug Abuse, Baltimore, MD
- 37 *Physiologic effects of dronabinol during opioid withdrawal in humans*  
P. A. Nuzzo<sup>1</sup>, M. R. Lofwall<sup>1</sup>, S. Elayi<sup>2</sup>, K. Gill<sup>1</sup>, S. Babalonis<sup>1</sup>, S. L. Walsh<sup>1</sup>, <sup>1</sup>Behavioral Science, Center on Drug and Alcohol Research, Univ. of Kentucky, Lexington, KY, <sup>2</sup>Internal Medicine, Univ. of Kentucky, Lexington, KY
- 38 *Effects of fixed or self-titrated dosages of Sativex on cannabis users*  
J. M. Trigo<sup>1</sup>, D. Lagzdins<sup>1</sup>, J. Rehm<sup>2</sup>, P. Selby<sup>3</sup>, I. Gamaledin<sup>1</sup>, B. Fischer<sup>2,4</sup>, A. Barnes<sup>5</sup>, M. Huestis<sup>5</sup>, B. Le Foll<sup>1</sup>, <sup>1</sup>Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Social and Epidemiological Research, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>3</sup>Ambulatory Care and Structured Treatments, Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>4</sup>Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, <sup>5</sup>National Institute on Drug Abuse, Baltimore, MD
- 39 *A randomized delayed implementation trial of computerized brief intervention for drug misuse*  
R. P. Schwartz<sup>1</sup>, J. Gryczynski<sup>1</sup>, S. G. Mitchell<sup>1</sup>, K. O'Grady<sup>3</sup>, S. Ondersma<sup>2</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Wayne State, Detroit, MI, <sup>3</sup>University of Maryland, College Park, MD
- 40 *Do alcohol-focused interventions reduce marijuana use in mandated college students?*  
A. Yurasek<sup>2</sup>, A. Fernandez<sup>2</sup>, M. Miller<sup>2</sup>, J. Metrik<sup>1</sup>, B. Borsari<sup>2</sup>, <sup>1</sup>Behavioral and Social Sciences, Brown University, Providence, RI, <sup>2</sup>Public Health, Brown University, Providence, RI

- 41 *A very brief intervention for cannabis users in an emergency department setting*  
L. Webb, N. Clement, E. Matalon, T. Joel, J. Copeland, National Cannabis Prevention and Information Centre, UNSW Medicine, Sydney, NSW, Australia
- 42 *Development of a brief cannabis use disorder screening tool: The CUDIT Short-Form*  
M. O. Bonn-Miller<sup>2,3,4</sup>, A. Heinz<sup>3</sup>, E. Smith<sup>5</sup>, R. Bruno<sup>1</sup>, S. Adamson<sup>6</sup>, <sup>1</sup>School of Psychology, University of Tasmania, Hobart, TAS, Australia, <sup>2</sup>Center of Excellence in Substance Abuse Treatment and Education, VA Palo Alto Health Care System, Menlo Park, CA, <sup>3</sup>National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, CA, <sup>4</sup>Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>5</sup>Department of Educational Psychology, University of Illinois at Chicago, Chicago, IL, <sup>6</sup>National Addiction Centre, University of Otago, Christchurch, New Zealand
- 43 *Challenges encountered while recruiting frequent marijuana smokers for an outpatient laboratory study*  
V. R. Votaw, S. Babalonis, M. R. Lofwall, P. A. Nuzzo, S. L. Walsh, Behavioral Science and Center on Drug and Alcohol Research, Univ. of Kentucky, Lexington, KY

### IMAGING

- 44 *Neuroimaging and cognitive abnormalities in anabolic androgenic steroid abusers*  
M. Kaufman, E. Jensen, A. Janes, J. Hudson, G. Kanayama, A. Kerrigan, H. Pope, McLean Hospital, Belmont, MA
- 45 *Impact of adolescent marijuana use on emotion processing: An fMRI study*  
L. M. Cope, J. Hardee, M. E. Martz, R. Zucker, M. Heitzeg, University of Michigan, Ann Arbor, MI
- 46 *Correlation between PFC gyrification and white matter integrity in young cannabis users*  
S. G. Shollenbarger<sup>2</sup>, J. S. Price<sup>1</sup>, K. E. Maple<sup>2</sup>, K. M. Lisdahl<sup>2</sup>, <sup>1</sup>McLean Hospital - Harvard Medical School, Belmont, MA, <sup>2</sup>Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI
- 47 *Cortical thinning in adolescent females with substance and conduct problems*  
P. Boulos<sup>1</sup>, M. Dalwani<sup>1</sup>, J. Tanabe<sup>1</sup>, S. K. Mikulich-Gilbertson<sup>1</sup>, M. T. Banich<sup>2</sup>, T. J. Crowley<sup>1</sup>, J. Sakai<sup>1</sup>, <sup>1</sup>University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado Boulder, Boulder, CO
- 48 *Sleep quality does not predict frontolimbic white matter integrity in young marijuana users*  
K. E. Maple, S. G. Shollenbarger, E. R. Gilbert, K. M. Lisdahl, Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI
- 49 *Neural activation to social influence in young adult cannabis users*  
J. Gilman<sup>1,2</sup>, M. Curran<sup>1</sup>, V. Calderon<sup>1</sup>, A. Evins<sup>1,2</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Harvard Medical School, Boston, MA
- 50 *Neural correlates of attentional bias for cannabis cues: Influence of sex*  
T. Franklin<sup>1</sup>, R. R. Wetherill<sup>1</sup>, K. Jagannathan<sup>1</sup>, N. Hager<sup>1</sup>, J. Suh<sup>1</sup>, A. Childress<sup>1</sup>, <sup>1</sup>Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
- 51 *Cannabis users show increased susceptibility to false memories*  
J. Riba<sup>1</sup>, F. Sampedro<sup>2</sup>, A. Rodríguez-Pujadas<sup>2</sup>, S. Martínez-Horta<sup>1</sup>, J. Kulisevsky<sup>1</sup>, J. Pérez-de-los-Cobos<sup>1</sup>, A. Rodríguez-Fornells<sup>1</sup>, M. Valle<sup>1</sup>, <sup>1</sup>Hospital Sant Pau, Barcelona, Spain, <sup>2</sup>University of Barcelona, Barcelona, Spain
- 52 *Regional grey matter volume and externalizing score: Not yet related in middle childhood*  
J. Sakai<sup>1</sup>, M. Dalwani<sup>1</sup>, M. A. McMahon<sup>1</sup>, S. K. Mikulich-Gilbertson<sup>1</sup>, J. Tanabe<sup>1</sup>, S. K. McWilliams<sup>1</sup>, K. Raymond<sup>1</sup>, M. T. Banich<sup>2</sup>, T. J. Crowley<sup>1</sup>, <sup>1</sup>University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado Boulder, Boulder, CO

- 53 *Positive association between cingulate brain volume and sensation seeking in young adults*  
T. H. Kelly<sup>1</sup>, M. J. Wesley<sup>1</sup>, C. E. Emurian<sup>1</sup>, C. A. Martin<sup>1</sup>, J. E. Joseph<sup>2</sup>, J. A. Lile<sup>1</sup>,  
<sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Medical University of South Carolina,  
Charleston, SC
- 54 *Inhibitory control: A brain connectivity study comparing cocaine-dependent subjects and controls*  
L. Ma<sup>1</sup>, J. L. Steinberg<sup>1</sup>, K. A. Cunningham<sup>2</sup>, S. D. Lane<sup>3</sup>, J. M. Bjork<sup>1</sup>, P. A. Narayana<sup>3</sup>,  
T. Kosten<sup>4</sup>, A. Bechara<sup>5</sup>, F. Moeller<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University Institute for Drug  
and Alcohol Studies, Richmond, VA, <sup>2</sup>University of Texas Medical Branch, Galveston, TX,  
<sup>3</sup>University of Texas Health Science Center, Houston, TX, <sup>4</sup>Baylor College of Medicine,  
Houston, TX, <sup>5</sup>University of Southern California, Los Angeles, CA
- 55 *Influence of dorsolateral prefrontal cortex and ventral striatum on risk avoidance in addiction: A mediation analysis*  
D. Yamamoto<sup>1</sup>, C. Woo<sup>2</sup>, T. Wager<sup>2</sup>, J. Tanabe<sup>1</sup>, <sup>1</sup>Radiology, University of Colorado Denver,  
Aurora, CO, <sup>2</sup>Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO
- 56 *Aberrant brain function as at-risk children make risky decisions*  
T. J. Crowley<sup>1</sup>, M. Dalwani<sup>1</sup>, S. Mikulich-Gilbertson<sup>1</sup>, J. Sakai<sup>1</sup>, S. Young<sup>1</sup>, K. Raymond<sup>1</sup>,  
S. K. McWilliams<sup>1</sup>, M. T. Banich<sup>1,2</sup>, <sup>1</sup>Univ. of Colorado Denver, Aurora, CO, <sup>2</sup>Univ. of  
Colorado Boulder, Boulder, CO
- 57 *A higher hill to climb! Older cocaine-addicted patients viewing 500 msec cocaine cues have reduced activation of modulatory circuits and increased activation of motivational circuits*  
Z. A. Monge<sup>1</sup>, K. Jagannathan<sup>1</sup>, J. Suh<sup>1,2</sup>, R. Ehrman<sup>1,2</sup>, Z. Wang<sup>1</sup>, T. Franklin<sup>1</sup>,  
R. R. Wetherill<sup>1</sup>, K. A. Young<sup>1</sup>, M. J. Gawrysiak<sup>1,2</sup>, D. Langleben<sup>1,2</sup>, C. P. O'Brien<sup>1,2</sup>,  
A. Childress<sup>1</sup>, <sup>1</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>VA VISN 4  
MIRECC, Philadelphia, PA
- 58 *“Dangerous liaisons”: Heightened intra-limbic connectivity during subliminal cocaine cues is a relapse-vulnerable endophenotype*  
A. Childress<sup>1,2</sup>, K. Jagannathan<sup>1</sup>, J. Suh<sup>1,2</sup>, Z. A. Monge<sup>1</sup>, K. A. Young<sup>1</sup>, Z. Wang<sup>1</sup>,  
T. Franklin<sup>1</sup>, D. Langleben<sup>1,2</sup>, Z. Li<sup>1</sup>, K. M. Kampman<sup>1,2</sup>, R. R. Wetherill<sup>1</sup>, R. Ehrman<sup>1,2</sup>,  
M. Gawrysiak<sup>1,2</sup>, R. Szucs-Reed<sup>1</sup>, C. P. O'Brien<sup>1</sup>, <sup>1</sup>Psychiatry, UPENN Perelman Sch. Med.,  
Philadelphia, PA, <sup>2</sup>VA Med Ctr., Philadelphia, PA
- 59 *Differential brain response to successful and failed response inhibition: Cocaine-dependent vs. healthy subjects*  
J. Suh<sup>1,2</sup>, K. Jagannathan<sup>1</sup>, R. Ehrman<sup>1,2</sup>, M. Goldman<sup>1</sup>, Z. A. Monge<sup>1</sup>, E. Berkowitz-  
Sturgis<sup>2</sup>, T. Franklin<sup>1</sup>, K. Marquez<sup>1</sup>, R. Szucs-Reed<sup>1</sup>, C. P. O'Brien<sup>1</sup>, A. Childress<sup>1</sup>, <sup>1</sup>Univ. of  
Pennsylvania, Philadelphia, PA, <sup>2</sup>MIRECC, PVAMC, Philadelphia, PA
- 60 *Reduced ACC response to presentation of negative feedback differentiates stimulant abusers from non-abusers and predicts abstinence at 12 months*  
M. S. Shane<sup>1</sup>, E. D. Claus<sup>2</sup>, <sup>1</sup>University of Ontario Institute of Technology, Oshawa, ON,  
Canada, <sup>2</sup>The Mind Research Network, Albuquerque, NM
- 61 *Classification of drug and placebo with functional magnetic resonance imaging*  
M. J. Wesley<sup>1</sup>, J. A. Lile<sup>1</sup>, C. E. Emurian<sup>1</sup>, C. A. Martin<sup>1</sup>, J. E. Joseph<sup>2</sup>, T. H. Kelly<sup>1</sup>,  
<sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Medical University of South Carolina,  
Charleston, SC
- 62 *Decreased brain creatine kinase activity in methamphetamine abusers: Preliminary results*  
Y. Sung<sup>1</sup>, X. Shi<sup>1</sup>, D. Kondo<sup>1,2</sup>, T. Hellem<sup>1</sup>, C. Riley<sup>1</sup>, E. Jeong<sup>1</sup>, K. Lundberg<sup>1</sup>, D. Yurgelun-  
Todd<sup>1,2,3</sup>, P. Renshaw<sup>1,2,3</sup>, <sup>1</sup>University of Utah, Salt Lake City, UT, <sup>2</sup>VISN 19 MIRECC, Salt  
Lake City, UT, <sup>3</sup>USTAR, Salt Lake City, UT

- 63 *Social processing in aging cocaine smokers*  
G. Bedi<sup>1</sup>, Z. D. Cooper<sup>1</sup>, N. Van Dam<sup>2</sup>, M. Haney<sup>1</sup>, <sup>1</sup>Psychiatry, Columbia University and NY State Psychiatric Institute, New York, NY, <sup>2</sup>Nathan Kline Institute, Orangeburg, NY
- 64 *Different patterns of neural activity among cocaine-dependent individuals with and without current methadone treatment: Relationship to treatment outcomes*  
S. W. Yip<sup>1</sup>, K. M. Carroll<sup>2</sup>, M. N. Potenza<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven, CT, <sup>2</sup>Psychiatry, Yale University School of Medicine, West Haven, CT
- 65 *Opioid antagonist treatment modulates the brain responses to baby schema in opioid-dependent patients*  
A. Wang<sup>1</sup>, S. B. Lowen<sup>3</sup>, S. J. Blady<sup>1</sup>, E. D. Dowd<sup>1</sup>, A. Bouril<sup>1</sup>, A. Childress<sup>2</sup>, C. P. O'Brien<sup>2</sup>, D. Langleben<sup>2</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Harvard University, Cambridge, MA
- 66 *Brain default mode network functional connectivity in polysubstance-using emerging adults during opioid dependence treatment*  
J. S. Price<sup>2</sup>, M. L. Copersino<sup>2</sup>, G. Vitaliano<sup>3</sup>, S. E. Lukas<sup>5</sup>, R. Weiss<sup>1</sup>, A. Janes<sup>2</sup>, <sup>1</sup>Harvard Medical School, Belmont, MA, <sup>2</sup>McLean Hospital - Harvard Medical School, Belmont, MA, <sup>3</sup>Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA
- 67 *Effect of hemispheric dominant versus non-dominant insular damage on smoking behaviors*  
A. Abdolahi<sup>1,2</sup>, G. Williams<sup>2</sup>, C. Benesch<sup>2</sup>, H. Wang<sup>2</sup>, E. Spitzer<sup>3</sup>, B. Scott<sup>3</sup>, R. Block<sup>2</sup>, E. van Wijngaarden<sup>2</sup>, <sup>1</sup>Philips Research, Briarcliff Manor, NY, <sup>2</sup>University of Rochester, Rochester, NY, <sup>3</sup>Rochester General Health System, Rochester, NY
- 68 *Functional connectivity in an insula-based network is associated with smoking cessation outcomes*  
M. Addicott<sup>1</sup>, M. Sweitzer<sup>1</sup>, B. Froeliger<sup>3</sup>, E. Westman<sup>2</sup>, J. Rose<sup>1</sup>, J. McClernon<sup>1</sup>, <sup>1</sup>Psychiatry and Behavioral Sciences, Duke University, Durham, NC, <sup>2</sup>Duke University Medical Center, Durham NC, NC, <sup>3</sup>Medical University of South Carolina, Charleston, SC
- 69 *A novel data-driven resting state connectivity analysis reveals distinct networks associated with delay discounting between controls and smokers*  
M. Um, S. Li, B. Salmeron, National Institute on Drug Abuse, Baltimore, MD
- 70 *WITHDRAWN*

#### ETHNIC DIFFERENCES

- 71 *The drug use patterns of Latino day laborers in Baltimore*  
N. Negi<sup>1</sup>, A. Valdez<sup>2</sup>, A. Cepeda<sup>2</sup>, <sup>1</sup>Social Work, University of Maryland, Baltimore, MD, <sup>2</sup>School of Social Work, University of Southern California, Los Angeles, CA
- 72 *Polysubstance use profiles among people who inject drugs in Los Angeles and San Francisco*  
D. Chu<sup>2</sup>, A. Kral<sup>1</sup>, J. Huh<sup>2</sup>, R. Bluthenthal<sup>2</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>Preventive Medicine, University of Southern California, Los Angeles, CA
- 73 *Born in the USA: Estimated annual incidence rates for use of cannabis in the 21st century United States*  
C. Lopez-Quintero, R. Brosig, J. C. Anthony, Michigan State University, Rochester, MI
- 74 *The truth about marijuana is all rolled up in a blunt: Prevalence and predictors of blunt use among young African-American adults*  
L. Montgomery<sup>1</sup>, O. Oluwoye<sup>2</sup>, <sup>1</sup>Counseling/Substance Abuse Counseling, University of Cincinnati, Cincinnati, OH, <sup>2</sup>Health Promotion and Education, University of Cincinnati, Cincinnati, OH



- 75 *Prescription drug abuse, heroin, & IV drug use among incarcerated Black men*  
D. Stevens-Watkins<sup>3</sup>, J. Knighton<sup>3</sup>, M. Staton-Tindall<sup>2</sup>, E. Winston<sup>4</sup>, C. G. Leukefeld<sup>1</sup>,  
<sup>1</sup>Behavioral Science, Univ of Kentucky, Lexington, KY, <sup>2</sup>College of Social Work,  
University of Kentucky, Lexington, KY, <sup>3</sup>Counseling Psychology, University of Kentucky,  
Lexington, KY, <sup>4</sup>CDAR, University of Kentucky, Lexington, KY
- 76 *Association of gender and genetic ancestry with frequency of methamphetamine use among  
methamphetamine-dependent Hispanic and Non-Hispanic Whites*  
K. Heinzerling<sup>1</sup>, L. Demirdjian<sup>1</sup>, M. Briones<sup>1</sup>, A. Swanson<sup>2</sup>, Y. Wu<sup>1</sup>, S. Shoptaw<sup>1</sup>, <sup>1</sup>UCLA, Los  
Angeles, CA, <sup>2</sup>Stanford University, Stanford, CA
- 77 *Incident alcohol use among adult Arab refugees and immigrants*  
C. L. Arfken<sup>1</sup>, B. Arnetz<sup>1</sup>, C. Broadbridge<sup>2</sup>, M. Lumley<sup>1</sup>, J. Arnetz<sup>1</sup>, N. Pole<sup>3</sup>, H. Jamil<sup>1</sup>,  
<sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>Kentucky Wesleyan College, Owensboro, KY, <sup>3</sup>Smith  
College, Northampton, MA

### EPIDEMIOLOGY II

- 78 *The epidemic that never happened: Zohydro ER and the impact of media coverage*  
S. H. Budman, E. C. McNaughton, T. A. Cassidy, S. F. Butler, Inflexxion, Inc., Newton, MA
- 79 *Incident non-medical use of prescription opioids is associated with heroin initiation among U.S.  
veterans: A prospective cohort study*  
G. Banerjee<sup>4</sup>, E. J. Edelman<sup>1</sup>, D. T. Barry<sup>1</sup>, W. Becker<sup>3</sup>, M. Cerda<sup>5</sup>, S. Crystal<sup>6</sup>, J. R. Gaither<sup>1</sup>,  
A. J. Gordon<sup>2</sup>, K. S. Gordon<sup>7</sup>, R. Kerns<sup>7</sup>, S. Martins<sup>5</sup>, D. A. Fiellin<sup>1</sup>, B. D. Marshall<sup>4</sup>, <sup>1</sup>Yale,  
New Haven, CT, <sup>2</sup>VA Pittsburgh, Pittsburgh, PA, <sup>3</sup>CT VA, West Haven, CT, <sup>4</sup>Brown,  
Providence, RI, <sup>5</sup>Columbia, New York, NY, <sup>6</sup>Rutgers, New Brunswick, NJ, <sup>7</sup>CT VA, New  
Haven, CT
- 80 *Non-oral abuse of immediate-release hydrocodone*  
A. DeVaugh-Geiss, H. Chilcoat, N. Sessler, P. Coplan, Purdue Pharma, Stamford, CT
- 81 *Changes in diagnosed addiction rates in patients prescribed opioids after introduction of  
oxycontin with abuse-deterrent properties*  
P. Coplan<sup>1,3</sup>, A. Kadakia<sup>2</sup>, <sup>1</sup>Epidemiology, Purdue Pharma, Stamford, CT, <sup>2</sup>Purdue,  
Stamford, CT, <sup>3</sup>Univ. of Pennsylvania, Philadelphia, PA
- 82 *Changes in age-specific rates of doctor-shopping for opioids following introduction of  
reformulated OxyContin® tablets*  
H. Chilcoat, P. Coplan, N. Sessler, V. Harikrishnan, Risk Management and Epidemiology,  
Purdue Pharma, Stamford, CT
- 83 *How long is too long? The continued misuse of non-abuse deterrent Oxycontin after removal  
from the market in a cohort of rural Appalachian opioid abusers*  
J. R. Havens<sup>2</sup>, M. R. Lofwall<sup>3</sup>, S. L. Walsh<sup>1</sup>, <sup>1</sup>Behavioral Science, Univ. of Kentucky,  
Lexington, KY, <sup>2</sup>Center on Drug and Alcohol Research, University of Kentucky,  
Lexington, KY, <sup>3</sup>University of Kentucky College of Medicine, Lexington, KY
- 84 *Diverted buprenorphine use among Appalachian people who use drugs*  
R. V. Smith, M. R. Lofwall, S. L. Walsh, J. R. Havens, Behavioral Science, Univ. of  
Kentucky, Lexington, KY
- 85 *Examining the relationship between social context and prescription opioid initiation routes  
among young adults entering detoxification*  
M. A. Levi-Minzi, H. Surratt, C. L. O'Grady, S. P. Kurtz, ARSH: Center for Research on  
Substance Use and Health Disparities, Nova Southeastern University, Miami, FL



- 86 *Polysubstance combinations involving prescription opioids and rationales for combining among people who use Internet drug discussion forums*  
T. Green<sup>1</sup>, M. Doe-Simkins<sup>2</sup>, M. Barratt<sup>3</sup>, T. A. Cassidy<sup>1</sup>, S. F. Butler<sup>1</sup>, <sup>1</sup>Inflexxion, Inc., Newton, MA, <sup>2</sup>Prescribetoprevent.org, Chicago, IL, <sup>3</sup>Curtin University, Perth, WA, Australia
- 87 *Trajectories of nonmedical prescription medication use among youth*  
C. Boyd<sup>1</sup>, J. A. Cranford<sup>1</sup>, S. E. McCabe<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI
- 88 *Substance use among sexual minority collegiate athletes: A national study*  
P. T. Veliz, C. J. Boyd, Q. Epstein-Ngo, S. E. McCabe, Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI
- 89 *Ultrahigh chronic opioid therapy subjects: A population description*  
U. Bhatt<sup>2</sup>, D. Plott<sup>1</sup>, <sup>1</sup>Mental Healthcare Line, Cincinnati VAMC, Cincinnati, OH, <sup>2</sup>OSUWMC, Columbus, OH
- 90 *The geospatial and temporal correlation of oxycodone and heroin deaths in Florida counties, 2011 to 2013*  
C. Delcher<sup>1</sup>, J. Hall<sup>1</sup>, D. Lee<sup>2</sup>, M. Maldonado-Molina<sup>1</sup>, <sup>1</sup>Health Outcomes and Policy, University of Florida, Gainesville, FL, <sup>2</sup>Departments of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL
- 91 *National trends in hospitalizations for opioid pill- and heroin-related overdose, 2005-2012*  
D. Ciccarone<sup>1</sup>, G. J. Unick<sup>2</sup>, <sup>1</sup>Family and Community Medicine, UCSF, San Francisco, CA, <sup>2</sup>School of Social Work, University of Maryland, Baltimore, MD
- 92 *The changing nature of opioid-related mortality in Australia*  
A. Roxburgh<sup>1</sup>, L. Burns<sup>1</sup>, W. Hall<sup>2,1</sup>, L. Degenhardt<sup>1,3</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, QLD, Australia, <sup>3</sup>School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia
- 93 *Changing patterns of treatment seeking for pharmaceutical opioids in Australia (2002-2011)*  
S. Nielsen<sup>2,1</sup>, A. Roxburgh<sup>2</sup>, R. Bruno<sup>3,2</sup>, N. Lintzeris<sup>1</sup>, A. Jefferson<sup>5</sup>, L. Degenhardt<sup>2</sup>, <sup>1</sup>Drug and Alcohol, SESLHD, Sydney, NSW, Australia, <sup>2</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>3</sup>School of Psychology, University of Tasmania, Hobart, TAS, Australia, <sup>4</sup>AIHW, Canberra, ACT, Australia
- 94 *Childhood traumatic experience and illicit drug use in adolescence, emerging adulthood, and adulthood*  
J. D. Scheidell<sup>1</sup>, S. McGorray<sup>2</sup>, K. Vaddiparti<sup>2</sup>, L. Cottler<sup>2</sup>, M. R. Khan<sup>1</sup>, <sup>1</sup>Population Health, New York University, New York, NY, <sup>2</sup>Colleges of Public Health & Health Professions and Medicine, University of Florida, Gainesville, FL
- 95 *Trend in substance use admissions among older adults*  
R. Jayadevappa<sup>1</sup>, S. Chhatre<sup>2</sup>, D. Metzger<sup>2</sup>, <sup>1</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Psychiatry, University of Pennsylvania, Philadelphia, PA
- 96 *U.S. estimates of hospitalization by substance use profile*  
J. Gryczynski<sup>1</sup>, R. P. Schwartz<sup>1</sup>, J. H. Jaffe<sup>1</sup>, K. O'Grady<sup>2</sup>, S. G. Mitchell<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Psychology, University of Maryland, College Park, MD
- 97 *One for the road: The role of substance misuse on outcomes from traumatic brain injury*  
L. A. Keyser-Marcus<sup>2</sup>, L. Thacker<sup>3</sup>, A. Starkweather<sup>3</sup>, D. Ramesh<sup>1</sup>, F. Moeller<sup>4</sup>, <sup>1</sup>Pharm Tox, VCU, Richmond, VA, <sup>2</sup>Psychiatry, VCU, Richmond, VA, <sup>3</sup>School of Nursing, VCU, Richmond, VA, <sup>4</sup>VCU IDAS, Richmond, VA

- 98 *Characteristics of gamblers choosing self-exclusion from casinos: A prospective study in a French overseas territory*  
N. Lhommeau<sup>2</sup>, J. Alexandre<sup>1</sup>, D. Mete<sup>2</sup>, M. Fatseas<sup>1</sup>, M. Auriacombe<sup>1</sup>, <sup>1</sup>Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, <sup>2</sup>CHU Reunion, Saint Denis, France
- 99 *Trait, state, and place: The role of personality and environment in drug use*  
K. A. Phillips<sup>1</sup>, D. Louie<sup>2</sup>, M. A. Furnari<sup>1</sup>, W. J. Kowalczyk<sup>1</sup>, D. Epstein<sup>1</sup>, K. L. Preston<sup>1</sup>, <sup>1</sup>NIDA, Baltimore, MD, <sup>2</sup>UCSF, San Francisco, CA
- 100 *Stable housing, stable substance use? Evaluation of two 'housing first' programs for homeless individuals*  
E. Whittaker, L. Burns, National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia
- 101 *No place to call home: What homelessness means for people who use drugs*  
L. Burns, E. Whittaker, National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia
- 102 *Increased risk of substance use and health-related problems among male homeless veterans*  
E. M. Dunne<sup>1</sup>, A. Diggins<sup>1</sup>, L. Burrell<sup>1</sup>, N. E. Whitehead<sup>1</sup>, W. W. Latimer<sup>2</sup>, <sup>1</sup>Clinical and Health Psychology, University of Florida, Gainesville, FL, <sup>2</sup>Lehman College, Bronx, NY
- 103 *Predictors of agreement between hair analysis and self-report of drug use*  
P. VanVeldhuisen<sup>1</sup>, G. Sharma<sup>1</sup>, M. Bogenschutz<sup>2</sup>, <sup>1</sup>The EMMES Corporation, Rockville, MD, <sup>2</sup>University of NM, Albuquerque, NM
- 104 *Does type of drug lead to quicker onset of injection?*  
R. Bluthenthal<sup>2</sup>, D. Chu<sup>2</sup>, L. Wenger<sup>1</sup>, T. Valente<sup>2</sup>, A. Kral<sup>1</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>Preventive Medicine, University of Southern California, Los Angeles, CA
- 105 *Ineligible for most protocols: What differentiates drug users?*  
C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 106 *Informed consent practices among NIH-funded researchers*  
C. Ryan, B. Seymour, M. Stephens, R. Comly, C. Sierka, T. G. Musselman, K. L. Dugosh, D. Festinger, Section on Law and Ethics, Treatment Research Institute, Philadelphia, PA

### RISK

- 107 *Substance use among highly sexually active gay and bisexual men: Examining sexual compulsivity, hypersexuality, and substance use*  
R. L. Moody<sup>1,2</sup>, J. T. Parsons<sup>1,2</sup>, A. Ventuneac<sup>1</sup>, H. J. Rendina<sup>1</sup>, C. Grov<sup>1</sup>, <sup>1</sup>Center for HIV Educational Studies & Training (CHEST), Hunter College, CUNY, New York, NY, <sup>2</sup>Graduate Center, CUNY, New York, NY
- 108 *Women can force men to have sex? Forced sex tactic and substance use among sexually victimized men*  
M. Cook, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
- 109 *Contraceptive use and risky sexual behavior varies with frequency of cocaine, crack cocaine, or methamphetamine use*  
D. J. Hand, S. H. Heil, Vermont Center on Behavior and Health, University of Vermont, Burlington, VT

- 110 *Trichomonas vaginalis* infection and drug abuse risk for women  
D. G. Fisher<sup>1</sup>, G. L. Reynolds<sup>1</sup>, P. Xandre<sup>2</sup>, <sup>1</sup>Center for Behavioral Research & Services, California State University, Long Beach, Long Beach, CA, <sup>2</sup>Nursing, California State University, Long Beach, Long Beach, CA
- 111 *Predicting sexually transmitted infections in sexually transmitted disease clinics in U.S.: A machine-learning approach*  
D. J. Feaster<sup>1</sup>, Y. Pan<sup>1</sup>, M. Nelson<sup>1</sup>, J. Sorensen<sup>2</sup>, L. R. Metsch<sup>3</sup>, <sup>1</sup>Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>University of California, San Francisco, San Francisco, CA, <sup>3</sup>Columbia University, New York, NY
- 112 *A new repeated measures approach of sexual and substance use risk behaviors among patients in transmitted disease clinics*  
Y. Pan<sup>1</sup>, L. R. Metsch<sup>2</sup>, J. Sorensen<sup>3</sup>, D. J. Feaster<sup>1</sup>, <sup>1</sup>Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>University of California, San Francisco, San Francisco, CA
- 113 *Binge drinkers have greater vulnerability to engage in risky behaviors in traffic and drug use*  
G. Pasa<sup>1</sup>, T. R. Sousa<sup>1</sup>, J. Lunnen<sup>2</sup>, F. P. Pechansky<sup>1</sup>, <sup>1</sup>Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 114 *A qualitative investigation comparing sexual effects of alcohol and marijuana among adults*  
J. J. Palamar<sup>1,2</sup>, P. Acosta<sup>1</sup>, V. Falb<sup>1</sup>, D. C. Ompad<sup>2,3</sup>, <sup>1</sup>Department of Population Health, New York University Langone Medical Center, Astoria, NY, <sup>2</sup>Center for Drug Use and HIV Research, New York University College of Nursing, New York, NY, <sup>3</sup>Global Institute of Public Health, New York University, New York, NY
- 115 *Non-medical prescription opioid use and commercial sex work among adults in residential substance use treatment*  
A. K. Matusiewicz<sup>1,2,3</sup>, A. S. Bohnert<sup>1,2,3</sup>, E. E. Bonar<sup>2</sup>, M. Ilgen<sup>1,2,3</sup>, <sup>1</sup>VA Center for Clinical Management Research, Ann Arbor, MI, <sup>2</sup>Psychiatry, University of Michigan Medical School, Ann Arbor, MI, <sup>3</sup>VA Ann Arbor Healthcare System, Ann Arbor, MI
- 116 *High rate of ED presentations in a cohort of people who inject drugs: 2008-2013*  
D. Nambiar<sup>1,2</sup>, M. Stooove<sup>1,2</sup>, P. Dietze<sup>1,2</sup>, <sup>1</sup>Centre for Population Health, Burnet Institute, Melbourne, VIC, Australia, <sup>2</sup>Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia
- 117 *Drug use and injection practices in Tajikistan: Qualitative study in Kulob and Khorog*  
D. Otiashvili<sup>1</sup>, A. Latypov<sup>2</sup>, U. Ibragimov<sup>3</sup>, I. Kirtadze<sup>1</sup>, W. Zule<sup>4</sup>, <sup>1</sup>Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, <sup>2</sup>Management Sciences for Health, Leadership, Management and Governance, Kiev, Ukraine, <sup>3</sup>Laney Graduate School, Emory University, Atlanta, GA, <sup>4</sup>RTI International, Research Triangle Park, NC

**BEHAVIOR**

- 118 *Staff acceptability of contingency management to promote longer breastfeeding duration at WIC*  
Y. Washio<sup>1</sup>, M. Humphreys<sup>2</sup>, D. Zeigler<sup>2</sup>, <sup>1</sup>Treatment Research Institute, Philadelphia, PA, <sup>2</sup>Temple University, Philadelphia, PA
- 119 *Do consumers substitute between cannabis and opium? Evidence from British India*  
S. Chandra, Asian Studies Center, Michigan State University, Okemos, MI
- 120 *An in-depth analysis of cocaine-induced negative subjective effects in humans*  
D. G. Thompson-Lake, S. Hernandez, M. Holst, J. Mahoney, C. N. Haile, T. F. Newton, R. De La Garza, II, Psychiatry, Baylor College of Medicine, Houston, TX

- 121 *Cocaine images and alcohol administration impair inhibitory control*  
E. Pike<sup>1,2</sup>, K. R. Marks<sup>1,2</sup>, W. W. Stoops<sup>1,2,3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Psychology, Univ. of KY, Lexington, KY, <sup>2</sup>Behav Sci, Univ. of KY, Lexington, KY, <sup>3</sup>Psychiatry, Univ. of KY, Lexington, KY
- 122 *The relationship between methamphetamine self-administration and subject-rated effects*  
J. C. Strickland<sup>2</sup>, W. W. Stoops<sup>1,2,3</sup>, C. R. Rush<sup>1,2,3</sup>, <sup>1</sup>Behavioral Science, Univ of KY, Lexington, KY, <sup>2</sup>Psychology, Univ of KY, Lexington, KY, <sup>3</sup>Psychiatry, Univ of KY, Lexington, KY
- 123 *Coordinated and homologous intravenous cocaine self-administration procedures in monkeys and humans: A translational approach to medications development*  
J. A. Lile<sup>2</sup>, S. S. Negus<sup>1</sup>, W. W. Stoops<sup>2</sup>, A. Johnson<sup>1</sup>, N. Kate<sup>1</sup>, M. Banks<sup>1</sup>, C. R. Rush<sup>2</sup>, L. Hays<sup>2</sup>, P. Glaser<sup>2</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>University of Kentucky, Lexington, KY
- 124 *Scientific writing seminar to help early-stage investigators publish research*  
J. Sorensen, C. L. Masson, A. Flentje, M. Shopshire, J. Guydish, Department of Psychiatry, University of California, San Francisco, San Francisco, CA

**THEORETICAL - COMMENTARY**

- 125 *Considerations on designs of intranasal studies for abuse-deterrent products*  
L. Chen<sup>1</sup>, S. N. Calderon<sup>1</sup>, S. H. Hertz<sup>1</sup>, <sup>1</sup>FDA/CDER, Silver Spring, MD
- 126 *Design considerations for integrating video into tablet-based mHealth interventions addressing HIV and substance use*  
I. D. Aronson<sup>2</sup>, D. Perlman<sup>1</sup>, <sup>1</sup>Beth Israel Medical Center, New York, NY, <sup>2</sup>NDRI, Inc., New York, NY
- 127 *Use of telemedicine to treat hepatitis C at a medication-assisted opioid treatment program*  
L. S. Brown<sup>1</sup>, A. Talal<sup>2</sup>, M. Zeremski<sup>3</sup>, R. Zavala<sup>1</sup>, B. Smith<sup>4</sup>, A. Martinez<sup>2</sup>, M. Lin<sup>1</sup>, R. Dimova<sup>2</sup>, J. Zibbell<sup>4</sup>, S. Kritz<sup>1</sup>, <sup>1</sup>START Treatment & Recovery Centers, Brooklyn, NY, <sup>2</sup>SUNY Buffalo School of Medical and Biological Sciences, Buffalo, NY, <sup>3</sup>Weill Cornell Medical College, New York, NY, <sup>4</sup>Centers for Disease Control and Prevention, Atlanta, GA
- 128 *Redefining the recreational drug user population in human abuse potential studies*  
T. Hopyan<sup>1</sup>, P. Geoffroy<sup>1</sup>, Y. Hirata<sup>1</sup>, M. Sokolowska<sup>2</sup>, A. Jorga<sup>3</sup>, B. Setnik<sup>1</sup>, <sup>1</sup>INC Research, Toronto, ON, Canada, <sup>2</sup>Grunenthal, Bedminster, NJ, <sup>3</sup>Pfizer, New York, NY
- 129 *FDA guidance assessment of abuse potential of drugs*  
C. P. Moody<sup>1</sup>, M. Klein<sup>2</sup>, <sup>1</sup>CDER/Controlled Substance Staff (CSS), US Food and Drug Administration (FDA), Silver Spring, MD, <sup>2</sup>Controlled Substance Staff, Food & Drug Administration, Silver Spring, MD
- 130 *Abuse Quotient: An essential measure of opioid analgesic Human Abuse Potential (HAP)*  
L. R. Webster, M. D. Smith, EDS, PRA Health Sciences, Salt Lake City, UT
- 131 *Assessing potential abuse and misuse of testosterone and other anabolic steroids among middle-aged and older men prescribed steroids*  
J. Randall-Thompson, A. Lerner, J. Hunt, M. Klein, Controlled Substance Staff (CSS), Food and Drug Administration (FDA), Silver Spring, MD
- 132 *Beyond pharmacotherapy: Emerging data that non-invasive brain stimulation may be an efficacious strategy for decreasing drug craving in substance-dependent individuals*  
C. A. Hanlon, L. T. Dowdle, W. DeVries, Medical University of South Carolina, Charleston, SC

- 133 *Internalizing and externalizing disorders as risk factors for the increase of cannabis use and the onset and stability of cannabis use disorders: A systematic review of cohort studies from the general population*  
M. Neumann<sup>1</sup>, S. Behrendt<sup>1</sup>, A. Perkonigg<sup>2</sup>, G. Buehringer<sup>1</sup>, <sup>1</sup>Institute of Clinical Psychology and Psychotherapy, Dresden, Germany, <sup>2</sup>University of Zurich, Zurich, Switzerland
- 134 *The use of a parallel latent growth model in understanding smoking as a comorbid disorder*  
M. Mamey<sup>2</sup>, S. McPherson<sup>1,3</sup>, <sup>1</sup>Program of Excellence in Addictions Research (PEAR), Washington State University, Spokane, WA, <sup>2</sup>Psychology, Washington State University, Pullman, WA, <sup>3</sup>College of Nursing, Washington State University, Spokane, WA
- 135 *Weaving evidenced-informed, culture-based interventions into treatment in Native American and Alaska Native communities*  
A. Skinstad<sup>1</sup>, R. Walker<sup>2</sup>, J. Gringer Richards<sup>1</sup>, S. A. Bear<sup>1</sup>, <sup>1</sup>Community and Behavioral Health, University of Iowa, Iowa City, IA, <sup>2</sup>Psychiatry, Oregon Health and Science University and the One Sky Center, Portland, OR
- 136 *Evaluation of electronic nicotine delivery systems: Regulatory precedents from the FDA 2013 draft guidance for abuse-deterrent opioids*  
J. Henningfield<sup>1</sup>, E. J. Cone<sup>1</sup>, A. R. Buchhalter<sup>1</sup>, R. V. Fant<sup>1</sup>, J. G. Gitchell<sup>1</sup>, J. M. Pinney<sup>1</sup>, <sup>1</sup>PinneyAssociates, Inc., Bethesda, MD
- 137 *Patient selection for extended-release naltrexone among criminal justice-involved persons with opioid use disorder*  
P. D. Friedmann<sup>1,3</sup>, J. D. Lee<sup>4</sup>, E. V. Nunes<sup>5</sup>, T. W. Kinlock<sup>6</sup>, C. P. O'Brien<sup>2</sup>, <sup>1</sup>Medicine, Rhode Island Hospital, Providence, RI, <sup>2</sup>U Penn, Phila, PA, <sup>3</sup>Research Service, Providence VA Medical Center, Providence, RI, <sup>4</sup>Population Health, New York University, New York, NY, <sup>5</sup>Psychiatry, Columbia University, New York, NY, <sup>6</sup>Friends Research Institute, Baltimore, MD

## **Symposium XIV**

### **INRC/CPDD Joint Symposium**

**AZ Biltmore Ballroom**  
**10:00 - 12:00 PM**

### **CANNABINOID MECHANISMS AND INTERVENTIONS**

Chair: Todd Vanderah

- 10:00 *Therapeutic interventions through the modulation of CB1/CB2 cannabinoid receptor function*  
Alexandros Makriyannis, Northeastern University, Boston, MA
- 10:30 *Inhibition of the 2-AG biosynthetic enzyme diacylglycerol lipase beta: Antinociception through a cannabinoid receptor independent pathway*  
Aron Lichtman, Virginia Commonwealth University, Richmond, VA
- 11:00 *Synergistic actions of opioid/cannabinoid agents for discrete pain etiologies*  
Todd Vanderah, University of Arizona-Tucson, Tucson, AZ
- 11:30 *The therapeutic promise of nonpsychoactive cannabinoid analgesics*  
Andrea G. Hohmann, Indiana University, Indianapolis, IN



Oral Communication 14

McArthur Ballroom 1/2

10:00 - 12:00 PM

**MEDICATIONS FOR ABUSE—LATEST FINDINGS: TREATMENTS FOR STIMULANT ABUSE**

Chairs: Sally L. Huskinson and Stephanie M. Groman

- 10:00 *Impact of an exercise intervention on methamphetamine use outcomes post residential treatment care*  
R. Rawson<sup>1</sup>, J. Chudzynski<sup>1</sup>, R. Gonzales-Castaneda<sup>2,1</sup>, A. Ang<sup>1</sup>, D. Dickerson<sup>1</sup>, L. Mooney<sup>1</sup>, J. Penate<sup>1</sup>, B. Salem<sup>1</sup>, B. Dolezal<sup>3</sup>, C. Cooper<sup>3</sup>, <sup>1</sup>Integrated Substance Abuse Programs, UCLA, Los Angeles, CA, <sup>2</sup>Psychology, Azusa Pacific University, Azusa, CA, <sup>3</sup>Exercise Physiology Research Laboratory, UCLA, Los Angeles, CA
- 10:15 *The cocaine use reduction with buprenorphine study: Cocaine use findings*  
L. Walter<sup>1</sup>, M. Hillhouse<sup>1</sup>, A. Saxon<sup>2</sup>, L. Mooney<sup>1</sup>, C. Thomas<sup>1</sup>, A. Ang<sup>1</sup>, A. Hasson<sup>1</sup>, J. Annon<sup>1</sup>, C. Study Group<sup>3</sup>, <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>VA Puget Sound Health Care System, Seattle, WA, <sup>3</sup>CTN, Bethesda, MD
- 10:30 *Unpredictable availability as a determinant of cocaine choice*  
S. L. Huskinson<sup>1</sup>, J. Rowlett<sup>1,3</sup>, N. Petry<sup>2</sup>, K. Freeman<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>University of Connecticut Health Center, Farmington, CT, <sup>3</sup>Tulane National Primate Research Center, Covington, LA
- 10:45 *Reversal learning is predictive of and affected by cocaine self-administration: Dissecting decision-making processes with computational models*  
S. M. Groman<sup>1</sup>, N. Smith<sup>1</sup>, L. Chen<sup>1</sup>, D. Lee<sup>2</sup>, J. Taylor<sup>1</sup>, <sup>1</sup>Psychiatry, Yale University, New Haven, CT, <sup>2</sup>Neurobiology, Yale University, New Haven, CT
- 11:00 *Cocaine impairs serial feature negative learning: Implications for cocaine abuse*  
A. L. Riley<sup>1</sup>, D. Kearns<sup>1</sup>, S. Hargrave<sup>1</sup>, T. Davidson<sup>1</sup>, <sup>1</sup>Psychology, American University, Washington, DC
- 11:15 *Mechanisms and reversal of adolescent cocaine-induced habits*  
L. DePoy<sup>1,2,3</sup>, S. Gourley<sup>1,2,3</sup>, <sup>1</sup>Department of Pediatrics, Emory School of Medicine, Atlanta, GA, <sup>2</sup>Yerkes National Primate Research Center, Atlanta, GA, <sup>3</sup>Graduate Program in Neuroscience, Emory University, Atlanta, GA
- 11:30 *PPAR $\gamma$  agonism attenuates cocaine-seeking behavior via ERK*  
K. Dineley<sup>2,1</sup>, W. Miller<sup>1</sup>, R. G. Fox<sup>1</sup>, S. J. Stutz<sup>1</sup>, <sup>1</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Neurology, University of Texas Medical Branch, Galveston, TX
- 11:45 *A novel neuropeptide regulator of behavioral sensitization to cocaine*  
J. M. Kasper<sup>1,2</sup>, D. L. McCue<sup>1,3</sup>, C. Benzon<sup>2</sup>, Z. Ding<sup>3</sup>, S. Carlton<sup>3</sup>, J. D. Hommel<sup>1,2</sup>, <sup>1</sup>Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, <sup>3</sup>Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX

**Oral Communications 15****McArthur Ballroom 5/6****10:00 - 12:00 PM****MEDICATIONS ANTIRETROVIRAL LEVELS AND FUNCTIONALITY: HIV/AIDS**

Chairs: Richard Saitz and David S. Festinger

- 10:00 *The microbiota-gut-brain axis as a potential therapeutic approach for HIV-1+ cocaine abuse*  
S. B. Harrod, S. J. Bertrand, C. F. Mactutus, D. Booze, Psychology, University of South Carolina, Columbia, SC
- 10:15 *Exposure to HIV-1 Tat protein potentiates the rewarding effects of morphine and reinstates extinguished conditioned place preference*  
J. P. McLaughlin<sup>2</sup>, M. L. Ganno<sup>2</sup>, J. J. Paris<sup>2</sup>, Y. Zhang<sup>1</sup>, M. J. Kreek<sup>1</sup>, <sup>1</sup>The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University, New York, NY, <sup>2</sup>Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL
- 10:30 *The North-South divide: Substance use risk, care engagement, and viral suppression among hospitalized HIV-infected patients in 11 U.S. cities*  
M. Philbin<sup>1</sup>, D. Feaster<sup>2,3</sup>, L. Gooden<sup>2,3</sup>, Y. Pan<sup>3</sup>, M. Das<sup>2</sup>, R. Pati<sup>2</sup>, G. Lucas<sup>2</sup>, H. Coley<sup>2</sup>, A. Nijhawan<sup>2</sup>, J. Jacobson<sup>2</sup>, R. Mandler<sup>2</sup>, E. Daar<sup>2</sup>, D. McMahon<sup>2</sup>, C. del Rio<sup>2</sup>, L. Metsch<sup>1,2,3</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>NIDA Clinical Trials Network, Bethesda, MD, <sup>3</sup>University of Miami, Miami, FL
- 10:45 *Childhood parental incarceration and HIV-related drug and sex risk over the young adult life course*  
M. R. Khan<sup>1</sup>, S. McGorray<sup>2</sup>, J. D. Scheidell<sup>1</sup>, K. Vaddiparti<sup>2</sup>, L. M. Brotman<sup>1</sup>, <sup>1</sup>Population Health, New York University, New York, NY, <sup>2</sup>Colleges of Public Health & Health Professions and Medicine, University of Florida, Gainesville, FL
- 11:00 *The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among opioid-dependent individuals with HIV/AIDS*  
B. Nosyk<sup>1,4,3</sup>, J. Min<sup>1</sup>, E. Evans<sup>2</sup>, L. Li<sup>3</sup>, L. Liu<sup>5</sup>, V. D. Lima<sup>1</sup>, E. Wood<sup>1</sup>, J. Montaner<sup>1</sup>, <sup>1</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, <sup>2</sup>UCLA, Los Angeles, CA, <sup>3</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>4</sup>Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, <sup>5</sup>Northwestern University, Chicago, IL
- 11:15 *Is opioid use associated with T cell dysfunction?*  
K. Armah<sup>2</sup>, E. J. Edelman<sup>1</sup>, D. M. Cheng<sup>2</sup>, M. Doyle<sup>4</sup>, S. Coleman<sup>2</sup>, C. Bridden<sup>2</sup>, N. Gnatienco<sup>2</sup>, D. Lioznov<sup>3</sup>, E. Blokhina<sup>3</sup>, B. Emu<sup>1</sup>, M. Freiberg<sup>5</sup>, E. Krupitsky<sup>3</sup>, J. Samet<sup>2</sup>, <sup>1</sup>Yale, New Haven, CT, <sup>2</sup>Boston University, Boston, MA, <sup>3</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, <sup>4</sup>UVM, Colchester, VT, <sup>5</sup>Vanderbilt, Nashville, TN
- 11:30 *Substance dependence criteria, not substance use, associated with HIV virologic control*  
S. Nolan<sup>1</sup>, A. Walley<sup>2</sup>, T. Heeren<sup>2</sup>, G. Patts<sup>2</sup>, A. S. Ventura<sup>2</sup>, M. Sullivan<sup>2</sup>, J. Samet<sup>2</sup>, R. Saitz<sup>2</sup>, <sup>1</sup>Department of Medicine, University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Boston University, Boston, MA
- 11:45 *Delivering HIV prevention services to drug court clients*  
D. Festinger, K. L. Dugosh, Section on Law and Ethics, Treatment Research Institute, Philadelphia, PA

**Symposium XV**

**McArthur Ballroom 4  
10:00 - 11:00 AM**

**A TRIO OF TRANSLATIONAL PROJECTS: BIOMARKERS,  
BIOIMMUNOLOGY, AND BEHAVIOR IN RODENTS AND HUMANS**

Chairs: Karran A. Phillips and Kenzie L. Preston

- 10:00 *Identification of novel lipid biomarkers of cocaine use in humans*  
Brian Cummings, University of Georgia, Athens, GA
- 10:20 *A novel mechanism of levamisole-induced autoimmunity in cocaine use*  
Peter Grayson, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
- 10:40 *Buprenorphine plus clonidine increases time to lapse and reduces heroin craving at low-to-moderate stress levels*  
Kenzie L. Preston, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD

**Symposium XVI**

**McArthur Ballroom 4  
11:15 - 12:15 PM**

**NEW STRATEGIES TO IDENTIFY THE GENETICS OF  
ADDICTION-RELATED BEHAVIORS IN MICE**

Chair: J. David Jentsch

- 11:15 *Impulsivity and cocaine reinforcement: Identifying genetic relationships in inbred mice*  
J. David Jentsch, University of California at Los Angeles, Los Angeles, CA
- 11:35 *Initial sensitivity to cocaine in genetically diverse inbred mouse strains*  
Lisa Tarantino, University of North Carolina, Chapel Hill, NC
- 11:55 *Behavioral predictors of drug self-administration in diversity outbred mice*  
Elissa J. Chesler, The Jackson Laboratory, Bar Harbor, ME

**BRUNCH WITH CHAMPIONS  
(PRE-REGISTRANTS ONLY)**

**Aztec  
12:15 - 1:15 PM**

**Oral Communications 16**

**McArthur Ballroom 1/2  
1:30 - 2:30 PM**

**LATE-NIGHT FUNKADELICS: CLUB DRUGS**

Chairs: Ryan A. Gregg and Michael S. Placzek

- 1:30 *Effects of the GLT-1 activator ceftriaxone on the rewarding and locomotor activating effects of 'bath salt' compound 3,4-methylenedioxypyrovalerone in rats*  
R. A. Gregg<sup>1</sup>, C. S. Tallarida<sup>1</sup>, S. Rawls<sup>1</sup>, <sup>1</sup>Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

- 1:45 *Self-administration of second-generation synthetic cathinones in rats*  
J. Naylor<sup>1</sup>, E. Townsend<sup>1</sup>, K. Freeman<sup>1</sup>, J. Rowlett<sup>2</sup>, B. E. Blough<sup>3</sup>, S. L. Huskinson<sup>1</sup>,  
<sup>1</sup>Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS,  
<sup>2</sup>University of Mississippi Medical Center, Jackson, MS, <sup>3</sup>Center for Drug Discovery,  
Research Triangle Institute, Research Triangle Park, NC
- 2:00 *Immediate and persistent effects of salvinorin A on the kappa opioid receptor in rodents, monitored in vivo with PET*  
M. S. Placzek<sup>2,1</sup>, G. C. Van de Bittner<sup>1</sup>, H. Wey<sup>1</sup>, S. E. Lukas<sup>2</sup>, J. M. Hooker<sup>1</sup>, <sup>1</sup>Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA
- 2:15 *Body temperature and cardiovascular effects of some synthetic cannabinoids found in “spice” products*  
C. W. Schindler<sup>1</sup>, Z. Justinova<sup>1</sup>, E. B. Thorndike<sup>1</sup>, S. R. Goldberg<sup>1</sup>, M. H. Baumann<sup>2</sup>,  
<sup>1</sup>Preclinical Pharmacology, NIH/NIDA Intramural Research, Baltimore, MD, <sup>2</sup>Designer Drug Research, NIH/NIDA Intramural Research, Baltimore, MD

### Oral Communications 17

McArthur Ballroom 4  
1:30 - 2:30 PM

#### **MALADAPTIVE ALCOHOL LIBATIONS AND FIREWATER: ALCOHOL ABUSE**

Chair: Elizabeth J. Santa Ana

- 1:30 *Early parental supply of alcohol and alcohol consumption in mid-adolescence: A longitudinal study*  
R. P. Mattick<sup>1</sup>, M. Wadolowski<sup>1</sup>, A. Aiken<sup>1</sup>, J. Najman<sup>3</sup>, K. Kypri<sup>4</sup>, T. Slade<sup>1</sup>, D. Hutchinson<sup>1</sup>,  
R. Bruno<sup>2</sup>, N. McBride<sup>5</sup>, <sup>1</sup>National Drug & Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, <sup>2</sup>School of Psychology, University of Tasmania, Hobart, TAS, Australia, <sup>3</sup>School of Public Health, University of Queensland, Brisbane, QLD, Australia, <sup>4</sup>Centre for Clinical Epidemiology & Biostatistics, School of Medicine & Public Health, University of Newcastle, Newcastle, NSW, Australia, <sup>5</sup>National Drug Research Institute, Curtin University, Perth, WA, Australia
- 1:45 *Delay discounting and alcohol abuse among early adolescents*  
C. Lopez-Nuñez, S. Weidberg, V. Martinez-Loredo, I. Pericot-Valverde, R. Secades-Villa, J. Fernández-Hermida, Department of Psychology, University of Oviedo, Oviedo, Spain
- 2:00 *6-month follow-up of baclofen treatment in patients with alcohol use disorder and other psychiatric comorbidities*  
B. Gelot<sup>1</sup>, M. Fatseas<sup>1</sup>, F. Serre<sup>1</sup>, C. M. Denis<sup>2,1</sup>, J. Dubernet<sup>3</sup>, S. Sarram<sup>3</sup>, M. Auriacombe<sup>1</sup>,  
<sup>1</sup>Addiction Psychiatry (CNRS USR 3413), Université Bordeaux, Bordeaux, France,  
<sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Addiction Psychiatry, CH Ch Perrens/CHU Bordeaux, Bordeaux, France
- 2:15 *Impact of telehealth in-home-messaging devices on alcohol use in dually diagnosed veterans*  
E. J. Santa Ana<sup>1</sup>, S. Martino<sup>2</sup>, M. Gebregziabher<sup>1</sup>, <sup>1</sup>Charleston VAMC and Medical University of South Carolina, Charleston, SC, <sup>2</sup>Yale University School of Medicine, West Haven, CT

**Oral Communications 18**

**McArthur Ballroom 5/6  
1:30 - 2:30 PM**

**MUST ACT, LITTLE FORETHOUGHT: IMPULSIVITY**

Chair: Ayca Coskunpinar

- 1:30 *The effects of mirtazapine on pramipexole-induced riskiness in a rat model of Parkinson's disease*  
N. A. Holtz<sup>2</sup>, S. E. Tedford<sup>2</sup>, A. Persons<sup>1</sup>, C. Napier<sup>1</sup>, <sup>1</sup>Rush University Medical Center, Chicago, IL, <sup>2</sup>Pharmacology, Rush University Medical Center, Chicago, IL
- 1:45 *The protective effect of enrichment on drug abuse vulnerability may reflect a decrease in mood-based impulsivity using a rat model of negative urgency*  
D. B. Vazquez-Sanroman<sup>1,2</sup>, M. T. Bardo<sup>1,2</sup>, <sup>1</sup>Psychology, University of Kentucky, Lexington, KY, <sup>2</sup>Center for Drug Abuse Research Translation, Lexington, KY
- 2:00 *Nicotine shows a therapeutic effect on impulsivity through a different mechanism from that of paroxetine*  
H. Miyata<sup>1</sup>, N. Murota<sup>2</sup>, K. Sawa<sup>3</sup>, N. Hironaka<sup>4</sup>, K. Nakayama<sup>1</sup>, <sup>1</sup>Psychiatry, Jikei University School of Medicine, Tokyo, Japan, <sup>2</sup>Pharmacology, Ina-Research, Tokyo, Japan, <sup>3</sup>Graduate School of Humanity, Senshu University, Kawasaki, Japan, <sup>4</sup>Pharmacology, Mitsubishi Chemical Medience Corp, Udo, Japan
- 2:15 *Sex differences in effects of trait impulsivity on vulnerability to substance dependence*  
A. Coskunpinar<sup>3</sup>, J. Vassileva<sup>2</sup>, E. Martin<sup>1</sup>, <sup>1</sup>Psychiatry, Rush University Medical Center, Chicago, IL, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Behavioral Sciences, Rush University Medical Center, Chicago, IL

**SWEEPSTAKES DRAWING**

**McArthur Ballroom 4  
2:45 - 3:15 PM**

***YOU MUST BE SEATED IN ONE OF THE SESSIONS  
STARTING AT 1:30 PM IN ORDER TO HAVE YOUR BADGE  
COLLECTED FOR THE DRAWING***

**HAVE A SAFE TRIP HOME!**

**SEE YOU IN LA QUINTA, CA, JUNE, 11-16, 2016**



## AUTHOR INDEX

- Aarde, S. M. 68  
 Abdolahi, A. 99  
 Abrouk, N. E. 94  
 Abts, K. 19  
 Acharaya, S. 22  
 Acheampong, A. 20, 64  
 Acosta, P. 103  
 Adamson, S. 97  
 Addicott, M. 99  
 Ades, P. 55  
 Adler, Martin W. 1  
 Agage, D. 18  
 Aguilar-Moya, R. 19  
 Ahamad, K. 17  
 Aharonovich, E. 19, 80  
 Ahmad, I. 86  
 Ahmed, M. S. 54, 55, 79  
 Ahmed, R. 87  
 Ahmed, S. 11  
 Ahn, W. 2, 14  
 Ahuama-Jonas, C. 20  
 Aiello, A. 3  
 Aiken, A. 109  
 Akpara, U. 62  
 Akutagava-Martins, G. 52  
 Al-Halabí, S. 78  
 Al-Tayyib, A. 79  
 Alamian, A. 57  
 Alaniz, V. M. 23  
 Albertella, L. 19, 95  
 Alcover, K. 65  
 Alden, H. 22  
 Aldrich, J. 15  
 Aleixandre-Agulló, R. 20  
 Aleixandre-Benavent, R. 19, 20  
 Alexander-Street, A. 62  
 Alexandre, J. 10, 102  
 Alfonso, A. 77  
 Alford, D. 15, 22  
 Allen, A. M. 82  
 Allen, C. 61  
 Allen, N. 71  
 Allen, S. 82  
 Allende-labastida, J. 13  
 Allsop, S. 67  
 Alonso Pérez, F. 56  
 Alshaarawy, O. 64  
 Altomare, D. 27  
 Altschuler, J. H. 70  
 Alvarós, J. 77  
 Alving, C. 25  
 Amador, C. 3  
 Amaro, H. 20  
 Amin, J. 81  
 Ananthan, S. 13  
 Anastasio, N. C. 9, 10, 11, 12, 14, 28, 71  
 Andersen, J. M. 11, 54  
 Andersen, R. 21, 22  
 Anderson-Carpenter, K. D. 78  
 Andrade, A. 78  
 Andrade, L. H. 78  
 Andrews, B. 56, 68  
 Anez, L. 84  
 Ang, A. 19, 60, 61, 76, 106  
 Angulo-C, E. 84  
 Annon, J. 59, 61, 76, 106  
 Anthony, E. 79  
 Anthony, James C. 4, 55, 63, 64, 65, 79, 94, 99  
 Antoine, D. G. 10, 18  
 Antoline, J. 25  
 Antonijoan, R. M. 96  
 Aphinyanaphongs, Y. 18  
 Arfken, C. L. 17, 100  
 Arger, C. A. 84  
 Arheart, K. 64  
 Armah, K. 107  
 Armenta, R. 66  
 Arnetz, B. 100  
 Arnetz, J. 100  
 Aronsen, D. 75  
 Aronson, I. D. 104  
 Arredondo, J. 23  
 Arria, A. M. 64  
 Arroyo, M. 21, 22  
 Ashrafioun, L. 89, 91  
 Aston, E. 14, 95  
 Atchison, J. J. 76  
 Auriacombe, M. 10, 16, 55, 81, 91, 102, 109  
 Austic, E. A. 20, 79, 80  
 Ayers, K. L. 3  
 Babalonis, S. 3, 96, 97  
 Babbín, S. F. 63  
 Bachman, J. 26  
 Back, Sudie E. 3, 7  
 Bagwell, B. 19  
 Baker, E. 80  
 Baker, N. 53  
 Bakhshaie, J. 78  
 Baldwin, A. 84  
 Bale, A. S. 59  
 Balodis, I. 53  
 Bandiera, F. 55  
 Banducci Rahe, B. 89  
 Banerjee, G. 100  
 Banerjee, S. 8  
 Banich, M. T. 97, 98  
 Banks, M. 104  
 Banta-Green, Caleb J. 2  
 Barbosa-Leiker, Celestina 5, 65  
 Bardo, C. M. 62  
 Bardo, Michael T. 2, 13, 52, 90, 110  
 Bares, Cristina B. 5, 62  
 Barnes, A. 96  
 Barnett, C. 86  
 Barnett, G. 79  
 Barnhouser, C. 10  
 Barr, J. L. 28  
 Barral, C. 77  
 Barratt, M. 101  
 Barrett, F. S. 57  
 Barry, D. T. 100  
 Barry, K. 87  
 Bart, G. 15, 16  
 Bartu, A. 67  
 Baskin, B. M. 26  
 Batchelder, A. 17, 24  
 Batki, Steven L. 91  
 Baumann, M. H. 13, 27, 109  
 Bear, S. A. 105  
 Beardsley, P. 71  
 Bebarta, V. 89  
 Bechara, A. 14, 60, 98  
 Beck, Z. 25

## AUTHOR INDEX

- Becker, W. 16, 70, 100  
 Beckmann, J. S. 2, 10  
 Bedell, P. 20  
 Bedi, G. 99  
 Begnis, A. P. 78  
 Behrendt, S. 105  
 Belendiuk, K. 53  
 Beletsky, L. 23  
 Benesch, C. 99  
 Benishek, L. 88  
 Bennett, A. S. 22, 58  
 Benoit, E. 81  
 Benowitz, N. 55  
 Benz, M. B. 77  
 Benzon, C. 106  
 Bereket, S. 18  
 Berger, I. 64  
 Bergeria, C. L. 69  
 Bergman, J. 2, 12  
 Berkowitz-Sturgis, E. 98  
 Bernstein, E. 26  
 Bernstein, I. M. 67  
 Bernstein, J. 22, 88  
 Bernstein, S. 82  
 Berritini, W. 52  
 Bertrand, S. J. 107  
 Besharat, A. C. 58  
 Betts, J. 14  
 Beylotte, F. 3  
 Bhatt, U. 101  
 Bickel, Warren K. 3, 13, 14, 56, 57, 67, 88  
 Bielavitz, S. 16  
 Bierma, S. 23  
 Bigelow, G. 10, 94  
 Bills, S. 25  
 Binswanger, I. A. 22  
 Bishop, T. M. 89, 91  
 Bixler, E. 15  
 Bjork, J. M. 14, 98  
 Black, A. C. 80  
 Blady, S. J. 99  
 Block, R. 99  
 Blokhina, E. 17, 18, 76, 107  
 Blough, B. E. 12, 109  
 Blow, F. 20, 21, 79, 87  
 Bluthenthal, R. 3, 65, 99, 102  
 Bobashev, Georgiy 4, 11  
 Bobes, J. 78  
 Bock, Beth 66  
 Bogen, I. 54  
 Bogenschutz, M. 87, 88, 102  
 Bohnert, A. S. 21, 87, 103  
 Bohnert, K. 64  
 Boix Escolan, F. 11, 54  
 Bolao, F. 85  
 Bolin, B. L. 61, 93  
 Bonab, A. A. 13  
 Bonadonna, J. 27  
 Bonar, Erin E. 21, 72, 79, 103  
 Bond, M. 58  
 Bone, C. 22  
 Bonn-Miller, M. O. 97  
 Bonson, K. 93  
 Booker, J. 4  
 Boos, T. L. 59  
 Booth, B. M. 79, 87  
 Booth, R. E. 3, 23  
 Booze, D. 107  
 Bordnick, P. 76  
 Borille, B. T. 85  
 Borodovsky, J. 89  
 Borsari, B. 77, 96  
 Bough, K. J. 59  
 Boukli, N. 16  
 Boulos, P. 97  
 Bouril, A. 99  
 Bowen, Sarah 66  
 Boyd, C. J. 80, 101  
 Boyer, E. W. 19  
 Bradshaw, C. 63  
 Brady, Kathleen T. 8, 28, 53, 57  
 Brands, B. 94, 96  
 Brandt, L. 24  
 Brason, II, Fred Wells 8, 51  
 Brecht, M. 76  
 Breen, C. L. 67  
 Breland, A. 55, 68  
 Bresani, E. 59, 79, 80  
 Brewer, Judson 66  
 Briceno, A. 87  
 Bridden, C. 17, 18, 107  
 Brigham, G. 61  
 Briones, M. 60, 100  
 Britch, S. 95  
 Britton, P. 22  
 Broadbridge, C. 100  
 Brochman, G. 54  
 Brooks, A. C. 20, 88  
 Brooks, Audrey 29  
 Brooks, D. J. 55, 95  
 Brooks, O. 55, 65  
 Brooner, R. K. 76  
 Brosig, R. 63, 99  
 Brotman, L. M. 107  
 Brown, L. S. 18, 104  
 Brown, Q. 24, 84  
 Brown, R. W. 62  
 Browne, F. 21  
 Browne, R. 76  
 Bruno, R. 14, 54, 70, 94, 97, 101, 109  
 Bryant, K. 16  
 Bubar, M. J. 12  
 Bucher-Bartelson, B. 8  
 Buchhalter, A. R. 18, 105  
 Bucholz, K. K. 77  
 Buck, M. 60  
 Budman, S. H. 58, 100  
 Budney, Alan J. 19, 30, 63, 68  
 Buehringer, G. 105  
 Bueno-Cañigral, F. 19, 20  
 Bugbee, B. A. 64  
 Bukhari, M. O. 27  
 Bukholt, N. 75  
 Bunce, S. 15  
 Bunn, J. 87  
 Burlew, K. 20  
 Burlew, Kathleen 73  
 Burnett, J. 4  
 Burns, L. 64, 67, 81, 88, 101, 102  
 Burón, P. 78  
 Burrell, L. 16, 102  
 Burrow-Sanchez, Jason 73  
 Burston, J. 96  
 Busch, S. 82  
 Bushara, N. 17, 76  
 Busse, A. 59

## AUTHOR INDEX

- Butelman, E. 70  
 Butler, K. 81  
 Butler, S. F. 58, 64, 100, 101  
 Buttram, M. E. 53, 57  
 Buu, A. 20, 79  
 Bybee, D. 21  
 Byrne, E. 88
- Cacciola, J. 80  
 Caetano, S. 78  
 Caldeira, K. M. 64  
 Calderon, S. N. 58, 104  
 Calderon, V. 97  
 Callaghan, R. C. 23, 24  
 Camenga, D. R. 62, 68  
 Campbell, Aimee 29, 87, 88  
 Campbell, Cynthia 4  
 Campbell, G. 14, 54, 70, 94  
 Campion, T. 69  
 Campollo, O. 84  
 Cannizzaro, D. 19  
 Cano, M. 23  
 Canterbury, M. 57  
 Canva, V. 81  
 Capaldi, D. 27  
 Capaldi, Deborah 7  
 Capatti, G. R. 89  
 Carbonaro, T. M. 75  
 Carise, D. 88  
 Carlezon, W. 12  
 Carliner, H. 3  
 Carlini, E. 78  
 Carlson, R. 19, 21  
 Carlton, S. 106  
 Carney, T. 21  
 Carpenedo, C. M. 20, 79, 88  
 Carpenter, M. J. 18  
 Carrico, Adam W. 17, 72  
 Carroll, K. M. 53, 58, 60, 84, 86, 99  
 Carroll, M. E. 8, 14, 52  
 Carroll, Marilyn E. 74  
 Carter, P. M. 20  
 Casas, M. 77  
 Case, T. 59  
 Cassidy, T. A. 58, 64, 100, 101
- Castaldelli-Maia, J. M. 78  
 Castillo, C. 58, 91  
 Castro, S. M. 85  
 Castro, Y. 23  
 Cavallo, D. A. 62, 68  
 Cepeda, A. 99  
 Cercone, Sarah A. 65, 67  
 Cerda, M. 23, 58, 64, 100  
 Cerulli, C. 20  
 Chaisson, C. 18  
 Chalmers, D. 94  
 Chalmers, S. 21  
 Chambers, J. E. 20, 88  
 Chan, C. 52  
 Chandler, Redonna K. 2  
 Chandra, M. 63  
 Chandra, S. 103  
 Chang, C. 25  
 Chang, K. 83  
 Chang, L. 59  
 Chauhan, K. 62  
 Chavez, K. 19  
 Chawarski, M. C. 76, 82, 86  
 Cheetham, S. 12  
 Chen, C. 23, 75, 78, 83  
 Chen, H. 76  
 Chen, K. 78  
 Chen, L. 104, 106  
 Chen, Li-Shiun 71  
 Chen, N. 94  
 Chen, W. 78  
 Chen, Xiangning 71  
 Chen, Y. 11  
 Cheng, D. M. 15, 17, 18, 22, 70, 88, 107  
 Chenoweth, Meghan 71  
 Chermack, S. 20, 21  
 Chesler, Elissa J. 108  
 Chhatre, S. 87, 101  
 Chilcoat, Howard 7, 100  
 Childress, Anna Rose 6, 97, 98, 99  
 Chisolm, M. S. 69, 84  
 Choi, H. 79  
 Chokron Garneau, H. 76  
 Choo, E. 19  
 Chooi, W. 86
- Chow, J. J. 10  
 Chrisphonte, M. 62  
 Chu, D. 99, 102  
 Chudzynski, J. 106  
 Chung, T. 76  
 Ciccarone, D. 101  
 Cicero, Ted 90  
 Claramunt, J. 96  
 Clark, H. Westley 28  
 Claus, E. D. 98  
 Clausen, Thomas 51  
 Clement, N. 97  
 Clingan, S. 14  
 Cochran, G. 82, 87  
 Coe, M. A. 15  
 Coffin, Phillip O. 2, 66  
 Cohen, A. 9  
 Cohen, M. 14, 54, 70, 94  
 Cohen, S. 81  
 Cohn, J. A. 17  
 Colby, S. 9, 56  
 Cole, M. 68  
 Coleman-Cowger, V. H. 84  
 Coleman, S. 107  
 Coley, H. 107  
 Collins, M. 8  
 Collombat, J. 10  
 Colucci, S. 54  
 Comer, Sandra D. 11, 21, 26, 76, 90  
 Comiran, E. 85  
 Comly, R. 102  
 Compton, Wilson 8  
 Cone, E. J. 18, 105  
 Connell, C. 62, 68  
 Conner, K. R. 91  
 Conniff, J. 86  
 Connor, J. 85  
 Constable, R. 53  
 Cook, C. 16  
 Cook, J. 93  
 Cook, M. 102  
 Cook, R. 16, 95  
 Cooper, C. 106  
 Cooper, Ziva D. 1, 99  
 Cope, L. M. 69, 97

## AUTHOR INDEX

- Copeland, A. L. 57  
 Copeland, Jan 4, 19, 22, 53, 95, 97  
 Copenhagen, M. 52  
 Copersino, M. L. 99  
 Coplan, Paul 7, 100  
 Coppe, B. C. 85  
 Cornelius, J. R. 76  
 Cornelius, M. 67  
 Cornelius, M. C. 70  
 Correa Fernández, V. 59  
 Corsi, K. F. 3, 23, 65  
 Coskunpinar, Ayca 110  
 Cotter, A. 27  
 Cottler, L. 20, 21, 53, 78, 79, 95, 101, 102  
 Cowan, Ronald 27, 28  
 Cox, N. 22  
 Coyle, J. 12  
 Craft, Rebecca 1  
 Crane, Natania A. 2, 27, 77  
 Cranford, J. A. 101  
 Cravatt, B. 71  
 Creek, K. E. 27  
 Crist, R. 52  
 Croff, R. 85  
 Crofton, E. J. 12  
 Crooks, P. A. 13  
 Crosby, R. 17  
 Crosier, B. S. 19, 68  
 Crothers, K. 16  
 Crowley, T. J. 97, 98  
 Cruz, Silvia L. 70  
 Cruz, V. 94  
 Crystal, S. 70, 100  
 Cubano, L. 16  
 Cuevas-Mota, J. 66  
 Culver, J. P. 13  
 Culverhouse, A. 9  
 Cummings, Brian 108  
 Cummings, K. 65  
 Cummins, E. D. 62  
 Cunningham, J. K. 24, 84  
 Cunningham, Kathryn A. 9, 10, 11, 12, 13, 14, 28, 90, 98  
 Cunningham, R. M. 20, 21, 79, 87  
 Curnyn, C. 17  
 Curran, M. 97  
 Cutler, A. 55  
 Czachowski, C. L. 9  
 Czoty, Paul W. 8, 69  
 D'Anna, L. 61  
 D'Onofrio, G. 82  
 Daar, E. 107  
 Daigre, C. 77  
 Daiter, J. 83  
 Dakwar, Elias 61, 66  
 Daley, D. 76  
 Dalwani, M. 97, 98  
 Daniel, T. O. 56  
 Daniulaityte, R. 19, 21  
 Darfler, K. 15, 16  
 Dargan, P. I. 58  
 Dart, Richard C. 8, 58, 74, 91  
 Darwish, M. 58  
 Das, M. 107  
 Dasgupta, Nabarun 7, 74  
 Daulouede, J. 10, 16  
 Davidson, P. J. 24, 87  
 Davidson, S. 19  
 Davidson, T. 106  
 Davis, D. R. 89  
 Davis, F. 85  
 Davis, J. 60  
 Davis, J. M. 3, 23  
 Davis, M. T. 88  
 Daws, R. 65  
 Day, N. 67  
 de Dios, M. 23  
 De Genna, Natacha 6, 67  
 De La Garza, II, R. 9, 27, 68, 103  
 De la Torre, R. 75  
 de Wit, H. 60  
 Dean, R. 15  
 Deaver, D. 94  
 Debrabant, R. 10, 91  
 DeBrule, D. S. 68  
 Decker, A. M. 13  
 Decker, S. 84  
 Dedert, Eric 7  
 Degenhardt, L. 14, 54, 63, 70, 81, 94, 101  
 del Rio, C. 80, 107  
 Delano, K. 67  
 Delcher, C. 101  
 DelDonno, S. 27  
 Delker, E. 19  
 Della Vedova, C. 15  
 Delucchi, K. 55  
 DeMicco, E. 80  
 Demirdjian, L. 100  
 Denis, C. M. 10, 16, 109  
 Dennis, L. 16  
 Dennis, Michael L. 29  
 Dental PBRN Collaborative Group, N. 57  
 DePoy, L. 106  
 Deren, S. 81  
 Derrick, J. L. 67  
 Des Jarlais, Don C. 72  
 Desrosiers, A. 86  
 DeVeugh-Geiss, A. 100  
 DeVito, E. E. 53, 60  
 DeVries, W. 104  
 Dewey, William L. 51  
 DeYoung, D. 60  
 Díaz-Mesa, E. 78  
 Dickerson, D. 106  
 Dickson, M. F. 18, 20  
 Dietrich, M. 28  
 Dietze, P. 103  
 Diggins, A. 102  
 DiGirolamo, G. 58, 82  
 DiLeone, R. J. 12  
 Dillon-Carter, O. 27  
 Dimova, R. 104  
 Dineley, K. 13, 106  
 Ding, Z. 106  
 Dixon, A. E. 55  
 Djomboue, P. 81  
 Dobrer, S. 17  
 Dodd, D. 58  
 Doe-Simkins, M. 101  
 Dolan, S. 94  
 Dolezal, B. 106  
 Domingo-Salvany, A. 58  
 Dominguez, B. 77  
 Donahue, R. 12

## AUTHOR INDEX

- Donny, E. 8, 77  
 Donohue, J. M. 82  
 Doran, A. 25  
 Doran, N. 86  
 Douaihy, A. 76  
 Dougen, B. 8  
 Douglas, S. B. 19, 79  
 Dowd, E. D. 99  
 Dowdle, L. T. 89, 104  
 Doyle, M. 107  
 Drainoni, Mari-Lynn 6, 26, 80  
 Dreifuss, J. A. 58  
 Drobos, D. J. 52, 77  
 Dry, M. 15  
 Du, H. C. 12  
 Duan, R. 80  
 Dubernet, J. 109  
 Duburque, C. 81  
 Dugosh, K. L. 20, 79, 88, 102, 107  
 Duke, A. N. 93  
 Duncan, A. 87  
 Dunn-Sims, E. 25  
 Dunn, E. 3  
 Dunn, Kelly E. 73, 94  
 Dunn, T. 13  
 Dunne, E. M. 102  
 Duperrouzel, J. C. 63  
 Dwoskin, L. P. 9, 13, 26  
  
 Eans, S. O. 15  
 Eaton, N. R. 86, 91  
 Echevarria, M. N. 89  
 Eddens, K. 17  
 Edelman, E. 70  
 Edelman, E. J. 16, 18, 100, 107  
 Edwards, Emmeline 66  
 Edwards, H. 60  
 Edwards, R. R. 15, 70  
 Egido, A. 77  
 Ehrman, R. 98  
 Eibl, J. K. 83  
 Eiden, R. D. 67  
 Eisenhofer, J. 68  
 Eissenberg, T. 55, 68  
 Elayi, C. 3, 82, 96  
 Elayi, S. 96  
  
 Elkoussi, A. A. 93  
 Elliott, E. 67  
 Elliott, L. 22, 58  
 Ellison, J. 26  
 Elston, R. C. 52  
 Emu, B. 107  
 Emurian, C. E. 98  
 Epstein-Ngo, Q. 20, 80, 101  
 Epstein, D. 3, 18, 26, 102  
 Epstein, L. H. 56  
 Erlyana, E. 65  
 Evans-Polce, R. J. 85  
 Evans, D. E. 52  
 Evans, Elizabeth 5, 53, 81, 83, 107  
 Evans, J. L. 87  
 Evelyn, M. 62  
 Evins, A. 57, 97  
 Ewald, A. 71  
 Ewin, S. 9  
  
 Fairman, B. J. 64  
 Fakunle, D. O. 20, 65  
 Falb, V. 103  
 Faller, S. 24  
 Falster, M. 81  
 Fan, X. 12  
 Fang, L. 59  
 Fang, S. 23  
 Fant, R. V. 105  
 Farber, E. 80  
 Farid Araki, K. 94  
 Farmer, S. L. 14, 55  
 Farre, M. 75, 91  
 Fatseas, M. 10, 55, 91, 102, 109  
 Faure, E. 82  
 Favor, K. 88  
 Feaster, D. F. 80, 107  
 Feaster, D. J. 85, 103  
 Feeney, G. 85  
 Feinstein, M. 11  
 Feldman, J. 26  
 Feldstein Ewing, Sarah 91  
 Fergusson, D. 63  
 Fernández-Artamendi, S. 78  
 Fernández-Hermida, J. 109  
 Fernandez, A. 96  
  
 Ferreira e Ferreira, E. 10  
 Ferreira-Pinto, J. 53  
 Ferronato, P. B. 62, 78  
 Fertuck, E. 76  
 Festinger, David S. 20, 59, 102, 107  
 Fidalgo, T. M. 78, 89  
 Fiellin, D. A. 16, 70, 82, 83, 100  
 Filbey, F. 96  
 Filbey, Francesca 91  
 Fillingim, R. B. 57  
 Fink, D. S. 58, 84  
 Finley, E. 89  
 Finnegan, Loretta 1, 69  
 Fiorentin, T. R. 85  
 Fischer, B. 96  
 Fischer, Gabriele 24, 51  
 Fischman, A. J. 13  
 Fisher, D. G. 14, 60, 61, 65, 103  
 Fishman, M. J. 79  
 Fitzmaurice, G. 58  
 Fitzsimons, H. 69, 84  
 Flack, D. 61  
 Flavel, S. C. 60  
 Flax, S. M. 11, 95  
 Fleming, A. B. 54  
 Flentje, A. 54, 104  
 Fletcher, J. B. 19, 61  
 Flores, David V. 3, 4  
 Fogel, J. S. 56, 95  
 Fokina, V. M. 54, 55  
 Follett, M. E. 93  
 Fong, C. 26  
 Fonseca, F. 58, 75, 91  
 Forcehimes, A. A. 59, 88  
 Forman, L. 17  
 Forray, A. 84  
 Forster, G. L. 28  
 Forster, M. J. 94  
 Foster, D. W. 84  
 Fox, H. C. 53  
 Fox, R. G. 9, 11, 12, 28, 106  
 Franck, C. T. 13, 14, 88  
 Frankforter, T. 84  
 Franklin, T. 97, 98  
 Freeman, K. 11, 93, 106, 109



## AUTHOR INDEX

- Freiberg, M. 107  
 French, H. T. 52  
 Friedman, E. 8  
 Friedman, K. 54  
 Friedman, S. R. 80, 81  
 Friedmann, P. D. 26, 105  
 Frimpong, J. A. 80  
 Frisell, F. 82  
 Froeliger, B. 89, 99  
 Fronk, G. 25  
 Funada, M. 75, 95  
 Furlan, A. 94  
 Furnari, M. A. 3, 26, 102  
 Furr-Holden, C. M. 64, 77  
 Fuster, D. 82, 85  
  
 Gaalema, Diann 55, 73  
 Gabriel, L. 27, 77  
 Gaines, T. 23  
 Gaither, J. R. 6, 16, 70, 100  
 Galea, S. 3, 58, 64, 65  
 Galván, G. 78  
 Galvez, R. 26  
 Gamaledin, I. 96  
 Ganno, M. L. 15, 107  
 Gao, J. 13  
 Gao, S. 69  
 Garcia-Keller, C. 71  
 García-Portilla, P. 78  
 Garcia-Rodriguez, O. 56  
 Garcia-Romeu, A. P. 56  
 Garcia, A. 89  
 Garcia, M. 84  
 Garcia, R. 27  
 Gardner, E. 22  
 Garey, L. 56  
 Garfein, R. 66  
 Garg, P. 64  
 Garina, D. 24  
 Garnick, D. W. 23  
 Garrido, M. 78, 96  
 Garza, J. 59  
 Gasior, M. 58  
 Gaskin, S. 80  
 Gatch, M. B. 94  
 Gatley, J. 23  
  
 Gauthier, J. M. 12  
 Gawrysiak, M. J. 98  
 Gebregziabher, M. 109  
 Gelberg, L. 21, 22  
 Gellad, W. F. 82  
 Gelot, B. 109  
 Gentry, W. B. 54  
 Geoffroy, P. 89, 104  
 George, M. 57  
 Gereghty, S. 21  
 German, J. 88  
 German, N. A. 13  
 Gerra, G. 59  
 Ghitza, U. 26  
 Ghozland, S. 59  
 Gibert, C. 16  
 Gibson, K. 9  
 Gifford, A. 17  
 Gilbert, E. R. 97  
 Gilbertson, S. 11, 12  
 Gill, K. E. 3, 96  
 Gillette, B. 59  
 Gilman, J. 97  
 Gilmour, B. P. 13  
 Ginsburg, B. C. 89  
 Gipson, Cassandra D. 71  
 Giraldo, L. 58  
 Gitchell, J. G. 105  
 Glanz, J. 22  
 Glaser, P. 104  
 Glasner-Edwards, Suzette 30, 76,  
 77  
 Glass, A. 55, 95  
 Gnatienco, N. 17, 18, 107  
 Goddard, K. 22  
 Goldberg, S. R. 109  
 Goldenson, N. 52, 60  
 Goldman, M. 98  
 Goldschmidt, L. 67  
 Goldsmith, J. 52  
 Golroo, F. 19  
 Golub, A. 22, 58  
 Gomez Luna, S. E. 62  
 Gomez, A. M. 27  
 Gonzales-Castaneda, R. 19, 79,  
 106  
  
 Gonzalez Moreno-Zuniga, P. 66  
 Gonzalez-Espinosa, C. 70  
 Gonzalez, B. 86  
 Gonzalez, G. 58, 82  
 Gonzalez, I. 63  
 Gonzalez, J. 17, 77  
 González, M. 96  
 Gonzalez, R. 16, 63  
 Gooden, L. 107  
 Goodwin, R. 65, 78  
 Gordan, V. V. 57  
 Gordon, A. J. 16, 82, 100  
 Gordon, K. 70  
 Gordon, K. S. 16, 100  
 Gordon, M. S. 26  
 Gore-Langton, J. K. 11  
 Gosden, J. 15  
 Gottås, A. 54  
 Gould, T. 27, 62  
 Goulet, J. 70  
 Gourley, S. 106  
 Gowins, J. 27  
 Grabinski, M. 21  
 Grabowski, J. 55, 95  
 Graham, D. P. 68  
 Grana Mayne, R. 19  
 Grasing, K. 27  
 Grasso, S. 12, 59  
 Grau-López, L. 77  
 Gray, K. M. 18, 82  
 Grayson, Peter 108  
 Graziano, P. 63  
 Grebely, J. 81  
 Green, C. 13, 95  
 Green, Carla 7  
 Green, J. L. 58  
 Green, T. 12, 64, 101  
 Green, T. A. 12  
 Green, Traci C. 2  
 Greenfield, Shelly F. 29, 77  
 Greenwald, M. K. 13, 14, 16, 17,  
 21, 95  
 Gregg, Ryan A. 108  
 Grella, C. E. 87  
 Grewen, K. M. 84  
 Griffin, M. L. 58

## AUTHOR INDEX

- Griffiths, Roland R. 1, 28, 56, 57, 75
- Gringer Richards, J. 105
- Groman, Stephanie M. 106
- Grossman, E. 18
- Grov, C. 102
- Gruber, Staci A. 90
- Gruber, V. 56
- Gryczynski, J. 78, 81, 83, 96, 101
- Guarino, H. 81
- Gubner, Noah R. 6, 68
- Guillen, A. 19
- Guillot, C. 52, 63
- Guimarães, L. S. 52, 62
- Guise, J. 61
- Gulley, J. M. 26, 62
- Gunter, B. W. 93
- Gurley, B. 54
- Gutierrez, K. M. 62, 68
- Guttmanova, Katarina 73
- Guydish, J. 24, 56, 68, 81, 104
- Guzman, A. 84
- Guzman, M. 62
- Ha, D. 16
- Haberfield, M. 60
- Haddox, J. David 74
- Hagemeier, N. E. 57
- Hager, N. 97
- Hagmann, C. 23
- Hahn, J. A. 87
- Haile, C. N. 9, 103
- Hakansson, A. 64
- Halkitis, P. N. 80
- Hall, J. 101
- Hall, W. 14, 54, 70, 101
- Hallam, M. 15
- Halpern, S. 24, 86
- Hamilton, J. 3
- Hammond, A. S. 18
- Hamon, S. C. 27
- Hancock, L. 22
- Hand, D. J. 102
- Haney, Margaret 11, 25, 96, 99
- Hankins, G. 54, 55
- Hanlon, Colleen A. 57, 74, 89, 104
- Hansen, H. 23
- Hao, W. 76
- Hao, Y. 13
- Harbonnier, J. 81
- Hardan-Khalil, K. 61
- Hardee, Jillian 69, 97
- Harding, M. H. 27
- Hargrave, S. 106
- Harikrishnan, V. 100
- Harkin, P. 81
- Harman, J. 16
- Harper, D. 75
- Harrell, P. T. 52
- Harris, D. L. 13
- Harris, J. 15
- Harris, S. 54
- Harrod, S. B. 27, 107
- Hartley, R. M. 9, 11
- Hartwell, E. E. 8, 76
- Hartwell, K. 57
- Harvanko, A. M. 56, 95
- Hasin, Deborah S. 19, 24, 64, 65, 73, 80, 84, 86, 91
- Hasson, A. 3, 59, 61, 76, 106
- Hatch-Maillette, Mary 29
- Hatsukami, D. 8, 77
- Havens, J. R. 20, 59, 100
- Hawk, K. 82
- Hayashi, K. 17, 24
- Haynes, L. 8
- Hays, L. 104
- He, Q. 60
- Heads, A. M. 3
- Heal, D. J. 12, 15
- Heath, A. C. 77
- Heeren, T. 16, 107
- Heil, Sarah H. 6, 67, 69, 82, 83, 84, 102
- Heinz, A. 97
- Heinzerling, Keith G. 60, 69, 100
- Heitzeg, M. 69, 97
- Hellem, T. 98
- Hendricks, Peter S. 28
- Hendrickson, H. 54
- Henningfield, Jack 18, 71, 105
- Herbst, E. 91
- Hernandez-Mora, F. 84
- Hernandez, M. 19, 79
- Hernandez, S. 103
- Hernout, B. 81
- Herrera, J. 13
- Herrmann, Evan S. 8, 72
- Hertz, S. H. 104
- Hidaka, Y. 75
- Hien, Denise 7
- Higgins, Stephen T. 55, 66, 67, 82, 84, 89
- Hiler, M. 68
- Hillhouse, M. P. 3, 52, 59, 60, 61, 76, 106
- Hinshaw, S. 53
- Hirata, Y. 104
- Hironaka, N. 110
- Hlaing, W. 64
- Ho, A. 27
- Hodgkin, D. 23, 88
- Hoekstra, T. 65
- Hoffer, L. 21
- Hoffman, W. 16
- Hoffmann, O. M. 82
- Hofford, R. S. 2, 52
- Hohmann, Andrea G. 105
- Holliday, E. 27, 62
- Holst, M. 103
- Holtz, N. A. 110
- Homish, D. 65
- Homish, G. G. 65, 67
- Hommel, J. D. 106
- Hooker, J. M. 15, 109
- Hopfer, C. 79
- Hopkins, S. S. 94
- Hopyan, T. 104
- Horgan, C. M. 23, 88
- Horton, D. B. 25
- Horwood, L. J. 63
- Hosmer, D. 61
- Howard, H. G. 83
- Howard, J. 22
- Howell, D. 55
- Hruska, B. 55, 56, 80, 82
- Hser, Yih-Ing 4, 5, 53, 60, 81, 83
- Hsu, J. 18, 75

## AUTHOR INDEX

- Hsu, T. 94  
 Hu, L. 61  
 Hu, M. 65, 86, 87, 88, 91  
 Hu, R. 58  
 Huang, D. Y. 53, 83  
 Huang, H. 78  
 Huang, L. 16  
 Hudson, J. 97  
 Huedo-Medina, T. B. 52  
 Huestis, M. A. 96  
 Hughes, J. 56  
 Hughes, S. M. 63  
 Huh, J. 99  
 Huhn, A. S. 15  
 Humphreys, M. 103  
 Hunkele, K. 86  
 Hunt, J. 104  
 Hunt, Priscilla 73  
 Hurd, Yasmin L. 25  
 Hurmic, H. 91  
 Huskinson, Sally L. 106, 109  
 Hutchinson, D. 63, 67, 109  
 Hynes, C. 82  
  
 Ibragimov, U. 103  
 Idrisov, B. 18  
 Ignacio, R. 87  
 Iguchi, Martin Y. 51, 73  
 Iles, B. 77  
 Ilgen, Mark A. 64, 73, 87, 103  
 Iwanicki, J. L. 6, 8  
 Izenwasser, Sari 90  
  
 Jaapar, S. 86  
 Jacobs, S. 67  
 Jacobson, A. 25  
 Jacobson, J. 107  
 Jacques, A. B. 85  
 Jaffe, J. H. 81, 83, 101  
 Jagannathan, K. 97, 98  
 Jagsch, R. 24  
 Jalah, R. 25  
 Jamil, H. 100  
 Jamison, R. N. 70  
 Janes, A. 55, 97, 99  
 Janganati, V. 13  
  
 Jansson, L. 69  
 Janulis, P. 54  
 Jayadevappa, R. 87, 101  
 Jayaram-Lindstrom, N. 53  
 Jefferson, A. 101  
 Jenab, S. 52  
 Jenkins, J. 60  
 Jensen, E. 97  
 Jensen, M. 78  
 Jentsch, J. David 74, 108  
 Jeon, S. 26  
 Jeong, E. 98  
 Jessell, L. 81  
 Jiang, H. 60  
 Jing, L. 9  
 Jobs, M. L. 3, 18, 26  
 Joel, T. 97  
 Johnson, A. 104  
 Johnson, E. 15  
 Johnson, J. A. 21  
 Johnson, Matthew W. 6, 28, 56,  
 57, 68, 75, 88  
 Johnson, P. S. 68, 88  
 Johnson, R. M. 63, 64  
 Johnston, L. A. 26  
 Jones, H. E. 17, 69, 84, 87  
 Jones, J. T. 84  
 Jones, Jermaine D. 21, 26, 76, 90  
 Jones, Y. 80  
 Jordan, C. J. 26  
 Jordan, Chloe J. 26  
 Jorga, A. 104  
 Joseph, J. E. 98  
 Justice, A. 16, 70, 83  
 Justinova, Z. 109  
 Jutras-Aswad, Didier 25  
  
 Kadakia, A. 100  
 Kahler, C. W. 14, 60, 95  
 Kalivas, P. W. 71  
 Kam, J. A. 63  
 Kampman, K. M. 3, 98  
 Kanayama, G. 97  
 Kang, S. 26  
 Kangiser, M. 9  
 Kantak, K. M. 12, 26  
  
 Kapadia, F. 80  
 Kaphalia, B. 13  
 Kaprio, J. 57  
 Kapur, B. 67  
 Karinen, R. 54  
 Karno, M. 77  
 Kasinather, V. B. 86  
 Kasper, J. M. 106  
 Kassel, M. T. 77  
 Kassem, L. 62  
 Kate, N. 104  
 Katz, E. C. 23, 60  
 Kaufman, M. 97  
 Kay-Lambkin, Frances 30  
 Kayser, A. 14  
 Kearns, D. 106  
 Kelly, S. M. 78, 81  
 Kelly, T. H. 56, 95, 98  
 Kelly, U. 21  
 Kelsh, D. 94  
 Kempf, M. C. 80  
 Kendler, K. S. 62  
 Kennedy, A. 18  
 Kerns, R. 70, 100  
 Kerr, D. C. 27  
 Kerr, T. 17, 24  
 Kerridge, B. T. 80  
 Kerrigan, A. 97  
 Kershaw, S. 15  
 Kervran, C. 91  
 Kessler, F. H. P. 10, 24, 52, 61, 62,  
 85, 86  
 Ketcherside, A. 96  
 Keyes, K. M. 3, 24, 58, 64, 84  
 Keyser-Marcus, L. A. 14, 101  
 Khan, Maria R. 69, 72, 101, 107  
 Khan, S. R. 53  
 Kidorf, M. S. 76  
 Kilgalen, B. 55  
 Killeen, Therese 8, 29  
 Kiluk, B. D. 60, 84  
 Kim, G. 19  
 Kim, J. 28  
 Kim, J. E. 65  
 Kim, J. H. 23  
 Kim, J. K. 12

## AUTHOR INDEX

- Kim, S. J. 18  
 Kim, T. W. 88  
 King, H. E. 11  
 King, V. L. 76  
 Kinlock, T. W. 26, 105  
 Kinnunen, T. H. 57  
 Kirby, K. C. 20, 59, 79, 80, 88  
 Kirby, S. 62  
 Kiriazova, T. K. 17  
 Kirisci, L. 53  
 Kirk, A. 78  
 Kirkpatrick, M. 52, 60, 63  
 Kirtadze, I. 17, 87, 103  
 Kirzhanova, V. 87  
 Kivell, Bronwyn M. 9, 71  
 Klambatsen, A. 52  
 Klein, A. B. 57  
 Klein, M. 58, 93, 104  
 Klein, Michael 74  
 Klemperer, E. M. 56  
 Klimas, J. 85  
 Kline, D. 21  
 Klinedinst, M. 75  
 Knight, J. 62  
 Knighton, J. 100  
 Knopf, S. P. 53  
 Knopik, V. 95  
 Knudsen, H. K. 20, 24  
 Koblan, K. S. 94  
 Koenen, K. C. 3  
 Koester, S. 22  
 Koffarnus, M. N. 13, 14, 88  
 Kohut, S. 12  
 Kollins, S. H. 23  
 Kondo, D. 98  
 Kong, G. 62, 68  
 Koon, K. 3  
 Koopmeiners, J. 77  
 Kopecky, E. A. 54  
 Koppelman, E. 26  
 Korcha, R. 20  
 Koren, G. 67  
 Korhonen, T. 57  
 Kornegay, C. 89  
 Korte, J. E. 8  
 Korthuis, P. T. 16  
 Koshkina, E. 87  
 Kosten, T. 9, 14, 27, 61, 98  
 Koszowski, B. 84  
 Koutsenok, I. 59  
 Kowalczyk, W. J. 3, 26, 102  
 Kral, A. 3, 65, 99, 102  
 Krebs, C. 71  
 Krebs, E. 81  
 Kreek, M. J. 27, 70, 107  
 Krishnan-Sarin, S. 62, 68  
 Kritz, S. 18, 104  
 Kromrey, Sarah A. 8  
 Krupitsky, E. 17, 18, 76, 87, 107  
 Kulisevsky, J. 97  
 Kulkarni, R. 12  
 Kumar, S. 18  
 Kurdziel, G. 23  
 Kurti, A. N. 89  
 Kurtz, S. P. 53, 57, 100  
 Kutlu, M. G. 27  
 Kutz, S. 75  
 Kyburz, B. A. 59  
 Kypri, K. 109  
 Lacadie, C. 53  
 LaConte, S. 14  
 Lacy, R. 11, 25  
 Laezza, F. 12  
 Lagzdins, D. 96  
 Lam, C. 59  
 Lamp, A. 55, 65  
 Landino, S. 12  
 Landovitz, R. J. 61  
 Lane, S. D. 13, 14, 95, 98  
 Langenecker, S. A. 27, 77  
 Langleben, D. 98, 99  
 Lanier, Ryan K. 9  
 Lankenau, Stephen 73  
 Larance, B. 14, 54, 70, 94  
 Larney, S. 81  
 Larson, M. 18  
 Lasher, B. 91  
 Lasopa, S. O. 79, 95  
 Latimer, W. W. 102  
 Latypov, A. 103  
 Lauby, J. 20, 88  
 Laudet, A. B. 88  
 Lawental, M. 53  
 Layton, M. 55, 65  
 Le Foll, B. 96  
 Le Lait, M. C. 8, 91  
 Le Pelley, M. 95  
 Le Truong, G. 16  
 Le, G. M. 15, 16  
 Le, K. 21  
 Le, T. 24, 56, 68  
 Lederhos, C. 55, 65  
 Ledgerwood, D. M. 17, 85  
 Lee, D. 101, 106  
 Lee, D. C. 19, 68  
 Lee, J. D. 18, 26, 105  
 Lee, S. 75  
 Leming, M. 84  
 Lemons III, A. 60  
 Leo, H. 56  
 Leong, S. 91  
 Lerner, A. 104  
 Lertch, E. 81  
 Leslie, K. 27  
 Leukefeld, C. G. 18, 20, 59, 100  
 Leventhal, Adam 52, 60, 63, 66  
 Levesque, A. 88  
 Levi-Minzi, Maria A. 72, 100  
 Levin, F. R. 55, 95  
 Levine, J. A. 81  
 Levy-Cooperman, N. 94  
 Lewis, D. 83  
 Lewis, M. 94  
 Leyro, T. M. 85  
 Lhommeau, N. 102  
 Li, D. 12  
 Li, F. 25  
 Li, J. 9, 13  
 Li, L. 53, 81, 83, 107  
 Li, P. 12  
 Li, S. 12, 99  
 Li, W. I. 54  
 Li, X. 57  
 Li, Z. 98  
 Liao, Y. 75  
 Lichtman, Aron 71, 105  
 Liebschutz, J. M. 15

## AUTHOR INDEX

- Lien, Y. 23  
 Lile, Joshua A. 1, 56, 60, 61, 95, 98, 104  
 Lim, J. 79  
 Lima, V. D. 107  
 Limberger, R. P. 85  
 Lin, H. 52  
 Lin, L. A. 79  
 Lin, M. 18, 104  
 Lin, S. 53  
 Lindblad, R. 59, 61  
 Lindstrom Johnson, S. 63  
 Ling, W. 3, 52, 57, 59, 60, 61, 76  
 Lintzeris, N. 14, 54, 70, 94, 101  
 Lioznov, D. 18, 107  
 Lira, M. C. 15, 70  
 Lisdahl, Krista M. 90, 91, 97  
 Lisowski, R. 16  
 Lister, J. J. 13, 14, 85  
 Liu, H. 67  
 Liu, J. 67  
 Liu, L. 24, 83, 107  
 Liu, W. 67  
 Liu, Y. 12  
 Livingston, N. 54  
 Ljungberg, T. 82  
 Lloyd-Travaglini, C. 88  
 Lo-Ciganic, W. 82  
 Loebel, A. 94  
 Lofwall, Michelle R. 2, 3, 15, 24, 82, 96, 97, 100  
 London, E. 85  
 Long, Ed 51  
 Lookatch, S. J. 23, 60  
 López-Núñez, C. 56, 109  
 Lopez-Quintero, C. 99  
 Lopez, A. A. 68, 84  
 Lopez, Marsha 73  
 Lopez, S. 16  
 Lorkiewicz, S. A. 16  
 Lorvick, J. 64  
 Louie, B. 18  
 Louie, D. 102  
 Lowen, S. B. 99  
 Loza, O. 53  
 Lu, Q. 52  
 Lu, T. 83  
 Luba, R. 21  
 Lucas, G. 107  
 Lucidarme, D. 81  
 Luis, T. 76  
 Lukas, S. E. 14, 99, 109  
 Lum, P. J. 87  
 Lumley, M. 100  
 Lundahl, L. H. 13, 14, 16, 17, 95  
 Lundberg, K. 98  
 Lung, R. 24  
 Lunnan, J. 103  
 Lunze, K. 17, 18  
 Luo, S. 52  
 Lynch, K. G. 3  
 Lynch, L. J. 51  
 Lynch, Minda 90  
 Lyons, M. 83  
 Lyvers, M. 85  
 M. Yasin, M. 86  
 Ma, L. 14, 98  
 Ma, Y. 58  
 MacKillop, J. 14, 95  
 Macmillan, D. 21  
 Mactutus, C. F. 107  
 Madera, G. 21  
 Madras, Bertha K. 1, 6, 13, 73  
 Maes, H. 62  
 Mahoney, E. 20  
 Mahoney, J. J. 9, 103  
 Mahony, A. 55, 95  
 Mai Thi Hoai, S. 16  
 Maisto, S. A. 89  
 Majumder, I. 15  
 Makanjuola, T. 68  
 Makhija, S. K. 57  
 Maki, P. 16  
 Makriyannis, Alexandros 105  
 Malamut, R. 58  
 Malcolm, R. J. 96  
 Maldonado-Molina, M. 101  
 Malek, A. 8  
 Malison, R. 53  
 Mamey, M. 105  
 Mancino, M. J. 54, 61  
 Mandeville, J. B. 15  
 Mandler, R. 80, 107  
 Mann, R. 96  
 Mannelli, P. 82  
 Manubay, J. M. 21, 26  
 Mao, J. 70  
 Maple, K. E. 97  
 Mariani, J. J. 55, 95  
 Mark, K. 84  
 Marks, K. R. 60, 61, 104  
 Marquez, K. 98  
 Marsch, L. A. 18, 21, 81, 89  
 Marsh, D. C. 83, 94  
 Marshall, B. D. 16, 58, 100  
 Martial, L. C. 96  
 Martin, C. A. 56, 98  
 Martin, E. 16, 27, 110  
 Martin, R. A. 9, 56  
 Martínez-Horta, S. 97  
 Martinez-Loredo, V. 109  
 Martinez-Luna, N. 77  
 Martinez-Raga, J. 64  
 Martinez-Sanvisens, D. 91  
 Martinez, A. 104  
 Martínez, D. 96  
 Martinez, E. M. 58  
 Martínez, M. 96  
 Martinez, V. 68  
 Martino, S. 109  
 Martins, S. S. 3, 19, 21, 23, 58, 64, 78, 84, 100  
 Martz, M. E. 97  
 Marusich, Julie A. 1  
 Mashhoon, Y. 14  
 Masson, Carmen L. 73, 81, 104  
 Matalon, E. 97  
 Mateu-Gelabert, Pedro 72, 81  
 Mateus, J. 75  
 Matheson, T. 80  
 Mattick, R. P. 54, 63, 67, 70, 109  
 Matusiewicz, A. K. 103  
 Matusow, H. 26, 81  
 Matyas, G. R. 25  
 Mauro, P. M. 77  
 Maxwell, J. C. 94  
 May, J. 61



## AUTHOR INDEX

- McAllister, C. E. 9  
 McBride, N. 109  
 McCabe, S. E. 80, 101  
 McCann, D. 87  
 McCarberg, William 74  
 McCarty, D. 23, 85  
 McCauley, J. L. 57  
 McClernon, J. 23, 99  
 McClure, E. A. 18  
 McConnell, J. 23  
 McCormack, C. 67  
 McCue, D. L. 106  
 McCutcheon, V. V. 77  
 McDermott, K. 58  
 McDonald, J. 91  
 McDonell, M. G. 25  
 McGaugh, J. 61  
 McGear, D. 89  
 McGear, J. 60, 95  
 McGinnis, K. 83  
 McGorray, S. 69, 101, 107  
 McGrath, E. 13  
 McHugh, Kate 58, 70  
 McKee, S. A. 4, 82  
 McKeown, A. 19  
 McLaughlin, J. P. 15, 107  
 McMahan, D. 107  
 McMahan, M. A. 97  
 McNaughton, E. C. 100  
 McPherson, Sterling 5, 25, 55, 65, 105  
 McRae-Clark, A. 53, 82  
 McRae, E. M. 91  
 McWilliams, S. K. 59, 95, 97, 98  
 Meacham, M. C. 66  
 Mead, A. N. 25  
 Medina-Mora, M. E. 86  
 Medvin, R. B. 88  
 Melbostad, H. S. 83  
 Melero-Fuentes, D. 19, 20  
 Meli, S. 22  
 Mello, M. 19  
 Meltzer, P. C. 13  
 Mendoza, N. 79  
 Mendoza, S. 23  
 Mennis, J. 87  
 Menzaghi, F. 94  
 Mericle, A. 20  
 Mermelstein, R. J. 27, 77  
 Merrick, E. L. 23  
 Messiah, S. 64  
 Mete, D. 102  
 Metrik, J. 14, 77, 95, 96  
 Metsch, L. 107  
 Metsch, L. R. 80, 103  
 Metz, V. 21, 26  
 Metzger, D. 16, 20, 87, 88, 101  
 Meyer, A. C. 55, 56, 80, 82, 87  
 Meyer, R. E. 15  
 Meyers, J. L. 3  
 Meyers, K. K. 77, 79, 80  
 Meyers, R. J. 59  
 Mickey, B. 27  
 Miech, R. 26  
 Miech, Richard 6, 26  
 Mikulich-Gilbertson, Susan K. 5, 59, 79, 95, 97, 98  
 Miliwojevic, V. 53  
 Miller, G. M. 51  
 Miller, J. 71  
 Miller, M. 96  
 Miller, S. 70  
 Miller, T. G. 59  
 Miller, W. 106  
 Milloy, M. 24  
 Milosevic, A. 85  
 Min, J. 53, 81, 83, 107  
 Mitchell, J. 14  
 Mitchell, J. T. 23  
 Mitchell, J. W. 85  
 Mitchell, M. R. 53  
 Mitchell, P. 26  
 Mitchell, S. G. 78, 81, 83, 96, 101  
 Miyata, H. 110  
 Mizrachi, E. 15  
 Moeller, F. G. 2, 11, 14, 98, 101  
 Mogali, S. 21, 26  
 Mohammed, A. M. 65  
 Mohr, B. 88  
 Mojtabai, R. 77  
 Molina, L. 70  
 Monge, Z. A. 98  
 Monico, L. 81, 83  
 Montaner, J. 17, 107  
 Montgomery, L. 99  
 Monti, P. M. 9, 56  
 Moody, C. P. 104  
 Moody, D. 55  
 Moody, L. 3  
 Moody, R. L. 102  
 Mooney, L. 3, 59, 61, 76, 106  
 Moore, S. 69  
 Moore, S. K. 21, 89  
 Moore, T. 23, 60  
 Moran-Santa Maria, M. 53, 57  
 Morani, A. 9  
 Morean, M. E. 62, 68  
 Morie, K. P. 86  
 Mørland, J. G. 54  
 Morse, D. 20  
 Moryl, N. 94  
 Moser, L. 24  
 Moshier, S. 85  
 Moukha-Chafiq, O. 13  
 Moura, H. F. 62  
 Moyers, T. 88  
 Mueller, S. 22  
 Muench, J. 85  
 Muga, R. 82, 85  
 Mugavero, M. 80  
 Müller, D. 52  
 Mumford, E. 67  
 Munguia, A. 84  
 Murawski, M. M. 57  
 Murota, N. 110  
 Murphy, S. M. 25, 65  
 Murphy, Sean M. 5  
 Murugan, V. 53  
 Musselman, T. G. 102  
 Myers, B. 21, 89  
 Nader, M. A. 8  
 Nagel, C. 27  
 Nahhas, R. W. 19, 21  
 Najman, J. 67, 109  
 Nakamura, A. 15  
 Nakayama, K. 110  
 Nambiar, D. 103

## AUTHOR INDEX

- Namjoshi, O. A. 93  
 Nanovskaya, T. 54, 55, 79  
 Napier, C. 12, 110  
 Narayana, P. A. 13, 14, 98  
 Narvaez, K. 16  
 Naselaris, T. 89  
 Natera, G. 21, 22  
 Naylor, J. 109  
 Neelakantan, H. 12, 14  
 Negi, N. 99  
 Negus, S. S. 104  
 Neisewander, J. L. 27  
 Nelson, E. C. 77  
 Nelson, M. 103  
 Nemoto, T. 20  
 Nenov, M. N. 12  
 Neumann, M. 105  
 Newman, A. 12  
 Newton, T. F. 9, 27, 103  
 Nguyen, A. 88  
 Nguyen, H. 15, 16  
 Nguyen, P. 17, 24  
 Nguyen, S. 16  
 Nich, C. 60, 86  
 Nickell, J. 13  
 Nielsen, D. A. 27  
 Nielsen, E. M. 27  
 Nielsen, S. 14, 54, 61, 70, 94, 101  
 Niikura, K. 70  
 Nijhawan, A. 107  
 Nikolova, T. 94  
 Noble, E. P. 85  
 Nolan, S. 107  
 Noorani, T. 56  
 Nosyk, B. 53, 81, 83, 107  
 Notzon, D. 95  
 Novak, S. P. 64, 65  
 Nucero, P. A. 27  
 Nunes, E. V. 23, 26, 52, 87, 88, 105  
 Nuzum, C. 19  
 Nuzzo, P. A. 3, 15, 82, 96, 97  
 Nyberg, Fred 51  
  
 O'Brien, C. P. 16, 26, 94, 98, 99, 105  
 O'Connor, M. 54  
 O'Connor, P. 82  
 O'Grady, C. L. 100  
 O'Grady, K. E. 17, 64, 78, 81, 83, 84, 96, 101  
 O'Malley, P. 26  
 O'Neill, K. 94  
 Oberleitner, L. 4  
 Ochalek, T. A. 55, 80, 82  
 Oesterle, Sabrina 30  
 Ogawa, L. M. 51  
 Øiestad, E. L. 54  
 Ojeda, L. 23  
 Okafor, C. 16, 95  
 Olive, M. F. 27  
 Oliver, C. 62  
 Oliveto, A. 54, 61  
 Olsen, Y. 83  
 Olsson, C. 63, 67  
 Oluwoye, O. 99  
 Ompad, D. C. 103  
 Oncken, C. 54, 55  
 Ondersma, S. 96  
 Ornell, F. 61  
 Orozco, R. 86  
 Osei, K. 55  
 Oser, C. B. 17, 18, 20, 59  
 Oslin, D. W. 91  
 Otiashvili, D. 17, 87, 103  
 Otiniano Verissimo, A. 87  
 Otto, M. W. 85  
 Owens, P. 82  
 Owens, R. 71  
 Oyama, M. 59  
  
 Pacek, L. R. 64, 68, 77  
 Pachado, M. P. 24, 86  
 Pack, R. P. 57  
 Padowski, J. 55  
 Page, K. 87  
 Pagnussat, E. 62  
 Palamar, J. J. 103  
 Palatkin, V. 76  
 Palfai, T. 22, 88  
 Palma, A. 17  
 Pan, J. 96  
 Pan, Y. 85, 103, 107  
  
 Pang, R. 52, 63  
 Pantaloni, M. 82  
 Papaseit, E. 75  
 Paris, J. J. 107  
 Paris, M. 84  
 Park, J. Y. 52  
 Parker, E. 63  
 Parker, M. A. 63  
 Parra-Cardona, Ruben 4, 21  
 Parsons, J. T. 102  
 Partilla, J. S. 13, 27  
 Pasa, G. 85, 103  
 Passalacqua, E. 24, 68  
 Pathak, V. 13  
 Pati, R. 107  
 Patrick, M. 26  
 Patton, G. 63  
 Patts, G. 18, 107  
 Pavlicova, M. 88, 95  
 Payne, F. 21  
 Paz, A. L. 86  
 Peacock, A. 14, 54, 94  
 Pears, K. C. 27  
 Pearson-Dennett, V. 60  
 Peasley, L. 4  
 Pechansky, F. P. 10, 24, 52, 61, 62, 75, 78, 85, 86, 103  
 Pecoraro, A. 76  
 Pedersen, W. C. 60  
 Peechatka, A. L. 55  
 Peindl, K. 82  
 Peirce, J. M. 76  
 Pellegrini, D. 83  
 Peltier, M. R. 57  
 Penate, J. 106  
 Pennington, D. 91  
 Pentel, Paul 90  
 Pentkowski, N. 27  
 Pérez de los Cobos, J. 19, 20, 96, 97  
 Pérez-Mañà, C. 75  
 Pérez-Pazos, J. 77  
 Perez, S. 62  
 Pericot-Valverde, I. 56, 109  
 Perkonigg, A. 105  
 Perlman, D. 104

## AUTHOR INDEX

- Perngparn, U. 78  
 Perrey, D. A. 13  
 Perry, B. 17  
 Persons, A. 12, 110  
 Peterson, D. J. 62  
 Petras, H. 79  
 Petry, N. 106  
 Pettaway, K. 68  
 Pettinati, H. M. 3  
 Pfaff, M. N. 9  
 Philbin, M. 107  
 Philip, P. 91  
 Phillips, Karran A. 3, 18, 26, 102, 108  
 Pianca, T. G. 62, 78  
 Pigeon, W. R. 91  
 Pike, E. 104  
 Pinder, L. 12  
 Pinney, J. M. 105  
 Pizzagalli, D. A. 55  
 Placzek, Michael S. 15, 108, 109  
 Platt, D. 93  
 Platt, J. 65  
 Plebani, J. G. 3  
 Plott, D. 53, 70, 101  
 Poe, M. 93  
 Polak, K. M. 22  
 Polcin, D. L. 20  
 Pole, N. 100  
 Polk, A. R. 59  
 Pomfrey, R. 11  
 Pomm, D. 22  
 Pope, E. 67  
 Pope, H. 97  
 Popova, L. 19  
 Porath-Waller, A. 21  
 Potenza, M. N. 53, 86, 99  
 Potter, J. S. 58, 61, 89  
 Pouget, E. R. 22, 58, 80  
 Prado, G. 64  
 Prat, M. 77  
 Pravetoni, Marco 90  
 Preston, Kenzie L. 3, 18, 26, 102, 108  
 Price, A. E. 14  
 Price, J. S. 97, 99  
 Prioleau, C. 59  
 Prisciandaro, J. 53  
 Prisinzano, T. E. 9, 71  
 Proudfoot, J. 24  
 Provost, S. 58  
 Pugh, M. 89  
 Puhl, M. 12  
 Pujadas, M. 75  
 Pullen, E. 17, 20  
 Puntès, M. 96  
 Quinn, A. 23  
 Quinn, E. 17, 18  
 Quinones-Jenab, V. 52  
 Quisenberry, A. 13  
 Rabinovich-Guilatt, L. 58  
 Rafat, B. 94  
 Rafful, C. 86  
 Raguin, G. 16  
 Rahm, S. P. 27  
 Raj, A. 17, 18  
 Ramesh, D. 14, 101  
 Ramirez, S. H. 12  
 Ramo, Danielle 19, 30, 57  
 Ramoa, C. 55  
 Ramos Rodriguez, M. 53  
 Ramos, R. 53  
 Rancaño, J. 78  
 Randall-Thompson, J. 104  
 Ranganathan, Mohini 25  
 Rapaka, R. 59  
 Rass, Olga 68, 88  
 Rassmussen, B. A. 28  
 Ratner, T. 68  
 Ravenell, O. 84  
 Rawls, S. 12, 28, 108  
 Rawson, R. 15, 16, 76, 77, 81, 106  
 Ray, L. A. 8  
 Raymond, K. 97, 98  
 Read, E. 65  
 Reback, Cathy J. 19, 61, 72  
 Reddy, A. 22  
 Redner, R. 89  
 Reed, S. 60, 76  
 Rehm, J. 96  
 Reid, H. H. 14  
 Reif, S. 23, 88  
 Reimer, J. 64  
 Reis, L. R. 10  
 Reis, T. A. 89  
 Reitzel, L. R. 59  
 Remy, L. S. 75  
 Rendina, H. J. 102  
 Renfro, S. 23  
 Renshaw, P. 98  
 Reynolds, G. L. 14, 60, 61, 65, 103  
 Reynolds, M. D. 53  
 Riba, J. 96, 97  
 Rice, K. 11, 25, 95  
 Rich, M. T. 11  
 Rico, M. 21, 22  
 Rieckmann, Traci R. 5, 15, 16, 23, 85  
 Ries, R. 25  
 Riggs, P. D. 59, 79, 95  
 Riley, A. L. 11, 95, 106  
 Riley, C. 98  
 Riley, E. 87  
 Riley, J. L. 57  
 Rimland, D. 70  
 Rios, E. 16  
 Ritter, G. 88  
 Ritter, K. 23  
 Rivas, I. 82, 85  
 Rivera, M. 16  
 Roberts, A. J. 60  
 Robertson, B. 94  
 Robeson, P. 21  
 Rocha, Beatriz 74  
 Rodgman, C. 68  
 Rodriguez-Barradas, M. 16  
 Rodriguez-Cintas, L. 77  
 Rodríguez-Fornells, A. 96, 97  
 Rodríguez-Pujadas, A. 97  
 Rodriguez, M. 16  
 Roehrs, T. 93  
 Rohde, L. A. 78  
 Rohsenow, D. 9, 56, 95  
 Roland, C. L. 89  
 Roley, J. 54  
 Roll, J. M. 25, 55, 65

## AUTHOR INDEX

- Roman, T. 52  
 Romero-Gonzalez, M. 58, 82  
 Roncancio, A. 23  
 Roncero, C. 77  
 Rooke, S. 19  
 Roquer, A. 91  
 Ros-Cucurull, E. 77  
 Rosa, Carmen 29  
 Rosa, M. C. 10  
 Rosa, R. L. 62, 78  
 Rosado, A. 25  
 Rose, J. 99  
 Rosen, B. R. 15  
 Rosen, M. 80  
 Rosenblum, Andrew 22, 25, 26, 58, 81  
 Ross, J. M. 63  
 Ross, K. 55  
 Rosselli, M. 86  
 Rossi, P. 91  
 Roth, T. 93  
 Rothman, R. B. 13, 27  
 Rotrosen, J. 23  
 Row-Sepowitz, D. 79  
 Rowe, C. 66  
 Rowe, R. 64  
 Rowlett, J. 93, 106, 109  
 Rowley, H. L. 12  
 Roxburgh, A. 101  
 Rubio, M. 82  
 Rueedi-bettschen, D. 93  
 Runyon, S. P. 13  
 Rush, A. J. 61  
 Rush, C. R. 19, 60, 61, 93, 104  
 Rutter, Joni 59, 71  
 Ryan, C. 102  
 Rytting, E. 54  
  
 Saenz, E. 59  
 Saini, S. K. 13  
 Saiphoklang, O. 78  
 Saitz, Richard 16, 22, 77, 88, 107  
 Sáiz, P. 78  
 Sakai, J. 97, 98  
 Saladin, M. E. 82  
 Salas-Ramirez, K. 8, 62  
  
 Saleh, H. 62  
 Salem, B. 106  
 Salmeron, B. 99  
 Saltino, D. 65  
 Samet, J. H. 15, 16, 17, 18, 22, 70, 88, 107  
 Sampedro, F. 97  
 Sanches, M. 23  
 Sanchez, Z. M. 78  
 Sandoval, M. R. 80  
 Santa Ana, Elizabeth J. 7, 109  
 Santaella, J. 23, 64  
 Santiago Rivera, O. J. 65  
 Santos, Glenn-Milo 66, 72  
 Sanvisens, A. 82, 85  
 Sarkar, S. 89  
 Sarma, K. 94  
 Sarram, S. 109  
 Sartor, C. E. 77  
 Satre, D. D. 80  
 Savage, P. 55  
 Sawa, K. 110  
 Saxon, A. 52, 106  
 Schacht, R. L. 76  
 Scheidell, J. D. 69, 101, 107  
 Scheinost, D. 53  
 Schenk, S. 27, 75  
 Scherer, J. N. 24, 61, 86  
 Schimmel, J. L. 51  
 Schindler, C. W. 109  
 Schmeling, B. 91  
 Schmidt, N. B. 56  
 Schmitz, Joy 3, 7, 13, 95  
 Schoedel, K. 58, 94  
 Schoenbaum, E. 17  
 Scholl, J. L. 28  
 Schottenfeld, R. S. 86  
 Schrodek, E. 91  
 Schroeder, J. R. 10  
 Schuch, S. 61  
 Schulenberg, J. 26  
 Schuler, M. S. 85  
 Schulte, M. T. 60, 79, 83  
 Schumacher, J. E. 80  
 Schwartz, D. 16  
 Schwartz, R. P. 78, 81, 82, 83, 96, 101  
 Scott, B. 99  
 Seale, P. 21  
 Sears, R. M. 12  
 Seay, Kristen D. 91  
 Secades-Villa, R. 56, 78, 109  
 Seedall, R. 79  
 Seider, N. 11  
 Selby, P. 96  
 Semino, S. 21  
 Senadheera, S. 15  
 Senmartin, N. 94  
 Serafini, K. 84  
 Serna, B. 59  
 Serre, F. 10, 55, 91, 109  
 Sessler, N. 100  
 Setnik, Beatrice 74, 89, 104  
 Severtson, S. G. 8  
 Seymour, B. 102  
 Shane, M. S. 98  
 Sharma, G. 87, 88, 102  
 Shellenberger, S. 21  
 Sherrill, L. 62  
 Sheth, A. P. 19  
 Shi, X. 98  
 Shimane, T. 75  
 Shin, S. 4  
 Shiu, K. 80  
 Shmulewitz, D. 24  
 Shollenbarger, S. G. 97  
 Shopshire, M. 104  
 Shoptaw, S. 57, 60, 100  
 Shram, Megan 54, 71, 72, 94  
 Shrestha, R. 52  
 Shu, I. 84  
 Shurtleff, David 66  
 Sierka, C. 102  
 Sigmon, S. C. 55, 56, 80, 82, 87  
 Silins, E. 63  
 Silveira, D. X. 89  
 Silverman, Kenneth 66  
 Simon, P. 62, 68  
 Sinha, R. 53  
 Sites, J. P. 93  
 Skanderson, M. 16, 70  
 Skelly, J. M. 67, 84

## AUTHOR INDEX

- Skinstad, A. 105  
 Slade, T. 109  
 Sloboda, Z. 79  
 Smelson, D. 82  
 Smethells, J. R. 14  
 Smith, A. 94  
 Smith, B. 104  
 Smith, Douglas C. 29  
 Smith, E. 97  
 Smith, K. 70  
 Smith, K. Z. 4  
 Smith, M. A. 11, 25  
 Smith, M. D. 104  
 Smith, Mark A. 25, 90  
 Smith, N. 106  
 Smith, Philip H. 3, 4  
 Smith, R. V. 100  
 Smith, S. 15  
 Snider, S. E. 14  
 Soares, V. S. 89  
 Sofuoglu, M. 86  
 Sokolowska, M. 89, 104  
 Solinas, Marcello 90  
 Solomon, L. J. 67  
 Sonne, S. 8  
 Sordi, A. O. 61, 86  
 Sorensen, J. 54, 80, 81, 103, 104  
 Sorsdahl, K. 89  
 Soto, C. 12  
 Sou, B. 55  
 Sousa, T. R. 85, 103  
 Souza, D. S. 24, 86  
 Sparenborg, Steven 4, 59  
 Spealman, Roger D. 2, 12  
 Spear, S. E. 77  
 Spears, C. A. 57  
 Spencer, R. H. 94  
 Spencer, S. 71  
 Spindle, T. 55  
 Spitzer, E. 99  
 Sproule, B. 89, 93, 94  
 Srebnik, D. 25  
 Srisarajivakul, E. 58  
 Stacey, T. 59  
 Stafford, J. 88  
 Stahler, G. 87  
 Stairs, D. J. 9  
 Stanger, C. 63  
 Stankeviciute, N. 71  
 Stanley, B. 76  
 Starkweather, A. 101  
 Staton-Tindall, M. 18, 20, 59, 100  
 Stauffer, J. W. 94  
 Stein, J. S. 56, 88  
 Steinberg, J. L. 14, 98  
 Stephens, M. 102  
 Sterling, Stacy 29  
 Stevens-Watkins, D. 100  
 Stewart, M. 23, 88  
 Stitzer, M. L. 80, 87  
 Stoddard, S. A. 80  
 Stoduto, G. 96  
 Stohl, M. 24, 80  
 Stolf, A. R. 52  
 Stoltman, J. J. 13  
 Stoops, William W. 19, 60, 61, 69, 93, 104  
 Stoove, M. 103  
 Storholm, E. D. 80  
 Stout, S. 61  
 Strain, Eric C. 1, 10, 18  
 Strasser, A. 8  
 Strathdee, S. 66, 86  
 Straussner, S. L. 81  
 Streck, J. M. 55, 80, 87  
 Strickland, J. C. 11, 19, 104  
 Striley, C. W. 20, 53, 79, 95, 102  
 Stringer, K. 80  
 Strong, D. 19  
 Study Group, C. 106  
 Stutz, S. J. 10, 11, 12, 28, 106  
 Styner, M. 84  
 Suchting, R. 13, 95  
 Sugarman, D. E. 77  
 Suh, J. 97, 98  
 Suleta, K. 23  
 Sullivan, K. 85  
 Sullivan, M. 16, 107  
 Sullivan, M. A. 21, 26  
 Sun, W. 27  
 Sung, Fung-Chang 5  
 Sung, Y. 98  
 Sung, Yung-Fong 1  
 Surratt, H. 75, 100  
 Sutherland, R. 64  
 Svikis, Dace 7, 22  
 Swalve, N. 52  
 Swanson, A. 60, 100  
 Swart, A. 81  
 Sweeney, M. M. 88  
 Sweitzer, M. 23, 99  
 Swendsen, J. 55  
 Swift, R. 60  
 Swinford-Jackson, Sarah E. 12, 27, 28  
 Syckes, C. 81  
 Syed Jaapar, S. Z. 86  
 Szobot, C. 78  
 Szucs-Reed, R. 98  
 Szuhany, K. 85  
 Taffe, Michael A. 68  
 Taghavi, S. 55  
 Tai, B. 61  
 Taillard, J. 91  
 Tajima, B. 24, 56, 68  
 Talal, A. 104  
 Tallarida, C. S. 28, 108  
 Tanabe, J. 97, 98  
 Tancer, M. E. 17  
 Tang, J. 75  
 Tanner-Smith, Emily 29  
 Tannu, N. S. 13  
 Tarantino, Lisa 108  
 Tarifa, N. 77  
 Tarter, R. E. 53  
 Tate, J. 16, 83  
 Taylor, D. M. 26  
 Taylor, J. 106  
 Tedford, S. E. 12, 110  
 Tella, S. R. 59  
 Temple, J. R. 79  
 Teneback, C. C. 55  
 Teper, A. 81  
 Terplan, M. 84  
 Thacker, L. 101  
 Theobald, J. 83  
 Thewlis, D. 60



## AUTHOR INDEX

- Thomas, B. F. 13  
 Thomas, C. 3, 59, 61, 76, 106  
 Thomas, L. 21  
 Thompson-Lake, D. G. 9, 68, 103  
 Thompson, R. G. 86, 91  
 Thorberg, F. A. 85  
 Thorn, D. 13  
 Thorndike, E. B. 109  
 Thostenson, J. D. 54, 61  
 Thrul, J. 57  
 Thurstone, C. 59  
 Tiberio, S. S. 27  
 Tidey, Jennifer W. 1, 8, 9, 56, 66, 77  
 Tindol, A. 21  
 Tiruveedhula, P. 93  
 Todd, G. 60  
 Todtenkopf, M. S. 15, 94  
 Tofghi, B. 18  
 Tolliver, J. M. 58  
 Tomiyama, K. 95  
 Tompkins, D. A. 10  
 Tor, J. 85  
 Torregrossa, M. M. 11  
 Torrens, M. 58, 75, 91  
 Torres, M. 88  
 Torres, O. 25  
 Toussova, O. 17  
 Townsend, D. 11  
 Townsend, E. 109  
 Tran, H. 15, 16  
 Trecki, J. 59  
 Treiber, F. A. 18  
 Tremblay, B. 16  
 Trias, V. 16  
 Trigo, J. M. 96  
 Trim, R. S. 86  
 Trinidad, M. 82  
 Tsay, W. 75  
 Tseng, F. 78  
 Tsoh, J. 56, 65  
 Tsui, J. I. 15, 70  
 Tucker, D. 24  
 Tunno, A. 23  
 Turan, J. M. 80  
 Turncliff, R. 54  
 Tuten, M. 69, 84  
 Tyburski, M. 18  
 Tyndale, Rachel 55, 72  
 Tyssen, R. 85  
 Tyurina, A. 18, 76  
 Uddin, M. 3  
 Um, M. 99  
 Umbricht, A. 10, 77  
 Unger, A. 24  
 Unick, G. J. 101  
 Unterwald, E. 27, 28  
 Urada, D. 53, 83  
 Uribe, K. 8  
 Ury, J. 61  
 Vaddiparti, K. 69, 101, 107  
 Vahidi, M. 22  
 Vajdic, C. 81  
 Valderrama-Zurián, J. 19, 20  
 Valdez, A. 99  
 Valente, T. 102  
 Valle, M. 96, 97  
 Vallender, E. J. 51  
 Van Dam, N. 99  
 Van de Bittner, G. C. 109  
 van Wijngaarden, E. 99  
 Vanderah, Todd 105  
 Vandrey, R. 8, 77, 87  
 VanVeldhuisen, P. 59, 61, 102  
 Varanasi, R. K. 54  
 Varenbut, M. 83  
 Varga, M. 9  
 Varma, D. S. 21  
 Vasilev, G. 2  
 Vassileva, J. 2, 16, 110  
 Vaughan, B. 26  
 Vaughan, E. 23  
 Vazquez-Sanroman, D. B. 110  
 Veglahn, H. 52  
 Velez, M. 69  
 Veliz, P. T. 80, 101  
 Venault, J. 27  
 Venner, Kamilla 59, 73  
 Ventuneac, A. 102  
 Ventura, A. S. 16, 107  
 Verbitskaya, E. 76  
 Verrico, C. D. 9  
 Vidot, Denise C. 5, 64  
 Villarreal, Y. 76  
 Vincent, J. 3  
 Vincent, K. B. 64  
 Vinci, C. 57  
 Vindenes, V. 54  
 Vitaliano, G. 99  
 Vittinghoff, E. 66  
 Vo, H. T. 79  
 Vogel, A. 60  
 Vogelman, J. 21  
 Volkow, Nora 51  
 von Diemen, L. 24, 61, 62, 86  
 Voon, Pauline 51  
 Votaw, V. R. 97  
 Vsevolozhskaya, O. 52, 64  
 Vujanovic, Anka 3, 7, 95  
 Vyshynskiy, K. 87  
 Wada, K. 75, 95  
 Wadolowski, M. 109  
 Wager, T. 98  
 Wager, T. T. 25  
 Wagner, B. D. 95  
 Wagner, F. P. 19  
 Wagner, K. D. 24  
 Wakeford, A. G. 95  
 Walker, M. 59  
 Walker, R. 59, 61, 80, 105  
 Wall, M. 65  
 Walley, Alexander Y. 2, 16, 17, 18, 26, 107  
 Walsh, Sharon L. 3, 15, 71, 82, 96, 97, 100  
 Walter, L. 106  
 Walton, M. A. 20, 21, 79, 87  
 Wang, A. 99  
 Wang, D. W. 18  
 Wang, G. 76  
 Wang, H. 99  
 Wang, J. 83  
 Wang, L. 13  
 Wang, X. 54, 55  
 Wang, Z. 98

## AUTHOR INDEX

- Ward, M. 15  
 Ward, S. 80  
 Washio, Y. 103  
 Waters, A. J. 84  
 Watson, C. 11  
 Weaver, M. 95  
 Webb, L. 19, 97  
 Webster, J. 75  
 Webster, L. R. 58, 94, 104  
 Webster, M. 18, 20, 59  
 Wechsberg, P. 21  
 Wechsberg, W. 17, 87  
 Wechsberg, Wendee 72  
 Weerts, E. 8  
 Wei, C. 52  
 Weidberg, S. E. 56, 109  
 Weimer, M. 61  
 Weinberger, A. H. 65  
 Weinstein, D. 14  
 Weiss, Bert 74  
 Weiss, Friedbert 25  
 Weiss, R. 58, 70, 99  
 Weiss, V. G. 52  
 Welch, J. 19  
 Weldon, A. L. 77  
 Wenger, L. 65, 102  
 Werb, D. 23  
 Werner, K. B. 77  
 Wesesky, M. A. 76  
 Wesley, M. J. 98  
 West, N. 91  
 Westman, E. 99  
 Wetherill, R. R. 97, 98  
 Wetherington, Cora Lee 1, 74, 82  
 Wetzell, B. B. 11  
 Wey, H. 15, 109  
 Wheeler, E. 24, 66  
 White, D. A. 59  
 White, J. 15, 55, 60  
 White, Thomas J. 5, 84, 89  
 Whitehead, N. E. 16, 102  
 Whittaker, E. 102  
 Whitton, A. E. 55  
 Wickens, C. 96  
 Wiesenthal, A. 94  
 Wiest, K. 85  
 Wijeratne, S. 19  
 Wilcox, R. A. 60  
 Wild, C. 9  
 Wilder, C. M. 83  
 Wildman, D. 3  
 Wiley, Jenny 1, 2  
 Willenbring, D. 59  
 Williams, G. 99  
 Williams, K. 3  
 Williamson, P. 15  
 Wills, T. 4  
 Wilson, A. 13  
 Wilson, J. 67  
 Wilson, J. L. 20  
 Wilson, K. 88  
 Wilson, V. 16  
 Wilson, W. T. 59  
 Windisch, K. A. 9  
 Winhusen, T. 61, 83  
 Winston, E. 100  
 Winter, M. R. 15, 16, 22, 70  
 Winters, Ken 21, 29  
 Wong, L. L. 59  
 Wong, T. 91  
 Wongboonsin, K. 78  
 Wongboonsin, P. 78  
 Woo, C. 98  
 Woo, D. 62  
 Wood, C. 71  
 Wood, D. M. 58  
 Wood, D. S. 76  
 Wood, E. 17, 24, 83, 107  
 Woodcock, E. A. 13  
 Woody, G. E. 76  
 Worley, M. 57, 60  
 Wright, C. 9  
 Wu, L. 82  
 Wu, M. 26  
 Wu, P. 13  
 Wu, R. 62  
 Wu, Y. 100  
 Wulach, L. A. 17  
 Xandre, P. 103  
 Xavier da Silveira, D. 89  
 Xu, F. 67  
 Xu, H. 27  
 Xu, R. 24  
 Xu, Z. 76  
 Xue, W. 55  
 Yacenda, J. 22  
 Yamamoto, D. 98  
 Yang, F. 27  
 Yang, M. 85  
 Yaroslavtseva, T. 17, 76  
 Yasin, M. M. 86  
 Yates, J. R. 52  
 Yeh, H. H. 23, 79  
 Yip, S. W. 99  
 Yohannes, S. 91  
 Yoon, J. H. 95  
 Young, K. A. 98  
 Young, M. M. 63  
 Young, R. M. 85  
 Young, S. 98  
 Yu, C. 75, 79  
 Yurasek, A. 96  
 Yurgelun-Todd, D. 98  
 Zaharim, N. M. 86  
 Zald, D. 28  
 Zaslav, D. 79  
 Zavala, R. 18, 104  
 Zeigler, D. 103  
 Zentgraf, K. 79  
 Zerbe, G. O. 95  
 Zeremski, M. 104  
 Zernig, Gerald 90  
 Zhang, G. 9  
 Zhang, M. 93  
 Zhang, S. 76  
 Zhang, Y. 9, 12, 13, 27, 70, 76, 107  
 Zhao, S. 19  
 Zheng, G. 13  
 Zhou, J. 9  
 Zhou, W. 12  
 Zhou, Z. 16  
 Zhu, J. 27  
 Zibbell, J. 104  
 Zimmerman, M. 20  
 Zlebnik, N. 52

## AUTHOR INDEX

Zlotnick, C. 19  
Zubieta, J. 27, 77  
Zucker, R. 69, 97  
Zule, W. 17, 87, 103  
Zuluaga, P. 85  
Zvartau, E. 76  
Zvolensky, M. J. 56, 65, 78  
Zvorsky, I. A. 84

## SYMPOSIA

**Sunday, June 14**

*I. Females and Flowers: Sex Differences in the Dependence-Related Effects of  $\Delta^9$ -THC*

Chairs: Jenny Wiley and Cora Lee Wetherington

Cannabis continues to be the most frequently used illicit substance in the U.S., with user numbers expected to increase as a result of the growing movement to decriminalize/legalize recreational use and the push for acceptance of medicinal use for a wide variety of putative therapeutic indications. While the number of male recreational users still exceeds that of female users, this gender gap is steadily decreasing. In addition, some of the disorders for which the use of medicinal cannabis is promoted (e.g., multiple sclerosis, chronic pain) may disproportionately affect women. This upward trend for cannabis use among females is particularly disconcerting, as previous research has shown that women tend to exhibit a faster progression from substance use to abuse. Further, the limited extant laboratory research has demonstrated sex differences in the effects of  $\Delta^9$ -tetrahydrocannabinol ( $\Delta^9$ -THC), the primary psychoactive constituent of marijuana, in humans and in animals, with females tending to be more sensitive. In concordance with the NIH initiative mandating consideration of both sexes in clinical *and* preclinical research, the primary goal of this symposium is to present the latest data from studies in humans and rodents on gender/sex differences in the subjective, neurocognitive, antinociceptive, and dependence-related effects of  $\Delta^9$ -THC. Mechanistic underpinnings of observed sex differences in behavior will be explored in the rodent models, with an emphasis on the modulatory role of gonadal hormones. Implications of these findings will form the basis for a lively audience discussion with the speaker panel.

*II. Naloxone for Overdose Prevention: Expansion to Multiple Settings and Populations*

Chairs: Caleb Banta-Green and Phillip Coffin

Naloxone for lay opioid overdose reversal has rapidly been gaining favor nationwide as a key response to the opioid overdose epidemic. Initially developed for heroin users and largely distributed through low-threshold drug service programs such as syringe exchange, naloxone is now also being dispensed through multiple venues, such as primary care, emergency medicine, retail pharmacies, substance use disorder treatment programs, and prisons. Speakers will review several modalities of naloxone provision, including implementation and initial outcome data from several state, local, private and NIDA-funded research studies. The development and refinement of interventions will be discussed including how to engage health care and other service providers, potential overdose victims and community responders. Measurement of intermediate and ultimate outcomes will be discussed including implications, findings and advancing the science in this arena. In addition to implementation issues within clinical and non-clinical settings, the rationale and strategies for working with relevant community partners such as law enforcement will be examined.

## SYMPOSIA

**Monday, June 15**

### *III. Posttraumatic Stress and Substance Use Disorders: Treatment Initiatives and Challenges*

Chairs: Anka A. Vujanovic and Joy M. Schmitz

Posttraumatic stress disorder (PTSD) co-occurs at high rates with substance use disorders (SUD) and is a significant risk factor for poorer SUD treatment outcomes (e.g., stronger cravings, faster time to relapse). Individuals with PTSD often use substances to escape/avoid aversive PTSD symptoms and regulate negative emotional states, thus underscoring the transactional nature of this comorbidity. Diverse integrated treatments that address both aspects of this highly prevalent and difficult-to-treat comorbidity are imperative for improving treatment outcomes and thus alleviating the related public health burden. This symposium aims to elucidate clinical research advances in this domain by showcasing novel SUD treatments for individuals with PTSD that incorporate biological and technological innovations as well as evidence-based psychosocial interventions. Speakers will present an integrated treatment for PTSD and alcohol use disorder that incorporates antidepressant medication and cognitive behavioral therapy (CBT); research integrating mobile technologies in the treatment of comorbid PTSD and SUD; results of randomized controlled trials (RCTs) of integrated treatment for PTSD-SUD that combine CBT for SUD with prolonged exposure therapy for PTSD; and preliminary findings of a RCT of an integrated treatment for PTSD-SUD that combines elements of relapse prevention with cognitive therapy and written exposure for PTSD. The importance of SUD treatment for populations with multiple psychiatric conditions will be discussed highlighting gains, challenges, and future directions.

### *IV. Emerging Evidence on Opioid-related Overdose Risk and Intervention*

Chairs: Howard Chilcoat and Nabarun Dasgupta

Opioid-related fatal and non-fatal overdoses have increased several-fold over the last decade. The emergence of this public health problem requires greater knowledge of the factors influencing overdose risk with the goal of developing strategies to reduce this risk in patients prescribed opioids as well those who abuse opioids. Recent epidemiologic research has begun to shed light on risk factors for opioid overdose, which in turn has influenced prescribing policies. However, in order to develop policies and practice guidelines that can be most effective in reducing overdose risk and ensure effective treatment for patients, a deeper understanding of the causal influences on overdose is needed. To address this need, we examine data from epidemiologic studies on factors that impact opioid risk in patients as well as in non-patients who abuse these drugs, and we consider their implications for policy and practice. These include findings from epidemiologic studies from the US and UK on the relationship between opioid dose and overdose risk, and the role of factors such as sedative/hypnotics and prescriptions of multiple opioids as confounders of this association. We augment these findings with results from a qualitative study of individuals who experienced an overdose to examine the factors and circumstances that led up to overdose. Finally, we present findings from a community-based intervention that has been shown to reduce overdose fatalities. The discussion will consider the implications of these findings and how they can be used to guide strategies to reduce overdose risk among patients and those that use nonmedically.



## SYMPOSIA

### Monday, June 15

#### *V. Cannabidiol and Drugs of Abuse: Preclinical and Clinical Studies of Cannabidiol and Cocaine, Ethanol, Opioids and Cannabinoids*

Chairs: Margaret Haney and Yasmin Hurd

Cannabidiol (CBD), a nonpsychoactive constituent of cannabis has attracted recent attention in the scientific and popular press for its potential medical utility as an anticonvulsant or antipsychotic, as well as for its potential to reduce the abuse liability of drugs. Yet empirical evidence of CBD's effects is quite limited. The aim of this symposium to provide novel preclinical and clinical data on the effects of CBD administration in combination with cocaine, ethanol, opioids and cannabinoids. Speakers will describe preclinical studies demonstrating that transdermal CBD reduced ethanol and cocaine seeking in response to both drug-related cues and stressful stimuli; clinical studies showing that oral CBD was well tolerated when co-administered with i.v. fentanyl and that CBD may reduce craving in response to heroin-paired cues; describe a human laboratory study showing that i.v. CBD reduced i.v. THC-induced psychotomimetic effects in non-cannabis smokers but did not reduce THC intoxication and worsened THC-induced deficits in learning; and present data from a multi-site human laboratory study showing that oral CBD was well tolerated but did not reduce cannabis self-administration or its positive subjective effects relative to placebo. The Discussant will summarize the effects of CBD and will describe preclinical and clinical studies testing CBD for opioid dependence.

### Tuesday, June 16

#### *VI. Mindfulness-Based Approaches: From Neurobiological Mechanisms to Treatment*

Chairs: David Shurtleff and Emmeline Edwards

Mindfulness – based therapies involve training individuals to non-judgmentally attend to, and be aware of thoughts and feelings on a moment-to-moment basis. The underlying principles for this approach involve perceptual distancing and acceptance leading to increased tolerance of symptoms, and maladaptive cognitive or emotional processes, greater self-awareness and self-motivation leading to improved coping strategies, and reduced autonomic arousal. At a basic level, researchers studying mindfulness-based interventions are gaining insight into the cognitive and neurobiological mechanisms associated with these approaches. At the applied level of research, mindfulness-based approaches are being studied and developed as therapies, and possible viable options for the treatment of many psychiatric disorders, including substance use disorder (SUD). Researchers are also exploring the use of medications to facilitate mindfulness-based training, which may improve its overall therapeutic effectiveness. This symposium will explore the underlying cognitive and neurobiological mechanism of mindfulness-based approaches as well as some of their practical uses and efficacy for both the proximal benefit and longer term sustainability of treatment gains for individuals suffering with chronic relapsing disorders, such as SUD.

## SYMPOSIA

**Tuesday, June 16**

*VII. Behavioral Economics of Health Disparities in Addiction*

Chairs: Adam Leventhal and Stephen Higgins

Efforts to offset the public health burden of addiction have not equally benefited all members of society, leading to disparities among those facing disadvantages. Investigation of sources of addiction-related disparities has typically focused on sociopolitical factors without meaningfully incorporating behavioral science. Similarly, behavioral addiction science has often overlooked the socioenvironmental context. This symposium synthesizes these perspectives by discussing and integrating human laboratory, clinical, and epidemiological research that applies behavioral economic approaches to understand and eliminate health disparities in addiction. The symposium's overarching framework is that the biopsychosocial context surrounding disparities disproportionately amplifies the salience of behavioral economic mechanisms underlying drug use motivation for disparate populations by enhancing the reinforcing value of drugs and diminishing the value of healthy non-drug reinforcers. Laboratory and epidemiologic research demonstrating how and why disparate populations are vulnerable to imbalances in the relative reinforcing value of drug vs. non-drug alternatives will be reviewed, as will laboratory research on the behavioral economics of tobacco use among individuals with serious mental illness. Data from socioeconomically disadvantaged women illustrating how a behavioral economic framework enhances scientific understanding and suggests effective interventions for reducing smoking and promoting other healthy behaviors, and data that applies the behavioral economic framework to feasible interventions among chronically unemployed intravenous drug abusers will be presented. A discussion with a view toward forward translation to intervention and back translation to etiology will follow.

*VIII. Using Translational Research to Develop Interventions for Stimulant Use*

*Disorders: Nonhuman Primate, Human Laboratory and Clinical Trial Findings*

Chairs: William W. Stoops and Paul W. Czoty

Stimulant use disorders present a persistent and significant public health concern. Despite considerable efforts to identify a treatment that reduces or eliminates stimulant use, no pharmacotherapies have been approved, nor have effective behavioral treatments been widely adopted. One barrier to identification and dissemination of effective treatments for stimulant use disorder may be a lack of a translational "pipeline" that moves putative interventions from laboratory models into clinical trials. Research efforts to identify stimulant treatments may also be hampered by methodological problems within individual disciplines. The speakers in this mini-symposium will present innovative and translational treatment development research, moving from nonhuman primate studies to human laboratory studies to clinical trials, as a means of promoting a more deliberate system of stimulant treatment evaluation. Speakers will highlight areas of strength and provide recommendations for improving upon existing practices to guide future research in this arena. In total, this mini-symposium will move the field of stimulant treatment development forward by providing a forum for a translational range of researchers to present and discuss their work, as well as by articulating suggestions for enhancing the utility and predictive validity of existing strategies.

## SYMPOSIA

**Tuesday, June 16**

*IX. New Perspectives on Genetics and Metabolomics of Nicotine Dependence and Smoking Cessation: Implications for Nicotine Dependence Treatment*

Chair: Joni L. Rutter

The hope of understanding the molecular basis of drug addiction is driven, in part, by the remarkable progress that has been made in the field of genetics during the past decade. Attributing to these successes is the notion that the addiction field benefits from a vast knowledge of a given drug's mechanism of action. Among these, for example, are genes encoding for enzymes involved with drug metabolism, such as cytochrome P450 2A6 that metabolizes nicotine at a rate driven by genetic variation and measured by the nicotine metabolite ratio (NMR), as well as gene variants that modulate the response to the rewarding or aversive effects of nicotine, such as the nicotinic subunit receptor cluster CHRNA5/A3/B4. In the United States, approximately 435,000 deaths are attributed to tobacco. Nearly half of the people who smoke want to stop; however most attempts fail. The more highly dependent smokers have greater difficulty quitting. Challenges remain in understating which and how these genetic variations contribute to nicotine addiction and to smoking cessation, and how to begin to apply current knowledge towards increasing and maintaining the quit rates. This mini-symposium will highlight the genetic and metabolomics science to date, and offer varying perspectives on the potential of this information for guiding treatment for nicotine dependence.

*X. The Interplay of Pharmacokinetics and Pharmacodynamics in Abuse Potential: Modeling Madness?*

Chairs: Megan Shram and Sharon Walsh

The aims of the symposium are to describe current knowledge of the pharmacokinetic-pharmacodynamic (PK-PD) relationship of abused drugs, factors that may influence this relationship, and how this might impact the future development of drug formulations. It is generally accepted that the rate of rise of drug concentrations contributes to the abuse potential of a drug; however, this relationship may vary by drug class. In addition, a number of non-PK factors can influence the subjective response to a drug, including prior drug experience, level of tolerance, measure and genetics; case examples will be presented to highlight some of these factors. Regarding development of formulations intended to deter prescription drug abuse, there is an increased need to understand the quantitative link between the PK of the drug formulation and the results of human abuse potential studies so that we may better predict outcomes based on the mechanism of deterrence. Questions will be raised for discussion with the audience.

## SYMPOSIA

**Wednesday, June 17**

*XII. Environmental and Social Influences on Drug-Taking: The Good, The Bad and The Ugly*

Chairs: Minda Lynch and Michael Bardo

A host of environmental influences have been investigated for their impact on drug-taking and drug-seeking. These include physical and sensory enhancements (“enriched” environments, including exercise) *versus* impoverished, isolated or sedentary behavioral conditions, and social facilitation/interaction (play, social learning/imitation, and social hierarchies). This preclinical research mimics environmental influences on drug abuse vulnerability that have been well documented in human and clinical research and provides a rich translational opportunity for examining neurobiological mechanisms conveying risk and protection. Experimental designs model the prevention and treatment potential of varied manipulations and allow for mechanistic investigations of biological embedding – how external influences ‘get under the skin’ to affect learning and motivation through key prefrontal and limbic neurocircuitry. Moreover, sex differences have been observed in the effects of these external influences, paralleling significant gender differences in human drug abuse and addiction. Speakers will introduce environmental enrichment as a protectant against abuse, and discuss sex differences in the effects of physical and social environmental manipulations; present evidence for potential neurobiological mechanisms through which enrichment confers resilience; and present research on social facilitation using behavioral models of drug self-administration, where the converse -- enhanced vulnerability, has been observed in pair-trained animals; and offer a different perspective on the social environment, revealing that social influences can act as alternative rewards to attenuate abuse.

*XIII. Cannabis Use in Youth: Neurocognitive Effects, Genetic Moderators, and Epigenetic Findings*

Chairs: Krista Lisdahl

Cannabis is the second most used drug and national attitudes about dangerousness are decreasing as governments consider legalization (Johnston et al., 2013). Therefore, it continues to be a top public health priority to characterize the public health impact of cannabis exposure and to identify potential at-risk groups for greater neurocognitive deficits. Adolescence is a sensitive period that involves significant neurodevelopmental changes (Giedd et al., 1996; Sowell et al., 2004) and drug exposure during these years may result in increased neurocognitive deficits. Genetic differences may also place individuals at increased risk for these neurocognitive effects. Two candidate genes include *FAAH*, which regulates anandamide, and SNPs in the CB1 receptor gene (*CNRI*) (Ho & Hillard, 2005). Speakers will present data demonstrating that earlier age of cannabis use onset is associated with poorer white matter integrity and neuropsychological deficits compared to late onset, identifying adolescence as a sensitive period; a series of studies that demonstrate that individual genetics in endocannabinoid signaling (*FAAH* and *CNRI*) moderate the impact of cannabis use on the young brain and cognition; and address whether cannabis use is associated with DNA methylation (C-phosphate-G) changes in at-risk youth. Therefore, the symposium will present converging lines of evidence that adolescence is a sensitive period for cannabinoid exposure, further our understanding of the role of endocannabinoid genetics, and provide preliminary data regarding potential epigenetic changes associated with cannabis exposure in youth. Future directions, clinical, and policy implications will be discussed.

## SYMPOSIA

**Thursday, June 18**

*XV. A Trio of Translational Projects: Biomarkers, Bioimmunology, and Behavior in Rodents and Humans*

Chair: Karran Phillips and Kenzie Preston

We will present three innovative translational research projects focusing on biomarkers, bioimmunology, and behavior in addiction. The biomarker research centers on cocaine-induced alterations of the blood lipidome, which were initially identified as markers of locomotor sensitization in rats, using a direct-infusion approach combined with electrospray-ionization mass spectrometry (ESI-MS). The analysis was subsequently applied to blood from human cocaine users, and it identified several specific phospholipids whose levels correlated not only with the use of cocaine, but also with route of administration (inhalation vs. smoking), time since last use, age at first use, number of lifetime uses, and a retrospective index of sensitization to cocaine's subjective effects. The bioimmunology research focuses on the common cocaine adulterant levamisole, an anti-helminth drug with immunostimulatory properties. Cocaine users exposed to levamisole can develop a clinical syndrome characterized by fever, cutaneous vasculitis, microthrombi, and generation of multiple different autoantibodies. This talk will focus on the effects of levamisole on neutrophils in humans and laboratory animals and will elucidate a novel mechanism of drug-induced autoimmunity that has implications across a spectrum of autoimmune diseases.

*XVI. New Strategies to Identify the Genetics of Addiction-Related Behaviors in Mice*

Chairs: J. David Jentsch

The precision and efficiency of mouse genetic analyses has increased remarkably over the past decade, allowing for their application to ever more sophisticated behavioral phenotypes. New, high-diversity genetic analyses reveal behavioral variation at an unprecedented range, and mapping methods and resources have accelerated the pace with which the trait-relevant loci can be identified. We will highlight three strategies, each highlighting the capabilities of mouse genetic resources for the characterization of exceptionally construct-valid measures of addiction-related behavior. Speakers will present new data gathered from a panel of inbred mouse strains indicating that impulsive responding in a reversal learning test is genetically correlated with intravenous cocaine self-administration behavior, and describe evidence that phasic dopamine transmission onto dopamine D2-like receptors is a key neurochemical mechanism that is intermediate between genetic variants of interest and the resulting behavioral phenotypes; present data on initial cocaine sensitivity and pharmacokinetics in a large panel of genetically diverse inbred mouse strains; discuss the utility of using expanded inbred strain data for identifying new models of addictive-like behavior and present follow-up linkage mapping and haplotype analysis of quantitative trait loci; highlight a new mouse population, the Diversity Outbred, in which high genetic diversity and precision enable the detection of a wide range of behavioral variation and co-variation; and present precise genetic mapping of behavior, specifically studies on the genetics of behavioral predictors of drug self-administration, including novelty seeking. These approaches reveal the power of mouse genetics to illuminate new biological influences on addictions.



## WORKSHOPS

**Sunday, June 14**

*I. Epidemiology and Public Health Research Methods (Co-Sponsored by CPDD  
International Programs Committee)*

Chairs: James Anthony and Jan Copeland

This year's annual workshop will again focus on methodological challenges in NIDA research in minority populations in the US and overseas, mindful of the meeting location in the American Southwest. Speakers will draw upon clinical research experiences working with Hispanic heritage families in Mexico and in the US, describing methods challenges faced in the intervention research context, including domestic violence and child protection issues, and will ask for workshop audience participation in discussion and feedback, with particular emphasis on workshop attendee experience in research ethics challenges that have been encountered in drug research with immigrant and transnational populations. US and international colleagues in the NIDA National Hispanic Science Network will be asked to share their related experiences in research with Hispanic heritage families. Audience comments and insights gained in research with non-Hispanic minority and diversity populations, not only in the US but also in other countries will be elicited. Methods issues faced when e-technology mobile or web-enabled applications are used to collect and monitor individual-level data on risky behaviors of individuals, with a focus on quantitation. Discussion about qualitative approaches that can be used in complement with the quantitative approaches will follow.

*II. Turning Electronic Health Records into Actionable Knowledge in Addiction Research*

Chairs: Yih-Ing Hser and Steven Sparenborg

Using data from electronic health records (EHR) for clinical and translational research is relatively new for addiction research in the United States. The recently enacted Affordable Care Act and the Federal Mental Health Parity and Addiction Equity Act are moving the substance use disorder (SUD) service delivery system toward greater integration with the primary care. The EHR system of these health care organizations offers opportunities for addiction research that can improve patient care, if related challenges can be overcome. This symposium examines the use of EHR for addiction research in several health care organizations: a private, integrated health care delivery system, a university-based medical hospital system, a health network system of Community Health Centers, and Taiwan's national health record system, and discusses the implications for clinical practice and policy. Speakers will describe prescription opioid use among members and associated risks and outcomes, based on EHR data from an integrated health care delivery system; the clinical course of patients diagnosed with marijuana use disorder to identify risk profiles and treatment use, based on a university-based medical hospital system; SUDs and HCV screening in CHARN (Community Health Applied Research Network) data among underserved populations.

## WORKSHOPS

**Sunday, June 14**

*III. Clinical Outcomes and Cost Evaluation in Clinical Trials: From Abstinence to Dollars and Cents*

Chairs: Sterling McPherson and Susan Mikulich-Gilbertson

In this *First Annual Design and Analysis Workshop*, the primary goal is to expose attendees to a variety of design and analysis issues relevant to randomized clinical trials (RCTs) of promising substance use disorder (SUD) treatments. Our specific aims are to present overviews with real-world examples on the following topics: 1) how distributions for substance use outcomes are often non-normal with zero-inflation and how erroneous specification of those distributions in analyses can change conclusions regarding that outcome, 2) how a missing data sensitivity analysis is essential when evaluating clinical trials and can help reduce bias and increase confidence in final model selection, 3) how selection of instruments that have demonstrated critical psychometric invariance properties is critical when planning a RCT, and 4) economic evaluation techniques for RCTs. Each of these topics is of critical significance in the design and analysis of a SUD RCT, and we will present them in a non-technical, accessible fashion in order to generate discussion among the presenters and the audience around how such considerations are applicable to various research situations. The overall goal is to raise the level of quality in the design and analysis of clinical trials addressing substance use disorders by attending to key issues raised during this informal workshop and to empower other researchers by dissemination of real-world analysis examples.

*IV. Navigating Key Stages of a Career in Addiction Science*

Chairs: Denise C. Vidot and Cristina Bares

This workshop will focus on issues specific to three key stages in a researcher's career: 1) Pre-Doctoral, 2) Post-Doctoral, and 3) Early Career/Faculty. Each presentation will outline steps that can be taken to maximize their career stage-specific experience and make themselves competitive job applicants for the next stage. Examples of topics included are as follows: striking a balance between executing your mentors vision and demonstrating your capacity to be an independent scientist, publishing amidst other responsibilities and long-term studies, getting grant-writing experience, applying for awards, establishing your niche and conveying its importance to potential employers, collaborating and networking, deciding whether to teach, different NIH funding mechanisms most appropriate for early career investigators, how to find a set of mentors, how to narrow down an innovative and significant research question, how to begin writing your grant, and organizing your time. Each talk will have a centered theme of the value of having mentors help along the process and the importance of being receptive to incorporating mentor feedback at all career stages.

## WORKSHOPS

**Monday, June 15**

*V. The Case for Rescheduling Psilocybin as a Treatment Medication: Regulatory Rationale, Abuse Liability, Safety, and Treatment Efficacy*

Chairs: Roland R. Griffiths and Matthew W. Johnson

Psilocybin, a 5-HT<sub>2A</sub>R agonist, is under investigation for clinical efficacy in the treatment of various conditions including addictive disorders and anxiety and depression associated with cancer. If approved by FDA, psilocybin will need to be rescheduled from its current placement in Schedule I where it was placed in 1971 with passage of the Controlled Substances Act (CSA) because it was not approved for medicinal use and was presumed to have a high potential for abuse. This workshop will summarize recent research suggesting that the toxicity and abuse liability of psilocybin are lower than previously assumed, while also suggesting that psilocybin may have efficacy in treatment of addictions and psychological distress in cancer patients. Recent findings suggesting the efficacy of psilocybin in treatment of anxiety and depression associated with a life-threatening cancer diagnosis and the relative abuse potential of psilocybin in the context of the 8-Factor regulatory framework used by FDA, NIDA and DEA to make regulatory scheduling decisions under the CSA will be discussed. Speakers will present National Household Survey data on the suicide and mental health of psilocybin and related compounds and recent studies suggesting the efficacy of psilocybin in treatment of nicotine and alcohol addiction. A discussion of these new data and their implications for the possible rescheduling of psilocybin for medicinal use will follow.

*VI. Use of SBIRT to Address Adolescent Drug Abuse*

Chair: Ken Winters and Michael L. Dennis

An emerging intervention framework to address early-stage alcohol and other drug involvement for youth is SBIRT, a model that offers guidelines for the provision of Screening (S), Brief Intervention (BI) and Referral to Treatment (RT). Whereas there is a fairly rich literature on the efficacy of BIs for adults, the research on SBIRT for adolescents is still emerging. This workshop will focus on research programs and efforts that examine SBIRT, with a focus on the “BI”, in teenagers involved with drugs. Speakers will describe an SBIRT research program in a school setting; patient outcomes in a trial of different modalities of SBIRT for adolescents during primary care well-visits; research using an SBIRT intervention with a very high risk population of kids (13-19) that were referred for treatment; and findings from a meta-analysis summarizing the effectiveness of brief alcohol interventions for adolescents (age 11-18) and young adults (age 19-30). A discussion of challenges and of opportunities of adolescent-based SBIRT models in the continuum of treatment options will precede a brief business meeting.

## WORKSHOPS

**Monday, June 15**

*VII: Substance Abuse Treatment Clinical Trials: Does Gender Matter?*

Chairs: Shelly Greenfield and Carmen Rosa

Evidence suggests gender differences in prevalence, progression and consequences of substance use disorders adversely affect treatment outcomes. Gender-related characteristics such as fewer mental health problems, less severe drug problems and social support are associated with better treatment outcomes. This workshop will present gender differences in four recent treatment trials and discuss their implications: (1) Exercise was implemented in a multisite sample of patients with stimulant use disorders. Gender differences in outcomes related to adherence to the prescribed exercise dose, reported barriers to exercise adherence; and differences in weight/BMI changes following the intensive phase of the exercise program are presented and discussed for gender-specific treatment adaptations. (2) Stimulant Abuse Treatment Groups to Engage in 12-Step, compared STAGE-12, an intervention to engage users in 12-Step support, to treatment-as-usual (TAU). Within STAGE-12, women had higher odds of during-treatment abstinence than men. However, in both groups, women attended outside 12-Step meetings less than men. (3) A web-based version of the Community Reinforcement Approach was compared to TAU among 507 (38% women) patients receiving outpatient treatment. Gender did not moderate the effect of treatment on outcome; however intervention acceptability was positively associated with abstinence, but only among women. (4) Patients endorsing problematic drug use during an emergency department visit received screening, assessment and referral to treatment (SAR) or SAR plus a brief intervention. Women reported more child custody and childcare barriers to treatment. Men were more likely to report poor treatment availability as a barrier. There were no gender differences in treatment utilization.

*VIII. Intervention 2.0: Using Social Digital Tools to Reach Difficult-to-Treat Substance Users*

Chairs: Danielle Ramo and Suzette Glasner-Edwards

With wide reach and engagement among users, digital social tools (the so-called “Web 2.0” environment) have the potential to change the face of addiction treatment by offering accessible strategies to monitor personal behaviors or extend clinician interventions. It is not clear, however, whether these strategies are successful at reaching substance users who are less likely to present for traditional treatment (e.g., young people) or have less successful treatment outcomes (e.g., those with health and/or mental health comorbidities). This workshop will bring together investigators who are using novel digital tools to reach traditionally hard-to-treat populations of substance users. The first study will be the first pilot randomized trial testing TXT-CBT, an integrated text-messaging intervention employing cognitive-behavioral therapy (CBT) to reduce substance use and improve antiretroviral adherence in HIV-infected substance users. The second study will be the first randomized controlled trial comparing online monitoring, online CBT and online social networking for comorbid binge drinking and depression in young adults. Moving into the social media space, the third study will compare Facebook and respondent-driven-sampling recruitment strategies for reaching parents of adolescents in Colorado and Washington State to complete a self-directed family program to prevent teen alcohol, tobacco, and marijuana use. The fourth study will present 1-year outcome data on feasibility and initial efficacy of the Tobacco Status Project, a motivationally tailored intervention to help young adults quit smoking on Facebook. Discussion will focus on the promise of Web 2.0 platforms for delivering addiction treatment to traditionally hard-to-reach populations, and areas of future investigation.

## WORKSHOPS

**Tuesday, June 16**

*IX. The Intertwining Epidemics of Drug Use and HIV/AIDS: The HIV/AIDS Workgroup*

Chairs: Adam W. Carrico and Don C. Des Jarlais

Groundbreaking randomized controlled trials have demonstrated that expanded access to anti-retroviral therapy (ART) can decrease HIV incidence. Because drug users were excluded in many of these trials, there is a critical need for research to inform the integration of biological and behavioral approaches to HIV/AIDS prevention with drug users. The overarching goal of the workshop is to provide a forum to examine how clinical and translational drug abuse research can inform the development of bio-behavioral HIV/AIDS prevention interventions. Specifically, we will highlight clinical research to examine methods of optimizing health outcomes and decreasing HIV transmission risk among HIV-positive drug users. We will also examine cutting-edge bio-behavioral approaches to prevent HIV seroconversion in both injection and non-injection drug users. NIDA-funded investigators who are pursuing programs of research to address the intertwining epidemics of drug use and HIV/AIDS will present. Ultimately, this workgroup represents a critical opportunity to begin to bridge the boundaries that have divided substance use and HIV/AIDS prevention research in order to optimize bio-behavioral HIV/AIDS prevention efforts with drug users.

*X. Marijuana Laws: The Changing Legal Landscape and Its Consequences*

Chair: Marsha Lopez

Marijuana is still illegal under federal law, but over half the states in the US have decriminalized or legalized it in some form. The effects of these changes are highly controversial. Public opinion about marijuana use is rapidly becoming more permissive, while proliferating marijuana dispensaries for medical or recreational use are providing ways to consume marijuana not previously seen at this scale, including marijuana-infused food and beverage products, electronic delivery devices, and emerging marijuana tourism in states with legalized recreational use. Many questions remain unanswered about the impact of these developments on the risk for marijuana use and related problems, questions that are the focus of intense public and scientific debate as the public considers and votes on medical and recreational marijuana laws, and as clinicians and policy-makers seek guidance from research findings. This workshop brings together important new findings from studies of these issues, including information on the relationship of state medical marijuana laws and attitudes to national adolescent marijuana use since 1991; on health conditions and marijuana use patterns in adult medical marijuana patients in Michigan and California; on risk factors for adolescent marijuana use in Washington and other states; and on how variation across state medical marijuana laws influences their effects on adolescent or adult marijuana use.



## WORKSHOPS

**Tuesday, June 16**

*XI. 21<sup>st</sup> Annual Contingency Management Working Group*

Chairs: Kelly Dunn and Diann Gaalema

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 21<sup>st</sup> annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

*XII. Culturally Adapted Substance Abuse Treatments for Racial/Ethnic Minorities:*

*Current Perspectives and Future Directions*

Chairs: Kathleen Burlew and Carmen L. Masson

Numerous interventions exist with demonstrated efficacy for substance use prevention and treatment. However, different racial/ethnic groups bring meaningful differences (e.g., cultural identity, drug histories, access to addiction treatment, pathways to treatment, prior experience with social services) that affect response to substance abuse therapies. Accordingly, interventions yielding positive outcomes for one racial/ethnic group may not work as well with another group. Growing evidence suggests that culturally adapting substance use interventions for a specific target group can improve outcomes. The aim of this session is to share lessons learned within the Minority Interest Group of the NIDA Clinical Trials Network to improve treatment outcomes by culturally adapting substance use interventions. This workshop is significant because it will disseminate the latest research examining methods and outcomes for culturally adapting evidence-based substance use treatments. The workshop includes research on cultural adaptations of evidence-based interventions that improved outcomes for Latino, American Indian/Alaska Native (AIAN), Asian American and Pacific Islander (API), and Black/African American (AA) substance users will discuss interventions for Latino adolescents; the incorporation of spirituality, cultural identification and discrimination into AIAN interventions; approaches to attract and retain APIs in treatment; and promising procedures for adapting HIV prevention interventions for Black substance users. All speakers will describe cultural adaptation methods useful for future projects. Accordingly, the presentations will describe lessons learned regarding recruitment, retention, and improving substance use treatment outcomes for racial/ethnic minorities.

## **Acknowledgements and Advertisements**

The following organizations have financially supported the work  
of the CPDD organization during the past year

**Collegium Pharmaceutical, Inc.**

**Grunenthal USA, Inc**

**NIDA (National Institute on Drug Abuse)**

**Vince & Associates Clinical Research**

Funding for this conference was made possible (in part) by  
Grant Agreement # R13 DA 013192 from NIDA.

The views expressed in written conference materials or publications and by  
speakers and moderators do not necessarily reflect the official policies of the  
Department of Health and Human Services; nor does mention of trade names,  
commercial practices, or organizations imply endorsement by the U.S.  
Government